0001493152-21-028235.txt : 20211112 0001493152-21-028235.hdr.sgml : 20211112 20211112171528 ACCESSION NUMBER: 0001493152-21-028235 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 211404847 BUSINESS ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 BUSINESS PHONE: (215) 345-0919 MAIL ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 10-Q 1 form10-q.htm
0000868278 false --12-31 2021 Q3 P0Y 1 2 0000868278 2021-01-01 2021-09-30 0000868278 2021-11-10 0000868278 2021-09-30 0000868278 2020-12-31 0000868278 2021-07-01 2021-09-30 0000868278 2020-07-01 2020-09-30 0000868278 2020-01-01 2020-09-30 0000868278 us-gaap:CommonStockMember 2021-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000868278 us-gaap:RetainedEarningsMember 2021-06-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000868278 us-gaap:TreasuryStockMember 2021-06-30 0000868278 2021-06-30 0000868278 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000868278 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000868278 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000868278 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000868278 us-gaap:CommonStockMember 2021-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000868278 us-gaap:RetainedEarningsMember 2021-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000868278 us-gaap:TreasuryStockMember 2021-09-30 0000868278 us-gaap:CommonStockMember 2020-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000868278 us-gaap:RetainedEarningsMember 2020-06-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000868278 us-gaap:TreasuryStockMember 2020-06-30 0000868278 2020-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000868278 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000868278 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000868278 us-gaap:CommonStockMember 2020-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000868278 us-gaap:RetainedEarningsMember 2020-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000868278 us-gaap:TreasuryStockMember 2020-09-30 0000868278 2020-09-30 0000868278 us-gaap:CommonStockMember 2020-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000868278 us-gaap:RetainedEarningsMember 2020-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000868278 us-gaap:TreasuryStockMember 2020-12-31 0000868278 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000868278 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000868278 us-gaap:TreasuryStockMember 2021-01-01 2021-09-30 0000868278 us-gaap:CommonStockMember 2019-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000868278 us-gaap:RetainedEarningsMember 2019-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000868278 us-gaap:TreasuryStockMember 2019-12-31 0000868278 2019-12-31 0000868278 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000868278 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000868278 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000868278 PRPH:MarketableSecuritiesMember srt:MinimumMember 2021-01-01 2021-09-30 0000868278 PRPH:MarketableSecuritiesMember srt:MaximumMember 2021-01-01 2021-09-30 0000868278 PRPH:USGovernmentObligationsMember 2021-09-30 0000868278 PRPH:CorporateObligationsMember 2021-09-30 0000868278 PRPH:USGovernmentObligationsMember 2020-12-31 0000868278 PRPH:CorporateObligationsMember 2020-12-31 0000868278 PRPH:InvestmentSharesMember 2021-06-25 0000868278 PRPH:USGovernmentObligationsMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0000868278 PRPH:USGovernmentObligationsMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000868278 PRPH:USGovernmentObligationsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0000868278 PRPH:CorporateObligationsMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0000868278 PRPH:CorporateObligationsMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000868278 PRPH:CorporateObligationsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0000868278 us-gaap:FairValueInputsLevel1Member 2021-09-30 0000868278 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000868278 us-gaap:FairValueInputsLevel3Member 2021-09-30 0000868278 PRPH:USGovernmentObligationsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000868278 PRPH:USGovernmentObligationsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0000868278 PRPH:USGovernmentObligationsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000868278 PRPH:CorporateObligationsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000868278 PRPH:CorporateObligationsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0000868278 PRPH:CorporateObligationsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000868278 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000868278 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000868278 us-gaap:FairValueInputsLevel3Member 2020-12-31 0000868278 PRPH:ZeroToTwelveMonthsMember 2021-09-30 0000868278 PRPH:ZeroToTwelveMonthsMember 2020-12-31 0000868278 PRPH:ThirteenToTwentyFourMember 2021-09-30 0000868278 PRPH:ThirteenToTwentyFourMember 2020-12-31 0000868278 PRPH:OverTwentyFourMember 2021-09-30 0000868278 PRPH:OverTwentyFourMember 2020-12-31 0000868278 PRPH:ContractManufacturingMember 2021-07-01 2021-09-30 0000868278 PRPH:ContractManufacturingMember 2020-07-01 2020-09-30 0000868278 PRPH:ContractManufacturingMember 2021-01-01 2021-09-30 0000868278 PRPH:ContractManufacturingMember 2020-01-01 2020-09-30 0000868278 PRPH:RetailAndOtherMember 2021-07-01 2021-09-30 0000868278 PRPH:RetailAndOtherMember 2020-07-01 2020-09-30 0000868278 PRPH:RetailAndOtherMember 2021-01-01 2021-09-30 0000868278 PRPH:RetailAndOtherMember 2020-01-01 2020-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-07-01 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-07-01 2020-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-01-01 2020-09-30 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2021-07-01 2021-09-30 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2020-07-01 2020-09-30 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2021-01-01 2021-09-30 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2020-01-01 2020-09-30 0000868278 PRPH:NebulaAcquisitionMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-08 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaStockPurchaseAgreementMember PRPH:NebulaAcquisitionMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember PRPH:NebulaStockPurchaseAgreementMember PRPH:CitiBankNAMember 2021-08-08 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember PRPH:MrKamalObbadMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-01-01 2021-09-30 0000868278 PRPH:NebulaAcquisitionMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:TradeNamesMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:TradeNamesMember 2021-08-09 2021-08-10 0000868278 us-gaap:IntellectualPropertyMember PRPH:NebulaAcquisitionMember 2021-08-10 0000868278 us-gaap:IntellectualPropertyMember PRPH:NebulaAcquisitionMember 2021-08-09 2021-08-10 0000868278 us-gaap:CustomerRelationshipsMember PRPH:NebulaAcquisitionMember 2021-08-10 0000868278 us-gaap:CustomerRelationshipsMember PRPH:NebulaAcquisitionMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-07-01 2021-09-30 0000868278 PRPH:PlazaMedicalLaboratoryCorpMember 2020-10-20 2020-10-23 0000868278 PRPH:PlazaMedicalLaboratoryCorpMember 2020-10-23 0000868278 PRPH:CPMAcquisitionMember 2020-10-22 2020-10-23 0000868278 PRPH:CPMAcquisitionMember 2021-01-01 2021-09-30 0000868278 PRPH:CPMAcquisitionMember 2020-10-23 0000868278 2021-10-23 0000868278 PRPH:ClinicalLaboratoryImprovementAmendmentsMember 2020-10-23 0000868278 us-gaap:TradeNamesMember 2021-09-30 0000868278 us-gaap:TradeNamesMember 2020-12-31 0000868278 us-gaap:TradeNamesMember 2021-01-01 2021-09-30 0000868278 us-gaap:IntellectualPropertyMember 2021-09-30 0000868278 us-gaap:IntellectualPropertyMember 2020-12-31 0000868278 us-gaap:IntellectualPropertyMember 2021-01-01 2021-09-30 0000868278 us-gaap:CustomerRelationshipsMember 2021-09-30 0000868278 us-gaap:CustomerRelationshipsMember 2020-12-31 0000868278 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-09-30 0000868278 us-gaap:LicenseMember 2021-09-30 0000868278 us-gaap:LicenseMember 2020-12-31 0000868278 us-gaap:LicenseMember 2021-01-01 2021-09-30 0000868278 us-gaap:LandMember 2021-09-30 0000868278 us-gaap:LandMember 2020-12-31 0000868278 us-gaap:BuildingImprovementsMember 2021-09-30 0000868278 us-gaap:BuildingImprovementsMember 2020-12-31 0000868278 srt:MinimumMember us-gaap:BuildingImprovementsMember 2021-01-01 2021-09-30 0000868278 srt:MaximumMember us-gaap:BuildingImprovementsMember 2021-01-01 2021-09-30 0000868278 us-gaap:MachineryAndEquipmentMember 2021-09-30 0000868278 us-gaap:MachineryAndEquipmentMember 2020-12-31 0000868278 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2021-01-01 2021-09-30 0000868278 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2021-01-01 2021-09-30 0000868278 us-gaap:EquipmentMember 2021-09-30 0000868278 us-gaap:EquipmentMember 2020-12-31 0000868278 srt:MinimumMember us-gaap:EquipmentMember 2021-01-01 2021-09-30 0000868278 srt:MaximumMember us-gaap:EquipmentMember 2021-01-01 2021-09-30 0000868278 us-gaap:ComputerEquipmentMember 2021-09-30 0000868278 us-gaap:ComputerEquipmentMember 2020-12-31 0000868278 srt:MinimumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-09-30 0000868278 srt:MaximumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-09-30 0000868278 us-gaap:FurnitureAndFixturesMember 2021-09-30 0000868278 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000868278 us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-09-30 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-09-13 2020-09-15 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-09-15 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2021-07-01 2021-09-30 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-07-01 2020-09-30 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2021-01-01 2021-09-30 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-01-01 2020-09-30 0000868278 2021-05-12 2021-05-13 0000868278 us-gaap:CommonStockMember 2021-06-02 2021-06-03 0000868278 PRPH:RegisteredDirectOfferingMember 2021-01-04 2021-01-05 0000868278 PRPH:RegisteredDirectOfferingMember 2021-01-05 0000868278 us-gaap:IPOMember 2021-01-17 2021-01-18 0000868278 us-gaap:IPOMember 2021-01-18 0000868278 2020-01-20 2021-01-21 0000868278 PRPH:NebulaAcquisitionMember 2021-09-30 0000868278 PRPH:NebulaAcquisitionMember 2021-01-17 2021-01-18 0000868278 PRPH:ShareRepurchaseProgramMember 2021-09-08 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2021-05-20 0000868278 PRPH:TwoThousandTenDirectorsPlanMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000868278 PRPH:TwoThousandTenDirectorsPlanMember us-gaap:CommonStockMember 2021-09-30 0000868278 PRPH:TwoThousandTenDirectorsEquityCompensationPlanMember 2020-07-01 2020-09-30 0000868278 PRPH:TwoThousandTenDirectorsEquityCompensationPlanMember 2020-01-01 2020-09-30 0000868278 PRPH:TwoThousandTenDirectorsEquityCompensationPlanMember 2021-09-30 0000868278 PRPH:AmendedTwoThousandTenPlanMember 2021-05-19 2021-05-20 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2021-01-01 2021-09-30 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2020-01-01 2020-09-30 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2020-01-01 2021-09-30 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2021-09-30 0000868278 PRPH:TwoThousandEighteenStockIncentivePlanMember 2018-04-12 0000868278 PRPH:TwoThousandEighteenStockIncentivePlanMember 2021-04-11 2021-04-12 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2018-09-04 2018-09-05 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-09-04 2021-09-05 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2018-09-04 2018-09-05 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-01-23 2019-01-24 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-01-23 2019-01-24 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-12-11 2021-12-12 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-12-11 2019-12-12 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-12-11 2019-12-12 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-06-02 2021-06-03 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-06-02 2021-06-03 0000868278 PRPH:InducementOptionAwardMember PRPH:MrKamalObbadMember 2021-01-01 2021-09-30 0000868278 PRPH:InducementOptionAwardMember 2021-09-30 0000868278 PRPH:InducementOptionAwardMember 2021-01-01 2021-09-30 0000868278 PRPH:InducementOptionAwardMember 2021-01-01 2021-09-30 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2021-07-01 2021-09-30 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2020-07-01 2020-09-30 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2021-01-01 2021-09-30 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2020-01-01 2020-09-30 0000868278 us-gaap:StockOptionMember 2020-12-31 0000868278 us-gaap:StockOptionMember 2021-01-01 2021-09-30 0000868278 us-gaap:StockOptionMember 2021-09-30 0000868278 PRPH:RegisteredDirectOfferingMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:IPOMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:WarrantMember 2021-01-01 2021-09-30 0000868278 us-gaap:WarrantMember 2020-12-31 0000868278 us-gaap:MeasurementInputExercisePriceMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:WarrantMember 2021-07-01 2021-09-30 0000868278 us-gaap:WarrantMember 2020-01-01 2020-09-30 0000868278 PRPH:MylanandEscrowAgentMember PRPH:EscrowAgreementMember 2021-01-01 2021-09-30 0000868278 PRPH:PlazaMedicalLaboratoryCorpMember 2021-09-30 0000868278 PRPH:OldBridgeNewJerseyMember PRPH:ConfuciusLabsMember 2020-10-22 2020-10-23 0000868278 PRPH:OldBridgeNewJerseyMember PRPH:ConfuciusLabsMember 2020-10-23 0000868278 PRPH:OldBridgeNewJerseyMember PRPH:ConfuciusLabsMember 2020-12-07 2020-12-08 0000868278 PRPH:OldBridgeNewJerseyMember PRPH:ConfuciusLabsMember PRPH:FinalMonthsMember 2020-12-07 2020-12-08 0000868278 PRPH:OldBridgeNewJerseyMember PRPH:ConfuciusLabsMember 2021-01-01 2021-09-30 0000868278 PRPH:OperatingLeaseLiabilitiesMember 2021-09-30 0000868278 PRPH:OperatingLeaseRightOfUseAssetMember 2021-09-30 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsOneMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsTwoMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsThreeMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000868278 us-gaap:SalesRevenueNetMember PRPH:ThirdPartyContractManufacturingCustomerOneMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000868278 us-gaap:SalesRevenueNetMember PRPH:ThirdPartyContractManufacturingCustomerTwoMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsOneMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsTwoMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 us-gaap:SalesRevenueNetMember PRPH:ThirdPartyContractManufacturingCustomerOneMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000868278 us-gaap:SalesRevenueNetMember PRPH:ThirdPartyContractManufacturingCustomerTwoMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsOneMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsTwoMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsThreeMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsFourMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsFiveMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:TradeReceivableMember PRPH:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000868278 PRPH:TradeReceivableMember PRPH:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000868278 PRPH:TradeReceivableMember PRPH:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000868278 PRPH:StockOptionsWarrantsAndConvertibleDebtMember 2021-07-01 2021-09-30 0000868278 PRPH:StockOptionsWarrantsAndConvertibleDebtMember 2021-01-01 2021-09-30 0000868278 PRPH:CommonStockEquivalentsTwoMember 2020-01-01 2020-09-30 0000868278 PRPH:UnrelatedThirdPartyMember srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember 2020-09-25 0000868278 PRPH:UnrelatedThirdPartyMember us-gaap:SecuredDebtMember 2020-09-25 0000868278 PRPH:UnrelatedThirdPartyMember srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember 2020-07-21 0000868278 PRPH:UnrelatedThirdPartyMember srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember 2020-07-29 0000868278 PRPH:UnrelatedThirdPartyMember srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember 2020-09-23 2020-09-25 0000868278 PRPH:ConsultingAgreementMember 2020-09-23 2020-09-25 0000868278 PRPH:UnrelatedThirdPartyMember srt:MinimumMember 2020-09-25 0000868278 PRPH:UnrelatedThirdPartyMember srt:MaximumMember 2020-09-25 0000868278 PRPH:TerminationAgreementMember 2021-01-15 2021-02-28 0000868278 us-gaap:SecuredDebtMember 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-07-01 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-07-01 2020-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-01-01 2020-09-30 0000868278 PRPH:ConsumerProductsMember 2021-07-01 2021-09-30 0000868278 PRPH:ConsumerProductsMember 2020-07-01 2020-09-30 0000868278 PRPH:ConsumerProductsMember 2021-01-01 2021-09-30 0000868278 PRPH:ConsumerProductsMember 2020-01-01 2020-09-30 0000868278 PRPH:UnallocatedCorporateMember 2021-07-01 2021-09-30 0000868278 PRPH:UnallocatedCorporateMember 2020-07-01 2020-09-30 0000868278 PRPH:UnallocatedCorporateMember 2021-01-01 2021-09-30 0000868278 PRPH:UnallocatedCorporateMember 2020-01-01 2020-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-12-31 0000868278 PRPH:ConsumerProductsMember 2021-09-30 0000868278 PRPH:ConsumerProductsMember 2020-12-31 0000868278 PRPH:UnallocatedCorporateMember 2021-09-30 0000868278 PRPH:UnallocatedCorporateMember 2020-12-31 0000868278 us-gaap:SubsequentEventMember 2021-11-08 2021-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft xbrli:pure PRPH:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2021

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____to _____

 

Commission file number 000-21617

 

ProPhase Labs, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   23-2577138

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

711 Stewart Ave, Suite 200    
Garden City, New York   11530
(Address of principal executive office)   (Zip Code)

 

  (215) 345-0919  
  (Registrant’s telephone number, including area code)  

 

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0005   PRPH   Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or shorter period that the registration was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company, See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding November 10, 2021
Common Stock, $0.0005 par value   15,511,455

 

 

 

 

 

 

ProPhase Labs, Inc. and Subsidiaries

TABLE OF CONTENTS

 

  PAGE
PART I. FINANCIAL INFORMATION  
     
Item 1. Financial Statements (Unaudited)
     
  Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020 3
     
  Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2021 and 2020 4
     
  Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2021 and 2020 5
     
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020 7
     
  Notes to Condensed Consolidated Financial Statements 8
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 33
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 38
     
Item 4. Controls and Procedures 39
     
PART II. OTHER INFORMATION  
   
Item 1. Legal Proceedings 39
Item 1A. Risk Factors 39
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 46
Item 3. Defaults Upon Senior Securities 46
Item 4. Mine Safety Disclosures 46
Item 5. Other Information 46
Item 6. Exhibits 47
     
Signatures   48

 

2
 

 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

   September 30,   December 31, 
   2021   2020 
   (Unaudited)     
ASSETS          
Current assets          
Cash and cash equivalents  $8,533   $6,816 
Restricted cash   250    - 
Marketable debt securities, available for sale   14,114    1,639 
Marketable equity securities, at fair value   214    - 
Accounts receivable, net   10,680    3,155 
Inventory, net   8,510    3,039 
Prepaid expenses and other current assets   1,602    1,238 
Total current assets   43,903    15,887 
           
Property, plant and equipment, net   6,454    3,578 
Secured promissory note receivable   3,774    2,750 
Prepaid expenses, net of current portion   460    2,084 
Right-of-use asset, net   4,484    4,731 
Intangible assets, net   11,562    1,234 
Goodwill   1,385    901 
Other assets   608    240 
TOTAL ASSETS  $72,630   $31,405 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $2,394   $3,771 
Accrued diagnostic services   

3,260

    - 
Accrued advertising and other allowances   344    463 
Lease liabilities   676    329 
Deferred revenue   

1,517

    

-

 
Other current liabilities   1,741    1,731 
Total current liabilities   9,932    6,294 
           
Non-current liabilities:          
Deferred revenue, net of current portion   106    162 
Note payable   81    - 
Unsecured convertible promissory notes, net   9,995    9,991 
Lease liabilities, net of current portion   4,252    4,402 
Total non-current liabilities   14,434    14,555 
Total liabilities   24,366    20,849 
           
COMMITMENTS AND CONTINGENCIES          
           
Stockholders’ equity          
Preferred stock authorized 1,000,000, $.0005 par value, no shares issued and outstanding   -    - 
Common stock authorized 50,000,000, $.0005 par value, 15,652,724 and 11,604,253 shares outstanding, respectively   16    14 
Additional paid-in capital   103,807    61,674 
Accumulated deficit   (7,947)   (3,631)
Treasury stock, at cost, 16,652,022 and 16,652,022 shares, respectively   (47,490)   (47,490)
Accumulated other comprehensive loss   (122)   (11)
Total stockholders’ equity   48,264    10,556 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $72,630   $31,405 

 

See accompanying notes to condensed consolidated financial statements

 

3
 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(in thousands, except per share amounts)

(unaudited)

 

                     
   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Revenues, net  $9,472   $3,840   $33,885   $9,351 
Cost of revenues   5,495    2,798    16,515    6,615 
Gross profit   3,977    1,042    17,370    2,736 
                     
Operating expenses:                    
Diagnostic expenses   1,478    -    6,117    - 
General and administration   5,938    1,552    14,713    3,875 
Research and development   208    57    416    181 
Total operating expenses   7,624    1,609    21,246    4,056 
Loss from operations   (3,647)   (567)   (3,876)   (1,320)
                     
Interest income, net   230    39    531    53 
Interest expense   (296)   (41)   (870)   (41)
Change in fair value of investment securities   (265)   -    (101)   - 
Loss from continuing operations   (3,978)   (569)   (4,316)   (1,308)
                     
Discontinued Operations:                    
Income from discontinued operations   -    161    -    161 
Net loss  $(3,978)  $(408)  $(4,316)  $(1,147)
                     
Other comprehensive loss:                    
Unrealized loss on marketable debt securities   (33)   (8)   (111)   (2)
Total comprehensive loss  $(4,011)  $(416)  $(4,427)  $(1,149)
                     
Basic and diluted earnings (loss) per share:                    
Loss from continuing operations  $(0.26)  $(0.05)  $(0.29)  $(0.11)
Income from discontinued operations   -    0.01    -    0.01 
Net loss per share  $(0.26)  $(0.04)  $(0.29)  $(0.10)
                     
Weighted average common shares outstanding:                    
Basic and diluted   15,439    11,604    15,055    11,593 

 

See accompanying notes to condensed consolidated financial statements

 

4
 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

(unaudited)

 

                                    
   For the Three Months Ended September 30, 2021 
  

Common Stock Shares Outstanding

   Par Value  

Additional

Paid in Capital

   Accumulated Deficit   Accumulated Comprehensive Income (Loss)   Treasury Stock   Total 
Balance as of July 1,2021   15,154,253   $16   $99,265   $(3,969)  $(89)  $(47,490)  $47,733 
                                   
Issuance of common shares related to business acqusition   483,685    -    3,608    -    -    -    3,608 
                                   
Unrealized loss on marketable debt securities, net of taxes   -    -    -    -    (33)   -    (33)
Cashless warrants exercise   5,986    -    -    -    -    -    - 
                                    
Stock-based compensation   8,800    -    934    -    -    -    934 
                                    
Net loss   -    -    -    (3,978)   -    -    (3,978)
                                    
Balance as of September 30, 2021   15,652,724   $16   $103,807   $(7,947)  $(122)  $(47,490)  $48,264 

 

   For the Three Months Ended September 30, 2020 
   Common Stock Shares Outstanding   Par Value   Additional Paid in Capital   Accumulated Deficit   Accumulated Comprehensive Income (Loss)   Treasury Stock   Total 
Balance as of July 1, 2020   11,591,648   $14   $60,611   $(2,245)   $4   $(47,490)  $10,894 
                                    
Unrealized loss on marketable debt securities, net of realized gains of $4, net of taxes   -    -    -    -    (8)   -    (8)
                                    
Stock-based compensation   12,605    -    283    -    -    -    283 
                                    
Net loss   -    -    -    (408)   -    -    (408)
                                    
Balance as of September 30, 2020   11,604,253   $14   $60,894   $(2,653)   $(4)  $(47,490)  $10,761 

 

5
 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

(unaudited)

 

   For the Nine Months Ended September 30, 2021 
   Common Stock Shares Outstanding   Par Value   Additional Paid in Capital   Accumulated Deficit   Accumulated Comprehensive Income (loss)   Treasury Stock   Total 
Balance as of January 1, 2021   11,604,253   $14   $61,674   $(3,631)  $(11)  $(47,490)  $10,556 
                                    
Issuance of common stock and warrants for cash from public offering, net of $2,365 offering cost   3,000,000    2    35,133    -    -    -    35,135 
                                    
Issuance of common stock and warrants for cash from private offering   550,000    -    5,500    -    -    -    5,500 
                                    
Issuance of common shares related to business acqusition   483,685    -    3,608    -    -    -    3,608 
                                    
Cash dividends   -    -    (4,546)   -    -    -    (4,546)
                                    
Unrealized loss on marketable debt securities, net of taxes   -    -    -    -    (111)   -    (111)
Cashless warrants exercise   

5,986

    -    -    -    -    -    - 
                                    
                                    
Stock-based compensation   8,800    -    2,438    -    -    -    2,438 
                                    
Net loss   -    -    -    (4,316)   -    -    (4,316)
                                    
Balance as of September 30, 2021   15,652,724   $16   $103,807   $(7,947)  $(122)  $(47,490)  $48,264 

 

   For the Nine Months Ended September 30, 2020 
   Common Stock Shares Outstanding   Par Value   Additional Paid in Capital   Accumulated Deficit   Accumulated Comprehensive Income (loss)   Treasury Stock   Total 
Balance as of January 1, 2020   11,573,593   $14   $60,215   $(1,506)  $(2)  $(47,490)  $11,231 
                                    
Unrealized loss on marketable debt securities, net of realized losses of $4, net of taxes   -    -    -    -    (2)   -    (2)
                                    
Stock-based compensation   30,660    -    679    -    -    -    679 
                                    
Net loss   -    -    -    (1,147)   -    -    (1,147)
                                    
Balance as of September 30, 2020   11,604,253   $14   $60,894   $(2,653)  $(4)  $(47,490)  $10,761 

 

See accompanying notes to condensed consolidated financial statements

 

6
 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

           
   For the nine months ended 
   September 30, 2021   September 30, 2020 
Cash flows from operating activities          
Net loss  $(4,316)  $(1,147)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Realized (gain) loss on marketable debt securities   40    (2)
Depreciation and amortization   2,044    253 
Amortization of debt discount   4    - 
Amortization on right-of-use assets   247    - 
Lower of cost or net realizable value inventory adjustment   -    17 
Stock-based compensation expense   2,438    679 
Change in fair value of investment securities   101    - 
Non-cash interest income on secured promissory note receivable   (315)   - 
Changes in operating assets and liabilities:          
Accounts receivable   (7,327)   (1,015)
Escrow receivable   -    4,812 
Inventory   (5,036)   (696)
Prepaid and other assets   1,639    (30)
Other assets   (368)   - 
Accounts payable and accrued expenses   (1,749)   470 
Accrued diagnostic services   

3,260

    - 
Deferred revenue   

1,461

     
Lease liabilities   197    - 
Other liabilities   (1,292)   835 
Net cash (used in) provided by operating activities   (8,972)   4,176 
           
Cash flows from investing activities          
Business acquisitions, net of cash acquired   (9,066)   - 
Issuance of secured promissory note receivable   (1,000)   (2,974)
Purchase of marketable securities   (21,527)   (4,317)
Proceeds from sale of marketable debt securities   10,701    3,839 
Capital expenditures   (4,258)   (222)
Net cash used in investing activities   (25,150)   (3,674)
           
Cash flows from financing activities          
Proceeds from issuance of common stock from public offering, net   35,135    - 
Proceeds from issuance of common stock and warrants from private offering   5,500    - 
Proceeds from unsecured convertible promissory notes   

-

    

10,000

 
Issuance costs on unsecured convertible promissory notes   -    

(10

)
Payment of issuance costs in connection with ATM   -    

(66

)
Payment of dividends   (4,546)   - 
Net cash provided by financing activities   36,089    9,924 
           
Increase in cash, cash equivalents and restricted cash   1,967    10,426 
Cash, cash equivalents and restricted cash, at the beginning of the period   6,816    434 
Cash, cash equivalents and restricted cash, at the end of the period  $8,783   $10,860 
           
Supplemental disclosures:          
Cash paid for income taxes  $-   $- 
Interest payment on the promissory notes  $750   $- 
           
Supplemental disclosure of non-cash investing and financing activities:          
Issuance of common shares related to business acqusition  $3,608   $- 
Net unrealized loss, investments in marketable debt securities  $(111)  $(2)

 

See accompanying notes to condensed consolidated financial statements

 

7
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 1 - Organization and Business

 

ProPhase Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a diversified biotech and genomics company with deep experience with over-the- counter (“OTC”) consumer healthcare products and dietary supplements. We currently conduct our operations through two operating segments: diagnostic services and consumer products. Until late Fiscal 2020, we were engaged primarily in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. However, commencing in December 2020, we also began offering COVID-19 and other Respiratory Pathogen Panel (RPP) molecular tests through our new diagnostic services business and in August 2021 we began offering personal genomics products and services.

 

Our wholly-owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers a variety of medical tests, including COVID-19 and Respiratory Pathogen Panel (RPP) molecular tests. On October 23, 2020, we acquired Confucius Plaza Medical Laboratory Corp. (“CPM”), including a 4,000 square foot Clinical Laboratory Improvement Amendments (“CLIA”) accredited laboratory located in Old Bridge, New Jersey (see Note 3, Business Acquisitions). As part of the acquisition of CPM in October 2020, we entered into a new business line, diagnostic services. In December 2020, we expanded our diagnostic service business with the build out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in February 2021.

 

Our wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.

 

On August 10, 2021, we acquired Nebula Genomics, Inc., a privately owned personal genomics company, through our new wholly-owned subsidiary, ProPhase Precision Medicine, Inc. (see Note 3, Business Acquisitions).

 

In addition, we continue to actively pursue acquisition opportunities for other companies, technologies and products within and outside the consumer products industry.

  

Note 2 - Business and Liquidity Uncertainties

 

Basis of Presentation

 

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of operating results that may be achieved over the course of the full year.

 

8
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Segments

 

Operating segments are defined as components of an enterprise that engage in business activities for which separate financial information is available and is evaluated by the Chief Operating Decision Maker (“CODM”), which for the Company is its Chief Executive Officer, in deciding how to allocate resources and assess performance. For the three and nine months ended September 30, 2021, we maintained two operating segments: diagnostic services (which includes our COVID-19 and other diagnostic testing services) and consumer products (which includes our contract manufacturing, retail customers and personal genomics products and services). For the three and nine months ended September 30, 2020, we only had the consumer products operating segment. (see Note 15, Segment Information).

 

Business and Liquidity Uncertainties

 

We launched our diagnostic service business in December 2020 and expanded in February 2021 with the opening of our new Garden City, New York CLIA accredited laboratory. Our diagnostic service business is and will continue to be influenced by the level of demand for COVID-19 and other diagnostic testing, the prices we are able to receive for performing our testing services, and the length of time for which that demand persists, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.

 

While our revenues increased for the three and nine months ended September 30, 2021 as a result of revenues from our new diagnostic services business line, we have made and will continue to make substantial investments to secure the necessary equipment, supplies and personnel to provide these testing services. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will be successful in the future or that the revenue and operating profits from such business will increase or maintain their current level.

 

We acquired and commenced our personal genomics business in August 2021. This business will be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.

 

There are still numerous uncertainties associated with the COVID-19 pandemic, including the efficacy of the vaccines that have been developed to treat the virus and their ability to protect against new strains of the virus, people’s willingness to receive a vaccine, possible resurgences of the coronavirus and/or new strains of the virus, the extent and duration of protective and preventative measures that may be adopted by local, state and/or the federal government in the future as a result of future outbreaks, the duration of any future business closures, the ongoing impact of COVID-19 on the U.S. and world economy and consumer confidence, and various other uncertainties.

 

The Company used cash in operating activities of $9.0 million for the nine months ended September 30, 2021. The Company had cash, cash equivalents and marketable securities of $22.9 million as of September 30, 2021. Based on management’s current business plan, the Company estimates it will have enough cash and liquidity to finance its operating requirements for at least one year from the date of filing these financial statements.

 

The Company’s future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily limited to, the actual cost and time necessary to achieve sustained profitability within its newly launched diagnostic services and personal genomics businesses. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.

 

9
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Use of Estimates

 

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, diagnostic services reimbursements, inventory obsolescence, useful lives of property and equipment, impairment of goodwill, intangibles and property and equipment, income tax valuations and assumptions related to accrued advertising. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these securities.

 

Marketable Debt Securities

 

We have classified our investments in marketable debt securities as available-for-sale and as a current asset. Our investments in marketable debt securities are carried at fair value, with unrealized gains and as a separate component of stockholders’ equity. Realized gains and losses from our marketable debt securities are recorded as interest income (expense). These investments in marketable debt securities, carry maturity dates between one and three years from date of purchase and interest rates of 1.90% to 3.62% during the first three quarters of Fiscal 2021. For the three and nine months ended September 30, 2021, we reported unrealized losses of $32,000 and $111,000, respectively. Unrealized gains and losses are classified as other comprehensive loss and the cost is determined on a specific identification basis. The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (see fair value of financial instruments) (in thousands):

 

   As of September 30, 2021 
   Amortized   Unrealized   Fair 
   Cost   Losses   Value 
U.S. government obligations  $324   $(1)  $323 
Corporate obligations   13,912    (121)   13,791 
   $14,236   $(122)  $14,114 

 

   As of December 31, 2020 
   Amortized   Unrealized   Fair 
   Cost   Losses   Value 
U.S. government obligations  $1,021   $(7)  $1,014 
Corporate obligations   629    (4)   625 
   $1,650   $(11)  $1,639 

 

We believe that the unrealized gains or losses generally are the result of a change in the risk premiums required by market participants rather than an adverse change in cash flows or a fundamental weakness in the credit quality of the issuer or underlying assets.

 

Marketable Equity Securities

 

Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net in the consolidated statements of income.

 

On June 25, 2021, we were issued 1,260,619 common shares (the “Investment Shares”) as an interest payment under our note receivable (see Note 14, Secured Promissory Note Receivable and Consulting Agreement) with a fair value of $315,000. The fair value of the Investment Shares as of September 30, 2021 was based upon the closing stock price of $0.17 per share. The investment was classified as a Level 1 financial instrument. We recorded a $265,000 and $101,000 decrease in fair value of investment securities within the statement of operations for the three and nine months ended September 30, 2021, respectively.

 

10
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Inventories, net

 

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or net realizable value. Inventory items are analyzed to determine cost and the net realizable value and appropriate valuation adjustments are then established. At September 30, 2021 and December 31, 2020, the financial statements include non-cash adjustments to adjust inventory for excess, obsolete or short-dated shelf-life inventory by $87,000 and $167,000, respectively. The components of inventory are as follows (in thousands):

 

   September 30,   December 31, 
   2021   2020 
Diagnostic services testing material  $6,203   $1,028 
Raw materials   1,464    1,404 
Work in process   407    437 
Finished goods   436    170 
Inventory, net  $8,510   $3,039 

 

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years.

 

We did not identify any indicators of impairment of our property, plant and equipment for the nine months ended September 30, 2021 and 2020 and concluded there were no impairments or changes in useful lives.

 

Concentration of Risks

 

Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity and marketing and distribution capabilities, as well as our ability to comply with the regulatory requirements associated with the development of OTC consumer healthcare products, dietary supplements and other remedies in order to compete on a national level and/or international level. Our diagnostic services business will be influenced by demand for our diagnostic testing services, particularly COVID-19 testing services, our marketing and service capabilities, and our ability to comply with regulatory requirements associated with operating under and maintaining our CLIA license. Our personal genomics business is and will continue to be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.

 

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products and services. The manufacturing and distribution of OTC healthcare and dietary supplement products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States. The FDA is also responsible for the regulation of diagnostic testing instruments, test kits, reagents and other devices used by clinical laboratories.

 

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and trade accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.

 

We maintain cash and cash equivalents with certain major financial institutions. As of September 30, 2021, our cash and cash equivalents balance were $8.5 million and our bank balance was $8.7 million. Of the total bank balance, $1.0 million was covered by federal depository insurance and $7.7 million was uninsured at September 30, 2021.

 

11
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depend on information provided and billing services of third parties. These credit concentrations impact our overall exposure to credit risk, which could be further affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of trade receivables and diagnostic test receivables. Additionally, the reimbursement receivables from the diagnostic service business are subject to billing errors and related disputes.

 

We also assess the financial condition of the debtor under our note receivable (see Note 14, Secured Promissory Note Receivable and Consulting Agreement), balances due to us. As of September 30, 2021, December 31, 2020 and the financial statements reporting date, the Company expects full realization upon maturity.

 

Leases

 

At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. We have elected not to recognize on the balance sheet leases with terms of 12 months or less. We typically only include an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in our assessment unless there is reasonable certainty that we will renew.

 

Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in our leases is typically not readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 11, Leases).

 

The components of a lease should be allocated between lease components (e.g., land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

 

Goodwill and Intangible Assets

 

Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill and other intangibles at that time.

 

In testing for goodwill impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, we conclude that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If we conclude otherwise, we are required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than the carrying value, an impairment charge will be recorded to reduce the reporting unit to fair value.

 

12
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Intangible assets deemed to have finite lives are amortized on a straight-line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to our future cash flows.

 

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, including property and equipment and finite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when the asset’s carrying value exceeds the total undiscounted cash flows expected from its use and eventual disposition. The amount of the impairment loss is determined as the excess of the carrying value of the asset over its fair value. For the three and nine months ended September 30, 2021 and 2020, the Company did not have an impairment of the intangible assets.

 

Fair Value of Financial Instruments

 

We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

  Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

  Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, secured note receivable and unsecured note payable, approximate their fair values because of the current nature of these instruments.

 

We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity change in fair value reported on the condensed consolidated statement of operations (see Note 14, Secured Promissory Note Receivable and Consulting Agreement). The components of marketable securities and are as follows (in thousands): 

 

   As of September 30, 2021 
   Level 1   Level 2   Level 3   Total 
Marketable debt securities                    
U.S. government obligations  $-   $323   $-   $323 
Corporate obligations   -    13,791    -    13,791 
Marketable equity securities   214    -    -    214 
   $214   $14,114   $-   $14,328 

 

   As of December 31, 2020 
   Level 1   Level 2   Level 3   Total 
Marketable debt securities                    
U.S. government obligations  $-   $1,014   $-   $1,014 
Corporate obligations   -    625    -    625 
   $-   $1,639   $-   $1,639 

 

There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the nine months ended September 30, 2021.

 

13
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Revenue Recognition

 

We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

Contract with Customers and Performance Obligations

 

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. We had historically generated sales principally through two types of customers, contract manufacturing and retail customers for our consumer products. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. As of December 2020, we also began generating revenues through diagnostic services and in August 2021 we acquired a personal genomics business, which we now include in our consumer products revenue. See Note 3, Business Acquisitions, for additional information on our October 2020 and August 2021 acquisitions. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue over time as the services are provided to the customer.

 

The Company’s performance obligation for contract manufacturing and retail customers is to provide the goods ordered by the customer. The Company’s has one performance obligation for its diagnostic services, which is to provide the results of the laboratory test to the customer. Our personal genomics business has separate performance obligations to provide initial testing and genome results and subscriptions services to our customers.

 

Transaction Price

 

For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.

 

Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

 

We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.

 

14
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers, including health plans, government agencies and consumers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on, the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.

 

For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. If the customer does not return the test kit, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. The Company recognizes the breakage amounts as revenue, proportionate to the pattern of revenue recognition of the returning test kits. The Company estimates breakage for the portion of test kits not expected to be returned using an analysis of historical data and considers other factors that could influence customer test kit return behavior. The Company recognized breakage revenue from unreturned test kits of $0.1 million for the three and nine months ended September 30, 2021. 

 

Recognize Revenue When the Company Satisfies a Performance Obligation

 

Performance obligations related to contract manufacturing and retail customers are satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped. For diagnostic services, the Company satisfies its performance obligation at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control. For genomic services, the Company satisfies its product performance obligation at a point in time when the genetics testing results are provided to the customer. For subscriptions services associated with its genomic testing, the Company satisfies its performance obligation over time as the applicable services are provided to the customer

 

Contract Balances

 

As of September 30, 2021 and December 31, 2020, we have deferred revenue of $1,623,000 and $331,000, respectively. Our newly launched personal genomics business contributed $1,403,000 to our deferred revenue as of September 30, 2021. The remainder of deferred revenue relates to research and development (“R&D”) stability and release testing programs recognized as contract manufacturing revenue. Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&D work. We recognize deferred revenues as revenues when the services are performed and the corresponding revenue recognition criteria are met. Customer prepayments are generally applied against invoices issued to customers when services are performed and billed.

 

The following table disaggregates our deferred revenue by recognition period (in thousands):

 

   As of September 30, 2021   As of December 31, 2020 
Recognition Period          
0-12 Months  $1,517   $169 
13-24 Months   71    84 
Over 24 Months   35    78 
Total  $1,623   $331 

 

Disaggregation of Revenue

 

We disaggregate revenue from contracts with customers into four categories: contract manufacturing, retail and others, diagnostic services and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

15
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table disaggregates our revenue by revenue source for the three and nine months ended September 30, 2021 and 2020 (in thousands):

 

                             
   For the three months ended   For the nine months ended 
Revenue by Customer Type  September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Contract manufacturing  $1,120   $3,630   $4,069   $8,825 
Retail and others   1,210    210    2,400    526 
Diagnostic services   7,142    -    27,416    - 
Total revenue, net  $9,472   $3,840   $33,885   $9,351 

 

Customer Consideration

 

The Company makes payments to certain diagnostic services customers for distinct services that approximate fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, logistics services, as well as other information requirements. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations. Diagnostic services cost of revenue includes specimen collection payments to customers and other costs incurred in connection with the Company operated laboratories, including reagent and other raw material costs, direct and indirect labor and other laboratory facility overhead (see Note 15, Segment Information).

 

Shipping and Handling Activities

 

We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the goods.

 

Advertising and Incentive Promotions

 

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended September 30, 2021 and 2020 were $136,000 and $451,000, respectively. Advertising and incentive promotion expenses incurred for the nine months ended September 30, 2021 and 2020 were $415,000 and $547,000, respectively.

 

Share-Based Compensation

 

We recognize all share-based payments to employees, directors and consultants, including grants of stock options and common shares, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.

 

Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans. Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.

 

For the three months ended September 30, 2021 and 2020, we charged to operations $934,000 and $283,000, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services. For the nine months ended September 30, 2021 and 2020, we charged to operations $2,438,000 and $679,000, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services.

 

16
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Research and Development

 

R&D costs are charged to operations in the period incurred. R&D costs incurred for the three months ended September 30, 2021 and 2020 were $208,000 and $57,000, respectively. R&D costs incurred for the nine months ended September 30, 2021 and 2020 were $416,000 and $181,000, respectively. R&D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation fees in association with the diagnostic services business including the validation work of the diagnostic services business.

 

Income Taxes

 

We utilize the asset and liability approach, which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided.

 

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to income taxes will be recorded as interest or administrative expense, respectively.

 

As a result of our historical losses from continuing operations, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefit.

 

Recently Issued Accounting Standards, Not Yet Adopted

 

In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.

 

The FASB recently issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We are currently assessing the impact of the adoption of this ASU on our financial statements.

 

17
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on the Company’s financial statements or disclosures.

 

In October 2021, the FASB issued ASU 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). The standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. ASU 2021-08 will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are in the process of evaluating the impact that ASU 2021-08 will have on our condensed consolidated financial statements and associated disclosures.

 

Note 3 - Business Acquisitions

 

Nebula Acquisition

 

On August 10, 2021 (the “Effective Date”), the Company and its wholly-owned subsidiary, ProPhase Precision Medicine, Inc. (“ProPhase Precision”), entered into and closed a Stock Purchase Agreement (the “Nebula Stock Purchase Agreement”) with Nebula Genomics, Inc., a privately owned personal genomics company (“Nebula”), each of the stockholders of Nebula (the “Seller Parties”), and Kamal Obbad, as Seller Party Representative. Pursuant to the terms of the Nebula Stock Purchase Agreement, ProPhase Precision acquired all of the issued and outstanding shares of common stock of Nebula from the Seller Parties, for an aggregate purchase price of approximately $14.6 million, subject to post-closing adjustments (the “Nebula Acquisition”). A portion of the purchase price equal to $3.6 million was paid in shares of the Company to certain Seller Parties and noteholders of Nebula, based on their election to receive shares of Company common stock in lieu of cash, which shares were valued at a price per share of $7.46, which is equal to the average closing price of the Company’s common stock on Nasdaq for the five trading days preceding the signing of the Nebula Stock Purchase Agreement. A portion of the purchase price equal to $1,080,000 (the “Escrow Amount”) will be held in escrow by Citibank, N.A. (the “Escrow Agent”) until February 23, 2023 (“Escrow Termination Date”), pursuant to the terms and conditions of an escrow agreement entered into with the Escrow Agent, as security for the indemnification obligations of the Seller Parties. At the Escrow Termination Date, the remaining amount, if any, of the Escrow Amount, less any amount reasonably necessary to pay any claim with respect to which a notice of claim has been timely and properly given, will be delivered to the Seller Parties, as applicable.

 

In connection with the Nebula Acquisition, ProPhase Precision entered into an employment agreement with Kamal Obbad, the Chief Executive Officer of Nebula, on the Effective Date, pursuant to which Mr. Obbad will serve as Senior Vice President, Director of Sales and Marketing of ProPhase Precision. As a condition to the employment agreement, Mr. Obbad was awarded a stock option to purchase 250,000 shares of Company common stock at an exercise price equal to $7.67 per share, the closing price of the Company common stock on the Effective Date. The award was issued as a material inducement to Mr. Obbad’s acceptance of employment with ProPhase Precision in accordance with Nasdaq Listing Rule 5635(c)(4) and was approved by the Company’s Compensation Committee (see Note 7, Stockholders’ Equity).

 

18
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Based on the preliminary valuation, the total consideration of $12.7 million, which is net of $1.6 million in cash acquired and $0.3 million anticipated to be paid back to the Company from the Escrow Amount, has been allocated to assets acquired and liabilities assumed based on their respective fair values as follows (amounts in thousands):

 

      
Short term investments  $1,800 
Accounts receivable   222 
Inventory   435 
Prepaid and other current assets   379 
Definite-lived intangible assets   10,990 
Total assets acquired   13,826 
Accounts payable   (372)
Accrued expenses and other current liabilities   (43)
Deferred revenue   (1,140)
Note payable   (81)
Total liabilities assumed   (1,636)
Net identifiable assets acquired   12,190 
Goodwill   484 
Total consideration, net of cash acquired (1)  $12,674 

 

(1) Net of $1,639 cash acquired and $257 anticipated amounts due back to the Company from the escrow account.

 

Goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired. The Company believes the goodwill related to the acquisition was a result of the expected synergies to be realized from combining operations and is not deductible for income tax purposes. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.

 

The intangible assets preliminarily identified in conjunction with the Nebula Acquisition are as follows (amount in thousands): 

   Gross Carrying Value  

Estimated Useful

Life (in years)

 
Trade names  $5,550    15 
Proprietary intellectual property   4,260    5 
Customer relationships   1,180    1 
Total  $10,990      

 

The Company recognized $336,000 amortization expense on the above identified intangible assets during the three and nine months September 30, 2021.

 

19
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Pro Forma Results

 

The following table summarizes, on a pro forma basis, the combined results of the Company as though the Nebula Acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are (in thousands):

 

   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Revenue, net  $9,843   $4,131   $36,007   $9,890 
Net loss  $(4,020)  $(764)  $(4,454)  $(2,425)

 

CPM Acquisition

 

On October 23, 2020, the Company acquired all of the issued and outstanding shares of capital stock of CPM for approximately $2.5 million in cash, subject to certain adjustments, pursuant to the terms of a Stock Purchase Agreement, by and among the Company, CPM, Pride Diagnostics LLC (“Pride Diagnostics”) and the members of Pride Diagnostics (together with Pride Diagnostics, the “Seller Parties”), and Arvind Gurnani, as representative of the Seller Parties. As part of the acquisition, we acquired a 4,000 square foot (CLIA) accredited laboratory located in Old Bridge, New Jersey owned by CPM (now known as ProPhase Diagnostics NJ, Inc.).

 

Based on valuation, the total consideration of $2.5 million has been allocated to assets acquired and liabilities assumed based on their respective fair values as follows (amount in thousands):

 

      
Clinical lab material  $180 
Lab equipment   112 
Definite-lived intangible asset   1,307 
Total assets acquired   1,599 
Liabilities assumed   - 
Net identifiable assets acquired   1,599 
Goodwill   901 
Total consideration  $2,500 

 

Goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed in the amount of $901,000, which was primarily related to the acquisition of the assembled workforce. Other definite-lived intangible asset of approximate $1.3 million were related to the CLIA license, which was determined to have an estimated useful life of three years. The Company recognized $924,000 and $1,131,000 aggregate amortization expense during the three and nine months September 30, 2021, respectively.

 

Note 4 – Goodwill and Acquired Intangible Assets

 

Goodwill

 

Changes in goodwill for the nine months ended September 30, 2021 are as follows (in thousands):

 

   September 30, 2021 
Goodwill, beginning of period  $901 
Acquisition of Nebula   484 
Goodwill, end of period  $1,385 

 

20
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Intangible Assets, Net

 

Intangible assets as of September 30, 2021 and December 31, 2020 consisted of the following (in thousands):

 

   September 30,   December 31,   Estimated Useful 
   2021   2020   Life (in years) 
Trade names  $5,550   $-    15 
Proprietary intellectual property   4,260    -    5 
Customer relationships   1,180    -    1 
CLIA license   1,307    1,307    3 
Total intangible assets, gross   12,297    1,307      
Less: accumulated amortization   (735)   (73)     
Total intangible assets, net  $11,562   $1,234      

 

Amortization expense for acquired intangible assets was $445,000 and $662,000 during the three and nine months ended September 30, 2021, respectively. The estimated future amortization expense of acquired intangible assets as of September 30, 2021 is as follows (in thousands):

 

      
Three months ended December 31, 2021  $709 
Year ended December 31, 2022   2,378 
Year ended December 31, 2023   1,585 
Year ended December 31, 2024   1,222 
Year ended December 31, 2025   1,222 
Thereafter   4,446 
Total  $11,562 

 

Note 5 - Property, Plant and Equipment

 

The components of property and equipment are as follows (in thousands):

 

   September 30,   December 31,    
   2021   2020   Estimated Useful Life
Land  $352   $352    
Building improvements   1,859    1,729   10-39 years
Machinery   4,672    4,441   3-7 years
Lab equipment   4,316    1,002   3-7 years
Computer equipment   1,189    881   3-5 years
Furniture and fixtures   468    194   5 years
Property, Plant and Equipment, Gross   12,856    8,599    
Less: accumulated depreciation   (6,402)   (5,021)   
Total property, plant and equipment, net  $6,454   $3,578    

 

Depreciation expense for the three months ended September 30, 2021 and 2020 was $481,000 and $86,000, respectively. Depreciation expense incurred for the nine months ended September 30, 2021 and 2020 was $1,381,000 and $253,000, respectively.

 

21
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 6 -Unsecured Convertible Promissory Notes Payable

 

On September 15, 2020, we issued two unsecured, partially convertible, promissory notes (the “September 2020 Notes”) for an aggregate principal amount of $10 million to two investors (collectively, the “Lenders”).

 

The September 2020 Notes are due and payable on September 15, 2023, and accrue interest at a rate of 10% per year from the closing date, payable on a quarterly basis, until the September 2020 Notes are repaid in full. We have the right to prepay the September 2020 Notes at any time after the 13 month anniversary of the closing date after providing written notice to the Lenders, and may prepay the September 2020 Notes prior to such time with the consent of the Lenders. The Lenders have the right, at any time, and from time to time, on and after the 13-month anniversary of the closing date to convert up to an aggregate of $3.0 million of the September 2020 Notes into common stock of the Company at a conversion price of $3.00 per share. Repayment of the September 2020 Notes has been guaranteed by our wholly-owned subsidiary, PMI.

 

The September 2020 Notes contain customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the September 2020 Notes may be accelerated. The September 2020 Notes also contain certain restrictive covenants which, among other things, restrict our ability to create, incur, assume or permit to exist, directly or indirectly, any lien (other than certain permitted liens described in the September 2020 Notes) securing any indebtedness of the Company, and prohibits us from distributing or reinvesting the proceeds from any divestment of assets (other than in the ordinary course) without the prior approval of the Lenders.

 

For the three months ended September 30, 2021 and 2020, we incurred $251,000 and $0, respectively, in interest expense under the September 2020 Notes. For the nine months ended September 30, 2021 and 2020, we incurred $753,000 and $0, respectively, in interest expense under the September 2020 Notes

 

Note 7 - Stockholders’ Equity

 

Our authorized capital stock consists of 50 million shares of common stock, $0.0005 par value, and one million shares of preferred stock, $0.0005 par value.

 

Preferred Stock

 

The preferred stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of September 30, 2021 and December 31, 2020, no shares of preferred stock have been issued.

 

Common Stock Dividends

 

On May 13, 2021, the Board declared a special cash dividend of $0.30 per share on the Company’s common stock to holders of record on May 25, 2021, resulting in the payment of $4.5 million to stockholders on June 3, 2021.

 

In Fiscal 2020, no cash dividends were declared.

 

Common Stock

 

Registered Direct Offering

 

On January 5, 2021, we entered into a securities purchase agreement with certain accredited investors and qualified institutional buyers, pursuant to which we issued and sold to the purchasers an aggregate of (i) 550,000 shares of our common stock, and (ii) warrants to purchase up to 275,000 shares of common stock in a registered direct offering.

 

The shares and warrants were sold at a purchase price of $10.00 per share for net proceeds to us of $5.5 million. Each Warrant has an exercise price equal to $11.00 per share of common stock, will be exercisable at any time and from time to time, subject to certain conditions described in the Warrant, after the date of issuance, and will expire on the date that is three years from the date of issuance. The Shares and the Warrants are immediately separable and were issued separately.

 

22
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Public Offering

 

On January 18, 2021, we entered into an underwriting agreement for the public offering of three million shares of common stock, at a price to the public of $12.50 per share. On January 21, 2021, we completed the offering for net proceeds of $35.1 million, after deducting the underwriting discounts and commissions and estimated offering expenses. As part of the offering, we also issued to the Underwriters warrants to purchase up to an aggregate of 180,000 shares of common stock (6% of the shares of common stock sold in the offering) at an exercise price of $15.625 per share (equal to 125% of the public offering price per share).

 

Nebula Acquisition

 

As part of Nebula Acquisition (see Note 3, Business Acquisitions), a portion of the purchase price was paid in shares to certain Seller Parties and noteholders of Nebula, based on their election to receive shares of Company common stock in lieu of cash, which shares have been valued at a price per share of $7.46, which is equal to the average closing price of the Company’s common stock on Nasdaq for the five trading days preceding the signing of the Nebula Stock Purchase Agreement.

 

The Company issued 483,685 shares of common stock in in lieu of $3.6 million cash payment to Seller Parties and noteholders of Nebula.

 

Stock Repurchase Program

 

On September 8, 2021, the Company announced that its board of directors (the “Board”) had approved a new stock repurchase program. Under the stock repurchase program, the Company is authorized to repurchase up to $6.0 million of its outstanding shares of common stock from time to time, over a six month period. The number of shares to be repurchased and the timing of the repurchases, if any, will depend on a number of factors, including, but not limited to, price, trading volume and general market conditions, along with the Company’s working capital requirements and general business conditions. The Board will re-evaluate the program from time to time, and may authorize adjustments to its terms.

 

The Company did not repurchase any shares of common stock during the three and nine months ended September 30, 2021.

 

The 2010 Directors’ Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Directors’ Equity Compensation Plan (the “Amended 2010 Directors’ Plan”) at the 2021 Annual Meeting of Stockholders of the Company (the “2021 Annual Meeting”). The Amended 2010 Directors’ Plan authorizes the issuance of up to 775,000 shares of common stock.

 

During the three and nine months ended September 30, 2021, stock options to purchase an aggregate of 224,874 shares of our common stock were granted to our directors in lieu of director fees under the 2010 Directors’ Plan with a strike price of $5.28 per share under the Amended 2010 Directors’ Plan. During the three and nine months ended September 30, 2020, common stock and stock options to purchase an aggregate of 212,605 and 230,660 shares of common stock, respectively, were granted to our directors under the 2010 Directors’ Plan in lieu of director fees.

 

23
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

At September 30, 2021, there were 424,874 stock options outstanding and there were 3,252 shares of common stock available to be issued pursuant to the terms of the Amended 2010 Directors’ Plan. No stock options were exercised during the three and nine months ended September 30, 2021.

 

The 2010 Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Equity Compensation Plan (the “Amended 2010 Plan”) at the 2021 Annual Meetings. The Amended 2010 Plan authorizes the issuance of up to 4,900,000 shares of common stock.

 

There were 975,000 stock options granted under the 2010 Plan during the nine months ended September 30, 2021 for a total fair value of $2,891,000.

 

There were 250,000 stock options granted under the 2010 Plan during the three and nine months ended September 30, 2020 for a total fair value of $269,000.

 

As of September 30, 2021, there were 1,884,449 stock options outstanding and there were 184,657 shares of common stock available to be issued pursuant to the terms of the Amended 2010 Plan. We will recognize an aggregate of approximately $1,373,000 of remaining share-based compensation expense related to outstanding stock options over a weighted average period of 2.8 years.

 

The 2018 Stock Incentive Plan

 

On April 12, 2018, our stockholders approved the 2018 Stock Incentive Plan (the “2018 Stock Plan”). At April 12, 2018, all 2.3 million shares available for issuance under the 2018 Stock Plan have been granted in the form of a stock option with an initial exercise price of $3.00 per share, which is exercisable in 36 monthly installments, to Ted Karkus (the “CEO Option”), our Chief Executive Officer. No portion of the CEO Option was exercised during the nine months ended September 30, 2021 and 2020.

 

The 2018 Stock Plan requires certain proportionate adjustments to be made to stock options granted upon the occurrence of certain events, including a special distribution (whether in the form of cash, shares, other securities, or other property) in order to maintain parity. Accordingly, the Compensation Committee of the board of directors, as required by the terms of the 2018 Stock Plan, adjusted the terms of the CEO Option, such that the exercise price of the CEO Option was reduced from $3.00 per share to $2.00 per share, effective as of September 5, 2018, the date a special $1.00 special cash dividend was paid to the Company’s stockholders. The exercise price of the CEO Option was further reduced from $2.00 to $1.75 per share, effective as of January 24, 2019, the date a $0.25 special cash dividend was paid to the Company’s stockholders. The exercise price of the CEO Option was further reduced from $1.75 to $1.50 per share, effective as of December 12, 2019, the date another $0.25 special cash dividend was paid to Company’s stockholders. The exercise price of the CEO Option was further reduced from $1.50 to $1.20 per share, effective as of June 3, 2021, the date another $0.30 special cash dividend was paid to Company’s stockholders.

 

Inducement Option Award

 

As part of Nebula Acquisition, the Company issued a non-qualified stock option to Kamal Obbad, the Chief Executive Officer of Nebula, as an inducement to his employment with the Company (the “Inducement Award”). The Inducement Award entitles Mr. Obbad to purchase up to 250,000 shares of the Company’s common stock at an exercise price of $7.67 per share, the closing price of the Company’s common stock on the closing date of the Nebula Acquisition. The Inducement Award was granted to Mr. Obbad on the closing date of the Nebula Acquisition. The Inducement Award vested 25% on the grant date and will vest 25% per year for the next three years subject to Mr. Obbad’s continued employment with the Company. The Inducement Award expires on the seventh anniversary of the grant date. Any portion of the Inducement Award that does not vest and become exercisable will be forfeited for no consideration. The grant date fair value of the Inducement Award was approximately $1,128,000.

 

For the three months ended September 30, 2021 and 2020, we charged to operations an aggregate of $863,000 and $267,000, respectively, for share-based compensation expense associated with the vesting of outstanding equity awards under the Amended 2010 Directors’ Plan, the Amended 2010 Plan, the 2018 Stock Plan and the Inducement Award. For the nine months ended September 30, 2021 and 2020, we charged to operations an aggregate of $2,175,000 and $663,000, respectively, for share-based compensation expense associated with the vesting of outstanding equity awards under the 2010 Directors’ Plan, the 2010 Plan, the 2018 Stock Plan and the Inducement Award..

 

24
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table summarizes stock options activity during the nine months ended September 30, 2021 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Award (in thousands, except per share data): 

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
   Total Intrinsic Value 
Outstanding as of January 1, 2021   3,795   $2.21    3.4   $26,441 
Granted   1,450    7.48    5.0    - 
Forfeited   (398)   8.32    -    - 
Outstanding as of September 30, 2021   4,847   $3.15    3.5   $12,559 
Options vested and exercisable   3,829   $2.46    2.7   $12,012 

 

The aggregate weighted average grant date fair value for the options granted during the three and nine months ended September 30, 2021 was approximately $2.7 and $4.7 million, respectively. The following table summarizes weighted average assumptions used in determining the fair value of the options at the date of grant for the nine months ended September 30, 2021:

 

   For the nine months ended 
   September 30, 2021 
Exercise price  $7.48 
Expected term (years)   3.9 
Expected stock price volatility   80%
Risk-free rate of interest   0.7%
Expected dividend yield (per share)   0%

 

Stock Warrants Issued

 

During the nine months ended September 30, 2021, we issued warrants to purchase 275,000 shares of common stock in a registered direct offering and warrants to purchase 180,000 shares of common stock to the underwriters in a public offering.

 

During the nine months ended September 30, 2021, we issued 5,986 shares of common stock through a cashless exercise of 50,000 common stock warrants.

 

The following table summarizes warrant activities during the nine months ended September 30, 2021 (in thousands, except per share data).

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of January 1, 2021   450   $3.22    2.7 
Warrants granted   455    12.83    3.0 
Cashless exercise   (50)   5.00    - 
Outstanding as of September 30, 2021   855   $8.23    2.1 
Warrants vested and exercisable   805   $8.56    2.1 

 

25
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table summarizes weighted average assumptions used in determining the fair value of the warrants at the date of grant for the nine months ended September 30, 2021:

 

   For the nine months ended 
   September 30, 2021 
Exercise price  $12.83 
Expected term (years)   3.0 
Expected stock price volatility   81%
Risk-free rate of interest   0.2%
Expected dividend yield (per share)   0%

 

As of September 30, 2021, there were warrants to purchase 855,000 shares of our common stock outstanding and we recognized $59,000 and $252,000 of share-based compensation expense during the three and nine months ended September 30, 2021, respectively. We recognized $16,000 in share-based compensation expense during the three and nine months ended September 30, 2020.

 

Note 8 - Defined Contribution Plans

 

We maintain the ProPhase Labs, Inc. 401(k) Savings and Retirement Plan, a defined contribution plan for our employees. Our contributions to the plan are based on the amount of the employee plan contributions and compensation. Our contributions to the plan in the three and nine months ended September 30, 2021 were $34,000 and $69,000, respectively. Our contributions to the plan in the three and nine months ended September 30, 2020 were $19,000 and $52,000, respectively.

 

Note 9 - Other Current Liabilities

 

The following table sets forth the components of other current liabilities at September 30, 2021 and December 31, 2020, respectively (in thousands):

 

   September 30,   December 31, 
   2021   2020 
Accrued commissions  $1,054   $461 
Accrued payroll   56    464 
Accrued expenses   251    304 
Accrued returns   331    291 
Accrued income tax payable   -    8 
Accrued benefits and vacation   49    34 
Deferred revenue   -    169 
Total other current liabilities  $1,741   $1,731 

 

26
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 10- Commitments and Contingencies

 

Manufacturing Agreement

 

The Company and its wholly-owned subsidiary, PMI, entered into a manufacturing agreement (the “Manufacturing Agreement”) with Mylan Consumer Healthcare Inc. (formerly known as Meda Consumer Healthcare Inc.) (“MCH”) and Mylan Inc. (together with MCH, “Mylan”) in connection with the asset purchase agreement we entered into with Mylan in 2017. Pursuant to the terms of the Manufacturing Agreement, Mylan (or an affiliate or designee) purchased the inventory of the Company’s Cold-EEZE® brand and product line, and PMI agreed to manufacture certain products for Mylan, as described in the Manufacturing Agreement, at prices that reflect current market conditions for such products and include an agreed upon mark-up on our costs. On May 1, 2021, the Manufacturing Agreement was assigned by Mylan to Nurya Brands, Inc. (“Nurya”) in connection with Nurya’s acquisitions of certain assets from Mylan, including the Cold-EEZE® brand and product line. Unless terminated sooner by the parties, the Manufacturing Agreement will remain in effect until March 29, 2022. Thereafter, the Manufacturing Agreement may be renewed by Nurya for up to five successive one-year periods by providing notice of its intent to renew not less than 90 days prior to the expiration of the then-current term.

 

Litigation

 

In the normal course of our business, we may be named as a defendant in legal proceedings. It is our policy to vigorously defend litigation or to enter into a reasonable settlements where management deems it appropriate.

 

Note 11 – Leases

 

On October 23, 2020, we completed the acquisition of CPM, which included the acquisition of a 4,000 square foot CLIA accredited laboratory located in Old Bridge, New Jersey, which was owned by CPM (which is now known as ProPhase Diagnostics NJ, Inc.). The lease is for a term of 24 months with a monthly base lease payment of $5,950.

 

On December 8, 2020, we entered into a Lease Agreement (the “New York Lease”) pursuant to which the Company has agreed to lease certain premises located on the second floor (the “Leased Premises”) of 711 Stewart Avenue, Garden City, New York (the “Building”). The Leased Premises serve as the Company’s second laboratory location, offering a wide range of laboratory testing services for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel Molecular tests.

 

The New York Lease was effective as of December 8, 2020 and commenced in December 2020 when the facility was made available to us by the landlord. The initial term of the New York Lease is 10 years and seven months (the “Initial Term”), unless sooner terminated as provided in the New York Lease. We may extend the term of the New York Lease for one additional option period of five years. We have the option to terminate the New York Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee.

 

For the first year of the New York Lease, the base rent is $56,963 per month (subject to a seven month abatement period), with a gradual rental rate increase of 2.75% for each 12 month period, culminating in a monthly base rent of $74,716 during the final months of the Initial Term. In addition to the monthly base rent, we are responsible for our proportionate share of real estate tax escalations in accordance with the terms of the New York Lease.

 

We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the New York Lease. We also have a right of first offer to purchase the Building during the term of the New York Lease.

 

At September 30, 2021, we had operating lease liabilities for the New York and New Jersey leases of approximately $4.9 million and right of use assets of approximately $4.5 million, which were included in the condensed consolidated balance sheet.

 

27
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following summarizes quantitative information about our operating leases (amounts in thousands): 

 

  

For the Nine Months Ended

September 30, 2021

 
Operating leases     
Operating lease cost  $611 
Variable lease cost   - 
Operating lease expense   611 
Short-term lease rent expense   - 
Total rent expense  $611 

 

   For the Nine Months Ended September 30, 2021 
Operating cash flows used in operating leases  $(168)
Right-of-use assets obtained in exchange for operating lease liabilities  $- 
Weighted-average remaining lease term – operating leases (in years)   9.7 
Weighted-average discount rate – operating leases   10.00%

 

Maturities of the Company’s operating leases, excluding short-term leases, are as follows (amounts in thousands):

 

      
Remaing Months Ended December 31, 2021  $190 
Year Ended December 31, 2022   774 
Year Ended December 31, 2023   738 
Year Ended December 31, 2024   747 
Year Ended December 31, 2025   768 
Thereafter   4,659 
Total   7,876 
Less present value discount   (2,948)
Operating lease liabilities  $4,928 

 

Note 12- Significant Customers

 

Revenue for the three months ended September 30, 2021 and 2020 was $9.5 million and $3.8 million, respectively. Three diagnostic services clients accounted for 19.6%, 12.0% and 10.4% of our revenue for the three months ended September 30, 2021. No contract manufacturing customer accounted for a significant portion of our revenue for the three months ended September 30, 2021. Two third-party contract manufacturing customers accounted for 57.6% and 15.9%, respectively, of our revenue from continuing operations for the three months ended September 30, 2020. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.

 

Revenue for the nine months ended September 30, 2021 and 2020 was $33.9 million and $9.4 million, respectively. Two diagnostic services clients accounted for 28.4% and 20.7%, respectively, of our revenue for the nine months ended September 30, 2021. Two third-party contract manufacturing customers accounted for 56.2% and 16.6%, respectively, of our revenue for the nine months ended September 30, 2020. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.

 

Five diagnostic services clients generated 19.5%, 19.3%, 12.0%, 11.7% and 11.6% of our total reimbursement receivable balances from government agencies and healthcare issuers at September 30, 2021. Three of our customers represented 36%, 20% and 13% of our total trade receivable balances at December 31, 2020.

 

28
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 13 - Earnings (Loss) Per Share

 

Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.

 

For the three and nine months ended September 30, 2021, dilutive loss per share were the same as basic loss per share due to the exclusion of Common Stock in the form of stock options (“Common Stock Equivalents”), which in a net loss position would have an anti-dilutive effect on loss per share. The potentially anti-dilutive effect of stock options, warrants, and convertible debt for the three and nine months ended September 30, 2021 was 2,929,000 and 3,029,000 shares, respectively.

 

For the three and nine months ended September 30, 2020, dilutive loss per share were the same as basic earnings per share due to the exclusion of Common Stock Equivalents. For the three and nine months ended September 30, 2020, there were 4,932,000 potentially dilutive Common Stock Equivalents that were excluded from the loss per share computation as a consequence of their anti-dilutive effect which in a net loss position would have an anti-dilutive effect on loss per share.

 

Note 14 - Secured Promissory Note Receivable and Consulting Agreement

 

Consulting Agreement

 

On September 25, 2020, we entered into a consulting agreement (the “Consulting Agreement”) with a company acting as a consultant (the “Consultant”). The Consulting Agreement was to be effective through September 1, 2022; provided, however, that we could terminate this agreement at any time on five days’ prior written notice.

 

The Consultant’s duties were to include, among other things, (i) identifying and introducing us to new opportunities in the medical technology and testing fields, (ii) assisting and advising us in acquiring one or more CLIA certified labs suitable for COVID-19 and other testing (“Test Labs”); (iii) assisting us in equipping and staffing any Test Labs acquired by us; (iv) advising and assisting in the operation of such Test Labs; (v) validating and obtaining certification of such Test Labs; and (vi) assisting us in obtaining a flow of business, orders and revenues from multiple sources in the industry, including but not limited to at least one significant, nation-wide manufacturer and distributor of COVID-19 saliva sample collection test kits (“COVID-19 Test Kits”).

 

All compensation earned by the Consultant would first be applied to the acceleration and prepayment of all sums due to us, including but not limited to sums due pursuant to the Amended and Restated Promissory Note (“Secured Note”) described below.

 

Promissory Note and Security Agreement

 

On September 25, 2020 (the “Restatement Effective Date”), we entered into the Secured Note with the Consultant, pursuant to which we loaned $3.0 million to the Consultant (inclusive of $1.0 million in the aggregate previously loaned to the Consultant, as described below).

 

The Secured Note amended and restated in its entirety (i) that certain Promissory Note and Security Agreement, dated July 21, 2020 (the “Original July 21 Note”), pursuant to which we loaned $750,000 to the Consultant and (ii) that certain Promissory Note and Security Agreement, dated July 29, 2020 (the “Original July 29 Note”, and, together with the Original July 21 Note, the “Original Notes”), pursuant to which we loaned $250,000 to the Consultant.

 

29
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The Secured Note bears interest at a rate of 15% per annum from and including the Restatement Effective Date until the principal amount is repaid in full plus any Principal Increases (as defined below) together with any accrued interest that has not been capitalized; provided, however, that upon the occurrence and during an Event of Default (as defined in the Secured Note), the interest rate payable under the Secured Note will automatically increase to 9% above the rate of interest then applicable to the Secured Note.

 

Interest under the Secured Note will be payable monthly in arrears on the first day of each month for the prior monthly period, as well as at maturity (whether upon demand, by acceleration or otherwise) (each such date, a “Payment Date”); provided, however, that prior to September 1, 2021, interest will be paid and capitalized in kind by increasing the principal amount of the Secured Note (any such increase, a “Principal Increase”) by an amount equal to the interest accrued on the principal amount (as increased by the Principal Increases) during the prior month. On each Payment Date commencing after September 1, 2021, in addition to payments of interest described in the preceding sentence, the Consultant will also make payments on the principal amount of the loan equal to 1/36 of the then outstanding principal amount. The amount of the monthly payments will be equal to the amount required to amortize fully the outstanding principal amount of the loan, together with interest, over a period of 36 months.

 

The entire remaining unpaid principal amount of the Secured Note, together with all accrued and unpaid interest thereon and all other amounts payable under the Secured Note, will be due and payable, if not sooner paid, on September 30, 2022 or an earlier date as a result of a maturity, whether by acceleration or otherwise. The Secured Note may be prepaid in full or in part at any time without penalty or premium.

 

The Secured Note contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the Secured Note may be accelerated.

 

The Secured Note contains customary representation and warranties and certain restrictive covenants which, among other things, restrict the Consultant’s ability to (i) sell, transfer, finance, lease, license, or dispose of all or substantially all of its property or assets, liquidate, windup, or dissolve, (ii) acquire all or substantially all of the property or assets of, or the equity interests in, any other person, (iii) participate in any merger, consolidation, share exchange, division, conversion, reclassification, or other absorption or reorganization, (iv) except for those existing as of the Restatement Effective Date, create, incur, assume, permit, or suffer to exist any pledges, liens, security interests, and other encumbrances of its property or assets, whether now owned or hereafter owned or acquired, and (v) create, incur or permit to exist any debt that is senior to, or pari passu with the Secured Note.

 

In order to secure the Consultant’s obligations under the Secured Note, the Consultant granted to the Company a continuing security interest in certain property and assets.

 

Total interest income recorded in the three and nine months ended September 30, 2021 was $230,000 and $531,000, respectively.

 

30
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Amendment and Termination Agreement

 

On January 14, 2021, we entered into an Amendment and Termination Agreement (the “Termination Agreement”) with the Consultant pursuant to which the parties amended the Secured Note and terminated the Consulting Agreement. Pursuant to the terms of the Termination Agreement, the Company loaned an additional $1 million to the Consultant in consideration for the termination of the Consulting Agreement and termination of the Company’s obligation to pay the Consultant additional consulting fees beyond the $250,000 already earned by the Consultant under the Consulting Agreement. As a result, the initial principal amount due under the Secured Note was increased from $2.75 million to $3.75 million plus all accrued and unpaid interest arising under the Secured Note through and including January 14, 2021.

 

Under the terms of the Termination Agreement, the Consultant will sell and process its viral test by RT-PCR (together with other viral and other types of tests). Until the Secured Note is paid in full, each COVID-19 Test Kit sold or processed from and after January 14, 2021, and for which payment of at least the specified amount as defined for the test, is received by the Consultant, the Consultant will pay us a specified amount (the “Test Fee”). The total payments will not exceed the aggregate amounts due under the Secured Note and shall be applied first to interest and other amounts due under the Secured Note and then to the then-current outstanding principal. Test Fees will be due and payable on the 10th business day after the end of each month commencing in February 2021, and until the Secured Note is paid in full. We received the first payment in the amount of $95,000 with respect to the Test Fees from January 15 through February 2021. On June 25, 2021, we were issued 1,260,619 common shares of the Consultant with a fair value of $315,000 as an interest payment under the Secured Note in lieu of Test Fees from March through June 2021.

 

Effective September 1, 2021, in addition to the payment of the Test Fees described above, the Consultant also is also required to make payments to us in an amount equal to the greater of (x) the Test Fee, or (y) 1/36th of the then outstanding principal amount together with interest thereon and interest accruing on the Secured Note, in accordance with the Secured Note. Accordingly, effective September 1, 2021, the minimum number of monthly payments due and payable to us is equal to the amount required to amortize fully the outstanding principal amount of the Secured Note, together with interest over a period of 36 months with level monthly payments.

 

The Secured Note is currently in default for nonpayment with accrued interest of $132,000 outstanding as of September 30, 2021.

 

Note 15 - Segment Information

 

The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO as CODM assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.

 

31
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table is a summary of segment information for three and nine months ended September 30, 2021 and 2020 (amounts in thousands): 

 

   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Net revenues                    
Diagnostic services  $7,142   $-   $27,416   $- 
Consumer products   2,330    3,840    6,469    9,351 
Consolidated net revenue   9,472    3,840    33,885    9,351 
Cost of revenue                    
Diagnostic services   4,009    -    11,833    - 
Consumer products   1,486    2,798    4,682    6,615 
Consolidated cost of revenue   5,495    2,798    16,515    6,615 
Depreciation and amortization expense                    
Diagnostic services   401    -    1,138    - 
Consumer products   -    3    6    13 
Total Depreciation and amortization expense   401    3    1,144    13 
Operating and other expenses   13,020    1,608    20,542    4,031 
Income (loss) from continuing operations, before income taxes                    
Diagnostic services   (1,145)   -    2,859    - 
Consumer products   (958)   1,039    (453)   2,723 
Unallocated corporate   (1,875)   (1,608)   (6,722)   (4,031)
Total loss from continuing operations, before income taxes   (3,978)   (569)   (4,316)   (1,308)
Income from discontinued operations, before income taxes   -    161    -    161 
                     
Net loss  $(3,978)  $(408)  $(4,316)  $(1,147)

 

The following table is a summary of segment balance sheets information as of September 30, 2021 and December 31, 2020 (in thousands):

 

   September 30,   December 31, 
   2021   2020 
         
ASSETS          
Diagnostic services  $28,738   $13,410 
Consumer products   20,986    6,261 
Unallocated corporate   22,906    11,734 
Total assets  $72,630   $31,405 

 

 

Note 16 – Subsequent Event

 

Pursuant to the stock repurchase program on September 8, 2021 (see Note 7), as of November 10, 2021, we have repurchased 140,769 shares for an aggregate amount of $791,000, including commissions.

 

32
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis should be read in conjunction with our interim unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q (“Quarterly Report”) and the audited condensed financial statements and notes thereto as of and for the year ended December 31, 2020 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2021 (the “2020 Annual Report”). As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” or “ProPhase” refer to ProPhase Labs, Inc. and its subsidiaries, unless the context otherwise requires.

 

Forward-Looking Statements

 

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements relate to future events or our future financial performance. Forward-looking statements typically are identified by use of terms such as “anticipate”, “believe”, “plan”, “expect”, “intend”, “may”, “will”, “should”, “estimate”, “predict”, “potential”, “continue” and similar words although some forward-looking statements are expressed differently. This Quarterly Report may also contain forward-looking statements attributable to third parties relating to their estimates regarding the growth of our markets.

 

You are cautioned that forward-looking statements are not guarantees of performance and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, achievements or prospects to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. Many of these factors are beyond our ability to predict.

 

Such risks and uncertainties include, but are not limited to:

 

  Our ability to generate sufficient profits from Respiratory Pathogen Panel (“RPP”) Molecular tests if and when demand for COVID-19 testing decreases or becomes no longer necessary;
     
  Our dependence on our largest manufacturing customers;
     
  Our ability to successfully offer, perform and generate revenues from our new diagnostic and personal genomics businesses;
     
  Our ability to secure additional capital, when needed to support our diagnostic services business, personal genomics business and product development and commercialization programs;
     
  Potential disruptions to our supply chain or increases to the price of or adulteration of key raw materials or supplies;
     
  Potential disruptions in our ability to manufacture our products and those of others;
     
  Seasonal fluctuations in demand for the products and services we provide;
     
  Our ability to successfully develop and commercialize our existing products and any new products;
     
  Our ability to compete effectively, including our ability to maintain and increase our markets and/or market share in the markets in which we do business;
     
  Our ability to attract, retain and motivate our key employees;
     
  Our ability to protect our proprietary rights;
     
  Our ability to comply with regulatory requirements applicable to our businesses; and
     
  The complexity of billing for, and collecting revenue for, testing services;
     
  Our dependence on third parties to provide services critical to our lab diagnostic services business;

 

33
 

 

Given the risks and uncertainties surrounding forward-looking statements, you should not place undue reliance on these statements. You should also consider carefully the statements we make under other sections of this Quarterly Report and in our 2020 Annual Report, as well as in other documents we file from time to time with the SEC that address additional risks that could cause our actual results to differ from those set forth in any forward-looking statements. Our forward-looking statements speak only as the date of this Quarterly Report. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

 

General

 

We are a diversified biotech and genomics company with deep experience with over-the-counter (“OTC”) consumer healthcare products and dietary supplements. We conduct our operations through two operating segments; diagnostic services and consumer products. Until late fiscal year 2020, we were engaged primarily in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. This includes the development and marketing of dietary supplements under the TK Supplements® brand. However, commencing in December 2020, we also began offering COVID- 19 and other RPP Molecular tests through our new diagnostic service business and in August 2021 we began offering personal genomics products and services.

 

Our wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label developer of a broad range of non- GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.

 

Our wholly-owned subsidiary, ProPhase Diagnostics, Inc., (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers a variety of medical tests, including COVID-19 and RPG Molecular tests. On October 23, 2020, we completed the acquisition of all of the issued and outstanding shares of capital stock of Confucius Plaza Medical Laboratory Corp. (“CPM”), which operates a 4,000 square foot Clinical Laboratory Improvement Amendments (“CLIA”) accredited laboratory located in Old Bridge, New Jersey for approximately $2.5 million. As part of the acquisition of CPM in October 2020, we entered into a new business line, diagnostic services. In December 2020, we expanded our diagnostic service business with the signing of a lease and the recent build out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in February 2021.

 

On August 10, 2021, we acquired Nebula Genomics, Inc., a privately owned personal genomics company, through our new wholly-owned subsidiary, ProPhase Precision Medicine, Inc. We offer whole genome sequencing and related services through this new subsidiary.

 

Our diagnostic service business is influenced by the level of demand for COVID-19, the price we are able to receive for performing our testing services, and the length of time for which that demand persists, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.

 

Our consumer sales are influenced by and subject to (i) the timing of acceptance of our TK Supplements® consumer products in the marketplace, and (ii) fluctuations in the timing of purchase and the ultimate level of demand for the OTC healthcare and cold remedy products that we manufacture for others, which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period from September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net sales from our contract manufacturing of OTC healthcare and cold remedy products. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.

 

Our personal genomics business is influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.

 

While our revenues increased for the nine months ended September 30, 2021 as a result of revenues from our new diagnostic services business, we have made and will continue to make substantial investments to secure the necessary equipment, supplies and personnel to provide these testing services. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will continue to be successful and the revenue and operating profits from such business will increase from or maintain their current level.

 

In addition, we continue to actively pursue acquisition opportunities for other companies, technologies and products within and outside the consumer products industry.

 

34
 

 

Financial Condition and Results of Operations Results for the Three Months Ended September 30, 2021 as Compared to the Three Months Ended September 30, 2020

 

For the three months ended September 30, 2021, net revenue was $9.5 million as compared to $3.8 million for the three months ended September 30, 2020. We recognized higher net revenue for the three months ended September 30, 2021, primarily as a result of an increase of $7.1 million in revenue related to our new diagnostic services business, which was offset by a decrease of $2.5 million in customer orders from our consumer products business as a result of the demand and inventory levels of third party contract manufacturing customers.

 

Cost of revenues for the three months ended September 30, 2021 was $5.5 million as compared to $2.8 million for the three months ended September 30, 2020. Cost of revenues related to consumer products for the three months ended September 30, 2021 was $1.5 million as compared to $2.8 million for the three months ended September 30, 2020. For the three months ended September 30, 2021 and 2020, we realized a gross margin of 42.0% and 27.1%, respectively. The increase in gross margin from the prior period is principally due to increased margins generally associated with our new diagnostic services business. Gross margins are generally influenced by fluctuations in quarter-to-quarter diagnostic testing and OTC production volume, fixed operating costs and related overhead absorption, raw ingredient costs, testing supplies and labor costs and inventory mark to market write-downs.

 

Diagnostic expenses for the three months ended September 30, 2021 were $1.5 million compared to no diagnostics expenses for the three months ended September 30, 2020. The $1.5 million in diagnostic expenses for the three months ended September 30, 2021 was comprised of network providers expenses associated with our new diagnostic services business.

 

Sales, general and administration expenses for the three months ended September 30, 2021 were $5.9 million as compared to $1.6 million for the three months ended September 30, 2020. The increase of $4.3 million in general and administration expenses was principally related to growth in personnel expenses and professional fees associated with our new diagnostic services business.

 

Research and development costs for the three months ended September 30, 2021 were $208,000 as compared to $57,000 for the three months ended September 30, 2020. The increase in research and development costs for the three months ended September 30, 2021 as compared to the three months ended September 30, 2020 was principally due to additional professional fees associated with our new diagnostics services business.

 

Interest and other income for the three months ended September 30, 2021 and 2020 was $230,000 and $39,000, respectively. The increase in interest income for the three months ended September 30, 2021 as compared to the three months ended September 30, 2020 was principally due to the issuance of the Secured Note receivable that bears interest at a rate of 15% per annum.

 

Interest expense for the three months ended September 30, 2021 was $296,000 compared to $41,000 for the three months ended September 30, 2020. The increase in interest expense for the three months ended September 30, 2021 as compared to the three months ended September 30, 2020 was principally due the new unsecured convertible September 2020 Notes payable that accrue interest at a rate of 10% per year.

 

Loss from change in fair value of investment securities for the three months ended September 30, 2021 was $265,000, which was due to the decrease of stock price as of September 30, 2021 compared to stock price as of June 30, 2021.

 

As a consequence of the effects of the above, net loss from continuing operations for the three months ended September 30, 2021 was $4.0 million, or ($0.26) per share, as compared to the net loss from continuing operations for the three months ended September 30, 2020 of $569,000, or ($0.05) per share. Net income from discontinued operations was $161,000, or $0.01 per share, for the three months ended September 30, 2020.

 

35
 

 

Financial Condition and Results of Operations Results for the Nine Months Ended September 30, 2021 as Compared to the Nine Months Ended September 30, 2020

 

For the nine months ended September 30, 2021, net revenue was $33.9 million as compared to $9.4 million for the nine months ended September 30, 2020. We recognized higher net revenue for the nine months ended September 30, 2021, primarily as a result of our receipt of $27.4 million in revenue from our new diagnostic services business, which was offset by a decrease of $4.8 million in customer orders from our consumer products business as a result of the timing and demand of third party contract manufacturing customers.

 

Cost of revenues for the nine months ended September 30, 2021 was $16.5 million as compared to $6.6 million for the nine months ended September 30, 2020. Cost of revenues related to consumer products for the nine months ended September 30, 2021 was $4.7 million as compared to $6.6 million for the nine months ended September 30, 2020. For the nine months ended September 30, 2021 and 2020, we realized a gross margin of 51.3% and 29.3%, respectively. The increase in gross margin from the prior period is principally due to increased margins generally associated with our new diagnostic services business. Gross margins are generally influenced by fluctuations in quarter-to-quarter diagnostic testing and OTC production volume, fixed operating costs and related overhead absorption, raw ingredient costs, testing supplies and labor costs and inventory mark to market write-downs.

 

Diagnostic expenses for the nine months ended September 30, 2021 were $6.1 million compared to no diagnostics expenses for the nine months ended September 30, 2020. The $6.1 million in diagnostic expenses for the nine months ended September 30, 2021 was comprised of network providers expenses associated with our new diagnostic services business.

 

Sales, general and administration expenses for the nine months ended September 30, 2021 were $14.7 million as compared to $3.9 million for the nine months ended September 30, 2020. The increase of $10.8 million in general and administration expenses was principally related to growth in personnel expenses and professional fees associated with our new diagnostic services business.

 

Research and development costs for the nine months ended September 30, 2021 were $416,000 as compared to $181,000 for the nine months ended September 30, 2020. The increase in research and development costs for the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020 was principally due to additional professional fees associated with our new diagnostics services business.

 

Interest and other income for the nine months ended September 30, 2021 and 2020 was $531,000 and $53,000, respectively. The increase in interest income for the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020 was principally due to the issuance of the Secured Note receivable that bears interest at a rate of 15% per annum.

 

Interest expense for the nine months ended September 30, 2021 was $870,000 compared $41,000 for the nine months ended September 30, 2020. The increase in interest expense for the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020 was principally due the new unsecured convertible September 2020 Notes payable that accrue interest at a rate of 10% per year.

 

Loss from change in fair value of investment securities for the nine months ended September 30, 2021 was $101,000, which was due to the decrease of stock price as of September 30, 2021 compared to stock price on the acquired date on June 25, 2021.

 

As a consequence of the effects of the above, net loss from continuing operations for the nine months ended September 30, 2021 was $4.3 million, or ($0.29) per share, as compared to the net loss from continuing operations for the nine months ended September 30, 2020 of $1.3 million, or ($0.11) per share. Net income from discontinued operations was $161,000, or $0.01 per share, for the nine months ended September 30, 2020.

 

Non-GAAP Financial Measure and Reconciliation

 

In an effort to provide investors with additional information regarding our results of operations as determined by accounting principles generally accepted in the United States of America (“GAAP”), we disclose certain non-GAAP financial measures. The primary non-GAAP financial measure we disclose are EBITDA and Adjusted EBITDA.

 

We define EBITDA as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, other non-cash items, and other unusual or non-recurring charges (as described in the table below).

 

36
 

 

We use EBITDA and Adjusted EBITDA internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s ongoing economic performance. We have chosen to provide this information to investors to enable them to perform more meaningful comparisons of operating results.

 

The following table sets forth the reconciliations of EBITDA and Adjusted EBITDA excluding other costs to the most comparable GAAP financial measures (in thousands):

 

   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
GAAP net loss (1)  $(3,978)  $(408)  $(4,316)  $(1,147)
Interest, net   65    2    339    (12)
Depreciation and amortization   926    3    2,044    13 
EBITDA   (2,987)   (403)   (1,933)   (1,146)
Acquisition costs (2)   674    -    674    - 
Share-based compensation expense   934    283    2,438    679 
Non-cash rent expense (3)   72    -    443    - 
Adjusted EBITDA  $(1,307)  $(120)  $1,622   $(467)

 

(1) We believe that net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most directly comparable to EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA measure the Company’s operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may vary from others in the industry. EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP.

 

(2) Transaction cost related to the Nebula acquisition.

 

(3) The non-cash portion of rent, which reflects the extent to which our GAAP rent expense recognized exceeds (or is less than) our cash rent payments. For newer leases, our rent expense recognized typically exceeds our cash rent payments, while for more mature leases, rent expense recognized is typically less than our cash rent payments.

 

Liquidity and Capital Resources

 

Our aggregate cash and cash equivalents, restricted cash and marketable debt securities as of September 30, 2021 was $22.9 million as compared to $8.5 million at December 31, 2020. Our working capital was $34.0 million and $9.6 million as of September 30, 2021 and December 31, 2020, respectively. The increase of $14.4 million in our cash and cash equivalents, restricted cash and marketable debt securities balance for the nine months ended September 30, 2021 was principally due to our receipt of aggregate net proceeds of $40.6 million from the issuance of common stock and warrants in a registered direct offering and public offering, and $10.7 million from the sale of marketable debt securities, offset by (i) capital expenditures of $4.2 million, (ii) cash dividend payments of $4.5 million, (iii) issuance of a promissory note of $1.0 million, (iv) payment of $9.1 million related to business acquisition, and (v) cash used in operations of $9.0 million.

 

COVID-19

 

The COVID-19 pandemic has not had a material adverse impact on our business to date. We experienced higher than normal net revenue for the last nine months ended September 30, 2021, primarily as a result of revenue from our new diagnostic services business, which offers COVID-19 testing.

 

There are still numerous uncertainties associated with the COVID-19 pandemic, including the efficacy of the vaccines that have been developed to treat the virus and their ability to protect against new strains of the virus, people’s willingness to receive a vaccine, possible resurgences of the coronavirus and/or new strains of the virus, the extent and duration of protective and preventative measures that may be adopted by local, state and/or the federal government in the future as a result of future outbreaks, including business closures, the ongoing impact of COVID-19 on the U.S. and world economy and consumer confidence, and various other uncertainties.

 

The COVID-19 pandemic has had a negative impact on the global capital markets and economies worldwide and could ultimately have a material adverse impact on our ability to raise capital needed to develop and commercialize products.

 

37
 

 

General

 

Management is not aware of any other trends, events or uncertainties that have had or are reasonably likely to have a material negative impact upon our (i) short-term or long-term liquidity, or (ii) net revenue or income from operations. Any challenge to our patent or trademark rights could have a material adverse effect on our future; however, we are not aware of any condition that would make such an event probable. Our business is generally subject to seasonal variations thereby impacting our liquidity and working capital during the course of our fiscal year.

 

During the nine months ended September, 2021, we used $9.0 million in cash from operations. To the extent that we do not generate sufficient cash from operations, our cash balances will decline. We may also use our cash to explore and/or acquire new product technologies, applications, product line extensions, new contract manufacturing applications and other new product opportunities. In the event that our available cash is insufficient to support such initiatives, we may need to incur indebtedness or issue common stock to finance our plans for growth. Volatility in the credit markets and the liquidity of major financial institutions, including as a result of the COVID-19 pandemic, may have an adverse impact on our ability to fund our business strategy through future borrowings, under either existing or newly created instruments in the public or private markets on terms that we believe to be reasonable, if at all.

 

Off-Balance Sheet Arrangements

 

It is not our usual business practice to enter into off-balance sheet arrangements such as guarantees on loans and financial commitments and retained interests in assets transferred to an unconsolidated entity for securitization purposes. We have no off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Impact of Inflation

 

We are subject to normal inflationary trends and anticipate that any increased costs would be passed on to our customers. Inflation has not had a material effect on our business.

 

Critical Accounting Policies and Estimates

 

The condensed consolidated financial statements are prepared in conformity with GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial statements and the judgments and assumptions used are consistent with those described under Part II, Item 7 of the 2020 Annual Report.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Like virtually all commercial enterprises, we can be exposed to the risk (“market risk”) that the cash flows to be received or paid relating to certain financial instruments could change as a result of changes in interest rate, exchange rates, commodity prices, equity prices and other market changes.

 

Our operations are not subject to risks of material foreign currency fluctuations, nor do we use derivative financial instruments in our investment practices. We place our marketable investments in instruments that meet high credit quality standards. We do not expect material losses with respect to our investment portfolio or excessive exposure to market risks associated with interest rates. The impact on our results of one percentage point change in short-term interest rates would not have a material impact on our future earnings, fair value, or cash flows related to investments in cash equivalents or interest-earning marketable securities.

 

38
 

 

Current economic conditions may cause a decline in business and consumer spending which could adversely affect our business and financial performance including the collection of accounts receivables, notes receivable, realization of inventory and recoverability of assets. In addition, our business and financial performance may be adversely affected by current and future economic conditions, including a reduction in the availability of credit, financial market volatility and recession.

 

Except for the broad effects of COVID-19 including its negative impact on the global economy and major financial markets, there have been no material changes to our market risk exposures since December 31, 2020.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2021. This evaluation was carried out under the supervision and with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer. Based upon that evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer concluded that our disclosure controls and procedures were effective as of September 30, 2021.

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed with or submitted to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control Over Financial Reporting

 

No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.

 

Part II. Other Information

 

Item 1. Legal Proceedings.

 

From time to time, we have been and may again become involved in legal proceedings arising in the ordinary course of business. We are not presently a party to any material litigation.

 

Item 1A. Risk Factors.

 

Except as described below, there have been no material changes to the risks described in Item 1A. Risk Factors of the 2020 Annual Report.

 

We have marked with an asterisk (*) those risk factors below that reflect a change from the risk factors included in our 2020 Annual Report and marked with a double asterisk (**) those risk factors below that are new and were not previously included in our 2020 Annual Report or subsequent periodic reports filed with the SEC.

 

Risks Related to Our Business 

 

*We have a history of losses and may not be able to achieve or sustain profitability. We have recently expanded into two new lines of business; there can be no assurance that these businesses will be successful

 

Since the sale of our Cold-EEZE™ business in March 2017, we have been actively exploring new product technologies, applications, product line extensions and other new product and business opportunities.  We have experienced net losses from continuing operations before income tax for our last two fiscal years.

 

In October 2020, we purchased our first CLIA licensed laboratory in Old Bridge, New Jersey, where we offer a variety of important medical tests, including, among others, COVID-19 diagnostic testing and Respiratory Pathogen Panel (RPP) Molecular tests. In December 2020, we expanded our diagnostic services to a second location in Garden City, New York. In August 2021, we acquired Nebula Genomics, Inc. (“Nebula”), a privately-owned personal genomics company. We intend to integrate Nebula’s whole genome sequencing services with the clinical diagnostic testing services already offered at our CLIA-certified molecular testing laboratories. We may in the future consider and pursue investments and acquisitions in other sectors and industries.

 

We have and will continue to incur significant expenses as we grow these two new businesses. In order for us to be profitable, we must generate sufficient revenue to cover our expenses. While we recognized net income from continuing operations before income tax for the first and third quarters of Fiscal 2021, we experienced a net loss in the second quarter of Fiscal 2021. There can be no assurance that our diagnostic services business or our personal genomics business will succeed or that we will be successful in initiating or acquiring any new lines of business in the future, or that any such new lines of business will achieve profitability.

 

As of September 30, 2021, we had working capital of approximately $34 million, which we believe is an acceptable and adequate level of working capital to support our business (including our two new business lines) for at least the next twelve months.

 

*We have a limited operating history in the diagnostic testing services business. There can be no assurance that we will be able to successfully offer, perform or generate revenues from our lab diagnostic services.

 

Despite our management’s extensive experience in the healthcare industry, we had no specific experience operating a diagnostic services business prior to entering this field in November 2020. We face substantial risks and uncertainties to which our diagnostic services business is subject. To address these risks and uncertainties, we must, among other things, successfully execute our business strategy, respond to competitive developments, and attract and retain qualified personnel. We cannot assure you that we will operate profitably or that our business strategy will be successful. As a result, our diagnostic services business may not succeed.

 

39
 

 

Our ability to generate revenues from COVID-19 and other RPP molecular testing, and our ability to generate profits from our diagnostic services business, will depend on a variety of factors, including:

 

  the level of demand for COVID-19 and other diagnostic testing, the price we are able to receive for performing our testing services, and the length of time for which that demand persists;
     
  the availability of COVID-19 testing from other laboratories;
     
  the period of time for which our laboratories are able to serve as authorized laboratories offering COVID-19 testing under various Emergency Use Authorizations;
     
  the ability of our laboratories to maintain status as authorized laboratories to perform COVID-19 and other diagnostic testing and related services and to respond to any changes in regulatory requirements;
     
  the potential for supply disruptions and our reliance on certain single-source suppliers;
     
  the potential for disruption in the delivery of patient samples to our laboratories;
     
  the capacity of our laboratories to satisfy both COVID-19 testing and other testing demands;
     
  the extent to which we choose to allocate limited laboratory capacity, supplies and other resources to areas of our business other than COVID-19 testing;
     
  the complexity of billing for, and collecting revenue for, our testing services;
     
  our ability to maintain laboratory operations during the COVID-19 pandemic and to perform the test accurately and punctually;
     
  our ability to expand and or diversity our diagnostic services and
     
  the ease of use of our ordering and reporting process.

 

In addition, the process of building and expanding our lab diagnostic service business may divert resources and distract management’s attention from other areas of our business that may be more profitable or strategic. If we are unable to successfully provide diagnostic services while continuing to operate our existing manufacturing and dietary supplements business, our results of operations, financial position and reputation may suffer.

 

**Prior to our acquisition of Nebula, we had no specific experience operating a personal genomics business. Our success will depend, in large part, on our ability to establish our presence in the personal genetics market, provide customers with a high level of service at a competitive price, achieve sufficient sales volume to realize economies of scale, and create innovative new features, products, and services to offer to our customers. Our failure to achieve any of these outcomes would adversely affect our business.

 

Prior to our acquisition of Nebula, we had no specific experience operating a personal genomics business. Our success will depend, in large part, on our ability to establish our presence in this market, provide customers with a high level of service at competitive prices, achieve sufficient sales volume to realize economies of scale, and create innovative new features, products and services to offer to our customers. If customers do not perceive our personal genomic reports to be reliable and of high quality, if we fail to introduce new and improved products and services, or if we introduce new products or services that are not favorably received by the market, we may not be able to attract or retain customers. The growth and expansion of our business and service offerings will place a continuous strain on our management, operational and financial resources. We will be required to manage multiple relationships with various strategic suppliers, customers and other third parties, including regulatory agencies. To effectively manage our growth, we must continue to implement and improve our operational, financial and management information systems and to expand, train and manage our employee base. In the event of further growth of our operations or in the number of our third-party relationships, our supply, systems, procedures or internal controls may not be adequate to support our operations and our management may not be able to manage any such growth effectively.

 

40
 

 

**If our estimates of the total addressable market for personal genomic services and the potential for market growth prove to be inaccurate, our business, financial condition, results of operations and prospects may be negatively affected.

 

Our estimates and forecasts for the personal genomic service market are based on a number of complex assumptions, internal and third-party estimates, and other business data, including assumptions and estimates relating to our ability to leverage our diagnostic testing facilities to generate revenue from personal genomic services. While we believe our assumptions and the data underlying our estimates are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and indicators. Consequently, our estimates of the total addressable market and our forecasts of market growth and future revenue from our products and services may prove to be incorrect. For example, if the annual total addressable market or the potential market growth for our products and services is smaller than we have estimated or if the key business metrics we utilize to forecast revenue are inaccurate, it may impair our sales growth and have an adverse impact on our business, financial condition, results of operations and prospects.

 

**Media reports have in the past reported on consumer privacy concerns and the use of genetic information accessed from other genetic databases by law enforcement and governmental agencies. These reports may decrease the overall consumer demand for personal genetic products and services, including ours.

 

Companies offering personal genomic services and products have received a high degree of media coverage in recent years. Unfavorable publicity or consumer perception of our product and service offerings, including consumer privacy concerns related to any of our existing or future collaborations, could adversely affect our reputation, resulting in a negative impact on the size of our customer base, the loyalty of our customers, the percentage of our customers that consent to participate in our future research programs, and our ability to attract new customers.

 

*We may require additional capital to support our growing diagnostic services business, personal genomics business, and product development and commercialization programs but additional funding may not be available to us on acceptable terms, or at all.

 

We may require additional capital to support our growing diagnostic services and personal genomics businesses and our consumer product development and commercialization programs. The amount of capital that may be needed to support our businesses will depend on many factors which may include, but are not limited to (i) the revenue we generate from our lab diagnostic services, personal genomics products and services, contract manufacturing services and dietary supplement sales, (ii) the expenses we incur in growing our lab diagnostic business and personal genomics business, and in marketing our manufacturing capabilities and dietary supplement line; (iii) the cost involved in applying for and obtaining FDA, international regulatory or other technical approvals, if required, and (iv) whether we elect to establish partnering or other strategic arrangements for the development, sales, manufacturing and marketing of our products and services.

 

Income from our diagnostic services business, personal genomics business, contract manufacturing business and TK Supplements® products line may not generate all the funds we need to support the growth of our diagnostic services and personal genomics businesses and future product development and commercialization. To the extent that we do not generate sufficient cash from operations, we may, in the short and long-term, seek to raise capital through the issuance of equity securities or through other financing sources. To the extent that we seek to raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may include financial and other covenants that could restrict our use of the proceeds from such financing or impose other business and financial restrictions on us. In addition, we may consider alternative approaches such as licensing, joint venture, or partnership arrangements to provide long term capital. Additional funding may not be available to us on acceptable terms, or at all.

 

41
 

 

*Disruptions to our supply chain or increases in the price or adulteration of key materials needed for our businesses could materially and adversely affect our business, financial condition and results of operations.

 

Disruptions to our supply chain, including our access to raw materials necessary for our contract manufacturing business and TK Supplements® product line, access to COVID-19 testing supplies and personal protective equipment for our diagnostic services business, and materials and equipment (such as our saliva collections kits) necessary for our personal genomics business, could have a material impact on our business, financial condition and results of operations. The COVID-19 pandemic has adversely impacted, and may continue to adversely impact, third parties that are critical to our businesses, including vendors, suppliers, and business partners. While our businesses have not been significantly impacted up to this point by the COVID-19 pandemic, it is difficult if not impossible to predict, whether that may change in the future.

 

Our TK Supplements® products and the products we manufacture for third parties are composed of certain key raw materials. If the prices of these raw materials were to increase significantly, it could result in a significant increase to us in the prices charged to us for our own branded products and third-party products. Raw material prices may increase in the future and we may not be able to pass on those increases to customers who purchase our products or to the customers whose products we manufacture. A significant increase in the price of raw materials that cannot be passed on to customers could have a material adverse impact on our business, financial condition and results of operations.

 

We are reliant upon the supply of raw materials that meet our specifications and the specifications of third parties for whom we manufacture. If any raw material is adulterated and does not meet our specifications or third parties’ specifications, it could significantly impact our ability to manufacture products and could materially and adversely impact our business, financial condition and results of operations.

 

Currently, we rely on a sole supplier to manufacture our saliva collection kits used by customers who purchase our personal genomics services. Change in the supplier or design of certain of the materials which we rely on, in particular the saliva collection kit, could result in a requirement for additional premarket review from the FDA before making such a change. For any new laboratory or laboratories that support our personal genomics business must first be validated in accordance with certain governmental standards prior to utilizing their services for our U.S. customers. We cannot be certain that we will be able to secure alternative laboratory processing services, materials and equipment, and bring such alternative materials and equipment on line and revalidate them without experiencing interruptions in our workflow, or that any alternative materials will meet our quality control and performance requirements of our current contracted laboratories that support our personal genomics business.

 

Although we maintain relationships with suppliers with the objective of ensuring that we have adequate supply for the delivery of our products and services, increases in demand for such items and services can result in shortages and higher costs. Our suppliers may not be able to meet our delivery schedules, we may lose a significant or sole supplier, a supplier may not be able to meet performance and quality specifications and we may not be able to purchase such items at a competitive cost. Further, we may experience shortages in certain items as a result of limited availability, increased demand, pandemics (such as the COVID-19 pandemic) or other outbreaks of contagious diseases, weather conditions and natural disasters, as well as other factors outside of our control. Our freight costs may increase due to factors such as limited carrier availability, increased fuel costs, increased compliance costs associated with new or changing government regulations, pandemics (such as the COVID-19 pandemic) or other outbreaks of contagious diseases and inflation. Higher prices for natural gas, propane, electricity and fuel also may increase our production and delivery costs. The prices charged for our products may not reflect changes in our packaging material, freight, tariff and energy costs at the time they occur, or at all.

 

In addition, if we are no longer able to obtain the resources, raw materials or components we need from one or more of our suppliers or service providers on terms reasonable to us or at all, including as a result of the increased demand that may be placed on our suppliers or service providers as a result of public health epidemics such as the COVID-19 pandemic, our customer relationships could be materially and adversely affected, which could have a material impact on our business, financial condition and results of operations.

 

42
 

 

**Any significant disruption in service on our website, mobile applications, or in our computer or logistics systems, whether due to a failure with our information technology systems or that of a third-party vendor, could harm our reputation and may result in a loss of customers.

 

Customers purchase our personal genomics testing services and access Nebula offerings through our website or our mobile applications. Our reputation and ability to attract, retain and serve our customers is dependent upon the reliable performance of our and our partner websites, mobile applications, network infrastructure and content delivery processes. Interruptions in any of these systems, whether due to system failures, computer viruses or physical or electronic break-ins, could affect the security or availability of our or our partner websites or mobile applications, including our databases, and prevent our customers from accessing and using our services.

 

Our systems and operations are also vulnerable to damage or interruption from fire, flood, power loss, telecommunications failure, terrorist attacks, acts of war, electronic and physical break-ins, earthquake and similar events. In the event of any catastrophic failure involving our or our partner websites, we may be unable to serve our customer web traffic. The occurrence of any of the foregoing risks could result in damage to our systems or could cause them to fail completely, and our insurance may not cover such risks or may be insufficient to compensate us for losses that may occur.

 

Additionally, our business model is dependent on our ability to deliver testing kits to customers and have kits processed and returned to us. This requires coordination between our logistics providers and third-party shipping services. Operational disruptions may be caused by factors outside of our control such as hostilities, political unrest, terrorist attacks, natural disasters, pandemics and public health emergencies, such as COVID-19, affecting the geographies where our operations and customers are located. We may not be effective at preventing or mitigating the effects of such disruptions, particularly in the case of a catastrophic event. In addition, operational disruptions may occur during the holiday season, causing delays or failures in deliveries of PGS kits. Any such disruption may result in lost revenues, a loss of customers and reputational damage, which would have an adverse effect on our business, results of operations and financial condition.

 

**Our personal genomics business will be subject to seasonal fluctuations.

 

Our personal genomics kit sales will be impacted by seasonal holiday demand. We expect to generate greater revenues from this business during the first quarter of our fiscal year, due to seasonal holiday demand and the fact that kits that are ordered during the holiday season (which occurs during the fourth quarter of our fiscal year) will generally be recognized as revenue when the customer sends in their kit to the laboratory to be processed and genetic reports are delivered to the customer, which for holiday purchases we expect will occur in the following fiscal quarter. Purchasing patterns of kit sales may also align with other gift-giving and family-oriented holidays such as Mother’s Day and Father’s Day. This seasonality could cause our operating results to vary considerably from quarter to quarter.

 

We may also experience an increase in lab processing times and costs associated with shipping orders due to freight surcharges due to peak capacity constraints and additional long-zone shipments necessary to ensure timely delivery for the holiday season. Such delays could lead to an inability to meet advertised estimated lab processing times, resulting in customer dissatisfaction or reputational damage. If too many customers access our website within a short period of time, we may experience system interruptions that make our website unavailable or prevent us from efficiently fulfilling orders, which may reduce the volume of kits sold. Also, third-party delivery and direct ship vendors may be unable to deliver merchandise on a timely basis.

 

*Our business is subject to significant competitive pressures.

 

We compete with other contract manufacturers of OTC drug and dietary supplement products. These suppliers range widely in size. We compete primarily on the basis of price, quality and service. Management believes that our manufacturing capacity and abilities offer a significant advantage over many of our competitors in the full service contract development and manufacturing industry. We have over 20 years of manufacturing experience and industry know how in large scale batch production of OTC lozenge products. To the extent that any of our competitors are able to offer better prices, quality and/or services, however, we could lose customers and our sales and margins may decline.

 

43
 

 

The OTC healthcare products and dietary supplements industries are highly competitive. Many of the participants in these industries have substantially greater capital resources, technical staffs, facilities, marketing resources, product development, and distribution experience than we do. We believe that our ability to continue to compete in these industries will depend on a number of factors, including product quality and price, availability, speed to market, consumer marketing, reliability, credit terms, brand name recognition, delivery time and post-sale service and support. However, our failure to appropriately and timely respond to consumer preferences and demand for new products could significantly harm our business, financial condition and results of operations. Furthermore, unfavorable publicity or consumer perception of products we develop and commercialize could have a material adverse effect on our business and operations.

 

Our principal competition for our lab diagnostic services are commercial laboratories, such as Quest Diagnostics Incorporated and Laboratory Corporation of America Holdings, both all of which have significant infrastructures and resources to support their diagnostic processing services. In addition, we compete with large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering COVID-19 and other RPP Molecular tests. Additionally, we compete against regional clinical laboratories providing diagnostic testing, including Interpace Biosciences, Inc. If we are unable to compete effectively, our earnings may be significantly negatively impacted.

 

The number of companies entering the personal genomics market has increased in recent years. We will also face competition from other companies attempting to capitalize on the same, or similar, opportunities as we are, including those with existing diagnostic, laboratory services and other companies entering the personal genetics market with new offerings such as direct access and/or consumer self-pay tests and genetic interpretation services. Some of our current and potential competitors have longer operating histories and greater financial, technical, marketing and other resources than we do. These factors may allow our competitors to respond more quickly or efficiently than we can to new or emerging technologies. These competitors may engage in more extensive research and development efforts, undertake more far-reaching marketing campaigns and adopt more aggressive pricing policies, which may allow them to build larger customer bases than we will be able to achieve. Our competitors may develop products or services that are similar to our products and services or that achieve greater market acceptance than our products and services. This could attract customers away from our services and reduce our market share. 

 

Risks Related to Governmental Regulation and Litigation

 

*We depend on third parties to provide services critical to our diagnostic testing business and personal genomic services business, and we depend on them to comply with applicable laws and regulations. Additionally, any breaches of the information technology systems of third parties could have a material adverse effect on our operations.

 

We depend on third parties to provide services critical to our diagnostic testing business and personal genomic services business, including laboratory service providers and equipment suppliers, ground and air transport of clinical and diagnostic testing supplies and specimens, research services (including ancestry report generation), and people, among other services. Third parties that provide services to us are subject to similar risks related to security of customer-related information and compliance with U.S., state, local, or international environmental, health and safety, and privacy and security laws and regulations as we are. Any failure by third parties to comply with applicable laws, or any failure of third parties to provide services more generally, could have a material impact on us, whether because of the loss of the ability to receive services from the third parties, our legal liability for the actions or inactions of third parties, or otherwise.

 

In addition, third parties to whom we outsource certain services or functions may process personal data, or other confidential information belonging to us. A breach or attack affecting these third parties could also harm our business, results of operations and reputation.

 

*We must comply with complex and overlapping laws protecting the privacy and security of health information and personal data.

 

There are a number of state, federal and international laws protecting the privacy and security of health information and personal data.

 

44
 

 

Under the administrative simplification provisions of HIPAA, HHS has issued regulations which establish uniform standards governing the conduct of certain electronic health care transactions and protecting the privacy and security of PHI used or disclosed by health care providers and other covered entities.

 

The privacy regulations regulate the use and disclosure of PHI by health care providers engaging in certain electronic transactions or “standard transactions.” They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered health care provider, including the right to access or amend certain records containing PHI or to request restrictions on the use or disclosure of PHI. The HIPAA security regulations establish administrative, physical, and technical standards for maintaining the integrity and availability of PHI in electronic form. These standards apply to covered health care providers and also to “business associates” or third parties providing services involving the use or disclosure of PHI. The HIPAA privacy and security regulations establish a uniform federal “floor” and do not supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI. As a result, we may be required to comply with both HIPAA privacy regulations and varying state privacy and security laws.

 

Moreover, HITECH, among other things, established certain health information security breach notification requirements. In the event of a breach of unsecured PHI, a covered entity must notify each individual whose PHI is breached, federal regulators and in some cases, must publicize the breach in local or national media. Breaches affecting 500 individuals or more are publicized by federal regulators who publicly identify the breaching entity, the circumstances of the breach and the number of individuals affected.

 

These laws contain significant fines and other penalties for wrongful use or disclosure of PHI. Given the complexity of HIPAA and HITECH and their overlap with state privacy and security laws, and the fact that these laws are rapidly evolving and are subject to changing and potentially conflicting interpretation, our ability to comply with the HIPAA, HITECH and state privacy requirements is uncertain and the costs of compliance are significant. Adding to the complexity is that our planned operations are currently evolving and the requirements of these laws will apply differently depending on such things as whether or not we bill electronically for our services, or provide services involving the use or disclosure of PHI and incur compliance obligations as a business associate. The costs of complying with any changes to the HIPAA, HITECH and state privacy restrictions may have a negative impact on our operations. Noncompliance could subject us to criminal penalties, civil sanctions and significant monetary penalties as well as reputational damage.

 

We are also required to collect and maintain personal information about our employees as well as receive and transfer certain payment information, to accept payments from our customers, including credit card information. Most states have adopted laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms to ensure ongoing protection of personal information. Activities outside of the United States implicate local and national data protection standards, impose additional compliance requirements, and generate additional risks of enforcement for non-compliance. The collection and use of such information may be subject to contractual obligations as well. If the security and information systems that we or our outsourced third-party providers use to store or process such information are compromised or if we, or such third parties, otherwise fail to comply with these laws, regulations, and contractual obligations, we could face litigation and the imposition of penalties that could adversely affect our financial performance.

 

Numerous additional local, municipal, state, federal, and international laws and regulations address privacy and the collection, storing, sharing, use, disclosure, and protection of certain types of data, including the California Online Privacy Protection Act, the Personal Information Protection and Electronic Documents Act, the Telephone Consumer Protection Act of 1991, or the TCPA, Section 5 of the Federal Trade Commission Act, and effective as of January 1, 2020, the California Consumer Privacy Act (the “CCPA”). These laws, rules, and regulations evolve frequently, and their scope may continually change, through new legislation, amendments to existing legislation, and changes in enforcement, and may be inconsistent from one jurisdiction to another. For example, the CCPA, which went into effect on January 1, 2020, among other things, requires new disclosures to California consumers and affords such consumers new abilities to opt out of certain sales of personal information. The CCPA provides for fines of up to $7,500 per violation. Aspects of the CCPA and its interpretation and enforcement remain uncertain. The effects of this legislation potentially are far-reaching and may require us to modify our data processing practices and policies and incur substantial compliance-related costs and expenses. The CCPA has been amended on multiple occasions. For example, the California Privacy Rights Act (“CPRA”) recently was approved by California voters and significantly modifies the CCPA, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. The CPRA does not become operative until January 1, 2023 (and then applies only to consumer data collected on or after January 1, 2022, (the “lookback period”), with enforcement beginning July 1, 2023. While the CCPA will remain operative and enforceable from now until July 1, 2023, we will continue to monitor developments related to the CPRA. The effects of this legislation potentially are far-reaching, however, and may require us to modify our data processing practices and policies and incur substantial compliance-related costs and expenses. Additionally, many laws and regulations relating to privacy and the collection, storing, sharing, use, disclosure, and protection of certain types of data are subject to varying degrees of enforcement and new and changing interpretations by courts. The CCPA and other changes in laws or regulations relating to privacy, data protection, breach notifications, and information security, particularly any new or modified laws or regulations, or changes to the interpretation or enforcement of such laws or regulations, that require enhanced protection of certain types of data or new obligations with regard to data retention, transfer, or disclosure, could greatly increase the cost of providing our platform, require significant changes to our operations, or even prevent us from providing our platform in jurisdictions in which we currently operate and in which we may operate in the future.

 

45
 

 

In the U.S., there have also been proposals for federal privacy legislation and many new state privacy laws proposed. In 2021, laws specific to genetic testing companies have passed in Utah, Arizona and Maryland, and legislation has been proposed in other states, including California.

 

We may face audits or investigations by one or more domestic government agencies or our customers pursuant to our contractual obligations relating to our compliance with these regulations. Complying with changing regulatory requirements requires us to incur substantial costs, exposes us to potential regulatory action or litigation, and may require changes to our business practices in certain jurisdictions, any of which could materially adversely affect our business operations and operating results. Despite our efforts to comply with applicable laws, regulations, and other obligations relating to privacy, data protection, and information security, it is possible that our interpretations of the law, practices, or platform could be inconsistent with, or fail or be alleged to fail to meet all requirements of, such laws, regulations, or obligations.

 

*We will face legal, reputational, and financial risks if we fail to protect our customer data from security breaches or cyberattacks. Changes in laws or regulations relating to privacy or the protection or transfer of data relating to individuals, or any actual or perceived failure by us to comply with such laws and regulations or any other obligations relating to privacy or the protection or transfer of data relating to individuals, could adversely affect our business.

 

We receive and store a large volume of personally identifiable information, genetic information, and other data relating to our customers, as well as other personally identifiable information and other data relating to individuals such as our employees. Security breaches, employee malfeasance, or human or technological error could lead to potential unauthorized disclosure of our customers’ personal information. Even the perception that the privacy of personal information is not satisfactorily protected or does not meet regulatory requirements could inhibit sales of our solutions and any failure to comply with such laws and regulations could lead to significant fines, penalties or other liabilities.

 

A security compromise of our information systems or of those of businesses with whom we interact that results in confidential information being accessed by unauthorized or improper persons could harm our reputation and expose us to regulatory actions, customer attrition, remediation expenses, disruption of our business, and claims brought by our customers or others for breaching contractual confidentiality and security provisions or data protection laws. Breaches of health information and/or personal data may be extremely expensive to remediate, may prompt federal or state investigation, fines, civil and/or criminal sanctions and significant reputational damage. Monetary damages imposed on us could be significant and not covered by our liability insurance. Techniques used by bad actors to obtain unauthorized access, disable or degrade service, or sabotage systems evolve frequently and may not immediately produce signs of intrusion, and we may be unable to anticipate these techniques or to implement adequate preventative measures. In addition, a security breach could require that we expend substantial additional resources related to the security of our information systems and providing required breach notifications, diverting resources from other projects and disrupting our businesses. If we experience a data security breach, our reputation could be damaged, and we could be subject to additional litigation, regulatory risks and business losses.

 

Our failure, or the failure by our third-party providers on our platform, to comply with applicable laws or regulations or any other obligations relating to privacy, data protection, or information security, or any compromise of security that results in unauthorized access to, or use or release of personally identifiable information or other data relating to our customers, or other individuals, or the perception that any of the foregoing types of failure or compromise have occurred, could damage our reputation, discourage new and existing customers from using our platform, or result in fines, investigations, or proceedings by governmental agencies and private claims and litigation, any of which could adversely affect our business, financial condition, and results of operations. Even if not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm our reputation and brand and adversely affect our business, financial condition, and results of operations.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None

 

Item 4. Mine Safety Disclosures.

 

Not applicable

 

Item 5. Other Information.

 

None

 

46
 

 

Item 6. Exhibits

 

Exhibit No.   Description
     
10.1   Stock Purchase Agreement by and among Nebula Genomics, Inc., the Seller Parties Named therein, Kammal Obbad in the capacity as Seller Party Representative, ProPhase Labs, Inc and ProPhase Precision Medicine, Inc., dated August 10, 2021 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 000-21617) filed on August 16, 2021).
     
31.1   Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2   Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1   Certification by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2   Certification by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101. INS#   XBRL Instance Document
     
101.SCH#   XBRL Taxonomy Extension Schema Document
     
101.CAL#   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF#   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB#   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE#   XBRL Taxonomy Extension Presentation Linkbase Document

 

47
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ProPhase Labs, Inc.
     
  By: /s/ Ted Karkus
    Ted Karkus
    Chairman of the Board and Chief Executive Officer (Principal Executive Officer)

Date: November 12, 2021

  By: /s/ Monica Brady
    Monica Brady
   

Chief Financial Officer

(Principal Financial Officer)

Date: November 12, 2021

 

48

 

EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, Ted Karkus, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;
   
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 12, 2021

 

  By: /s/ Ted Karkus
    Ted Karkus
   

Chairman of the Board and Chief Executive

Officer (Principal Executive Officer)

 

 

 

EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, Monica Brady, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;
   
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the registrant and have:
   
  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 12, 2021

 

  By: /s/ Monica Brady
    Monica Brady
   

Chief Financial Officer

(Principal Financial Officer)

 

 

 

EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ted Karkus, Chief Executive Officer of ProPhase Labs, Inc., a Delaware corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

  /s/ Ted Karkus
  Ted Karkus
 

Chairman of the Board and Chief Executive Officer

(Principal Executive Officer)

  November 12, 2021

 

 

 

EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Monica Brady, Chief Financial Officer of ProPhase Labs, Inc., a Delaware corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

  /s/ Monica Brady
  Monica Brady
 

Chief Financial Officer

(Principal Financial Officer)

November 12, 2021

 

 

 

 

EX-101.SCH 6 prph-20210930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Business and Liquidity Uncertainties link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Goodwill and Acquired Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Unsecured Convertible Promissory Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Defined Contribution Plans link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Significant Customers link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Secured Promissory Note Receivable and Consulting Agreement link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Business and Liquidity Uncertainties (Policies) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Business and Liquidity Uncertainties (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Business Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Goodwill and Acquired Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Summary of Components of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Disaggregation by Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Business and Liquidity Uncertainties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Intangible Assets Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Pro-forma Results (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Business Acquisitions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Changes In Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Amortization Expense for Acquired Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Goodwill and Acquired Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Property, Plant and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Unsecured Convertible Promissory Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Summary of Weighted Average Assumptions Used In Determining Fair Value of Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Defined Contribution Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Schedule of Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Summary of Quantitative Information About Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Schedule of Maturity of Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Significant Customers (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Earnings (Loss) Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Secured Promissory Note Receivable and Consulting Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Schedule of Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Segment Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Subsequent Event (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 prph-20210930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 prph-20210930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 prph-20210930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Treasury Stock [Member] Debt Security Category [Axis] Marketable Securities [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Financial Instrument [Axis] U.S. Government Obligations [Member] Corporate Obligations [Member] Investment Type [Axis] Investment Shares [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Scenario [Axis] 0-12 Months [Member] 13-24 Months [Member] Over 24 Months [Member] Concentration Risk Benchmark [Axis] Contract Manufacturing [Member] Retail And Other [Member] Diagnostic Services [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Cooperative Incentive Promotion Costs [Member] Business Acquisition [Axis] Nebula Acquisition [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Nebula Stock Purchase Agreement [Member] Credit Facility [Axis] CitiBankm, N.A. [Member] Title of Individual [Axis] Mr. Kamal Obbad [Member] Finite-Lived Intangible Assets by Major Class [Axis] Trade Names [Member] Intellectual Property [Member] Customer Relationships [Member] Plaza Medical Laboratory Corp [Member] C P M Acquisition [Member] CLIA License [Member] License [Member] Long-Lived Tangible Asset [Axis] Land [Member] Building Improvements [Member] Machinery and Equipment [Member] Equipment [Member] Computer Equipment [Member] Furniture and Fixtures [Member] Debt Instrument [Axis] September 2020 Notes [Member] Long-term Debt, Type [Axis] Unsecured Debt [Member] Award Type [Axis] Registered Direct Offering [Member] IPO [Member] Share Repurchase Program [Axis] Share Repurchase Program [Member] Plan Name [Axis] Two Thousand And Twenty Directors Equity Compensation Plan [Member] Two Thousand Ten Directors Plan [Member] Two Thousand Ten Directors Equity Compensation Plan [Member] Amended 2010 Plan [Member] Two Thousand Ten Equity Compensation Plan [Member] Two Thousand Eighteen Stock Incentive Plan [Member] CEO Options [Member] Two Thousand Eighteen Stock [Member] Stock Holders [Member] Inducement Option Award [Member] Derivative Instrument [Axis] Equity Option [Member] Warrant [Member] Measurement Input Type [Axis] Measurement Input, Exercise Price [Member] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Series [Axis] Mylan and Escrow Agent [Member] Escrow Agreement [Member] Geographic Distribution [Axis] Old Bridge New Jersey [Member] Confucius Labs [Member] Final Months [Member] Balance Sheet Location [Axis] Operating Lease Liabilities [Member] Operating Lease Right Of Use Asset [Member] Revenue Benchmark [Member] Customer [Axis] Diagnostic Services Clients One [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Diagnostic Services Clients Two [Member] Diagnostic Services Clients Three [Member] Third Party Contract Manufacturing Customer One [Member] Third Party Contract Manufacturing Customer Two [Member] Trade Receivable [Member] Diagnostic Services Clients Four [Member] Diagnostic Services Clients Five [Member] Customer One [Member] Customer Two [Member] Customer Three [Member] Antidilutive Securities [Axis] Stock Options Warrants And Convertible Debt [Member] Common Stock Equivalents Two [Member] Related Party [Axis] Unrelated Third party [Member] Revision of Prior Period [Axis] Revision of Prior Period, Adjustment [Member] Secured Debt [Member] Consulting Agreement [Member] Termination Agreement [Member] Segments [Axis] Consumer Products [Member] Unallocated Corporate [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Restricted cash Marketable debt securities, available for sale Marketable equity securities, at fair value Accounts receivable, net Inventory, net Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Secured promissory note receivable Prepaid expenses, net of current portion Right-of-use asset, net Intangible assets, net Goodwill Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable Accrued diagnostic services Accrued advertising and other allowances Lease liabilities Deferred revenue Other current liabilities Total current liabilities Non-current liabilities: Deferred revenue, net of current portion Note payable Unsecured convertible promissory notes, net Lease liabilities, net of current portion Total non-current liabilities Total liabilities COMMITMENTS AND CONTINGENCIES Stockholders’ equity Preferred stock authorized 1,000,000, $.0005 par value, no shares issued and outstanding Common stock authorized 50,000,000, $.0005 par value, 15,652,724 and 11,604,253 shares outstanding, respectively Additional paid-in capital Accumulated deficit Treasury stock, at cost, 16,652,022 and 16,652,022 shares, respectively Accumulated other comprehensive loss Total stockholders’ equity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Preferred Stock, Shares Authorized Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Outstanding Preferred Stock, Shares Issued Common Stock, Shares Authorized Common Stock, Par or Stated Value Per Share Common Stock, Shares, Outstanding Treasury Stock, Shares Income Statement [Abstract] Revenues, net Cost of revenues Gross profit Operating expenses: Diagnostic expenses General and administration Research and development Total operating expenses Loss from operations Interest income, net Interest expense Change in fair value of investment securities Loss from continuing operations Discontinued Operations: Income from discontinued operations Net loss Other comprehensive loss: Unrealized loss on marketable debt securities Total comprehensive loss Basic and diluted earnings (loss) per share: Loss from continuing operations Income from discontinued operations Net loss per share Weighted average common shares outstanding: Basic and diluted Statement [Table] Statement [Line Items] Beginning balance, value Balance, shares Issuance of common stock and warrants for cash from public offering, net of offering cost Issuance of common stock and warrants for cash from public offering, net of $2,365 offering cost, shares Issuance of common stock and warrants for cash from private offering Issuance of common stock and warrants for cash from private offering, shares Issuance of common shares related to business acqusition Issuance of common shares related to business acqusition, shares Cash dividends Unrealized loss on marketable debt securities, net of realized losses of net of taxes Cashless warrants exercise Cashless warrants exercise Stock-based compensation Stock-based compensation,shares Net loss Ending balance, value Balance, shares Statement of Stockholders' Equity [Abstract] Marketable Securities, Gain (Loss) Offering cost Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Realized (gain) loss on marketable debt securities Depreciation and amortization Amortization of debt discount Amortization on right-of-use assets Lower of cost or net realizable value inventory adjustment Stock-based compensation expense Change in fair value of investment securities Non-cash interest income on secured promissory note receivable Changes in operating assets and liabilities: Accounts receivable Escrow receivable Inventory Prepaid and other assets Other assets Accounts payable and accrued expenses Accrued diagnostic services Deferred revenue Lease liabilities Other liabilities Net cash (used in) provided by operating activities Cash flows from investing activities Business acquisitions, net of cash acquired Issuance of secured promissory note receivable Purchase of marketable securities Proceeds from sale of marketable debt securities Capital expenditures Net cash used in investing activities Cash flows from financing activities Proceeds from issuance of common stock from public offering, net Proceeds from issuance of common stock and warrants from private offering Proceeds from unsecured convertible promissory notes Issuance costs on unsecured convertible promissory notes Payment of issuance costs in connection with ATM Payment of dividends Net cash provided by financing activities Increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash, at the beginning of the period Cash, cash equivalents and restricted cash, at the end of the period Supplemental disclosures: Cash paid for income taxes Interest payment on the promissory notes Supplemental disclosure of non-cash investing and financing activities: Net unrealized loss, investments in marketable debt securities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Business And Liquidity Uncertainties Business and Liquidity Uncertainties Business Combination and Asset Acquisition [Abstract] Business Acquisitions Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Acquired Intangible Assets Property, Plant and Equipment [Abstract] Property, Plant and Equipment Debt Disclosure [Abstract] Unsecured Convertible Promissory Notes Payable Equity [Abstract] Stockholders’ Equity Retirement Benefits [Abstract] Defined Contribution Plans Other Liabilities Disclosure [Abstract] Other Current Liabilities Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Leases Leases Risks and Uncertainties [Abstract] Significant Customers Earnings Per Share [Abstract] Earnings (Loss) Per Share Secured Promissory Note Receivable And Consulting Agreement Secured Promissory Note Receivable and Consulting Agreement Segment Reporting [Abstract] Segment Information Subsequent Events [Abstract] Subsequent Event Impairment of Long-Lived Assets Summary of Components of Marketable Securities Schedule of Components of Inventory Schedule of Fair Value of Financial Instruments Schedule of Deferred Revenue Schedule of Disaggregation by Revenue Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Schedule of Assets Acquired and Liabilities Assumed Schedule of Intangible Assets Acquisition Schedule of Pro-forma Results Schedule of Changes In Goodwill Schedule of Intangible Assets Schedule of Amortization Expense for Acquired Intangible Assets Schedule of Property, Plant and Equipment Schedule of Stock Options Activity Summary of Weighted Average Assumptions Used In Determining Fair Value of Options Schedule of Warrant Activity Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants Schedule of Other Current Liabilities Summary of Quantitative Information About Operating Leases Schedule of Maturity of Operating Leases Schedule of Segment Information Debt Securities, Held-to-maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items] Amortized Cost Unrealized Losses Fair Value Schedule Of Components Of Inventory Diagnostic services testing material Raw materials Work in process Finished goods Inventory, net Fair value of marketable debt securities Marketable equity securities Total Schedule of Product Information [Table] Product Information [Line Items] Total revenue, net Schedule of Other than Temporary Impairment, Credit Losses Recognized in Earnings [Table] Other than Temporary Impairment, Credit Losses Recognized in Earnings [Line Items] Net Cash Provided by (Used in) Operating Activities Cash Equivalents, at Carrying Value Debt Instrument, Interest Rate During Period Marketable securities, unrealized loss Investment Owned, Balance, Shares Investment Owned, at Fair Value Share Price [custom:DecreaseInFairValueOfInvestmentSecurities] Inventory Adjustments Estimated useful lives description Cash and Cash Equivalents, at Carrying Value Cash Cash, FDIC Insured Amount Cash, Uninsured Amount Breakage revenue Contract with Customer, Liability Deferred revenue Advertising and incentive promotion expenses, continuing operation Share-based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Expense Research and Development Expense Short term investments Accounts receivable Clinical lab material Lab equipment Inventory Prepaid and other current assets Definite-lived intangible asset Total assets acquired Accounts payable Accrued expenses and other current liabilities Deferred revenue Note payable Liabilities assumed Net identifiable assets acquired Total consideration Cash acquired Escrow amount Gross carying value Estimated useful life Revenue, net Net loss [custom:PurchasePriceOfCommonStock] Business combination amount paid in cash Shares Issued, Price Per Share [custom:PurchasePriceOfEscrowAmount] [custom:EscrowMaturityDate] Stock option awarded Option, exercise price Total consideration Cash Acquired from Acquisition Amortization expenses Area of Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Amortization Goodwill, beginning of period Acquisition of Nebula Goodwill, end of period Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Total intangible assets, gross Estimated useful life Less: accumulated amortization Total intangible assets, net Three months ended December 31, 2021 Year ended December 31, 2022 Year ended December 31, 2023 Year ended December 31, 2024 Year ended December 31, 2025 Thereafter Total Amortization of Intangible Assets Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Gross Property, Plant and Equipment, Useful Life Less: accumulated depreciation Total property, plant and equipment, net Depreciation Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Debt Instrument, Maturity Date Debt Instrument, Face Amount Debt Instrument, Interest Rate, Stated Percentage Debt Conversion, Description Convertible Debt Debt Instrument, Convertible, Conversion Price Interest expense Offsetting Assets [Table] Offsetting Assets [Line Items] Number of Shares Options Outstanding - Beginning Weighted Average Exercise Price Options Outstanding - Beginning Weighted Average Remaining Contractual Life (in Years) - Beginning Total Intrinsic Value - Beginning Number of Shares, Granted Weighted Average Exercise Price, Granted Weighted Average Remaining Contractual Life (in Years) - Granted Total Intrinsic Value - Granted Number of Shares, Forfeited Weighted Average Exercise Price, Forfeited Total Intrinsic Value - Forfeited Number of Shares Options Outstanding - Ending Weighted Average Exercise Price Options Outstanding - Ending Weighted Average Remaining Contractual Life (in Years) - Ending Total Intrinsic Value - Ending Number of Shares Options Vested and Exercisable Weighted Average Exercise Price, Options Vested and Exercisable Weighted Average Remaining Contractual Life (in Years) - Options Vested and Exercisable Total Intrinsic Value, Options Vested and Exercisable Exercise price Expected term (years) Expected stock price volatility Risk-free rate of interest Expected dividend yield (per share) Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of Shares Warrants Outstanding - Beginning Weighted Average Exercise Price Warrants Outstanding - Beginning Weighted Average Remaining Contractual Life (in Years) - Beginning Warrants granted Weighted Average Exercise Price, Granted Weighted Average Remaining Contractual Life (in Years) - Granted Weighted Average Exercise Price, Exercise Weighted Average Exercise Price Warrants Outstanding - Exerisce Weighted Average Remaining Contractual Life (in Years) - Exercised Number of Shares Warrants Outstanding - Ending Weighted Average Exercise Price Warrants Outstanding - Ending Weighted Average Remaining Contractual Life (in Years) - Ending Number of Shares Warrants Vested and Exercisable Weighted Average Exercise Price, Warrants Vested and Exercisable Weighted Average Remaining Contractual Life (in Years) - Vested and Exercisable Warrants outstanding, measurement input, percentage Warrants measurement, expected term Common Stock, Dividends, Per Share, Cash Paid Payments of Ordinary Dividends, Common Stock Number of shares issued Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Proceeds from offering Business Acquisition, Share Price Stock Issued During Period, Value, New Issues Stock Repurchase Program, Remaining Authorized Repurchase Amount Number of shares authorized in share based compensation Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Common Stock, Capital Shares Reserved for Future Issuance Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Stock Option Plan Reduced Exercise Price Per Share Description Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Share-based Payment Arrangement, Plan Modification, Incremental Cost Share based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Class of Warrant or Right, Outstanding Defined contribution amount Accrued commissions Accrued payroll Accrued expenses Accrued returns Accrued income tax payable Accrued benefits and vacation Deferred revenue Total other current liabilities Agreement termination date Summary Of Quantitative Information About Operating Leases Operating lease cost Variable lease cost Operating lease expense Short-term lease rent expense Total rent expense Operating cash flows used in operating leases Right-of-use assets obtained in exchange for operating lease liabilities Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Schedule Of Maturity Of Operating Leases Remaing Months Ended December 31, 2021 Year Ended December 31, 2022 Year Ended December 31, 2023 Year Ended December 31, 2024 Year Ended December 31, 2025 Thereafter Total Less present value discount Operating lease liabilities Operating Lease, Payments Lessor, Operating Lease, Term of Contract Lessee, Operating Lease, Description Gradual rental rate increase percentage Operating Lease, Liability Operating Lease, Right-of-Use Asset Concentration Risk [Table] Concentration Risk [Line Items] Revenues net Concentration Risk, Percentage Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Increase in interest rate payable percentage Debt Instrument, Term Interest and Fee Income, Loans and Leases Business Combination, Acquisition Related Costs Test fees received Accrued interest, debt Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Consolidated cost of revenue Total Depreciation and amortization expense Diagnostic services Total loss from continuing operations, before income taxes Income from discontinued operations, before income taxes Total assets Number of Operating Segments Subsequent Event [Table] Subsequent Event [Line Items] Number of shares repurchased Aggregate amount of shares repurchased Marketable equity securities, at fair value. Issuance of common stock and warrants for cash from private offering. Issuance of common stock and warrants for cash from public offering, net of $855 warrant liability and $2,365 offering cost. Issuance of common shares related to business acqusition. ssuance of common shares related to business acqusition. Offering cost. Proceeds From Issuance Of Common Stock And Warrants From Private Offering. Plaza Medical Laboratory Corp [Member] Marketable Equity Securities [policy text block]. U.S. Government Obligations [Member] Corporate Obligations [Member] Inventory lab material. 0-12 Months [Member] 13-24 Months [Member] Over 24 Months [Member] Marketable Securities [Member] Investment Shares [Member] Increase in fair value of investment securities. Consumer Products [Member] Estimated sales returns, continuing operation. Cooperative Incentive Promotion Costs [Member] Advertising and incentive promotion expenses, continuing operation. Business combination recognized identifiable assets acquired and liabilities assumed definite lived intangible assets. Aggregate cost consideration. Consulting Agreement [Member] Mr Gurnani [Member] foot Clinical Laboratory Improvement Amendments [Memebr] September 2020 Notes [Member] Registered Direct Offering [Member] Two Thousand Ten Directors Equity Compensation Plan [Member] Two Thousand Ten Directors Plan [Member] Share based compensation arrangement by share based payment award director fees. Two Thousand Ten Equity Compensation Plan [Member] Stock option plan reduced exercise price per share description. CEO Options [Member] Two Thousand Eighteen Stock [Member] Stock Holders [Member] Sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1. Sharebased compensation arrangement by sharebased payment award options granted weighted average remaining contractual term. Share based compensation arrangement by share based payment award options grants in period intrinsic value. Share based compensation Arrangement by share Based payment award options forfeited in Period intrinsic value. Share based compensation arrangement by share based payment award non options vested and expected to vest exercisable number. Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price 1. Share based compensation arrangement by share based payment award non options outstanding granted weighted average exercise price 1. Share based compensation arrangement by share based payment award non options vested and exercisable weighted average exercise price 1. Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term 1. Share based compensation arrangement by share based payment award non options granted weighted average remaining contractual term. Share based compensation arrangement by share based payment award non options vested and exercisable weighted average remaining contractual term 2. Accrued Diagnostic Services. Accrued return. Agreement termination date. Mylan and Escrow Agent [Member] Escrow Agreement [Member] Old Bridge New Jersey [Member] Confucius Labs [Member] Maximum construction allowance from lessor. Gradual rental rate increase percentage. Final Months [Member] Operating Lease Liabilities [Member] Operating Lease Right Of Use Asset [Member] Diagnostic Services Clients One [Member] Diagnostic Services Clients Two [Member] Third Party Contract Manufacturing Customer One [Member] Third Party Contract Manufacturing Customer Two [Member] Trade Receivable [Member] Customer One [Member] Customer Two [Member] Stock Options Warrants And Convertible Debt [Member] Common Stock Equivalents One [Member] Unrelated Third party [Member] Increase in interest rate payable percentage. Test fees received. Termination Agreement [Member] Operating and other expenses. Amount of unrealized loss on investment in marketable security. The aggregate Purchase Price Of Common Stock. Nebula Stock Purchase Agreement [Member] Purchase Price Of Escrow Amount. CitiBankm, N.A. [Member] Escrow Maturity Date. Mr. Kamal Obbad [Member] Business and Liquidity Uncertainties [Text Block] Breakage revenue. Amended 2010 Plan [Member] Assets, Current Liabilities, Current Liabilities, Noncurrent Liabilities Treasury Stock, Value Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Interest Expense Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share Shares, Outstanding Dividends, Common Stock, Cash StockIssuedDuringPeriodSharesCashlessWarrantsExercise Marketable Securities, Realized Gain (Loss) LowerOfCostOrNetRealizableValueInventoryAdjustment NoncashInterestIncomeOnSecuredPromissoryNoteReceivable Increase (Decrease) in Accounts Receivable IncreaseDecreaseInEscrowReceivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Other Noncurrent Assets IncreaseDecreaseInAccruedDiagnosticServices Increase (Decrease) in Deferred Revenue IncreaseDecreaseInLeaseLiabilities Net Cash Provided by (Used in) Operating Activities BusinessAcquisitionsNetOfCashAcquired IssuanceOfSecuredPromissoryNoteReceivable Payments to Acquire Marketable Securities Payments to Acquire Productive Assets Net Cash Provided by (Used in) Investing Activities Payments of Debt Issuance Costs Payments of Stock Issuance Costs Payments of Dividends Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Lessee, Operating Leases [Text Block] Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Deferred Revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Business Acquisition, Pro Forma Net Income (Loss) Finite-Lived Intangible Asset, Useful Life Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber Contract with Customer, Liability, Current Operating Lease, Expense Lease, Cost Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount EX-101.PRE 10 prph-20210930_pre.xml XBRL PRESENTATION FILE XML 11 form10-q_htm.xml IDEA: XBRL DOCUMENT 0000868278 2021-01-01 2021-09-30 0000868278 2021-11-10 0000868278 2021-09-30 0000868278 2020-12-31 0000868278 2021-07-01 2021-09-30 0000868278 2020-07-01 2020-09-30 0000868278 2020-01-01 2020-09-30 0000868278 us-gaap:CommonStockMember 2021-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000868278 us-gaap:RetainedEarningsMember 2021-06-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000868278 us-gaap:TreasuryStockMember 2021-06-30 0000868278 2021-06-30 0000868278 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000868278 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000868278 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000868278 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000868278 us-gaap:CommonStockMember 2021-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000868278 us-gaap:RetainedEarningsMember 2021-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000868278 us-gaap:TreasuryStockMember 2021-09-30 0000868278 us-gaap:CommonStockMember 2020-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000868278 us-gaap:RetainedEarningsMember 2020-06-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000868278 us-gaap:TreasuryStockMember 2020-06-30 0000868278 2020-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000868278 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000868278 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000868278 us-gaap:CommonStockMember 2020-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000868278 us-gaap:RetainedEarningsMember 2020-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000868278 us-gaap:TreasuryStockMember 2020-09-30 0000868278 2020-09-30 0000868278 us-gaap:CommonStockMember 2020-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000868278 us-gaap:RetainedEarningsMember 2020-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000868278 us-gaap:TreasuryStockMember 2020-12-31 0000868278 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000868278 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000868278 us-gaap:TreasuryStockMember 2021-01-01 2021-09-30 0000868278 us-gaap:CommonStockMember 2019-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000868278 us-gaap:RetainedEarningsMember 2019-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000868278 us-gaap:TreasuryStockMember 2019-12-31 0000868278 2019-12-31 0000868278 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000868278 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000868278 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000868278 srt:MinimumMember PRPH:MarketableSecuritiesMember 2021-01-01 2021-09-30 0000868278 srt:MaximumMember PRPH:MarketableSecuritiesMember 2021-01-01 2021-09-30 0000868278 PRPH:USGovernmentObligationsMember 2021-09-30 0000868278 PRPH:CorporateObligationsMember 2021-09-30 0000868278 PRPH:USGovernmentObligationsMember 2020-12-31 0000868278 PRPH:CorporateObligationsMember 2020-12-31 0000868278 PRPH:InvestmentSharesMember 2021-06-25 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:USGovernmentObligationsMember 2021-09-30 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:USGovernmentObligationsMember 2021-09-30 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:USGovernmentObligationsMember 2021-09-30 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:CorporateObligationsMember 2021-09-30 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:CorporateObligationsMember 2021-09-30 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:CorporateObligationsMember 2021-09-30 0000868278 us-gaap:FairValueInputsLevel1Member 2021-09-30 0000868278 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000868278 us-gaap:FairValueInputsLevel3Member 2021-09-30 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:USGovernmentObligationsMember 2020-12-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:USGovernmentObligationsMember 2020-12-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:USGovernmentObligationsMember 2020-12-31 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:CorporateObligationsMember 2020-12-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:CorporateObligationsMember 2020-12-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:CorporateObligationsMember 2020-12-31 0000868278 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000868278 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000868278 us-gaap:FairValueInputsLevel3Member 2020-12-31 0000868278 PRPH:ZeroToTwelveMonthsMember 2021-09-30 0000868278 PRPH:ZeroToTwelveMonthsMember 2020-12-31 0000868278 PRPH:ThirteenToTwentyFourMember 2021-09-30 0000868278 PRPH:ThirteenToTwentyFourMember 2020-12-31 0000868278 PRPH:OverTwentyFourMember 2021-09-30 0000868278 PRPH:OverTwentyFourMember 2020-12-31 0000868278 PRPH:ContractManufacturingMember 2021-07-01 2021-09-30 0000868278 PRPH:ContractManufacturingMember 2020-07-01 2020-09-30 0000868278 PRPH:ContractManufacturingMember 2021-01-01 2021-09-30 0000868278 PRPH:ContractManufacturingMember 2020-01-01 2020-09-30 0000868278 PRPH:RetailAndOtherMember 2021-07-01 2021-09-30 0000868278 PRPH:RetailAndOtherMember 2020-07-01 2020-09-30 0000868278 PRPH:RetailAndOtherMember 2021-01-01 2021-09-30 0000868278 PRPH:RetailAndOtherMember 2020-01-01 2020-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-07-01 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-07-01 2020-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-01-01 2020-09-30 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2021-07-01 2021-09-30 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2020-07-01 2020-09-30 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2021-01-01 2021-09-30 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2020-01-01 2020-09-30 0000868278 PRPH:NebulaAcquisitionMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-08 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember PRPH:CitiBankNAMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-08 2021-08-10 0000868278 PRPH:MrKamalObbadMember PRPH:NebulaAcquisitionMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-01-01 2021-09-30 0000868278 PRPH:NebulaAcquisitionMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:TradeNamesMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:TradeNamesMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:IntellectualPropertyMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:IntellectualPropertyMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-07-01 2021-09-30 0000868278 PRPH:PlazaMedicalLaboratoryCorpMember 2020-10-20 2020-10-23 0000868278 PRPH:PlazaMedicalLaboratoryCorpMember 2020-10-23 0000868278 PRPH:CPMAcquisitionMember 2020-10-22 2020-10-23 0000868278 PRPH:CPMAcquisitionMember 2021-01-01 2021-09-30 0000868278 PRPH:CPMAcquisitionMember 2020-10-23 0000868278 2021-10-23 0000868278 PRPH:ClinicalLaboratoryImprovementAmendmentsMember 2020-10-23 0000868278 us-gaap:TradeNamesMember 2021-09-30 0000868278 us-gaap:TradeNamesMember 2020-12-31 0000868278 us-gaap:TradeNamesMember 2021-01-01 2021-09-30 0000868278 us-gaap:IntellectualPropertyMember 2021-09-30 0000868278 us-gaap:IntellectualPropertyMember 2020-12-31 0000868278 us-gaap:IntellectualPropertyMember 2021-01-01 2021-09-30 0000868278 us-gaap:CustomerRelationshipsMember 2021-09-30 0000868278 us-gaap:CustomerRelationshipsMember 2020-12-31 0000868278 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-09-30 0000868278 us-gaap:LicenseMember 2021-09-30 0000868278 us-gaap:LicenseMember 2020-12-31 0000868278 us-gaap:LicenseMember 2021-01-01 2021-09-30 0000868278 us-gaap:LandMember 2021-09-30 0000868278 us-gaap:LandMember 2020-12-31 0000868278 us-gaap:BuildingImprovementsMember 2021-09-30 0000868278 us-gaap:BuildingImprovementsMember 2020-12-31 0000868278 srt:MinimumMember us-gaap:BuildingImprovementsMember 2021-01-01 2021-09-30 0000868278 srt:MaximumMember us-gaap:BuildingImprovementsMember 2021-01-01 2021-09-30 0000868278 us-gaap:MachineryAndEquipmentMember 2021-09-30 0000868278 us-gaap:MachineryAndEquipmentMember 2020-12-31 0000868278 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2021-01-01 2021-09-30 0000868278 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2021-01-01 2021-09-30 0000868278 us-gaap:EquipmentMember 2021-09-30 0000868278 us-gaap:EquipmentMember 2020-12-31 0000868278 srt:MinimumMember us-gaap:EquipmentMember 2021-01-01 2021-09-30 0000868278 srt:MaximumMember us-gaap:EquipmentMember 2021-01-01 2021-09-30 0000868278 us-gaap:ComputerEquipmentMember 2021-09-30 0000868278 us-gaap:ComputerEquipmentMember 2020-12-31 0000868278 srt:MinimumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-09-30 0000868278 srt:MaximumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-09-30 0000868278 us-gaap:FurnitureAndFixturesMember 2021-09-30 0000868278 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000868278 us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-09-30 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-09-13 2020-09-15 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-09-15 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2021-07-01 2021-09-30 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-07-01 2020-09-30 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2021-01-01 2021-09-30 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-01-01 2020-09-30 0000868278 2021-05-12 2021-05-13 0000868278 us-gaap:CommonStockMember 2021-06-02 2021-06-03 0000868278 PRPH:RegisteredDirectOfferingMember 2021-01-04 2021-01-05 0000868278 PRPH:RegisteredDirectOfferingMember 2021-01-05 0000868278 us-gaap:IPOMember 2021-01-17 2021-01-18 0000868278 us-gaap:IPOMember 2021-01-18 0000868278 2020-01-20 2021-01-21 0000868278 PRPH:NebulaAcquisitionMember 2021-09-30 0000868278 PRPH:NebulaAcquisitionMember 2021-01-17 2021-01-18 0000868278 PRPH:ShareRepurchaseProgramMember 2021-09-08 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2021-05-20 0000868278 PRPH:TwoThousandTenDirectorsPlanMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000868278 PRPH:TwoThousandTenDirectorsPlanMember us-gaap:CommonStockMember 2021-09-30 0000868278 PRPH:TwoThousandTenDirectorsEquityCompensationPlanMember 2020-07-01 2020-09-30 0000868278 PRPH:TwoThousandTenDirectorsEquityCompensationPlanMember 2020-01-01 2020-09-30 0000868278 PRPH:TwoThousandTenDirectorsEquityCompensationPlanMember 2021-09-30 0000868278 PRPH:AmendedTwoThousandTenPlanMember 2021-05-19 2021-05-20 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2021-01-01 2021-09-30 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2020-01-01 2020-09-30 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2020-01-01 2021-09-30 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2021-09-30 0000868278 PRPH:TwoThousandEighteenStockIncentivePlanMember 2018-04-12 0000868278 PRPH:TwoThousandEighteenStockIncentivePlanMember 2021-04-11 2021-04-12 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2018-09-04 2018-09-05 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-09-04 2021-09-05 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2018-09-04 2018-09-05 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-01-23 2019-01-24 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-01-23 2019-01-24 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-12-11 2021-12-12 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-12-11 2019-12-12 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-12-11 2019-12-12 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-06-02 2021-06-03 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-06-02 2021-06-03 0000868278 PRPH:MrKamalObbadMember PRPH:InducementOptionAwardMember 2021-01-01 2021-09-30 0000868278 PRPH:InducementOptionAwardMember 2021-09-30 0000868278 PRPH:InducementOptionAwardMember 2021-01-01 2021-09-30 0000868278 PRPH:InducementOptionAwardMember 2021-01-01 2021-09-30 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2021-07-01 2021-09-30 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2020-07-01 2020-09-30 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2021-01-01 2021-09-30 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2020-01-01 2020-09-30 0000868278 us-gaap:StockOptionMember 2020-12-31 0000868278 us-gaap:StockOptionMember 2021-01-01 2021-09-30 0000868278 us-gaap:StockOptionMember 2021-09-30 0000868278 PRPH:RegisteredDirectOfferingMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:IPOMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:WarrantMember 2021-01-01 2021-09-30 0000868278 us-gaap:WarrantMember 2020-12-31 0000868278 us-gaap:MeasurementInputExercisePriceMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2021-09-30 0000868278 us-gaap:WarrantMember 2021-07-01 2021-09-30 0000868278 us-gaap:WarrantMember 2020-01-01 2020-09-30 0000868278 PRPH:EscrowAgreementMember PRPH:MylanandEscrowAgentMember 2021-01-01 2021-09-30 0000868278 PRPH:PlazaMedicalLaboratoryCorpMember 2021-09-30 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-10-22 2020-10-23 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-10-23 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-12-07 2020-12-08 0000868278 PRPH:FinalMonthsMember PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-12-07 2020-12-08 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2021-01-01 2021-09-30 0000868278 PRPH:OperatingLeaseLiabilitiesMember 2021-09-30 0000868278 PRPH:OperatingLeaseRightOfUseAssetMember 2021-09-30 0000868278 PRPH:DiagnosticServicesClientsOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000868278 PRPH:DiagnosticServicesClientsTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000868278 PRPH:DiagnosticServicesClientsThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000868278 PRPH:ThirdPartyContractManufacturingCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000868278 PRPH:ThirdPartyContractManufacturingCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000868278 PRPH:DiagnosticServicesClientsOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:DiagnosticServicesClientsTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:ThirdPartyContractManufacturingCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000868278 PRPH:ThirdPartyContractManufacturingCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000868278 PRPH:DiagnosticServicesClientsOneMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:DiagnosticServicesClientsTwoMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:DiagnosticServicesClientsThreeMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:DiagnosticServicesClientsFourMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:DiagnosticServicesClientsFiveMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000868278 PRPH:CustomerOneMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000868278 PRPH:CustomerTwoMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000868278 PRPH:CustomerThreeMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000868278 PRPH:StockOptionsWarrantsAndConvertibleDebtMember 2021-07-01 2021-09-30 0000868278 PRPH:StockOptionsWarrantsAndConvertibleDebtMember 2021-01-01 2021-09-30 0000868278 PRPH:CommonStockEquivalentsTwoMember 2020-01-01 2020-09-30 0000868278 srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember PRPH:UnrelatedThirdPartyMember 2020-09-25 0000868278 us-gaap:SecuredDebtMember PRPH:UnrelatedThirdPartyMember 2020-09-25 0000868278 srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember PRPH:UnrelatedThirdPartyMember 2020-07-21 0000868278 srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember PRPH:UnrelatedThirdPartyMember 2020-07-29 0000868278 srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember PRPH:UnrelatedThirdPartyMember 2020-09-23 2020-09-25 0000868278 PRPH:ConsultingAgreementMember 2020-09-23 2020-09-25 0000868278 srt:MinimumMember PRPH:UnrelatedThirdPartyMember 2020-09-25 0000868278 srt:MaximumMember PRPH:UnrelatedThirdPartyMember 2020-09-25 0000868278 PRPH:TerminationAgreementMember 2021-01-15 2021-02-28 0000868278 us-gaap:SecuredDebtMember 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-07-01 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-07-01 2020-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-01-01 2020-09-30 0000868278 PRPH:ConsumerProductsMember 2021-07-01 2021-09-30 0000868278 PRPH:ConsumerProductsMember 2020-07-01 2020-09-30 0000868278 PRPH:ConsumerProductsMember 2021-01-01 2021-09-30 0000868278 PRPH:ConsumerProductsMember 2020-01-01 2020-09-30 0000868278 PRPH:UnallocatedCorporateMember 2021-07-01 2021-09-30 0000868278 PRPH:UnallocatedCorporateMember 2020-07-01 2020-09-30 0000868278 PRPH:UnallocatedCorporateMember 2021-01-01 2021-09-30 0000868278 PRPH:UnallocatedCorporateMember 2020-01-01 2020-09-30 0000868278 PRPH:DiagnosticServicesMember 2021-09-30 0000868278 PRPH:DiagnosticServicesMember 2020-12-31 0000868278 PRPH:ConsumerProductsMember 2021-09-30 0000868278 PRPH:ConsumerProductsMember 2020-12-31 0000868278 PRPH:UnallocatedCorporateMember 2021-09-30 0000868278 PRPH:UnallocatedCorporateMember 2020-12-31 0000868278 us-gaap:SubsequentEventMember 2021-11-08 2021-11-10 iso4217:USD shares iso4217:USD shares utr:sqft pure PRPH:Segment 0000868278 false --12-31 2021 Q3 P0Y 1000000 2 10-Q true 2021-09-30 false 000-21617 ProPhase Labs, Inc. DE 23-2577138 711 Stewart Ave Suite 200 Garden City NY 11530 (215) 345-0919 Common Stock, par value $0.0005 PRPH NASDAQ Yes Yes Non-accelerated Filer true false false 15511455 8533000 6816000 250000 14114000 1639000 214000 10680000 3155000 8510000 3039000 1602000 1238000 43903000 15887000 6454000 3578000 3774000 2750000 460000 2084000 4484000 4731000 11562000 1234000 1385000 901000 608000 240000 72630000 31405000 2394000 3771000 3260000 344000 463000 676000 329000 1517000 1741000 1731000 9932000 6294000 106000 162000 81000 9995000 9991000 4252000 4402000 14434000 14555000 24366000 20849000 1000000 1000000 0.0005 0.0005 0 0 0 0 50000000 0.0005 15652724 11604253 16000 14000 103807000 61674000 -7947000 -3631000 16652022 16652022 47490000 47490000 -122000 -11000 48264000 10556000 72630000 31405000 9472000 3840000 33885000 9351000 5495000 2798000 16515000 6615000 3977000 1042000 17370000 2736000 1478000 6117000 5938000 1552000 14713000 3875000 208000 57000 416000 181000 7624000 1609000 21246000 4056000 -3647000 -567000 -3876000 -1320000 230000 39000 531000 53000 296000 41000 870000 41000 -265000 -101000 -3978000 -569000 -4316000 -1308000 161000 161000 -3978000 -408000 -4316000 -1147000 -33000 -8000 -111000 -2000 -4011000 -416000 -4427000 -1149000 -0.26 -0.05 -0.29 -0.11 0.01 0.01 -0.26 -0.04 -0.29 -0.10 15439000 11604000 15055000 11593000 15154253 16000 99265000 -3969000 -89000 -47490000 47733000 483685 3608000 3608000 -33000 -33000 5986 8800 934000 934000 -3978000 -3978000 15652724 16000 103807000 -7947000 -122000 -47490000 48264000 11591648 14000 60611000 -2245000 4000 -47490000 10894000 4000 -8000 -8000 12605 283000 283000 -408000 -408000 11604253 14000 60894000 -2653000 -4000 -47490000 10761000 11604253 14000 61674000 -3631000 -11000 -47490000 10556000 2365000 3000000 2000 35133000 35135000 2000 35133000 35135000 550000 5500000 5500000 483685 3608000 3608000 4546000 4546000 -111000 -111000 5986000 8800 2438000 2438000 -4316000 -4316000 15652724 16000 103807000 -7947000 -122000 -47490000 48264000 11573593 14000 60215000 -1506000 -2000 -47490000 11231000 4000 -2000 -2000 -2000 -2000 30660 679000 679000 -1147000 -1147000 11604253 14000 60894000 -2653000 -4000 -47490000 10761000 -4316000 -1147000 -40000 2000 2044000 253000 4000 247000 -17000 2438000 679000 -101000 315000 7327000 1015000 -4812000 5036000 696000 -1639000 30000 368000 -1749000 470000 3260000 1461000 197000 -1292000 835000 -8972000 4176000 9066000 1000000 2974000 21527000 4317000 10701000 3839000 4258000 222000 -25150000 -3674000 35135000 5500000 10000000 10000 66000 4546000 36089000 9924000 1967000 10426000 6816000 434000 8783000 10860000 750000 3608000 -111000 -2000 <p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zzoaHCZtyoga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 1 - <span id="xdx_824_zokbICUAgUsd">Organization and Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">ProPhase Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a diversified biotech and genomics company with deep experience with over-the- counter (“OTC”) consumer healthcare products and dietary supplements. We currently conduct our operations through two operating segments: diagnostic services and consumer products. Until late Fiscal 2020, we were engaged primarily in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. However, commencing in December 2020, we also began offering COVID-19 and other Respiratory Pathogen Panel (RPP) molecular tests through our new diagnostic services business and in August 2021 we began offering personal genomics products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Our wholly-owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers a variety of medical tests, including COVID-19 and Respiratory Pathogen Panel (RPP) molecular tests. On October 23, 2020, we acquired Confucius Plaza Medical Laboratory Corp. (“CPM”), including a 4,000 square foot Clinical Laboratory Improvement Amendments (“CLIA”) accredited laboratory located in Old Bridge, New Jersey (see Note 3, Business Acquisitions). As part of the acquisition of CPM in October 2020, we entered into a new business line, diagnostic services. In December 2020, we expanded our diagnostic service business with the build out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in February 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Our wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On August 10, 2021, we acquired Nebula Genomics, Inc., a privately owned personal genomics company, through our new wholly-owned subsidiary, ProPhase Precision Medicine, Inc. (see Note 3, Business Acquisitions).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">In addition, we continue to actively pursue acquisition opportunities for other companies, technologies and products within and outside the consumer products industry.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">  </span></p> <p id="xdx_80A_ecustom--BusinessAndLiquidityUncertaintiesTextBlock_zhE7MqES88N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 2 - <span id="xdx_820_zhZXOd6T7Ynk">Business and Liquidity Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span>Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of operating results that may be achieved over the course of the full year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Segments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">Operating segments are defined as components of an enterprise that engage in business activities for which separate financial information is available and is evaluated by the Chief Operating Decision Maker (“CODM”), which for the Company is its Chief Executive Officer, in deciding how to allocate resources and assess performance. For the three and nine months ended September 30, 2021, we maintained two operating segments: diagnostic services (which includes our COVID-19 and other diagnostic testing services) and consumer products (which includes our contract manufacturing, retail customers and personal genomics products and services). For the three and nine months ended September 30, 2020, we only had the consumer products operating segment. (see Note 15, Segment Information).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Business and Liquidity Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i/></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We launched our</span><span style="font: 10pt Times New Roman, Times, Serif"> diagnostic service business in December 2020 and expanded in February 2021 with the opening of our new Garden City, New York CLIA accredited laboratory. Our diagnostic service business is and will continue to be influenced by the level of demand for COVID-19 and other diagnostic testing, the prices we are able to receive for performing our testing services, and the length of time for which that demand persists, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">While our revenues increased for the three and nine months ended September 30, 2021 as a result of revenues from our new diagnostic services business line, we have made and will continue to make substantial investments to secure the necessary equipment, supplies and personnel to provide these testing services. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will be successful in the future or that the revenue and operating profits from such business will increase or maintain their current level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in">We acquired and commenced our personal genomics business in August 2021. This business will be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">There are still numerous uncertainties associated with the COVID-19 pandemic, including the efficacy of the vaccines that have been developed to treat the virus and their ability to protect against new strains of the virus, people’s willingness to receive a vaccine, possible resurgences of the coronavirus and/or new strains of the virus, the extent and duration of protective and preventative measures that may be adopted by local, state and/or the federal government in the future as a result of future outbreaks, the duration of any future business closures, the ongoing impact of COVID-19 on the U.S. and world economy and consumer confidence, and various other uncertainties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Company used cash in operating activities of $<span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn6n6_di_c20210101__20210930_zYsN5JNaOYsk">9</span>.0 million for the nine months ended September 30, 2021. The Company had cash, cash equivalents and marketable securities of $<span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20210930_zVhir01E33x1">22.9</span> million as of September 30, 2021. Based on management’s current business plan, the Company estimates it will have enough cash and liquidity to finance its operating requirements for at least one year from the date of filing these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 25.35pt"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily limited to, the actual cost and time necessary to achieve sustained profitability within its newly launched diagnostic services and personal genomics businesses. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 25.35pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 25.35pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, diagnostic services reimbursements, inventory obsolescence, useful lives of property and equipment, impairment of goodwill, intangibles and property and equipment, income tax valuations and assumptions related to accrued advertising. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Cash and Cash Equivalents</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Marketable Debt Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We have classified our investments in marketable debt securities as available-for-sale and as a current asset. Our investments in marketable debt securities are carried at fair value, with unrealized gains and as a separate component of stockholders’ equity. Realized gains and losses from our marketable debt securities are recorded as interest income (expense). These investments in marketable debt securities, carry maturity dates between one and three years from date of purchase and interest rates of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20210101__20210930__us-gaap--InformationByCategoryOfDebtSecurityAxis__custom--MarketableSecuritiesMember__srt--RangeAxis__srt--MinimumMember_zHYvFmbDgW41">1.90</span></span><span style="font: 10pt Times New Roman, Times, Serif">% to <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20210101__20210930__us-gaap--InformationByCategoryOfDebtSecurityAxis__custom--MarketableSecuritiesMember__srt--RangeAxis__srt--MaximumMember_zzoxj5FCUXA2">3.62</span></span><span style="font: 10pt Times New Roman, Times, Serif">% during the first three quarters of Fiscal 2021. For the three and nine months ended September 30, 2021, we reported unrealized losses of $<span id="xdx_907_ecustom--MarketableSecuritiesUnrealizedLoss_pp0p0_c20210701__20210930_zVNXeVckbLr7">32,000</span></span> <span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_ecustom--MarketableSecuritiesUnrealizedLoss_pp0p0_c20210101__20210930_zuSjdxeEUxZ7">111,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively. Unrealized gains and losses are classified as other comprehensive loss and the cost is determined on a specific identification basis. The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (see fair value of financial instruments) (in thousands):</span></p> <p id="xdx_89A_eus-gaap--MarketableSecuritiesTextBlock_zjzEFbpj7xe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_z9Xf9jAvX0z9" style="display: none">Summary of Components of Marketable Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 14%; text-align: right" title="Amortized Cost">324</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zPCxnaod9qzb" style="width: 14%; text-align: right" title="Unrealized Losses">(1</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 14%; text-align: right" title="Fair Value">323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Corporate obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortized Cost">13,912</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zTA7nQ6Vsrsd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Losses">(121</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecuritiesCurrent_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">13,791</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">14,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20210930_zYsByAM3oAj8" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized Losses">(122</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">14,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 14%; text-align: right" title="Amortized Cost">1,021</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zQvM3Kt0Q1Kg" style="width: 14%; text-align: right" title="Unrealized Losses">(7</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesCurrent_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 14%; text-align: right" title="Fair Value">1,014</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Corporate obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortized Cost">629</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zCAOavB9O2b1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Losses">(4</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">625</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">1,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231_zdRSUCduKdD" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized Losses">(11</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">1,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zsZziW8jOGtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We believe that the unrealized gains or losses generally are the result of a change in the risk premiums required by market participants rather than an adverse change in cash flows or a fundamental weakness in the credit quality of the issuer or underlying assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Marketable Equity Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net in the consolidated statements of income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On June 25, 2021, we were issued <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_pdd">1,260,619 </span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares (the “Investment Shares”) as an interest payment under our note receivable (see Note 14, Secured Promissory Note Receivable and Consulting Agreement) with a fair value of $<span id="xdx_90F_eus-gaap--InvestmentOwnedAtFairValue_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_pp0p0">315,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">. The fair value of the Investment Shares as of September 30, 2021 was based upon the closing stock price of $<span id="xdx_907_eus-gaap--SharePrice_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_pdd">0.17 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. The investment was classified as a Level 1 financial instrument. We recorded a $<span id="xdx_907_ecustom--DecreaseInFairValueOfInvestmentSecurities_pp0p0_c20210701__20210930_zSdSQd9QLU0g">265,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_ecustom--DecreaseInFairValueOfInvestmentSecurities_pp0p0_c20210101__20210930_zDQNSeCFXbqf">101,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">decrease in fair value of investment securities within the statement of operations for the three and nine months ended September 30, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Inventories, net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or net realizable value. Inventory items are analyzed to determine cost and the net realizable value and appropriate valuation adjustments are then established. At September 30, 2021 and December 31, 2020, the financial statements include non-cash adjustments to adjust inventory for excess, obsolete or short-dated shelf-life inventory by $<span id="xdx_908_eus-gaap--InventoryAdjustments_c20210930_pp0p0" title="Inventory Adjustments">87,000</span> and $<span id="xdx_902_eus-gaap--InventoryAdjustments_c20201231_pp0p0" title="Inventory Adjustments">167,000</span>, respectively. The components of inventory are as follows (in thousands):</span></p> <p id="xdx_895_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zVP79XRjmrfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BE_zwsySuMpKEQ" style="display: none">Schedule of Components of Inventory</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49A_20210930_zz84HKglXJTi" style="text-align: center; vertical-align: bottom">September 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_499_20201231_zpjooufSZcml" style="vertical-align: bottom; text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_ecustom--InventoryLabMaterial_iI_pn3n3_maINzdd2_zp4uYZ5PE5Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Diagnostic services testing material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,203</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,028</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzdd2_z8gE3H4YVSf5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Raw materials</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,464</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,404</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzdd2_zZu0NrjhaUe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">407</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzdd2_zYFytiKnV8Of" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">436</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">170</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryNet_iTI_pn3n3_mtINzdd2_zgP103sVXts7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Inventory, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,510</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zXnNg2T9OJfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Property, Plant and Equipment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20210930_zrU0etT1zmka" title="Estimated useful lives description">ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We did not identify any indicators of impairment of our property, plant and equipment for the nine months ended September 30, 2021 and 2020 and concluded there were no impairments or changes in useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Concentration of Risks</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity and marketing and distribution capabilities, as well as our ability to comply with the regulatory requirements associated with the development of OTC consumer healthcare products, dietary supplements and other remedies in order to compete on a national level and/or international level. Our diagnostic services business will be influenced by demand for our diagnostic testing services, particularly COVID-19 testing services, our marketing and service capabilities, and our ability to comply with regulatory requirements associated with operating under and maintaining our CLIA license. Our personal genomics business is and will continue to be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products and services. The manufacturing and distribution of OTC healthcare and dietary supplement products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States. The FDA is also responsible for the regulation of diagnostic testing instruments, test kits, reagents and other devices used by clinical laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and trade accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We maintain cash and cash equivalents with certain major financial institutions. As of September 30, 2021, our cash and cash equivalents balance were $<span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20210930_zyUpnSvxiTmk" title="Cash and Cash Equivalents, at Carrying Value">8.5</span> million and our bank balance was $<span id="xdx_901_eus-gaap--Cash_iI_pn5n6_c20210930_zMIZjxlKRn6i" title="Cash">8.7</span> million. Of the total bank balance, $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_pn5n6_c20210930_z67W5Dtx4Keh" title="Cash, FDIC Insured Amount">1.0</span> million was covered by federal depository insurance and $<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20210930_zWeplMQg9Joh" title="Cash, Uninsured Amount">7.7</span> million was uninsured at September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depend on information provided and billing services of third parties. These credit concentrations impact our overall exposure to credit risk, which could be further affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of trade receivables and diagnostic test receivables. Additionally, the reimbursement receivables from the diagnostic service business are subject to billing errors and related disputes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We also assess the financial condition of the debtor under our note receivable (see Note 14, Secured Promissory Note Receivable and Consulting Agreement), balances due to us. As of September 30, 2021, December 31, 2020 and the financial statements reporting date, the Company expects full realization upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. We have elected not to recognize on the balance sheet leases with terms of 12 months or less. We typically only include an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in our assessment unless there is reasonable certainty that we will renew.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in our leases is typically not readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 11, Leases).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The components of a lease should be allocated between lease components (<i>e.g</i>., land, building, etc.) and non-lease components (<i>e.g</i>., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Goodwill and Intangible Assets</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill and other intangibles at that time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In testing for goodwill impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, we conclude that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If we conclude otherwise, we are required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than the carrying value, an impairment charge will be recorded to reduce the reporting unit to fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Intangible assets deemed to have finite lives are amortized on a straight-line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to our future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in; background-color: white"> </p> <p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zreaP4XO3SYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><b><i><span id="xdx_86D_zOJbuorW6sT1">Impairment of Long-Lived Assets</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in">The Company reviews long-lived assets, including property and equipment and finite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when the asset’s carrying value exceeds the total undiscounted cash flows expected from its use and eventual disposition. The amount of the impairment loss is determined as the excess of the carrying value of the asset over its fair value. For the three and nine months ended September 30, 2021 and 2020, the Company did not have an impairment of the intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Fair Value of Financial Instruments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following are the hierarchical levels of inputs to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, secured note receivable and unsecured note payable, approximate their fair values because of the current nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity change in fair value reported on the condensed consolidated statement of operations (see Note 14, Secured Promissory Note Receivable and Consulting Agreement). The components of marketable securities and are as follows (in thousands): </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zFamhhQZSJM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B5_zWDIbF7wcXf4" style="display: none">Schedule of Fair Value of Financial Instruments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable debt securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Corporate obligations</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="text-align: right" title="Fair value of marketable debt securities">13,791</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="text-align: right" title="Fair value of marketable debt securities">13,791</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Marketable equity securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNi_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities">214</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNi_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNi_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--EquitySecuritiesFvNi_c20210930_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities">214</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecurities_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">14,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">14,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable debt securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">1,014</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">1,014</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Corporate obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0870">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities">625</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities">625</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">1,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecurities_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">1,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zipXctKY0dZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Revenue Recognition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Contract with Customers and Performance Obligations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. We had historically generated sales principally through two types of customers, contract manufacturing and retail customers for our consumer products. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. As of December 2020, we also began generating revenues through diagnostic services and in August 2021 we acquired a personal genomics business, which we now include in our consumer products revenue. See Note 3, Business Acquisitions, for additional information on our October 2020 and August 2021 acquisitions. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue over time as the services are provided to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s performance obligation for contract manufacturing and retail customers is to provide the goods ordered by the customer. The Company’s has one performance obligation for its diagnostic services, which is to provide the results of the laboratory test to the customer. Our personal genomics business has separate performance obligations to provide initial testing and genome results and subscriptions services to our customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Transaction Price</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers, including health plans, government agencies and consumers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on, the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. If the customer does not return the test kit, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. The Company recognizes the breakage amounts as revenue, proportionate to the pattern of revenue recognition of the returning test kits. The Company estimates breakage for the portion of test kits not expected to be returned using an analysis of historical data and considers other factors that could influence customer test kit return behavior. The Company recognized breakage revenue from unreturned test kits of $<span id="xdx_903_ecustom--BreakageRevenue_pn5n6_c20210701__20210930_zzuxoK3mu3rc" title="Breakage revenue"><span id="xdx_90A_ecustom--BreakageRevenue_pn5n6_c20210101__20210930_zGZBIjrcsonb">0.1</span></span> million for the three and nine months ended September 30, 2021. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recognize Revenue When the Company Satisfies a Performance Obligation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Performance obligations related to contract manufacturing and retail customers are satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped. For diagnostic services, the Company satisfies its performance obligation at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control. </span><span style="font-size: 10pt">For genomic services, the Company satisfies its product performance obligation at a point in time when the genetics testing results are provided to the customer. For subscriptions services associated with its genomic testing, the Company satisfies its performance obligation over time as the applicable services are provided to the customer</span>. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Contract Balances</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021 and December 31, 2020, we have deferred revenue of $<span id="xdx_90E_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20210930_zABFoISnIaYj">1,623,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_908_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20201231_zVWw3WH7jpN5">331,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively. Our newly launched personal genomics business contributed $<span id="xdx_90D_eus-gaap--DeferredRevenue_iI_c20210930_zQhJQXCqJEKc" title="Deferred revenue">1,403,000</span> to our deferred revenue as of September 30, 2021. The remainder of deferred revenue relates to research and development (“R&amp;D”) stability and release testing programs recognized as contract manufacturing revenue. Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&amp;D work. We recognize deferred revenues as revenues when the services are performed and the corresponding revenue recognition criteria are met. Customer prepayments are generally applied against invoices issued to customers when services are performed and billed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_895_ecustom--ScheduleOfDeferredRevenueTableTextBlock_zORuEtHoHu6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table disaggregates our deferred revenue by recognition period (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zWo6Kb6iZnL5" style="display: none">Schedule of Deferred Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">As of September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Recognition Period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%">0-12 Months</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20210930__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_zCStaN0WdAN4" style="width: 22%; text-align: right" title="Total">1,517</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_z6gYtA7bSiGi" style="width: 22%; text-align: right" title="Total">169</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>13-24 Months</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20210930__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_z1iDIxy5ZMSh" style="text-align: right" title="Total">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_zOBlTNlqg1Xb" style="text-align: right" title="Total">84</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Over 24 Months</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20210930__srt--StatementScenarioAxis__custom--OverTwentyFourMember_zIelwfOWca1j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__srt--StatementScenarioAxis__custom--OverTwentyFourMember_zLUguhGV6kR9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">78</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iI_pp0n3_c20210930_zO3lsfSncqe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">1,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiability_iI_pp0n3_c20201231_z6PWaRUsu5J1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">331</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zuaWOeDdHaI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Disaggregation of Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We disaggregate revenue from contracts with customers into four categories: contract manufacturing, retail and others, diagnostic services and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_zzOgcXGHtyE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table disaggregates our revenue by revenue source for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_zq2vGC8JhO39" style="display: none">Schedule of Disaggregation by Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20210701__20210930_zvhztiz7xSAb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20200701__20200930_zIi02dOVzP4j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_495_20210101__20210930_zVUQoJt3vBQh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20200101__20200930_z565MZxlYYEh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Revenue by Customer Type</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractManufacturingMember_ziUheGtDeSA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Contract manufacturing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,120</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,630</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,069</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,825</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--RetailAndOtherMember_zKGwyV8A7Ase" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Retail and others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">526</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--DiagnosticServicesMember_zv6rycwAtkVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Diagnostic services</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,142</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,416</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenue, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,472</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,840</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,885</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zmFgqsMEIsfh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Customer Consideration</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Company makes payments to certain diagnostic services customers for distinct services that approximate fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, logistics services, as well as other information requirements. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations. Diagnostic services cost of revenue includes specimen collection payments to customers and other costs incurred in connection with the Company operated laboratories, including reagent and other raw material costs, direct and indirect labor and other laboratory facility overhead (see Note 15, Segment Information).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Shipping and Handling Activities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the goods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Advertising and Incentive Promotions</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended September 30, 2021 and 2020 were $<span id="xdx_903_ecustom--AdvertisingAndIncentivePromotionExpensesContinuingOperation_pp0p0_c20210701__20210930__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zfgEpkGzMv06" title="Advertising and incentive promotion expenses, continuing operation">136,000</span> and $<span id="xdx_905_ecustom--AdvertisingAndIncentivePromotionExpensesContinuingOperation_pp0p0_c20200701__20200930__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zy3wSqcaXjP5" title="Advertising and incentive promotion expenses, continuing operation">451,000</span>, respectively. Advertising and incentive promotion expenses incurred for the nine months ended September 30, 2021 and 2020 were $<span id="xdx_902_ecustom--AdvertisingAndIncentivePromotionExpensesContinuingOperation_pp0p0_c20210101__20210930__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zFCi1WvvjJxi" title="Advertising and incentive promotion expenses, continuing operation">415,000</span> and $<span id="xdx_905_ecustom--AdvertisingAndIncentivePromotionExpensesContinuingOperation_pp0p0_c20200101__20200930__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zcgDMGe6rjg2" title="Advertising and incentive promotion expenses, continuing operation">547,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Share-Based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We recognize all share-based payments to employees, directors and consultants, including grants of stock options and common shares, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans. Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended September 30, 2021 and 2020, we charged to operations $<span><span id="xdx_907_eus-gaap--ShareBasedCompensation_pn3n3_c20210701__20210930_zXPotRkZYwg7">934</span>,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span><span id="xdx_901_eus-gaap--ShareBasedCompensation_pn3n3_c20200701__20200930_zfgy7wEtCYv3">283</span>,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services. For the nine months ended September 30, 2021 and 2020, we charged to operations $<span><span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210930_zADqXMET6Zx9">2,438</span>,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span><span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200930_zAui84V4jnbc">679</span>,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Research and Development </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">R&amp;D costs are charged to operations in the period incurred. R&amp;D costs incurred for the three months ended September 30, 2021 and 2020 were $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20210701__20210930_zyzGhffcBNO">208</span>,000 and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200701__20200930_zO87b7HnsvX9">57</span>,000, respectively. R&amp;D costs incurred for the nine months ended September 30, 2021 and 2020 were $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20210101__20210930_zjur3jfTPJ6d" title="Research and Development Expense">416</span>,000 and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20200930_z0wTSVz75uFk" title="Research and Development Expense">181</span>,000, respectively. R&amp;D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation fees in association with the diagnostic services business including the validation work of the diagnostic services business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Income Taxes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We utilize the asset and liability approach, which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to income taxes will be recorded as interest or administrative expense, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">As a result of our historical losses from continuing operations, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Recently Issued Accounting Standards, Not Yet Adopted</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The FASB recently issued ASU 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i>, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, <i>Earnings Per Share</i>, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We are currently assessing the impact of the adoption of this ASU on our financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on the Company’s financial statements or disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">In October 2021, the FASB issued ASU 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). The standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. ASU 2021-08 will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are in the process of evaluating the impact that ASU 2021-08 will have on our condensed consolidated financial statements and associated disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> -9000000 22900000 0.0190 0.0362 32000 111000 <p id="xdx_89A_eus-gaap--MarketableSecuritiesTextBlock_zjzEFbpj7xe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_z9Xf9jAvX0z9" style="display: none">Summary of Components of Marketable Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 14%; text-align: right" title="Amortized Cost">324</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zPCxnaod9qzb" style="width: 14%; text-align: right" title="Unrealized Losses">(1</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 14%; text-align: right" title="Fair Value">323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Corporate obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortized Cost">13,912</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zTA7nQ6Vsrsd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Losses">(121</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecuritiesCurrent_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">13,791</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">14,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20210930_zYsByAM3oAj8" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized Losses">(122</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">14,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 14%; text-align: right" title="Amortized Cost">1,021</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zQvM3Kt0Q1Kg" style="width: 14%; text-align: right" title="Unrealized Losses">(7</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesCurrent_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 14%; text-align: right" title="Fair Value">1,014</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Corporate obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortized Cost">629</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zCAOavB9O2b1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Losses">(4</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">625</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">1,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231_zdRSUCduKdD" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized Losses">(11</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">1,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 324000 1000 323000 13912000 121000 13791000 14236000 122000 14114000 1021000 7000 1014000 629000 4000 625000 1650000 11000 1639000 1260619 315000 0.17 265000 101000 87000 167000 <p id="xdx_895_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zVP79XRjmrfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BE_zwsySuMpKEQ" style="display: none">Schedule of Components of Inventory</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49A_20210930_zz84HKglXJTi" style="text-align: center; vertical-align: bottom">September 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_499_20201231_zpjooufSZcml" style="vertical-align: bottom; text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_ecustom--InventoryLabMaterial_iI_pn3n3_maINzdd2_zp4uYZ5PE5Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Diagnostic services testing material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,203</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,028</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzdd2_z8gE3H4YVSf5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Raw materials</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,464</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,404</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzdd2_zZu0NrjhaUe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">407</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzdd2_zYFytiKnV8Of" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">436</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">170</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryNet_iTI_pn3n3_mtINzdd2_zgP103sVXts7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Inventory, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,510</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6203000 1028000 1464000 1404000 407000 437000 436000 170000 8510000 3039000 ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years. 8500000 8700000 1000000.0 7700000 <p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zreaP4XO3SYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><b><i><span id="xdx_86D_zOJbuorW6sT1">Impairment of Long-Lived Assets</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in">The Company reviews long-lived assets, including property and equipment and finite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when the asset’s carrying value exceeds the total undiscounted cash flows expected from its use and eventual disposition. The amount of the impairment loss is determined as the excess of the carrying value of the asset over its fair value. For the three and nine months ended September 30, 2021 and 2020, the Company did not have an impairment of the intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Fair Value of Financial Instruments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following are the hierarchical levels of inputs to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, secured note receivable and unsecured note payable, approximate their fair values because of the current nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity change in fair value reported on the condensed consolidated statement of operations (see Note 14, Secured Promissory Note Receivable and Consulting Agreement). The components of marketable securities and are as follows (in thousands): </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zFamhhQZSJM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B5_zWDIbF7wcXf4" style="display: none">Schedule of Fair Value of Financial Instruments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable debt securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Corporate obligations</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="text-align: right" title="Fair value of marketable debt securities">13,791</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="text-align: right" title="Fair value of marketable debt securities">13,791</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Marketable equity securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNi_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities">214</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNi_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNi_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--EquitySecuritiesFvNi_c20210930_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities">214</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecurities_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">14,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">14,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable debt securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">1,014</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">1,014</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Corporate obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0870">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities">625</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities">625</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">1,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecurities_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">1,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zipXctKY0dZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Revenue Recognition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Contract with Customers and Performance Obligations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. We had historically generated sales principally through two types of customers, contract manufacturing and retail customers for our consumer products. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. As of December 2020, we also began generating revenues through diagnostic services and in August 2021 we acquired a personal genomics business, which we now include in our consumer products revenue. See Note 3, Business Acquisitions, for additional information on our October 2020 and August 2021 acquisitions. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue over time as the services are provided to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s performance obligation for contract manufacturing and retail customers is to provide the goods ordered by the customer. The Company’s has one performance obligation for its diagnostic services, which is to provide the results of the laboratory test to the customer. Our personal genomics business has separate performance obligations to provide initial testing and genome results and subscriptions services to our customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Transaction Price</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers, including health plans, government agencies and consumers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on, the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. If the customer does not return the test kit, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. The Company recognizes the breakage amounts as revenue, proportionate to the pattern of revenue recognition of the returning test kits. The Company estimates breakage for the portion of test kits not expected to be returned using an analysis of historical data and considers other factors that could influence customer test kit return behavior. The Company recognized breakage revenue from unreturned test kits of $<span id="xdx_903_ecustom--BreakageRevenue_pn5n6_c20210701__20210930_zzuxoK3mu3rc" title="Breakage revenue"><span id="xdx_90A_ecustom--BreakageRevenue_pn5n6_c20210101__20210930_zGZBIjrcsonb">0.1</span></span> million for the three and nine months ended September 30, 2021. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recognize Revenue When the Company Satisfies a Performance Obligation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Performance obligations related to contract manufacturing and retail customers are satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped. For diagnostic services, the Company satisfies its performance obligation at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control. </span><span style="font-size: 10pt">For genomic services, the Company satisfies its product performance obligation at a point in time when the genetics testing results are provided to the customer. For subscriptions services associated with its genomic testing, the Company satisfies its performance obligation over time as the applicable services are provided to the customer</span>. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Contract Balances</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021 and December 31, 2020, we have deferred revenue of $<span id="xdx_90E_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20210930_zABFoISnIaYj">1,623,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_908_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20201231_zVWw3WH7jpN5">331,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively. Our newly launched personal genomics business contributed $<span id="xdx_90D_eus-gaap--DeferredRevenue_iI_c20210930_zQhJQXCqJEKc" title="Deferred revenue">1,403,000</span> to our deferred revenue as of September 30, 2021. The remainder of deferred revenue relates to research and development (“R&amp;D”) stability and release testing programs recognized as contract manufacturing revenue. Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&amp;D work. We recognize deferred revenues as revenues when the services are performed and the corresponding revenue recognition criteria are met. Customer prepayments are generally applied against invoices issued to customers when services are performed and billed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_895_ecustom--ScheduleOfDeferredRevenueTableTextBlock_zORuEtHoHu6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table disaggregates our deferred revenue by recognition period (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zWo6Kb6iZnL5" style="display: none">Schedule of Deferred Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">As of September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Recognition Period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%">0-12 Months</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20210930__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_zCStaN0WdAN4" style="width: 22%; text-align: right" title="Total">1,517</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_z6gYtA7bSiGi" style="width: 22%; text-align: right" title="Total">169</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>13-24 Months</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20210930__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_z1iDIxy5ZMSh" style="text-align: right" title="Total">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_zOBlTNlqg1Xb" style="text-align: right" title="Total">84</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Over 24 Months</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20210930__srt--StatementScenarioAxis__custom--OverTwentyFourMember_zIelwfOWca1j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__srt--StatementScenarioAxis__custom--OverTwentyFourMember_zLUguhGV6kR9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">78</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iI_pp0n3_c20210930_zO3lsfSncqe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">1,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiability_iI_pp0n3_c20201231_z6PWaRUsu5J1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">331</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zuaWOeDdHaI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Disaggregation of Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We disaggregate revenue from contracts with customers into four categories: contract manufacturing, retail and others, diagnostic services and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_zzOgcXGHtyE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table disaggregates our revenue by revenue source for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_zq2vGC8JhO39" style="display: none">Schedule of Disaggregation by Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20210701__20210930_zvhztiz7xSAb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20200701__20200930_zIi02dOVzP4j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_495_20210101__20210930_zVUQoJt3vBQh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20200101__20200930_z565MZxlYYEh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Revenue by Customer Type</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractManufacturingMember_ziUheGtDeSA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Contract manufacturing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,120</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,630</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,069</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,825</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--RetailAndOtherMember_zKGwyV8A7Ase" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Retail and others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">526</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--DiagnosticServicesMember_zv6rycwAtkVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Diagnostic services</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,142</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,416</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenue, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,472</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,840</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,885</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zmFgqsMEIsfh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Customer Consideration</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Company makes payments to certain diagnostic services customers for distinct services that approximate fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, logistics services, as well as other information requirements. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations. Diagnostic services cost of revenue includes specimen collection payments to customers and other costs incurred in connection with the Company operated laboratories, including reagent and other raw material costs, direct and indirect labor and other laboratory facility overhead (see Note 15, Segment Information).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Shipping and Handling Activities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the goods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Advertising and Incentive Promotions</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended September 30, 2021 and 2020 were $<span id="xdx_903_ecustom--AdvertisingAndIncentivePromotionExpensesContinuingOperation_pp0p0_c20210701__20210930__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zfgEpkGzMv06" title="Advertising and incentive promotion expenses, continuing operation">136,000</span> and $<span id="xdx_905_ecustom--AdvertisingAndIncentivePromotionExpensesContinuingOperation_pp0p0_c20200701__20200930__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zy3wSqcaXjP5" title="Advertising and incentive promotion expenses, continuing operation">451,000</span>, respectively. Advertising and incentive promotion expenses incurred for the nine months ended September 30, 2021 and 2020 were $<span id="xdx_902_ecustom--AdvertisingAndIncentivePromotionExpensesContinuingOperation_pp0p0_c20210101__20210930__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zFCi1WvvjJxi" title="Advertising and incentive promotion expenses, continuing operation">415,000</span> and $<span id="xdx_905_ecustom--AdvertisingAndIncentivePromotionExpensesContinuingOperation_pp0p0_c20200101__20200930__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zcgDMGe6rjg2" title="Advertising and incentive promotion expenses, continuing operation">547,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Share-Based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We recognize all share-based payments to employees, directors and consultants, including grants of stock options and common shares, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans. Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended September 30, 2021 and 2020, we charged to operations $<span><span id="xdx_907_eus-gaap--ShareBasedCompensation_pn3n3_c20210701__20210930_zXPotRkZYwg7">934</span>,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span><span id="xdx_901_eus-gaap--ShareBasedCompensation_pn3n3_c20200701__20200930_zfgy7wEtCYv3">283</span>,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services. For the nine months ended September 30, 2021 and 2020, we charged to operations $<span><span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210930_zADqXMET6Zx9">2,438</span>,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span><span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200930_zAui84V4jnbc">679</span>,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Research and Development </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">R&amp;D costs are charged to operations in the period incurred. R&amp;D costs incurred for the three months ended September 30, 2021 and 2020 were $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20210701__20210930_zyzGhffcBNO">208</span>,000 and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200701__20200930_zO87b7HnsvX9">57</span>,000, respectively. R&amp;D costs incurred for the nine months ended September 30, 2021 and 2020 were $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20210101__20210930_zjur3jfTPJ6d" title="Research and Development Expense">416</span>,000 and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20200930_z0wTSVz75uFk" title="Research and Development Expense">181</span>,000, respectively. R&amp;D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation fees in association with the diagnostic services business including the validation work of the diagnostic services business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Income Taxes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We utilize the asset and liability approach, which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to income taxes will be recorded as interest or administrative expense, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">As a result of our historical losses from continuing operations, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Recently Issued Accounting Standards, Not Yet Adopted</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The FASB recently issued ASU 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i>, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, <i>Earnings Per Share</i>, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We are currently assessing the impact of the adoption of this ASU on our financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on the Company’s financial statements or disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">In October 2021, the FASB issued ASU 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). The standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. ASU 2021-08 will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are in the process of evaluating the impact that ASU 2021-08 will have on our condensed consolidated financial statements and associated disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zFamhhQZSJM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B5_zWDIbF7wcXf4" style="display: none">Schedule of Fair Value of Financial Instruments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable debt securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Corporate obligations</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="text-align: right" title="Fair value of marketable debt securities">13,791</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--MarketableSecurities_c20210930__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="text-align: right" title="Fair value of marketable debt securities">13,791</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Marketable equity securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNi_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities">214</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNi_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNi_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--EquitySecuritiesFvNi_c20210930_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable equity securities">214</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecurities_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">14,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">14,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable debt securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">U.S. government obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">1,014</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="width: 10%; text-align: right" title="Fair value of marketable debt securities">1,014</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Corporate obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0870">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities">625</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--MarketableSecurities_c20201231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of marketable debt securities">625</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">1,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecurities_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of marketable debt securities">1,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 323000 323000 13791000 13791000 214000 214000 214000 14114000 14328000 1014000 1014000 625000 625000 1639000 1639000 100000 100000 1623000 331000 1403000 <p id="xdx_895_ecustom--ScheduleOfDeferredRevenueTableTextBlock_zORuEtHoHu6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table disaggregates our deferred revenue by recognition period (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zWo6Kb6iZnL5" style="display: none">Schedule of Deferred Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">As of September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Recognition Period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%">0-12 Months</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20210930__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_zCStaN0WdAN4" style="width: 22%; text-align: right" title="Total">1,517</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_z6gYtA7bSiGi" style="width: 22%; text-align: right" title="Total">169</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>13-24 Months</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20210930__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_z1iDIxy5ZMSh" style="text-align: right" title="Total">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_zOBlTNlqg1Xb" style="text-align: right" title="Total">84</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Over 24 Months</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20210930__srt--StatementScenarioAxis__custom--OverTwentyFourMember_zIelwfOWca1j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__srt--StatementScenarioAxis__custom--OverTwentyFourMember_zLUguhGV6kR9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">78</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iI_pp0n3_c20210930_zO3lsfSncqe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">1,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiability_iI_pp0n3_c20201231_z6PWaRUsu5J1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">331</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1517000 169000 71000 84000 35000 78000 1623000 331000 <p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_zzOgcXGHtyE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table disaggregates our revenue by revenue source for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_zq2vGC8JhO39" style="display: none">Schedule of Disaggregation by Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20210701__20210930_zvhztiz7xSAb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20200701__20200930_zIi02dOVzP4j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_495_20210101__20210930_zVUQoJt3vBQh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20200101__20200930_z565MZxlYYEh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Revenue by Customer Type</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractManufacturingMember_ziUheGtDeSA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Contract manufacturing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,120</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,630</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,069</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,825</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--RetailAndOtherMember_zKGwyV8A7Ase" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Retail and others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">526</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--DiagnosticServicesMember_zv6rycwAtkVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Diagnostic services</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,142</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,416</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenue, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,472</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,840</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,885</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1120000 3630000 4069000 8825000 1210000 210000 2400000 526000 7142000 27416000 9472000 3840000 33885000 9351000 136000 451000 415000 547000 934000 283000 2438000 679000 208000 57000 416000 181000 <p id="xdx_803_eus-gaap--BusinessCombinationDisclosureTextBlock_z3IZ5jVe6kkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 3 - <span id="xdx_827_z2wZnl4EQmVf">Business Acquisitions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Nebula Acquisition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On August 10, 2021 (the “Effective Date”), the Company and its wholly-owned subsidiary, ProPhase Precision Medicine, Inc. (“ProPhase Precision”), entered into and closed a Stock Purchase Agreement (the “Nebula Stock Purchase Agreement”) with Nebula Genomics, Inc., a privately owned personal genomics company (“Nebula”), each of the stockholders of Nebula (the “Seller Parties”), and Kamal Obbad, as Seller Party Representative. Pursuant to the terms of the Nebula Stock Purchase Agreement, ProPhase Precision acquired all of the issued and outstanding shares of common stock of Nebula from the Seller Parties, for an aggregate purchase price of approximately $<span id="xdx_907_ecustom--PurchasePriceOfCommonStock_pn5n6_c20210808__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--TypeOfArrangementAxis__custom--NebulaStockPurchaseAgreementMember_z9sF2p9X54hk">14.6 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million, subject to post-closing adjustments (the “Nebula Acquisition”). A portion of the purchase price equal to $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_z2kaFPrAxGT7" title="Business combination amount paid in cash">3.6</span> million was paid in shares of the Company to certain Seller Parties and noteholders of Nebula, based on their election to receive shares of Company common stock in lieu of cash, which shares were valued at a price per share of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20210810__us-gaap--TypeOfArrangementAxis__custom--NebulaStockPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zrVUfpGl1v0l">7.46</span></span><span style="font: 10pt Times New Roman, Times, Serif">, which is equal to the average closing price of the Company’s common stock on Nasdaq for the five trading days preceding the signing of the Nebula Stock Purchase Agreement. A portion of the purchase price equal to $<span id="xdx_906_ecustom--PurchasePriceOfEscrowAmount_pp0p0_c20210808__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--TypeOfArrangementAxis__custom--NebulaStockPurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--CitiBankNAMember_zVZMGSpZjrR">1,080,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">(the “Escrow Amount”) will be held in escrow by Citibank, N.A. (the “Escrow Agent”) until <span id="xdx_908_ecustom--EscrowMaturityDate_dd_c20210808__20210810__us-gaap--TypeOfArrangementAxis__custom--NebulaStockPurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--CitiBankNAMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zeE3UvKALlh2">February 23, 2023</span></span> <span style="font: 10pt Times New Roman, Times, Serif">(“Escrow Termination Date”), pursuant to the terms and conditions of an escrow agreement entered into with the Escrow Agent, as security for the indemnification obligations of the Seller Parties. At the Escrow Termination Date, the remaining amount, if any, of the Escrow Amount, less any amount reasonably necessary to pay any claim with respect to which a notice of claim has been timely and properly given, will be delivered to the Seller Parties, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In connection with the Nebula Acquisition, ProPhase Precision entered into an employment agreement with Kamal Obbad, the Chief Executive Officer of Nebula, on the Effective Date, pursuant to which Mr. Obbad will serve as Senior Vice President, Director of Sales and Marketing of ProPhase Precision. As a condition to the employment agreement, Mr. Obbad was awarded a stock option to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__srt--TitleOfIndividualAxis__custom--MrKamalObbadMember_zWqJuScQqdxl" title="Stock option awarded">250,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">shares of Company common stock</span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"> at an exercise price equal to $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__srt--TitleOfIndividualAxis__custom--MrKamalObbadMember_zicQvJtthJ9i" title="Option, exercise price">7.67 </span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">per share, the closing price of the Company common stock on the Effective Date. The award was issued as a material inducement to Mr. Obbad’s acceptance of employment with ProPhase Precision in accordance with Nasdaq Listing Rule 5635(c)(4) and was approved by the Company’s Compensation Committee (see Note 7, Stockholders’ Equity).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Based on the preliminary valuation, the total consideration of $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zxBzO3rU6Us9">12.7 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million, which is net of $<span id="xdx_909_eus-gaap--CashAcquiredFromAcquisition_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zdUnpZgsaXzb">1.6 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million in cash acquired and $<span id="xdx_906_eus-gaap--EscrowDepositDisbursementsRelatedToPropertyAcquisition1_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zSxK7ZnFApkc" title="Escrow amount">0.3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million anticipated to be paid back to the Company from the Escrow Amount, has been allocated to assets acquired and liabilities assumed based on their respective fair values as follows (amounts in thousands):</span></p> <p id="xdx_899_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zpJ3LH1K8PF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_zSV6dNTaNY4j" style="display: none">Schedule of Assets Acquired and Liabilities Assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zaaiyRg9QyLe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInShortTermInvestments_iI_maBCRIAzEyY_z0XRir2k4kQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Short term investments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzEyY_ziqf098GaO6g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">222</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pn3n3_maBCRIAzEyY_zCN1aaChL5al" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clinical lab material</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maBCRIAzEyY_zQ0J0itvmZtb" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_maBCRIAzEyY_znqGS8mYANR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">435</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzEyY_z5QJkQ3A86C8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid and other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">379</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_maBCRIAzEyY_zUql69oS4s68" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Definite-lived intangible assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,990</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_mtBCRIAzEyY_maBCRIAzRvy_zQmIDiorjtZ1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total assets acquired</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,826</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_maBCRIAzlqj_zbYwgprj5RWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(372</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_iI_maBCRIAzlqj_zBvxcD0eG2nf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses and other current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(43</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iNI_di_maBCRIAzlqj_zxPp78l9ue1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,140</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_iI_maBCRIAzlqj_zO2NFdLZK8bj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_di_mtBCRIAzlqj_msBCRIAzRvy_zSURKCtoGX1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities assumed</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,636</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzRvy_maBCRIAzV2Y_zK2LzdNg3fFf" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net identifiable assets acquired</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">12,190</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Goodwill_iI_maBCRIAzV2Y_zZu0oxoPokM6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTI_mtBCRIAzV2Y_zimjKvH4shG" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b id="xdx_F40_z1njPl8FBPi7">Total consideration, net of cash acquired <sup id="xdx_F4F_zZw2qsiiTr65">(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">12,674</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="padding-left: 10pt; text-indent: -10pt; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif"><sup id="xdx_F0D_zuvgYoQ34Yqf">(1)</sup></span></td> <td style="padding-left: 10pt; text-indent: -10pt; width: 97%"><span id="xdx_F11_z9GoEuVpI0X7" style="font: 10pt Times New Roman, Times, Serif">Net of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFzc2V0cyBBY3F1aXJlZCBhbmQgTGlhYmlsaXRpZXMgQXNzdW1lZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--CashAcquiredFromAcquisition_pn3n3_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_z1XqyxpBuKC6" title="Cash acquired">1,639</span> cash acquired and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFzc2V0cyBBY3F1aXJlZCBhbmQgTGlhYmlsaXRpZXMgQXNzdW1lZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--EscrowDepositDisbursementsRelatedToPropertyAcquisition1_pn3n3_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zOJjVEAXiCk1" title="Escrow amount">257</span> anticipated amounts due back to the Company from the escrow account.</span></td></tr> </table> <p id="xdx_8AB_zjwcLqFaX9Xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired. The Company believes the goodwill related to the acquisition was a result of the expected synergies to be realized from combining operations and is not deductible for income tax purposes. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zRGWyLAkbKY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The intangible assets preliminarily identified in conjunction with the Nebula Acquisition are as follows (amount in thousands):</span> </p> <p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"><span id="xdx_8BE_zE5wqKO0sQJ9" style="display: none">Schedule of Intangible Assets Acquisition</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 11pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Estimated Useful</p> <p style="text-align: center; margin-top: 0; margin-bottom: 0">Life (in years)</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Trade names</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zmmzocnGG585" style="width: 16%; text-align: right" title="Gross carying value">5,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ztQkbnXCq3c9" title="Estimated useful life">15</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Proprietary intellectual property</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210810__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zbHYofIvg7Ki" style="text-align: right">4,260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zn338Ybqur2k">5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210810__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zBd0MrqtL6df" style="border-bottom: Black 1.5pt solid; text-align: right">1,180</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zRDO9cur0cK8">1</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zAfcO4GHQnw4" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carying value">10,990</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 11pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dxL_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_z4EkV1yHFosi" title="::XDX::P0Y"><span style="-sec-ix-hidden: xdx2ixbrl1017"> </span></span></span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p id="xdx_8AC_zchhxfp7Dnb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognized $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210930__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zqdKm9C7N2x1" title="Amortization expenses"><span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20210701__20210930__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zK2CVTJy5Qif">336,000</span></span> amortization expense on the above identified intangible assets during the three and nine months September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Pro Forma Results</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zgCbnPywUoTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes, on a pro forma basis, the combined results of the Company as though the Nebula Acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zgRHcDvDP4W9" style="display: none">Schedule of Pro-forma Results</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20210701__20210930_z6n4PUg1lFO7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20200701__20200930_zwrGyNIFqSii" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20210101__20210930_zK9VybUFluj7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20200101__20200930_zpgm7Ukj5rn3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessAcquisitionsProFormaRevenue_pn3n3_zJ8pdMQoQ7lg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: left">Revenue, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,843</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,131</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,007</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,890</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_pn3n3_zQ1tScTxK2p3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,020</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(764</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,454</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,425</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8A1_zXuuGAJeiN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>CPM Acquisition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On October 23, 2020, the Company acquired all of the issued and outstanding shares of capital stock of CPM for approximately $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_c20201020__20201023__us-gaap--BusinessAcquisitionAxis__custom--PlazaMedicalLaboratoryCorpMember_pn5n6">2.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million in cash, subject to certain adjustments, pursuant to the terms of a Stock Purchase Agreement, by and among the Company, CPM, Pride Diagnostics LLC (“Pride Diagnostics”) and the members of Pride Diagnostics (together with Pride Diagnostics, the “Seller Parties”), and Arvind Gurnani, as representative of the Seller Parties. As part of the acquisition, we acquired a <span id="xdx_909_eus-gaap--AreaOfLand_iI_uSqft_c20201023__us-gaap--BusinessAcquisitionAxis__custom--PlazaMedicalLaboratoryCorpMember_zoDcLrMrqtQf">4,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">square foot (CLIA) accredited laboratory located in Old Bridge, New Jersey owned by CPM (now known as ProPhase Diagnostics NJ, Inc.).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Based on valuation, the total consideration of $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20201022__20201023__us-gaap--BusinessAcquisitionAxis__custom--CPMAcquisitionMember_zzzJQlHSJZTk" title="Total consideration">2.5</span> million has been allocated to assets acquired and liabilities assumed based on their respective fair values as follows (amount in thousands):</span></p> <p id="xdx_890_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--CPMAcquisitionMember_zJz0vmuAAEA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B4_zHao7h2RoXf5" style="display: none">Schedule of Assets Acquired and Liabilities Assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20201023__us-gaap--BusinessAcquisitionAxis__custom--CPMAcquisitionMember_z5mtjTQbY3O8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pn3n3_zwYAqqdZchS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Clinical lab material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">180</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_zMphfXdtyByj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Definite-lived intangible asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,307</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTIC_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt; font-weight: bold; text-align: left">Total assets acquired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,599</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_pn3n3_di_zsYQFt6FWap3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTIC_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Net identifiable assets acquired</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right">1,599</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iI_pn3n3_zpd240eSbgE1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">901</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTIC_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Total consideration</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,500</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zr2uq7tcNC17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed in the amount of $<span id="xdx_901_eus-gaap--Goodwill_iI_pn3n3_c20211023_zbQhKJHplbGc">901</span></span><span style="font: 10pt Times New Roman, Times, Serif">,000, which was primarily related to the acquisition of the assembled workforce. Other definite-lived intangible asset of approximate $<span id="xdx_903_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c20201023__us-gaap--TypeOfArrangementAxis__custom--ClinicalLaboratoryImprovementAmendmentsMember_pn5n6">1.3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million were related to the CLIA license, which was determined to have an estimated useful life of three years. The Company recognized $<span id="xdx_90C_eus-gaap--AdjustmentForAmortization_pp0p0_c20210701__20210930_z5BwjbrXr5T6">924,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_906_eus-gaap--AdjustmentForAmortization_pp0p0_c20210101__20210930_zioz8fvjp4R6">1,131,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">aggregate amortization expense during the three and nine months September 30, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 14600000 3600000 7.46 1080000 2023-02-23 250000 7.67 12700000 1600000 300000 <p id="xdx_899_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zpJ3LH1K8PF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_zSV6dNTaNY4j" style="display: none">Schedule of Assets Acquired and Liabilities Assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zaaiyRg9QyLe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInShortTermInvestments_iI_maBCRIAzEyY_z0XRir2k4kQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Short term investments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzEyY_ziqf098GaO6g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">222</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pn3n3_maBCRIAzEyY_zCN1aaChL5al" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clinical lab material</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maBCRIAzEyY_zQ0J0itvmZtb" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_maBCRIAzEyY_znqGS8mYANR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">435</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzEyY_z5QJkQ3A86C8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid and other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">379</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_maBCRIAzEyY_zUql69oS4s68" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Definite-lived intangible assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,990</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_mtBCRIAzEyY_maBCRIAzRvy_zQmIDiorjtZ1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total assets acquired</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,826</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_maBCRIAzlqj_zbYwgprj5RWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(372</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_iI_maBCRIAzlqj_zBvxcD0eG2nf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses and other current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(43</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iNI_di_maBCRIAzlqj_zxPp78l9ue1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,140</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_iI_maBCRIAzlqj_zO2NFdLZK8bj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_di_mtBCRIAzlqj_msBCRIAzRvy_zSURKCtoGX1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities assumed</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,636</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzRvy_maBCRIAzV2Y_zK2LzdNg3fFf" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net identifiable assets acquired</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">12,190</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Goodwill_iI_maBCRIAzV2Y_zZu0oxoPokM6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTI_mtBCRIAzV2Y_zimjKvH4shG" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b id="xdx_F40_z1njPl8FBPi7">Total consideration, net of cash acquired <sup id="xdx_F4F_zZw2qsiiTr65">(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">12,674</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="padding-left: 10pt; text-indent: -10pt; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif"><sup id="xdx_F0D_zuvgYoQ34Yqf">(1)</sup></span></td> <td style="padding-left: 10pt; text-indent: -10pt; width: 97%"><span id="xdx_F11_z9GoEuVpI0X7" style="font: 10pt Times New Roman, Times, Serif">Net of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFzc2V0cyBBY3F1aXJlZCBhbmQgTGlhYmlsaXRpZXMgQXNzdW1lZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--CashAcquiredFromAcquisition_pn3n3_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_z1XqyxpBuKC6" title="Cash acquired">1,639</span> cash acquired and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFzc2V0cyBBY3F1aXJlZCBhbmQgTGlhYmlsaXRpZXMgQXNzdW1lZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--EscrowDepositDisbursementsRelatedToPropertyAcquisition1_pn3n3_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zOJjVEAXiCk1" title="Escrow amount">257</span> anticipated amounts due back to the Company from the escrow account.</span></td></tr> </table> 1800000 222000 435000 379000 10990000 13826000 372000 -43000 1140000 -81000 1636000 12190000 484000 12674000 1639000 257000 <p id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zRGWyLAkbKY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The intangible assets preliminarily identified in conjunction with the Nebula Acquisition are as follows (amount in thousands):</span> </p> <p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"><span id="xdx_8BE_zE5wqKO0sQJ9" style="display: none">Schedule of Intangible Assets Acquisition</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 11pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Estimated Useful</p> <p style="text-align: center; margin-top: 0; margin-bottom: 0">Life (in years)</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Trade names</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zmmzocnGG585" style="width: 16%; text-align: right" title="Gross carying value">5,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ztQkbnXCq3c9" title="Estimated useful life">15</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Proprietary intellectual property</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210810__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zbHYofIvg7Ki" style="text-align: right">4,260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zn338Ybqur2k">5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210810__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zBd0MrqtL6df" style="border-bottom: Black 1.5pt solid; text-align: right">1,180</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zRDO9cur0cK8">1</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zAfcO4GHQnw4" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carying value">10,990</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 11pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dxL_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_z4EkV1yHFosi" title="::XDX::P0Y"><span style="-sec-ix-hidden: xdx2ixbrl1017"> </span></span></span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> 5550000 P15Y 4260000 P5Y 1180000 P1Y 10990000 336000 336000 <p id="xdx_89A_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zgCbnPywUoTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes, on a pro forma basis, the combined results of the Company as though the Nebula Acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zgRHcDvDP4W9" style="display: none">Schedule of Pro-forma Results</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20210701__20210930_z6n4PUg1lFO7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20200701__20200930_zwrGyNIFqSii" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20210101__20210930_zK9VybUFluj7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20200101__20200930_zpgm7Ukj5rn3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessAcquisitionsProFormaRevenue_pn3n3_zJ8pdMQoQ7lg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: left">Revenue, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,843</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,131</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,007</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,890</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_pn3n3_zQ1tScTxK2p3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,020</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(764</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,454</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,425</td><td style="text-align: left">)</td></tr> </table> 9843000 4131000 36007000 9890000 -4020000 -764000 -4454000 -2425000 2500000 4000 2500000 <p id="xdx_890_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--CPMAcquisitionMember_zJz0vmuAAEA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B4_zHao7h2RoXf5" style="display: none">Schedule of Assets Acquired and Liabilities Assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20201023__us-gaap--BusinessAcquisitionAxis__custom--CPMAcquisitionMember_z5mtjTQbY3O8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pn3n3_zwYAqqdZchS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Clinical lab material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">180</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_zMphfXdtyByj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Definite-lived intangible asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,307</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTIC_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt; font-weight: bold; text-align: left">Total assets acquired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,599</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_pn3n3_di_zsYQFt6FWap3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTIC_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Net identifiable assets acquired</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right">1,599</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iI_pn3n3_zpd240eSbgE1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">901</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTIC_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Total consideration</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,500</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> 180000 112000 1307000 1599000 1599000 901000 2500000 901000 1300000 924000 1131000 <p id="xdx_805_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zyruEhGcD0fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 4 –<span id="xdx_826_zbWS50mRSLh2"> Goodwill and Acquired Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Goodwill</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i/></b></span></p> <p id="xdx_894_eus-gaap--ScheduleOfGoodwillTextBlock_z1o90XIW8Yr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Changes in goodwill for the nine months ended September 30, 2021 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B4_zM7USqGniyji" style="display: none">Schedule of Changes In Goodwill</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20210101__20210930_zn7vCeQEu1g1" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--Goodwill_iS_pn3n3_zgEfpoiR8Vx2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%">Goodwill, beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">901</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GoodwillAcquiredDuringPeriod_pn3n3_z4K9GXdwhWfh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Acquisition of Nebula</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Goodwill_iE_pn3n3_zwEc7JLB0dOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Goodwill, end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,385</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z5OaAyiu3Ija" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Intangible Assets, Net</i></b><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p id="xdx_89C_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_zEzHSOuQDF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible assets as of September 30, 2021 and December 31, 2020 consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zZGkOSL8y9Tl" style="display: none">Schedule of Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: right; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20210930_z5NWRuC1s7Rc" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_496_20201231_z13xPFPlWccc" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Estimated Useful</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life (in years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Trade names</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zmPUqTtkIVZ1" style="width: 14%; text-align: right" title="Total intangible assets, gross">5,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z8Ttkik1Tfv3" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zevlO9FZUi1i" title="Estimated useful life">15</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Proprietary intellectual property</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zdaNKNIoYUz1" style="text-align: right">4,260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zh07iUISymLi" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1077">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zYT5o0O3pasa">5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzQCD2PK3Opa" style="text-align: right">1,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zLc5qkAG3Moi" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zVBamDCH7TLk">1</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">CLIA license</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z8qYbsvTtqHh" style="border-bottom: Black 1.5pt solid; text-align: right">1,307</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zHP7sdyjzto2" style="border-bottom: Black 1.5pt solid; text-align: right">1,307</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zrPVOhkIgdXl">3</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANz7W1_zm77ikr851Dc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif">Total intangible assets, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,297</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,307</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_msFLIANz7W1_za2ZWu5N6gGd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_mtFLIANz7W1_z37tHYhGHQ85" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><div style="clear: both"/> <p id="xdx_8AF_zU8txgWFYgmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Amortization expense for acquired intangible assets was $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20210701__20210930_zyj8P4CF0Dxc">445,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210930_zOQWLL2bX2ki">662,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three and nine months ended September 30, 2021, respectively. The estimated future amortization expense of acquired intangible assets as of September 30, 2021 is as follows (in thousands):</span></p> <p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z2PcDp7xzy24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_zxgfbQMH3sig" style="display: none">Schedule of Amortization Expense for Acquired Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20210930_zVner9H2I6ul" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzNa6_zF2uJEMlvcX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Three months ended December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">709</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzNa6_zT55XTV2w6di" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,378</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzNa6_z6z3WbO8Xiv5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzNa6_z8eT7Cqrintk" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,222</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzNa6_zFpd2VUyHUml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,222</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzNa6_zVHfyJwsOzS9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,446</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_mtFLIANzNa6_zB6xrSxqA3tj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z33Sls3SeHlk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_894_eus-gaap--ScheduleOfGoodwillTextBlock_z1o90XIW8Yr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Changes in goodwill for the nine months ended September 30, 2021 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B4_zM7USqGniyji" style="display: none">Schedule of Changes In Goodwill</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20210101__20210930_zn7vCeQEu1g1" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--Goodwill_iS_pn3n3_zgEfpoiR8Vx2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%">Goodwill, beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">901</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GoodwillAcquiredDuringPeriod_pn3n3_z4K9GXdwhWfh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Acquisition of Nebula</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Goodwill_iE_pn3n3_zwEc7JLB0dOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Goodwill, end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,385</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 901000 484000 1385000 <p id="xdx_89C_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_zEzHSOuQDF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible assets as of September 30, 2021 and December 31, 2020 consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zZGkOSL8y9Tl" style="display: none">Schedule of Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: right; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20210930_z5NWRuC1s7Rc" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_496_20201231_z13xPFPlWccc" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Estimated Useful</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life (in years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Trade names</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zmPUqTtkIVZ1" style="width: 14%; text-align: right" title="Total intangible assets, gross">5,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z8Ttkik1Tfv3" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zevlO9FZUi1i" title="Estimated useful life">15</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Proprietary intellectual property</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zdaNKNIoYUz1" style="text-align: right">4,260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zh07iUISymLi" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1077">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zYT5o0O3pasa">5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzQCD2PK3Opa" style="text-align: right">1,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zLc5qkAG3Moi" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zVBamDCH7TLk">1</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">CLIA license</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z8qYbsvTtqHh" style="border-bottom: Black 1.5pt solid; text-align: right">1,307</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zHP7sdyjzto2" style="border-bottom: Black 1.5pt solid; text-align: right">1,307</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zrPVOhkIgdXl">3</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANz7W1_zm77ikr851Dc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif">Total intangible assets, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,297</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,307</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_msFLIANz7W1_za2ZWu5N6gGd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_mtFLIANz7W1_z37tHYhGHQ85" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><div style="clear: both"/> 5550000 P15Y 4260000 P5Y 1180000 P1Y 1307000 1307000 P3Y 12297000 1307000 -735000 -73000 11562000 1234000 445000 662000 <p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z2PcDp7xzy24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_zxgfbQMH3sig" style="display: none">Schedule of Amortization Expense for Acquired Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20210930_zVner9H2I6ul" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzNa6_zF2uJEMlvcX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Three months ended December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">709</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzNa6_zT55XTV2w6di" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,378</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzNa6_z6z3WbO8Xiv5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzNa6_z8eT7Cqrintk" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,222</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzNa6_zFpd2VUyHUml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,222</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzNa6_zVHfyJwsOzS9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,446</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_mtFLIANzNa6_zB6xrSxqA3tj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 709000 2378000 1585000 1222000 1222000 4446000 11562000 <p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zFGBh0SaQYv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 5 - <span id="xdx_828_zPbp7gvZuzg">Property, Plant and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zljG08KlTEg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The components of property and equipment are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B5_zf699r7saAx4" style="display: none">Schedule of Property, Plant and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_498_20210930_zElymUy66Et2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20201231_zWVcEo5d7tsk" style="text-align: center">December 31,</td><td> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Land</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_pn3n3" style="width: 20%; text-align: right" title="Property, Plant and Equipment, Gross">352</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_pn3n3" style="width: 20%; text-align: right" title="Property, Plant and Equipment, Gross">352</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="text-align: right; width: 20%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Building improvements</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,729</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_z01O2Xy49wp2" title="Property, Plant and Equipment, Useful Life">10</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zYYuu4GVfwLg" title="Property, Plant and Equipment, Useful Life">39</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Machinery</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">4,672</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">4,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zQb9rbGSsAz2" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zShd9JeXg7Q8" title="Property, Plant and Equipment, Useful Life">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">4,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,002</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z9LLU2ibW8Ne" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zmRfPgy9R0D6" title="Property, Plant and Equipment, Useful Life">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z8Z1cHBkbwSa" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zZAr65I1FyZ9" title="Property, Plant and Equipment, Useful Life">5</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, Plant and Equipment, Gross">468</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, Plant and Equipment, Gross">194</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmmdjg7TKuxh" title="Property, Plant and Equipment, Useful Life">5</span> years</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz94Z_zBtCxk5jWRL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif">Property, Plant and Equipment, Gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,856</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,599</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz94Z_zebs6QRIJQ6a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,402</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,021</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_mtPPAENz94Z_za6ti7rLpnzc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total property, plant and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,578</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_8AF_zGGD26hlO4Ih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in">Depreciation expense for the three months ended September 30, 2021 and 2020 was $<span id="xdx_90D_eus-gaap--Depreciation_c20210701__20210930_zQxFbm6j47hi">481,000 </span>and $<span id="xdx_90A_eus-gaap--Depreciation_c20200701__20200930_zyokl19f1Hy6">86,000</span>, respectively. <span style="font: 10pt Times New Roman, Times, Serif">Depreciation expense incurred for the nine months ended September 30, 2021 and 2020 was $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210101__20210930_zSJ4EHKcD56g">1,381,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20200101__20200930_zaGAvDJSvV8g">253,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zljG08KlTEg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The components of property and equipment are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B5_zf699r7saAx4" style="display: none">Schedule of Property, Plant and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_498_20210930_zElymUy66Et2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20201231_zWVcEo5d7tsk" style="text-align: center">December 31,</td><td> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Land</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_pn3n3" style="width: 20%; text-align: right" title="Property, Plant and Equipment, Gross">352</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_pn3n3" style="width: 20%; text-align: right" title="Property, Plant and Equipment, Gross">352</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="text-align: right; width: 20%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Building improvements</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,729</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_z01O2Xy49wp2" title="Property, Plant and Equipment, Useful Life">10</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zYYuu4GVfwLg" title="Property, Plant and Equipment, Useful Life">39</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Machinery</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">4,672</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">4,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zQb9rbGSsAz2" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zShd9JeXg7Q8" title="Property, Plant and Equipment, Useful Life">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">4,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,002</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z9LLU2ibW8Ne" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zmRfPgy9R0D6" title="Property, Plant and Equipment, Useful Life">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z8Z1cHBkbwSa" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zZAr65I1FyZ9" title="Property, Plant and Equipment, Useful Life">5</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, Plant and Equipment, Gross">468</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, Plant and Equipment, Gross">194</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmmdjg7TKuxh" title="Property, Plant and Equipment, Useful Life">5</span> years</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz94Z_zBtCxk5jWRL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif">Property, Plant and Equipment, Gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,856</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,599</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz94Z_zebs6QRIJQ6a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,402</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,021</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_mtPPAENz94Z_za6ti7rLpnzc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total property, plant and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,578</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td></tr> </table> 352000 352000 1859000 1729000 P10Y P39Y 4672000 4441000 P3Y P7Y 4316000 1002000 P3Y P7Y 1189000 881000 P3Y P5Y 468000 194000 P5Y 12856000 8599000 6402000 5021000 6454000 3578000 481000 86000 1381000 253000 <p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_zxGwqf1Fzsrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 6 -<span id="xdx_82C_zpXjp4aU2EHj">Unsecured Convertible Promissory Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20200913__20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zqnnB8oqtgDh" title="Debt Instrument, Maturity Date">September 15, 2020</span>, we issued two unsecured, partially convertible, promissory notes (the “September 2020 Notes”) for an aggregate principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zDcDlpdveGU4" title="Debt Instrument, Face Amount">10</span> million to two investors (collectively, the “Lenders”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The September 2020 Notes are due and payable on September 15, 2023, and accrue interest at a rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zJNNS9EpoLV3" title="Debt Instrument, Interest Rate, Stated Percentage">10</span>% per year from the closing date, payable on a quarterly basis, until the September 2020 Notes are repaid in full. <span id="xdx_90E_eus-gaap--DebtConversionDescription_c20200913__20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember" title="Debt Conversion, Description">We have the right to prepay the September 2020 Notes at any time after the 13 month anniversary of the closing date after providing written notice to the Lenders, and may prepay the September 2020 Notes prior to such time with the consent of the Lenders. The Lenders have the right, at any time, and from time to time, on and after the 13-month anniversary of the closing date to convert up to an aggregate of $</span><span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_pn5n6_c20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zHLIQUTUIsKf" title="Convertible Debt">3.0</span> million of the September 2020 Notes into common stock of the Company at a conversion price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zLJF1Dd1K4gk" title="Debt Instrument, Convertible, Conversion Price">3.00</span> per share. Repayment of the September 2020 Notes has been guaranteed by our wholly-owned subsidiary, PMI.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The September 2020 Notes contain customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the September 2020 Notes may be accelerated. The September 2020 Notes also contain certain restrictive covenants which, among other things, restrict our ability to create, incur, assume or permit to exist, directly or indirectly, any lien (other than certain permitted liens described in the September 2020 Notes) securing any indebtedness of the Company, and prohibits us from distributing or reinvesting the proceeds from any divestment of assets (other than in the ordinary course) without the prior approval of the Lenders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended September 30, 2021 and 2020, we incurred $<span id="xdx_900_eus-gaap--InterestExpenseOther_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhCkJZbrjCyb" title="Interest expense">251,000</span> and $<span id="xdx_90A_eus-gaap--InterestExpenseOther_c20200701__20200930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z1HHdRf9q61f" title="Interest expense">0</span>, respectively, in interest expense under the September 2020 Notes.</span><span style="font: 10pt Times New Roman, Times, Serif"> For the nine months ended September 30, 2021 and 2020, we incurred $<span id="xdx_904_eus-gaap--InterestExpenseOther_pp0p0_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zDoJdBNCQB05">753,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--InterestExpenseOther_pp0p0_c20200101__20200930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z8hKRE4yzuDe">0</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively, in interest expense under the September 2020 Notes</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 2020-09-15 10000000 0.10 We have the right to prepay the September 2020 Notes at any time after the 13 month anniversary of the closing date after providing written notice to the Lenders, and may prepay the September 2020 Notes prior to such time with the consent of the Lenders. The Lenders have the right, at any time, and from time to time, on and after the 13-month anniversary of the closing date to convert up to an aggregate of $ 3000000.0 3.00 251000 0 753000 0 <p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zPONhWhUMFR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 7 - <span id="xdx_829_zpFyRqSUlrPh">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our authorized capital stock consists of <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20210930_z7CMX5mC3DO3" title="Common Stock, Shares Authorized">50</span> million shares of common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210930_zPvGwkd2gABk" title="Common Stock, Par or Stated Value Per Share">0.0005</span> par value, and <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pn6n6_dxL_c20210930_zKOSdseAmii5" title="Preferred Stock, Shares Authorized::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl1198">one</span></span> million shares of preferred stock, $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210930_zfwEJa7i8B28" title="Preferred Stock, Par or Stated Value Per Share">0.0005</span> par value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The preferred stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of September 30, 2021 and December 31, 2020, <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_do_c20210930_ztaa1KCg1iw4" title="Preferred Stock, Shares Issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20201231_zlGmh6mxMYva" title="Preferred Stock, Shares Issued">no</span></span></span> <span style="font: 10pt Times New Roman, Times, Serif">shares of preferred stock have been issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Common Stock Dividends</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On May 13, 2021, the Board declared a special cash dividend of $<span id="xdx_903_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_uUSDPShares_c20210512__20210513_zLe9bpPNDhe3" title="Common Stock, Dividends, Per Share, Cash Paid">0.30</span> per share on the Company’s common stock to holders of record on May 25, 2021, resulting in the payment of $<span id="xdx_906_eus-gaap--PaymentsOfDividendsCommonStock_pn5n6_c20210602__20210603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJKXb1CorHwk" title="Payments of Ordinary Dividends, Common Stock">4.5</span> million to stockholders on June 3, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In Fiscal 2020, <span id="xdx_90D_eus-gaap--CommonStockDividendsPerShareCashPaid_c20200101__20201231_pdd" title="Common Stock, Dividends, Per Share, Cash Paid">no</span> cash dividends were declared.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Registered Direct Offering</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On January 5, 2021, we entered into a securities purchase agreement with certain accredited investors and qualified institutional buyers, pursuant to which we issued and sold to the purchasers an aggregate of (i) <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210104__20210105__us-gaap--AwardTypeAxis__custom--RegisteredDirectOfferingMember_zH6SBjfvjIw5" title="Stock Issued During Period, Shares, New Issues">550,000</span> shares of our common stock, and (ii) warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210105__us-gaap--AwardTypeAxis__custom--RegisteredDirectOfferingMember_zfmHQbdgmcJ5" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">275,000</span> shares of common stock in a registered direct offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The shares and warrants were sold at a purchase price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210105__us-gaap--AwardTypeAxis__custom--RegisteredDirectOfferingMember_zDhj6Kkk0901">10.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share for net proceeds to us of $<span id="xdx_906_ecustom--ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering_pn5n6_c20210104__20210105__us-gaap--AwardTypeAxis__custom--RegisteredDirectOfferingMember_zLaXrRw5F9i5">5.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million. Each Warrant has an exercise price equal to $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210105__us-gaap--AwardTypeAxis__custom--RegisteredDirectOfferingMember_zs7LdJrZu2Rh">11.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share of common stock, will be exercisable at any time and from time to time, subject to certain conditions described in the Warrant, after the date of issuance, and will expire on the date that is three years from the date of issuance. The Shares and the Warrants are immediately separable and were issued separately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Public Offering</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On January 18, 2021, we entered into an underwriting agreement for the public offering of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn6n6_dc_c20210117__20210118__us-gaap--AwardTypeAxis__us-gaap--IPOMember_zecy6f8jdj6j">three </span></span><span style="font: 10pt Times New Roman, Times, Serif">million shares of common stock, at a price to the public of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210118__us-gaap--AwardTypeAxis__us-gaap--IPOMember_zPWVXJm0ZHYd">12.50 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. On January 21, 2021, we completed the offering for net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20200120__20210121_zI1r75Pyguf4" title="Proceeds from offering">35.1</span> million, after deducting the underwriting discounts and commissions and estimated offering expenses. As part of the offering, we also issued to the Underwriters warrants to purchase up to an aggregate of </span><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210118__us-gaap--AwardTypeAxis__us-gaap--IPOMember_zF29VAGUmX1g" style="font: 10pt Times New Roman, Times, Serif">180,000 </span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock (6% of the shares of common stock sold in the offering) at an exercise price of $</span><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210118__us-gaap--AwardTypeAxis__us-gaap--IPOMember_zUKg4BdBJSd9" style="font: 10pt Times New Roman, Times, Serif">15.625 </span><span style="font: 10pt Times New Roman, Times, Serif">per share (equal to 125% of the public offering price per share). </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Nebula Acquisition</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As part of Nebula Acquisition (see Note 3, Business Acquisitions), a portion of the purchase price was paid in shares to certain Seller Parties and noteholders of Nebula, based on their election to receive shares of Company common stock in lieu of cash, which shares have been valued at a price per share of $<span id="xdx_909_eus-gaap--BusinessAcquisitionSharePrice_iI_pid_c20210930__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zF60YYR2sVe5">7.46</span></span><span style="font: 10pt Times New Roman, Times, Serif">, which is equal to the average closing price of the Company’s common stock on Nasdaq for the five trading days preceding the signing of the Nebula Stock Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210930__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zIhxLjvCkIFj" title="Number of shares issue">483,685</span> shares of common stock in in lieu of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210117__20210118__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zjutvQ4hjrD6">3.6</span> million cash payment to Seller Parties and noteholders of Nebula.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Stock Repurchase Program</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On September 8, 2021, the Company announced that its board of directors (the “Board”) had approved a new stock repurchase program. Under the stock repurchase program, the Company is authorized to repurchase up to $<span id="xdx_904_eus-gaap--StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_iI_pn5n6_c20210908__us-gaap--ShareRepurchaseProgramAxis__custom--ShareRepurchaseProgramMember_zZ11dY00wv8c">6.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">million of its outstanding shares of common stock from time to time, over a six month period. The number of shares to be repurchased and the timing of the repurchases, if any, will depend on a number of factors, including, but not limited to, price, trading volume and general market conditions, along with the Company’s working capital requirements and general business conditions. The Board will re-evaluate the program from time to time, and may authorize adjustments to its terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company did not repurchase any shares of common stock during the three and nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>The 2010 Directors’ Equity Compensation Plan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Directors’ Equity Compensation Plan (the “Amended 2010 Directors’ Plan”) at the 2021 Annual Meeting of Stockholders of the Company (the “2021 Annual Meeting”). The Amended 2010 Directors’ Plan authorizes the issuance of up to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210520__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyDirectorsEquityCompensationPlanMember_z7NZi43qfdBc" title="Number of shares authorized in share based compensation">775,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"><i/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">During the three and nine months ended September 30, 2021, stock options to purchase an aggregate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210701__20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenDirectorsPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1bNhLU7Mx3f">224,874 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of our common stock were granted to our directors in lieu of director fees under the 2010 Directors’ Plan with a strike price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenDirectorsPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z44lQVRBOq8k">5.28 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share under the Amended 2010 Directors’ Plan. During the three and nine months ended September 30, 2020, common stock and stock options to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200701__20200930__us-gaap--PlanNameAxis__custom--TwoThousandTenDirectorsEquityCompensationPlanMember_zAimBGO9pIvl">212,605 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20200930__us-gaap--PlanNameAxis__custom--TwoThousandTenDirectorsEquityCompensationPlanMember_zaDhYdRm7iF3">230,660 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock, respectively, were granted to our directors under the 2010 Directors’ Plan in lieu of director fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">At September 30, 2021, there were <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenDirectorsEquityCompensationPlanMember_z54GCAtQX9Hk">424,874 </span></span><span style="font: 10pt Times New Roman, Times, Serif">stock</span><span style="font: 10pt Times New Roman, Times, Serif"> options outstanding and there were <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenDirectorsEquityCompensationPlanMember_zZ00G9VfBts8">3,252 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock available to be issued pursuant to the terms of the Amended 2010 Directors’ Plan. No stock options were exercised during the three and nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>The 2010 Equity Compensation Plan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Equity Compensation Plan (the “Amended 2010 Plan”) at the 2021 Annual Meetings. The Amended 2010 Plan authorizes the issuance of up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210519__20210520__us-gaap--PlanNameAxis__custom--AmendedTwoThousandTenPlanMember_zIhfjqZeyNLb" title="Number of shares issued">4,900,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">There were <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zQOWQrBHWSSl">975,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">stock</span><span style="font: 10pt Times New Roman, Times, Serif"> options granted under the 2010 Plan during the nine months ended September 30, 2021 for a total fair value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pp0p0_c20210101__20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zMcw52yptwOh">2,891,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">There were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20200930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zRlNpuR34c19">250,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">stock</span><span style="font: 10pt Times New Roman, Times, Serif"> options granted under the 2010 Plan during the three and nine months ended September 30, 2020 for a total fair value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pp0p0_c20200101__20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zUiT6k4wFj0d">269,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, there were <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zUMSgyFj0V72">1,884,449 </span></span><span style="font: 10pt Times New Roman, Times, Serif">stock</span><span style="font: 10pt Times New Roman, Times, Serif"> options outstanding and there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zB3PLjyUWnL4">184,657 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock</span><span style="font: 10pt Times New Roman, Times, Serif"> available to be issued pursuant to the terms of the Amended 2010 Plan. We will recognize an aggregate of approximately $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zyH7iIVPeLj6">1,373,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of remaining share-based compensation expense related to outstanding stock options over a weighted average period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zpa9VhqELEHi">2.8 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>The 2018 Stock Incentive Plan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On April 12, 2018, our stockholders approved the 2018 Stock Incentive Plan (the “2018 Stock Plan”). At April 12, 2018, all <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pin6_c20180412__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockIncentivePlanMember_z1tHobslb9Ye">2.3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million shares available for issuance under the 2018 Stock Plan have been granted in the form of a stock option with an initial exercise price of $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210411__20210412__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockIncentivePlanMember_zews0auAp8x">3.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, which is exercisable in 36 monthly installments, to Ted Karkus (the “CEO Option”), our Chief Executive Officer. <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20210101__20210930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_z3FiKCJP2kDi"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20200101__20200930__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_z2NxEUULnUGe">No</span></span> portion of the CEO Option was exercised during the nine months ended September 30, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The 2018 Stock Plan requires certain proportionate adjustments to be made to stock options granted upon the occurrence of certain events, including a special distribution (whether in the form of cash, shares, other securities, or other property) in order to maintain parity. Accordingly, the Compensation Committee of the board of directors, as required by the terms of the 2018 Stock Plan, adjusted the terms of the CEO Option, such that the <span>exercise price of the CEO Option was reduced from $</span></span><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210411__20210412__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockIncentivePlanMember_zOGkDaZI4nRk" style="font: 10pt Times New Roman, Times, Serif">3.00 </span><span id="xdx_903_ecustom--StockOptionPlanReducedExercisePricePerShareDescription_c20180904__20180905__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember" style="font: 10pt Times New Roman, Times, Serif">per share to $</span><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210904__20210905__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zrE420Bh8Ao" style="font: 10pt Times New Roman, Times, Serif">2.00 </span><span style="font: 10pt Times New Roman, Times, Serif">per share, effective as of September 5, 2018, the date a special $<span id="xdx_904_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20180904__20180905__srt--TitleOfIndividualAxis__custom--StockHoldersMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zrVBq7SdxMa9">1.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">special cash dividend was paid to the Company’s stockholders. <span id="xdx_904_ecustom--StockOptionPlanReducedExercisePricePerShareDescription_c20190123__20190124__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember">The exercise price of the CEO Option was further reduced from $</span></span><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210904__20210905__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zuR4ME1thfKb" style="font: 10pt Times New Roman, Times, Serif">2.00 </span><span style="font: 10pt Times New Roman, Times, Serif">to $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20190123__20190124__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zsfWMbNTBObh">1.75 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, effective as of January 24, 2019, the date a $<span id="xdx_909_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20190123__20190124__srt--TitleOfIndividualAxis__custom--StockHoldersMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zWK8igMWaKzk">0.25 </span></span><span style="font: 10pt Times New Roman, Times, Serif">special cash dividend was paid to the Company’s stockholders. <span id="xdx_905_ecustom--StockOptionPlanReducedExercisePricePerShareDescription_c20211211__20211212__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember">The exercise price of the CEO Option was further reduced from $</span></span><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20190123__20190124__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zQQJW2sQk4Kg" style="font: 10pt Times New Roman, Times, Serif">1.75 </span><span style="font: 10pt Times New Roman, Times, Serif">to $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20191211__20191212__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zfBH0OXFa0e7">1.50 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, effective as of December 12, 2019, the date another $<span id="xdx_90D_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20191211__20191212__srt--TitleOfIndividualAxis__custom--StockHoldersMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_z57ZaFnGgqik">0.25 </span></span><span style="font: 10pt Times New Roman, Times, Serif">special cash dividend was paid to Company’s stockholders. <span id="xdx_90E_ecustom--StockOptionPlanReducedExercisePricePerShareDescription_c20210602__20210603__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember">The exercise price of the CEO Option was further reduced from $</span></span><span style="font: 10pt Times New Roman, Times, Serif">1.50 to $<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210602__20210603__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zO7sQOnzdK52">1.20 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, effective as of June 3, 2021, the date another $<span id="xdx_90B_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20210602__20210603__srt--TitleOfIndividualAxis__custom--StockHoldersMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zkdPDpBnBTii">0.30 </span></span><span style="font: 10pt Times New Roman, Times, Serif">special cash dividend was paid to Company’s stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Inducement Option Award</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">As part of Nebula Acquisition, the Company issued a non-qualified stock option to <span style="background-color: white">Kamal Obbad, the Chief Executive Officer of Nebula</span>, as an inducement to his employment with the Company (the “Inducement Award”). The Inducement Award entitles Mr. Obbad to purchase up to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_pid_c20210101__20210930__us-gaap--AwardTypeAxis__custom--InducementOptionAwardMember__srt--TitleOfIndividualAxis__custom--MrKamalObbadMember_zYw9zjjYZiXb">250,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company’s common stock at an exercise price of $<span id="xdx_901_eus-gaap--BusinessAcquisitionSharePrice_iI_pid_c20210930__us-gaap--BusinessAcquisitionAxis__custom--InducementOptionAwardMember_zncphUCLaQyh">7.67 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, the closing price of the Company’s common stock on the closing date of the Nebula Acquisition. The Inducement Award was granted to Mr. Obbad on the closing date of the Nebula Acquisition. The Inducement Award vested <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20210101__20210930__us-gaap--AwardTypeAxis__custom--InducementOptionAwardMember_zrRQHVpE9K9h">25</span></span><span style="font: 10pt Times New Roman, Times, Serif">% on the grant date and will vest <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20210101__20210930__us-gaap--AwardTypeAxis__custom--InducementOptionAwardMember_zCFDt8PXtIZg">25</span></span><span style="font: 10pt Times New Roman, Times, Serif">% per year for the next three years subject to Mr. Obbad’s continued employment with the Company. The Inducement Award expires on the seventh anniversary of the grant date. Any portion of the Inducement Award that does not vest and become exercisable will be forfeited for no consideration. The grant date fair value of the Inducement Award was approximately $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0d_c20210101__20210930__us-gaap--BusinessAcquisitionAxis__custom--InducementOptionAwardMember_z6J9DffrWPC9">1,128,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">For the three months ended September 30, 2021 and 2020, we charged to operations an aggregate of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20210701__20210930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyDirectorsEquityCompensationPlanMember_zWA9L3R912fa" title="Share based compensation expense">863,000</span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20200701__20200930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyDirectorsEquityCompensationPlanMember_zhCqdYx457s7">267,000</span>, respectively, for share-based compensation expense associated with the vesting of outstanding equity awards under the Amended 2010 Directors’ Plan, the Amended 2010 Plan, the 2018 Stock Plan and the Inducement Award. For the nine months ended September 30, 2021 and 2020, we charged to operations an aggregate of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyDirectorsEquityCompensationPlanMember_zQRYsmRLs5Lj">2,175,000</span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20200101__20200930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyDirectorsEquityCompensationPlanMember_zodkYrtd9gG7">663,000</span>, respectively, for share-based compensation expense associated with the vesting of outstanding equity awards under the 2010 Directors’ Plan, the 2010 Plan, the 2018 Stock Plan and the Inducement Award..</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPgdRjJ4LcBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes stock options activity during the nine months ended September 30, 2021 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Award (in thousands, except per share data): </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BF_zamQkMCfXQxl" style="display: none">Schedule of Stock Options Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life <br/> (in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding as of January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJfIHv8iVEQ1" style="width: 12%; text-align: right" title="Number of Shares Options Outstanding - Beginning">3,795</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6caS0V4uqil" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Options Outstanding - Beginning">2.21</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7l5pS2EC8ok" title="Weighted Average Remaining Contractual Life (in Years) - Beginning">3.4</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwUuRZWj77ma" style="width: 12%; text-align: right" title="Total Intrinsic Value - Beginning">26,441</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpFWOcCO6B7" style="text-align: right" title="Number of Shares, Granted">1,450</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCDpENFz5wFc" style="text-align: right" title="Weighted Average Exercise Price, Granted">7.48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zaoeiAk0t3Ld" title="Weighted Average Remaining Contractual Life (in Years) - Granted">5.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_pn3n3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTxwtXj2z3Z3" style="text-align: right" title="Total Intrinsic Value - Granted"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pin3_di_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSAlcUMs46H9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Forfeited">(398</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSMuDmDgnoSi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">8.32</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_pn3n3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoFoksio6vs3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Intrinsic Value - Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs2WfdWXF9kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Options Outstanding - Ending">4,847</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zL52bPmCt0D1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Options Outstanding - Ending">3.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFq6FJgyXVe9" title="Weighted Average Remaining Contractual Life (in Years) - Ending">3.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8WWpI9Uozfj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Intrinsic Value - Ending">12,559</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pin3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXr2kn6CjCbc" style="text-align: right" title="Number of Shares Options Vested and Exercisable">3,829</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zynKMdVhqqI5" style="text-align: right" title="Weighted Average Exercise Price, Options Vested and Exercisable">2.46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2BmYiWVntfg" title="Weighted Average Remaining Contractual Life (in Years) - Options Vested and Exercisable">2.7</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zha9gcypyQod" style="text-align: right" title="Total Intrinsic Value, Options Vested and Exercisable">12,012</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_zorB4j9CAaAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zvcqtkwlYpba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The aggregate weighted average grant date fair value for the options granted during the three and nine months ended September 30, 2021 was approximately $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn5n6_c20210701__20210930_zevdRHFNivPh" title="Fair value of options">2.7</span> and $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn5n6_c20210101__20210930_zDiqGaBZPlRe">4.7</span> million, respectively. The following table summarizes weighted average assumptions used in determining the fair value of the options at the date of grant for the nine months ended September 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.8pt; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zS4n73QwHpN3" style="display: none">Summary of Weighted Average Assumptions Used In Determining Fair Value of Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zOtez4J3gvt4" style="width: 20%; text-align: right" title="Exercise price">7.48</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930_zoLmtq8Mv8ri" title="Expected term (years)">3.9</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930_z6gCDo1a1zLi" style="text-align: right" title="Expected stock price volatility">80</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate of interest</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930_zaz9xfOWLwX2" style="text-align: right" title="Risk-free rate of interest">0.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected dividend yield (per share)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zcOgcjJWhPT6" style="text-align: right" title="Expected dividend yield (per share)">0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A5_zWiMJxhR07y4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock Warrants Issued </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, we issued warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210930__us-gaap--AwardTypeAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkIP7Wg9QFli" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">275,000</span> shares of common stock in a registered direct offering and warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVyKF1CJbuul" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">180,000</span> shares of common stock to the underwriters in a public offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, we issued <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNhne40kruqd">5,986</span> shares of common stock through a cashless exercise of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSsRquvL2Vn">50,000</span> common stock warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfWarrantActivityTableTextBlock_z8AwxgZigrs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes warrant activities during the nine months ended September 30, 2021 (in thousands, except per share data).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.8pt; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zBuHdI3rhNWl" style="display: none">Schedule of Warrant Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life <br/> (in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding as of January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pin3_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziTQP6KacOO7" style="width: 14%; text-align: right" title="Number of Shares Warrants Outstanding - Beginning">450</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqL871BhflTh" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Beginning">3.22</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPrhZVW1dL1d" title="Weighted Average Remaining Contractual Life (in Years) - Beginning">2.7</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pin3_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEV4R7tAJwr1" style="text-align: right" title="Warrants granted">455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYDegDtLPTzc" style="text-align: right" title="Weighted Average Exercise Price, Granted">12.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvrHifS3duo9" title="Weighted Average Remaining Contractual Life (in Years) - Granted">3.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cashless exercise</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pin3_di_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPkH1jDBbOBl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercise">(50</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGOJpkM4iLek" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Exerisce">5.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrgeLMPJ06kf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Contractual Life (in Years) - Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pin3_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNTpDamo5Hqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding - Ending">855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqcpLPQVp2Kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Ending">8.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM3AJMWNX5uj" title="Weighted Average Remaining Contractual Life (in Years) - Ending">2.1</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber_iS_pin3_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn98XUGxaMbc" style="text-align: right" title="Number of Shares Warrants Vested and Exercisable">805</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfws3YG9swD4" style="text-align: right" title="Weighted Average Exercise Price, Warrants Vested and Exercisable">8.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgZIvqiRK8S5" title="Weighted Average Remaining Contractual Life (in Years) - Vested and Exercisable">2.1</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_zTKiscJr7YT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zqxD0es3A9Fi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes weighted average assumptions used in determining the fair value of the warrants at the date of grant for the nine months ended September 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B9_zwppRV9htTPh" style="display: none">Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjbmlFhl4C6i" style="width: 16%; text-align: right" title="Warrants outstanding, measurement input, percentage">12.83</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlLi9gkFeWmh" title="Warrants measurement, expected term">3.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0o2P11ffgOf" style="text-align: right" title="Warrants outstanding, measurement input, percentage">81</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate of interest</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn4aTb2jC47a" style="text-align: right" title="Warrants outstanding, measurement input, percentage">0.2</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected dividend yield (per share)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6RKgL2vVAFa" style="text-align: right" title="Warrants outstanding, measurement input, percentage">0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A0_zTgKxHopIVS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, there were warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pp0p0_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQPpi6ATFsXf">855,000 shares of our common stock outstanding and we recognized $</span></span><span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n6_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX0wcfZHZoT6" style="font: 10pt Times New Roman, Times, Serif">59,000 </span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQN0CNBtevUg">252,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of share-based compensation expense during the three and nine months ended September 30, 2021, respectively. We recognized $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zobtpGSc4BO4">16,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in share-based compensation expense during the three and nine months ended September 30, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 50000000 0.0005 0.0005 0 0 0.30 4500000 550000 275000 10.00 5500000 11.00 3000000 12.50 35100000 180000 15.625 7.46 483685 3600000 6000000.0 775000 224874 5.28 212605 230660 424874 3252 4900000 975000 2891000 250000 269000 1884449 184657 1373000 P2Y9M18D 2300000 3.00 0 0 3.00 per share to $ 2.00 1.00 The exercise price of the CEO Option was further reduced from $ 2.00 1.75 0.25 The exercise price of the CEO Option was further reduced from $ 1.75 1.50 0.25 The exercise price of the CEO Option was further reduced from $ 1.20 0.30 250000 7.67 0.25 0.25 1128000 863000 267000 2175000 663000 <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPgdRjJ4LcBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes stock options activity during the nine months ended September 30, 2021 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Award (in thousands, except per share data): </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BF_zamQkMCfXQxl" style="display: none">Schedule of Stock Options Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life <br/> (in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding as of January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJfIHv8iVEQ1" style="width: 12%; text-align: right" title="Number of Shares Options Outstanding - Beginning">3,795</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6caS0V4uqil" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Options Outstanding - Beginning">2.21</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7l5pS2EC8ok" title="Weighted Average Remaining Contractual Life (in Years) - Beginning">3.4</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwUuRZWj77ma" style="width: 12%; text-align: right" title="Total Intrinsic Value - Beginning">26,441</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpFWOcCO6B7" style="text-align: right" title="Number of Shares, Granted">1,450</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCDpENFz5wFc" style="text-align: right" title="Weighted Average Exercise Price, Granted">7.48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zaoeiAk0t3Ld" title="Weighted Average Remaining Contractual Life (in Years) - Granted">5.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_pn3n3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTxwtXj2z3Z3" style="text-align: right" title="Total Intrinsic Value - Granted"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pin3_di_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSAlcUMs46H9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Forfeited">(398</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSMuDmDgnoSi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">8.32</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_pn3n3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoFoksio6vs3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Intrinsic Value - Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs2WfdWXF9kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Options Outstanding - Ending">4,847</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zL52bPmCt0D1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Options Outstanding - Ending">3.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFq6FJgyXVe9" title="Weighted Average Remaining Contractual Life (in Years) - Ending">3.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8WWpI9Uozfj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Intrinsic Value - Ending">12,559</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pin3_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXr2kn6CjCbc" style="text-align: right" title="Number of Shares Options Vested and Exercisable">3,829</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zynKMdVhqqI5" style="text-align: right" title="Weighted Average Exercise Price, Options Vested and Exercisable">2.46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2BmYiWVntfg" title="Weighted Average Remaining Contractual Life (in Years) - Options Vested and Exercisable">2.7</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zha9gcypyQod" style="text-align: right" title="Total Intrinsic Value, Options Vested and Exercisable">12,012</td><td style="text-align: left"> </td></tr> </table> 3795000 2.21 P3Y4M24D 26441000 1450000 7.48 P5Y 398000 8.32 4847000 3.15 P3Y6M 12559000 3829000 2.46 P2Y8M12D 12012000 <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zvcqtkwlYpba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The aggregate weighted average grant date fair value for the options granted during the three and nine months ended September 30, 2021 was approximately $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn5n6_c20210701__20210930_zevdRHFNivPh" title="Fair value of options">2.7</span> and $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn5n6_c20210101__20210930_zDiqGaBZPlRe">4.7</span> million, respectively. The following table summarizes weighted average assumptions used in determining the fair value of the options at the date of grant for the nine months ended September 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.8pt; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zS4n73QwHpN3" style="display: none">Summary of Weighted Average Assumptions Used In Determining Fair Value of Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zOtez4J3gvt4" style="width: 20%; text-align: right" title="Exercise price">7.48</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930_zoLmtq8Mv8ri" title="Expected term (years)">3.9</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930_z6gCDo1a1zLi" style="text-align: right" title="Expected stock price volatility">80</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate of interest</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930_zaz9xfOWLwX2" style="text-align: right" title="Risk-free rate of interest">0.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected dividend yield (per share)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zcOgcjJWhPT6" style="text-align: right" title="Expected dividend yield (per share)">0</td><td style="text-align: left">%</td></tr> </table> 7.48 P3Y10M24D 0.80 0.007 0 275000 180000 5986 50000 <p id="xdx_89B_ecustom--ScheduleOfWarrantActivityTableTextBlock_z8AwxgZigrs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes warrant activities during the nine months ended September 30, 2021 (in thousands, except per share data).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.8pt; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zBuHdI3rhNWl" style="display: none">Schedule of Warrant Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life <br/> (in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding as of January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pin3_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziTQP6KacOO7" style="width: 14%; text-align: right" title="Number of Shares Warrants Outstanding - Beginning">450</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqL871BhflTh" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Beginning">3.22</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPrhZVW1dL1d" title="Weighted Average Remaining Contractual Life (in Years) - Beginning">2.7</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pin3_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEV4R7tAJwr1" style="text-align: right" title="Warrants granted">455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYDegDtLPTzc" style="text-align: right" title="Weighted Average Exercise Price, Granted">12.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvrHifS3duo9" title="Weighted Average Remaining Contractual Life (in Years) - Granted">3.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cashless exercise</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pin3_di_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPkH1jDBbOBl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercise">(50</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGOJpkM4iLek" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Exerisce">5.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrgeLMPJ06kf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Contractual Life (in Years) - Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding as of September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pin3_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNTpDamo5Hqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding - Ending">855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqcpLPQVp2Kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Ending">8.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM3AJMWNX5uj" title="Weighted Average Remaining Contractual Life (in Years) - Ending">2.1</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber_iS_pin3_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn98XUGxaMbc" style="text-align: right" title="Number of Shares Warrants Vested and Exercisable">805</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfws3YG9swD4" style="text-align: right" title="Weighted Average Exercise Price, Warrants Vested and Exercisable">8.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgZIvqiRK8S5" title="Weighted Average Remaining Contractual Life (in Years) - Vested and Exercisable">2.1</span></td><td style="text-align: left"> </td></tr> </table> 450000 3.22 P2Y8M12D 455000 12.83 P3Y 50000 5.00 855000 8.23 P2Y1M6D 805000 8.56 P2Y1M6D <p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zqxD0es3A9Fi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes weighted average assumptions used in determining the fair value of the warrants at the date of grant for the nine months ended September 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B9_zwppRV9htTPh" style="display: none">Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjbmlFhl4C6i" style="width: 16%; text-align: right" title="Warrants outstanding, measurement input, percentage">12.83</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlLi9gkFeWmh" title="Warrants measurement, expected term">3.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0o2P11ffgOf" style="text-align: right" title="Warrants outstanding, measurement input, percentage">81</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate of interest</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn4aTb2jC47a" style="text-align: right" title="Warrants outstanding, measurement input, percentage">0.2</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected dividend yield (per share)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6RKgL2vVAFa" style="text-align: right" title="Warrants outstanding, measurement input, percentage">0</td><td style="text-align: left">%</td></tr> </table> 12.83 P3Y 0.81 0.2 0 855000 59000000000 252000 16000 <p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zqhcag9PlWBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 8 - <span id="xdx_821_zPObYr5nUyYg">Defined Contribution Plans</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">We maintain the ProPhase Labs, Inc. 401(k) Savings and Retirement Plan, a defined contribution plan for our employees. Our contributions to the plan are based on the amount of the employee plan contributions and compensation. Our contributions to the plan in the three and nine months ended September 30, 2021 were $<span id="xdx_90C_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20210701__20210930_pp0p0" title="Defined contribution amount">34,000</span> and $<span id="xdx_90A_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20210101__20210930_pp0p0" title="Defined contribution amount">69,000</span>, respectively. Our contributions to the plan in the three and nine months ended September 30, 2020 were $<span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20200701__20200930_pp0p0" title="Defined contribution amount">19,000</span> and $<span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20200101__20200930_pp0p0" title="Defined contribution amount">52,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 34000 69000 19000 52000 <p id="xdx_807_eus-gaap--OtherLiabilitiesDisclosureTextBlock_z1AmRjz4sNaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 9 - <span id="xdx_821_zp5Zxhpvw7Fa">Other Current Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_89E_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zI45ay1mpX79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table sets forth the components of other current liabilities at September 30, 2021 and December 31, 2020, respectively (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B0_zPSPwsBseoMg" style="display: none">Schedule of Other Current Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49A_20210930_zseiBaSrna1d" style="text-align: center; vertical-align: bottom">September 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_499_20201231_zWBGmPyfkKI" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesForCommissionsExpenseAndTaxes_iI_pn3n3_maOLCzlcZ_zyMRDb4FGgN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 60%">Accrued commissions</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 16%">1,054</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 16%">461</td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_404_eus-gaap--AccruedPayrollTaxesCurrent_iI_pn3n3_maOLCzlcZ_z86o1AglmiS2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payroll</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">464</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maOLCzlcZ_z6HOk7hOaHU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">251</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">304</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedReturn_iI_pn3n3_maOLCzlcZ_zUnKrQJfJovf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued returns</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedIncomeTaxes_iI_pn3n3_maOLCzlcZ_zLr52oeft6Wj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued income tax payable</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1409"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maOLCzlcZ_zurPHi26LYmc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued benefits and vacation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_maOLCzlcZ_zwpVlbBzvOYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1415"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">169</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzlcZ_zKbB3cDm3gLk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,741</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,731</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zHeWfvJGPPAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_89E_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zI45ay1mpX79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table sets forth the components of other current liabilities at September 30, 2021 and December 31, 2020, respectively (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B0_zPSPwsBseoMg" style="display: none">Schedule of Other Current Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49A_20210930_zseiBaSrna1d" style="text-align: center; vertical-align: bottom">September 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_499_20201231_zWBGmPyfkKI" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesForCommissionsExpenseAndTaxes_iI_pn3n3_maOLCzlcZ_zyMRDb4FGgN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 60%">Accrued commissions</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 16%">1,054</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 16%">461</td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_404_eus-gaap--AccruedPayrollTaxesCurrent_iI_pn3n3_maOLCzlcZ_z86o1AglmiS2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payroll</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">464</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maOLCzlcZ_z6HOk7hOaHU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">251</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">304</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedReturn_iI_pn3n3_maOLCzlcZ_zUnKrQJfJovf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued returns</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedIncomeTaxes_iI_pn3n3_maOLCzlcZ_zLr52oeft6Wj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued income tax payable</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1409"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maOLCzlcZ_zurPHi26LYmc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued benefits and vacation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_maOLCzlcZ_zwpVlbBzvOYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1415"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">169</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzlcZ_zKbB3cDm3gLk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,741</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,731</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1054000 461000 56000 464000 251000 304000 331000 291000 8000 49000 34000 169000 1741000 1731000 <p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLvElJhcKGS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 10- <span id="xdx_828_zTaNtHA20hhi">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Manufacturing Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The </span><span style="font: 10pt Times New Roman, Times, Serif">Company and its wholly-owned subsidiary, PMI, entered into a manufacturing agreement (the “Manufacturing Agreement”) with Mylan Consumer Healthcare Inc. (formerly known as Meda Consumer Healthcare Inc.) (“MCH”) and Mylan Inc. (together with MCH, “Mylan”) in connection with the asset purchase agreement we entered into with Mylan in 2017. Pursuant to the terms of the Manufacturing Agreement, Mylan (or an affiliate or designee) purchased the inventory of the Company’s Cold-EEZE® brand and product line, and PMI agreed to manufacture certain products for Mylan, as described in the Manufacturing Agreement, at prices that reflect current market conditions for such products and include an agreed upon mark-up on our costs. On May 1, 2021, the Manufacturing Agreement was assigned by Mylan to Nurya Brands, Inc. (“Nurya”) in connection with Nurya’s acquisitions of certain assets from Mylan, including the Cold-EEZE® brand and product line. Unless terminated sooner by the parties, the Manufacturing Agreement will remain in effect until <span id="xdx_906_ecustom--AgreementTerminationDate_dd_c20210101__20210930__dei--LegalEntityAxis__custom--MylanandEscrowAgentMember__us-gaap--TypeOfArrangementAxis__custom--EscrowAgreementMember_z21Ev81oMIUa">March 29, 2022</span></span><span style="font: 10pt Times New Roman, Times, Serif">. Thereafter, the Manufacturing Agreement may be renewed by Nurya for up to five successive one-year periods by providing notice of its intent to renew not less than 90 days prior to the expiration of the then-current term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">In the normal course of our business, we may be named as a defendant in legal proceedings. It is our policy to vigorously defend litigation or to enter into a reasonable settlements where management deems it appropriate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 2022-03-29 <p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zNXig8INqpYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 11 – <span id="xdx_82A_zPvZvxDeZOIh">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On October 23, 2020, we completed the acquisition of CPM, which included the acquisition of a <span id="xdx_909_eus-gaap--AreaOfLand_iI_uSqft_c20210930__us-gaap--BusinessAcquisitionAxis__custom--PlazaMedicalLaboratoryCorpMember_zbfLRoDffFri">4,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">square foot CLIA accredited laboratory located in Old Bridge, New Jersey, which was owned by CPM (which is now known as ProPhase Diagnostics NJ, Inc.). The lease is for a term of 24 months with a monthly base lease payment of $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_pp0p0_c20201022__20201023__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember_z1lROSZxjQEe">5,950</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On December 8, 2020, we entered into a Lease Agreement (the “New York Lease”) pursuant to which the Company has agreed to lease certain premises located on the second floor (the “Leased Premises”) of 711 Stewart Avenue, Garden City, New York (the “Building”). The Leased Premises serve as the Company’s second laboratory location, offering a wide range of laboratory testing services for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel Molecular tests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The New York Lease was effective as of December 8, 2020 and commenced in December 2020 when the facility was made available to us by the landlord. The initial term of the New York Lease is <span id="xdx_904_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtYp_c20201023__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember_zTOn9xcSPoY7">10 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years and seven months (the “Initial Term”), unless sooner terminated as provided in the New York Lease. We may extend the term of the New York Lease for one additional option period of five years. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20201022__20201023__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember">We have the option to terminate the New York Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span id="xdx_905_eus-gaap--LesseeOperatingLeaseDescription_c20201207__20201208__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember" style="font: 10pt Times New Roman, Times, Serif">For the first year of the New York Lease, the base rent is $</span><span id="xdx_90D_eus-gaap--OperatingLeasePayments_pp0p0_c20201207__20201208__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember_zfbanr6uWeni" style="font: 10pt Times New Roman, Times, Serif">56,963 </span><span style="font: 10pt Times New Roman, Times, Serif">per month (subject to a seven month abatement period), with a gradual rental rate increase of <span id="xdx_907_ecustom--GradualRentalIncreaseRate_pid_dp_uPure_c20201207__20201208__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember_zYjDEkn3Fvc8">2.75</span></span><span style="font: 10pt Times New Roman, Times, Serif">% for each 12 month period, culminating in a monthly base rent of $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_pp0p0_c20201207__20201208__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember__srt--StatementScenarioAxis__custom--FinalMonthsMember_zVzxrHEDCLR8">74,716 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the final months of the Initial Term. In addition to the monthly base rent, we are responsible for our proportionate share of real estate tax escalations in accordance with the terms of the New York Lease.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseDescription_c20210101__20210930__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember" title="Lessee, Operating Lease, Description">We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the New York Lease. We also have a right of first offer to purchase the Building during the term of the New York Lease</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">At September 30, 2021, we had operating lease liabilities for the New York and New Jersey leases of approximately $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pn5n6_c20210930__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilitiesMember_z5xIaLw2uewl" title="Operating Lease, Liability">4.9</span> million and right of use assets of approximately $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20210930__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseRightOfUseAssetMember_zbJv4bZIIgEd" title="Operating Lease, Right-of-Use Asset">4.5</span> million, which were included in the condensed consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zzrmVZyrAo11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following summarizes quantitative information about our operating leases (amounts in thousands): </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.6pt"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zJfW99Q1hsI4" style="display: none">Summary of Quantitative Information About Operating Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20210101__20210930_zlvkCXb8A124" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0">For the Nine Months Ended</p> <p style="margin-top: 0; margin-bottom: 0">September 30, 2021</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maOLEzr9v_zlSqyuuw0Bm1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 76%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">611</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--VariableLeaseCost_maOLEzr9v_zeO5UxAP63C3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Variable lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1444"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseExpense_iT_mtOLEzr9v_maLCzK1A_znD0fKvVyNh7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">611</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShortTermLeaseCost_maLCzK1A_zv5UCGtcNd45" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Short-term lease rent expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1448"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_iT_mtLCzK1A_zLFwsI6xxpai" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total rent expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.6pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.6pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20210101__20210930_z5g1pMT58Za8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeasePayments_iN_di_zyEC7jcJWzAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating cash flows used in operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">(168</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zD2WY3H8exf4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets obtained in exchange for operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1454">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term – operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210930_z2bAoUVvZ3Nd">9.7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210930_zH1xbr8N3pz5">10.00</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AA_zIC7NSkalwp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ziR0ogeP0SWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Maturities of the Company’s operating leases, excluding short-term leases, are as follows (amounts in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.6pt"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_zTL84D81seud" style="display: none">Schedule of Maturity of Operating Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20210930_zdXWo9dNnbT7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPznSE_zAcD9evkYL8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Remaing Months Ended December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">190</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPznSE_zyJlqzykMcZ2" style="vertical-align: bottom; background-color: White"> <td>Year Ended December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">774</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPznSE_z9HGTDF8ym07" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year Ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">738</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPznSE_zASTDq2CnEq3" style="vertical-align: bottom; background-color: White"> <td>Year Ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">747</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPznSE_ztmwwv99dAjb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year Ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">768</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPznSE_zZx3BzYTzMac" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,659</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPznSE_zL3OOXbllV7k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,876</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zUxsP9OHQy73" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less present value discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,948</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,928</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_z6gUOvGczVr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 4000 5950 P10Y We have the option to terminate the New York Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee. For the first year of the New York Lease, the base rent is $ 56963 0.0275 74716 We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the New York Lease. We also have a right of first offer to purchase the Building during the term of the New York Lease 4900000 4500000 <p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zzrmVZyrAo11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following summarizes quantitative information about our operating leases (amounts in thousands): </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.6pt"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zJfW99Q1hsI4" style="display: none">Summary of Quantitative Information About Operating Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20210101__20210930_zlvkCXb8A124" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0">For the Nine Months Ended</p> <p style="margin-top: 0; margin-bottom: 0">September 30, 2021</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maOLEzr9v_zlSqyuuw0Bm1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 76%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">611</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--VariableLeaseCost_maOLEzr9v_zeO5UxAP63C3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Variable lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1444"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseExpense_iT_mtOLEzr9v_maLCzK1A_znD0fKvVyNh7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">611</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShortTermLeaseCost_maLCzK1A_zv5UCGtcNd45" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Short-term lease rent expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1448"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_iT_mtLCzK1A_zLFwsI6xxpai" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total rent expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.6pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.6pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20210101__20210930_z5g1pMT58Za8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeasePayments_iN_di_zyEC7jcJWzAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating cash flows used in operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">(168</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zD2WY3H8exf4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets obtained in exchange for operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1454">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term – operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210930_z2bAoUVvZ3Nd">9.7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210930_zH1xbr8N3pz5">10.00</span></td><td style="text-align: left">%</td></tr> </table> 611000 611000 611000 168000 P9Y8M12D 0.1000 <p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ziR0ogeP0SWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Maturities of the Company’s operating leases, excluding short-term leases, are as follows (amounts in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.6pt"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_zTL84D81seud" style="display: none">Schedule of Maturity of Operating Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20210930_zdXWo9dNnbT7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPznSE_zAcD9evkYL8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Remaing Months Ended December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">190</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPznSE_zyJlqzykMcZ2" style="vertical-align: bottom; background-color: White"> <td>Year Ended December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">774</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPznSE_z9HGTDF8ym07" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year Ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">738</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPznSE_zASTDq2CnEq3" style="vertical-align: bottom; background-color: White"> <td>Year Ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">747</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPznSE_ztmwwv99dAjb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year Ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">768</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPznSE_zZx3BzYTzMac" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,659</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPznSE_zL3OOXbllV7k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,876</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zUxsP9OHQy73" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less present value discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,948</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,928</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 190000 774000 738000 747000 768000 4659000 7876000 2948000 4928000 <p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zUKOZbd5K3n1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 12- <span id="xdx_820_zByQ7ISTa3n2">Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Revenue for the three months ended September 30, 2021 and 2020 was $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210701__20210930_zF5x8SxdaXS" title="Revenues net">9.5</span> million and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20200701__20200930_zrJ0wNeLCb76" title="Revenues net">3.8</span> million, respectively. Three diagnostic services clients accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzMHBUdHSLIj" title="Concentration Risk, Percentage">19.6</span>%, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNHjjadjJQ6e" title="Concentration Risk, Percentage">12.0</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zY9zD5IDQDq">10.4</span>% of our revenue for the three months ended September 30, 2021. No contract manufacturing customer accounted for a significant portion of our revenue for the three months ended September 30, 2021. Two third-party contract manufacturing customers accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200701__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThirdPartyContractManufacturingCustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFeXW4pN0bL" title="Concentration Risk, Percentage">57.6</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200701__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThirdPartyContractManufacturingCustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXRfTlX6RFgi" title="Concentration Risk, Percentage">15.9</span>%, respectively, of our revenue from continuing operations for the three months ended September 30, 2020. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Revenue for the nine months ended September 30, 2021 and 2020 was $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210101__20210930_zt7sHJCULTY6" title="Revenues net">33.9</span> million and $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20200101__20200930_z1iITM8iaym7" title="Revenues net">9.4</span> million, respectively. Two diagnostic services clients accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zN8oZB9A3XK5" title="Concentration Risk, Percentage">28.4</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqZF7pv9bETj" title="Concentration Risk, Percentage">20.7</span>%, respectively, of our revenue for the nine months ended September 30, 2021. Two third-party contract manufacturing customers accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThirdPartyContractManufacturingCustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z75rJe1mAi5" title="Concentration Risk, Percentage">56.2</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThirdPartyContractManufacturingCustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zc0HUIxiltPl" title="Concentration Risk, Percentage">16.6</span>%, respectively, of our revenue for the nine months ended September 30, 2020. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Five diagnostic services clients generated <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6ZKFVmsvHDf">19.5</span></span><span style="font: 10pt Times New Roman, Times, Serif">%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zm4fFKgPSCOg">19.3</span></span><span style="font: 10pt Times New Roman, Times, Serif">%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcOGoEakZRpa">12.0</span></span><span style="font: 10pt Times New Roman, Times, Serif">%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zI3Mp5QlnNW8">11.7</span></span><span style="font: 10pt Times New Roman, Times, Serif">% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsFiveMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMu35U8oj6Eb">11.6</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of our total reimbursement receivable balances from government agencies and healthcare issuers at September 30, 2021. Three of our customers represented <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zX8phcpyyl6l">36</span></span><span style="font: 10pt Times New Roman, Times, Serif">%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOxaiU1IzlMd">20</span>% and </span><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zM156pzGWTRc" style="font: 10pt Times New Roman, Times, Serif">13</span><span style="font: 10pt Times New Roman, Times, Serif">% of our total trade receivable balances at December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 9500000 3800000 0.196 0.120 0.104 0.576 0.159 33900000 9400000 0.284 0.207 0.562 0.166 0.195 0.193 0.120 0.117 0.116 0.36 0.20 0.13 <p id="xdx_801_eus-gaap--EarningsPerShareTextBlock_z3kIoJKv2GOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 13 -<span id="xdx_829_zPiv6hvdIT1a"> Earnings (Loss) Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine months ended September 30, 2021, dilutive loss per share were the same as basic loss per share due to the exclusion of Common Stock in the form of stock options (“Common Stock Equivalents”), which in a net loss position would have an anti-dilutive effect on loss per share. The potentially anti-dilutive effect of stock options, warrants, and convertible debt for the three and nine months ended September 30, 2021 was <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsWarrantsAndConvertibleDebtMember_zeOnaveJ5w36">2,929,000</span> and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsWarrantsAndConvertibleDebtMember_zuI4jorwmQCl">3,029,000</span> shares, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine months ended September 30, 2020, dilutive loss per share were the same as basic earnings per share due to the exclusion of Common Stock Equivalents. For the three and nine months ended September 30, 2020, there were <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockEquivalentsTwoMember_zXdbKqJyZfth">4,932,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">potentially dilutive Common Stock Equivalents that were excluded from the loss per share computation as a consequence of their anti-dilutive effect which in a net loss position would have an anti-dilutive effect on loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 2929000 3029000 4932000 <p id="xdx_80E_ecustom--SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock_zb3Rg5pWGbCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 14 - <span id="xdx_827_zBJMZbu05h78">Secured Promissory Note Receivable and Consulting Agreement</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Consulting Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On September 25, 2020, we entered into a consulting agreement (the “Consulting Agreement”) with a company acting as a consultant (the “Consultant”). The Consulting Agreement was to be effective through September 1, 2022; provided, however, that we could terminate this agreement at any time on five days’ prior written notice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Consultant’s duties were to include, among other things, (i) identifying and introducing us to new opportunities in the medical technology and testing fields, (ii) assisting and advising us in acquiring one or more CLIA certified labs suitable for COVID-19 and other testing (“Test Labs”); (iii) assisting us in equipping and staffing any Test Labs acquired by us; (iv) advising and assisting in the operation of such Test Labs; (v) validating and obtaining certification of such Test Labs; and (vi) assisting us in obtaining a flow of business, orders and revenues from multiple sources in the industry, including but not limited to at least one significant, nation-wide manufacturer and distributor of COVID-19 saliva sample collection test kits (“COVID-19 Test Kits”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">All compensation earned by the Consultant would first be applied to the acceleration and prepayment of all sums due to us, including but not limited to sums due pursuant to the Amended and Restated Promissory Note (“Secured Note”) described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Promissory Note and Security Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On September 25, 2020 (the “Restatement Effective Date”), we entered into the Secured Note with the Consultant, pursuant to which we loaned $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20200925__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RestatementAxis__srt--RestatementAdjustmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zk86yDbENl9k" title="Debt Instrument, Face Amount">3.0</span> million to the Consultant (inclusive of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20200925__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zXoyC7ylHRv9" title="Debt Instrument, Face Amount">1.0</span> million in the aggregate previously loaned to the Consultant, as described below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Secured Note amended and restated in its entirety (i) that certain Promissory Note and Security Agreement, dated July 21, 2020 (the “Original July 21 Note”), pursuant to which we loaned $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200721__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RestatementAxis__srt--RestatementAdjustmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zucQouoJwzb">750,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">to the Consultant and (ii) that certain Promissory Note and Security Agreement, dated July 29, 2020 (the “Original July 29 Note”, and, together with the Original July 21 Note, the “Original Notes”), pursuant to which we loaned $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200729__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RestatementAxis__srt--RestatementAdjustmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zfME5DI48pZd">250,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">to the Consultant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Secured Note bears interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200925__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RestatementAxis__srt--RestatementAdjustmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_z6SfhSdnIH9b" title="Debt Instrument, Interest Rate, Stated Percentage">15</span>% per annum from and including the Restatement Effective Date until the principal amount is repaid in full plus any Principal Increases (as defined below) together with any accrued interest that has not been capitalized; <i>provided, however</i>, that upon the occurrence and during an Event of Default (as defined in the Secured Note), the interest rate payable under the Secured Note will automatically increase to <span id="xdx_90F_ecustom--IncreaseInInterestRatePayablePercentage_iI_pid_dp_uPure_c20200925__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RestatementAxis__srt--RestatementAdjustmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zFxIR6raiTlc" title="Increase in interest rate payable percentage">9</span>% above the rate of interest then applicable to the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Interest under the Secured Note will be payable monthly in arrears on the first day of each month for the prior monthly period, as well as at maturity (whether upon demand, by acceleration or otherwise) (each such date, a “Payment Date”); provided, however, that prior to September 1, 2021, interest will be paid and capitalized in kind by increasing the principal amount of the Secured Note (any such increase, a “Principal Increase”) by an amount equal to the interest accrued on the principal amount (as increased by the Principal Increases) during the prior month. On each Payment Date commencing after September 1, 2021, in addition to payments of interest described in the preceding sentence, the Consultant will also make payments on the principal amount of the loan equal to 1/36 of the then outstanding principal amount. The amount of the monthly payments will be equal to the amount required to amortize fully the outstanding principal amount of the loan, together with interest, over a period of <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtM_c20200923__20200925__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RestatementAxis__srt--RestatementAdjustmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zEotWrdb3E77">36 </span></span><span style="font: 10pt Times New Roman, Times, Serif">months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The entire remaining unpaid principal amount of the Secured Note, together with all accrued and unpaid interest thereon and all other amounts payable under the Secured Note, will be due and payable, if not sooner paid, on September 30, 2022 or an earlier date as a result of a maturity, whether by acceleration or otherwise. The Secured Note may be prepaid in full or in part at any time without penalty or premium.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Secured Note contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the Secured Note may be accelerated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Secured Note contains customary representation and warranties and certain restrictive covenants which, among other things, restrict the Consultant’s ability to (i) sell, transfer, finance, lease, license, or dispose of all or substantially all of its property or assets, liquidate, windup, or dissolve, (ii) acquire all or substantially all of the property or assets of, or the equity interests in, any other person, (iii) participate in any merger, consolidation, share exchange, division, conversion, reclassification, or other absorption or reorganization, (iv) except for those existing as of the Restatement Effective Date, create, incur, assume, permit, or suffer to exist any pledges, liens, security interests, and other encumbrances of its property or assets, whether now owned or hereafter owned or acquired, and (v) create, incur or permit to exist any debt that is senior to, or <i>pari passu </i>with the Secured Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">In order to secure the Consultant’s obligations under the Secured Note, the Consultant granted to the Company a continuing security interest in certain property and assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Total interest income recorded in the three and nine months ended September 30, 2021 was $<span id="xdx_90B_eus-gaap--InterestAndFeeIncomeLoansAndLeases_pp0p0_c20210701__20210930_zjFQ5PcWUww1">230,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span><span id="xdx_90D_eus-gaap--InterestAndFeeIncomeLoansAndLeases_pp0p0_c20210101__20210930_znzif32Y1PX4">531,000</span>, </span></span><span style="font: 10pt Times New Roman, Times, Serif">respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Amendment and Termination Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">On January 14, 2021, we entered into an Amendment and Termination Agreement (the “Termination Agreement”) with the Consultant pursuant to which the parties amended the Secured Note and terminated the Consulting Agreement. Pursuant to the terms of the Termination Agreement, the Company loaned an additional $1 million to the Consultant in consideration for the termination of the Consulting Agreement and termination of the Company’s obligation to pay the Consultant additional consulting fees beyond the $<span id="xdx_90E_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pp0p0_c20200923__20200925__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zdYIkeqIf4jc">250,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">already earned by the Consultant under the Consulting Agreement. As a result, the initial principal amount due under the Secured Note was increased from $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn4n6_c20200925__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RangeAxis__srt--MinimumMember_zd42yLVmDNV9">2.75 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million to $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_c20200925__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RangeAxis__srt--MaximumMember_pn4n6">3.75 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million plus all accrued and unpaid interest arising under the Secured Note through and including January 14, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">Under the terms of the Termination Agreement, the Consultant will sell and process its viral test by RT-PCR (together with other viral and other types of tests). Until the Secured Note is paid in full, each COVID-19 Test Kit sold or processed from and after January 14, 2021, and for which payment of at least the specified amount as defined for the test, is received by the Consultant, the Consultant will pay us a specified amount (the “Test Fee”). The total payments will not exceed the aggregate amounts due under the Secured Note and shall be applied first to interest and other amounts due under the Secured Note and then to the then-current outstanding principal. Test Fees will be due and payable on the 10th business day after the end of each month commencing in February 2021, and until the Secured Note is paid in full. We received the first payment in the amount of $<span id="xdx_908_ecustom--TestFeesReceived_pp0p0_c20210115__20210228__us-gaap--TypeOfArrangementAxis__custom--TerminationAgreementMember_zrM6THVqjnoj">95,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">with respect to the Test Fees from January 15 through February 2021. On June 25, 2021, we were issued <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zlCluO7UDSbg">1,260,619 </span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares of the Consultant with a fair value of $<span id="xdx_90D_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zLWueL0YbU4e">315,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">as an interest payment under the Secured Note in lieu of Test Fees from March through June 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in">Effective September 1, 2021, in addition to the payment of the Test Fees described above, the Consultant also is also required to make payments to us in an amount equal to the greater of (x) the Test Fee, or (y) 1/36th of the then outstanding principal amount together with interest thereon and interest accruing on the Secured Note, in accordance with the Secured Note. Accordingly, effective September 1, 2021, the minimum number of monthly payments due and payable to us is equal to the amount required to amortize fully the outstanding principal amount of the Secured Note, together with interest over a period of 36 months with level monthly payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in">The Secured Note is currently in default for nonpayment with accrued interest of $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_c20210930__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zqiROF2w1Yp3" title="Accrued interest, debt">132,000</span> outstanding as of September 30, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 3000000.0 1000000.0 750000 250000 0.15 0.09 P36M 230000 531000 250000 2750000 3750000 95000 1260619 315000 132000 <p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_z0jTPq7h42R" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 15 - <span id="xdx_82E_zuXW2zFMthV1">Segment Information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The Company has identified <span id="xdx_903_eus-gaap--NumberOfOperatingSegments_dxL_uSegment_c20210101__20210930_zrqHZ8tJcEO" title="::XDX::2"><span style="-sec-ix-hidden: xdx2ixbrl1542">two</span></span></span> <span style="font: 10pt Times New Roman, Times, Serif">operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO as CODM assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zXGvDKcIO5g1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table is a summary of segment information for three and nine months ended September 30, 2021 and 2020 (amounts in thousands): </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_zAfS8LK4ahv" style="display: none">Schedule of Segment Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20210701__20210930_z1brvJke6ONk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20200701__20200930_z0ilnKe2pZdg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20210101__20210930_ztp1WAOzs57k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20200101__20200930_zXXqN9ZxSUhi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_ztRPmJbf9bU2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Diagnostic services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,142</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,416</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1549">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zepn8jdXZic3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,330</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,840</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,469</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,351</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zKbgIwDoQM54" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Consolidated net revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,472</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,840</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,351</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zwvZuhrApMd1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1562"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1564"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zsgseTCNxl19" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,798</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,682</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,615</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_zzpWkoFTFIC" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Consolidated cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,798</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,515</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,615</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DepreciationAndAmortization_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_z4ftH91e1kGc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1577"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1579"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DepreciationAndAmortization_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zadTbUjQcvoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1581"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DepreciationAndAmortization_pn3n3_zMFGKO0GGQSj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,144</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingAndOtherExpenses_pn3n3_zB2lN5JBLMr" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating and other expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,608</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,031</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Income (loss) from continuing operations, before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingAndOtherExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zivkI9kcCfb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,145</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1597"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1599"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zNvjlZneOkub" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(958</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,039</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(453</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,723</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zwspeDI90tQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,875</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,608</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,722</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zakr6YdJQdN" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total loss from continuing operations, before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,978</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(569</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,316</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,308</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_pn3n3_zaBSb3JA6kHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Income from discontinued operations, before income taxes</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1616"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1618"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_pn3n3_zDbeluAss9o7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,978</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(408</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,316</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,147</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table is a summary of segment balance sheets information as of September 30, 2021 and December 31, 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20210930_zPjDXtIKlNHi" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20201231_zmxkAK2bX3Bd" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">ASSETS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zBun8egSav7h" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Diagnostic services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">28,738</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,410</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zEOR6syPEaub" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,986</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,261</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zX35ty3lBmka" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,906</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,734</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Assets_iI_pn3n3_zWMnQNCYiQt" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zYW6BuDvD0B9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zXGvDKcIO5g1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table is a summary of segment information for three and nine months ended September 30, 2021 and 2020 (amounts in thousands): </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_zAfS8LK4ahv" style="display: none">Schedule of Segment Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20210701__20210930_z1brvJke6ONk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20200701__20200930_z0ilnKe2pZdg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20210101__20210930_ztp1WAOzs57k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20200101__20200930_zXXqN9ZxSUhi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_ztRPmJbf9bU2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Diagnostic services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,142</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,416</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1549">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zepn8jdXZic3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,330</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,840</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,469</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,351</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zKbgIwDoQM54" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Consolidated net revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,472</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,840</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,351</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zwvZuhrApMd1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1562"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1564"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zsgseTCNxl19" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,798</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,682</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,615</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_zzpWkoFTFIC" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Consolidated cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,798</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,515</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,615</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DepreciationAndAmortization_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_z4ftH91e1kGc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1577"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1579"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DepreciationAndAmortization_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zadTbUjQcvoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1581"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DepreciationAndAmortization_pn3n3_zMFGKO0GGQSj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,144</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingAndOtherExpenses_pn3n3_zB2lN5JBLMr" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating and other expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,608</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,031</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Income (loss) from continuing operations, before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingAndOtherExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zivkI9kcCfb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,145</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1597"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1599"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zNvjlZneOkub" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(958</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,039</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(453</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,723</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zwspeDI90tQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,875</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,608</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,722</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zakr6YdJQdN" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total loss from continuing operations, before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,978</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(569</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,316</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,308</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_pn3n3_zaBSb3JA6kHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Income from discontinued operations, before income taxes</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1616"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1618"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_pn3n3_zDbeluAss9o7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,978</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(408</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,316</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,147</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font: 10pt Times New Roman, Times, Serif">The following table is a summary of segment balance sheets information as of September 30, 2021 and December 31, 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20210930_zPjDXtIKlNHi" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20201231_zmxkAK2bX3Bd" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">ASSETS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zBun8egSav7h" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Diagnostic services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">28,738</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,410</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zEOR6syPEaub" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,986</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,261</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zX35ty3lBmka" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,906</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,734</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Assets_iI_pn3n3_zWMnQNCYiQt" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 7142000 27416000 2330000 3840000 6469000 9351000 9472000 3840000 33885000 9351000 4009000 11833000 1486000 2798000 4682000 6615000 5495000 2798000 16515000 6615000 401000 1138000 3000 6000 13000 401000 3000 1144000 13000 13020000 1608000 20542000 4031000 -1145000 2859000 -958000 1039000 -453000 2723000 -1875000 -1608000 -6722000 -4031000 -3978000 -569000 -4316000 -1308000 161000 161000 -3978000 -408000 -4316000 -1147000 28738000 13410000 20986000 6261000 22906000 11734000 72630000 31405000 <p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zQJIh2VUwdH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 16 – <span id="xdx_825_zDsXZssQtUJc">Subsequent Event</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Pursuant to the stock repurchase program on September 8, 2021 (see Note 7), as of November <span style="background-color: white">10</span>, 2021, we have repurchased <span style="background-color: white"><span id="xdx_90B_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20211108__20211110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmTcCU4hcqii" title="Number of shares repurchased">140,769</span> </span> shares for an aggregate amount of $<span id="xdx_90B_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_c20211108__20211110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjH5qQz2gtFi" title="Aggregate amount of shares repurchased">791,000</span>, including commissions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> 140769 791000 Net of $1,639 cash acquired and $257 anticipated amounts due back to the Company from the escrow account. XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
9 Months Ended
Sep. 30, 2021
Nov. 10, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Entity File Number 000-21617  
Entity Registrant Name ProPhase Labs, Inc.  
Entity Central Index Key 0000868278  
Entity Tax Identification Number 23-2577138  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 711 Stewart Ave  
Entity Address, Address Line Two Suite 200  
Entity Address, City or Town Garden City  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 11530  
City Area Code (215)  
Local Phone Number 345-0919  
Title of 12(b) Security Common Stock, par value $0.0005  
Trading Symbol PRPH  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   15,511,455
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 8,533 $ 6,816
Restricted cash 250
Marketable debt securities, available for sale 14,114 1,639
Marketable equity securities, at fair value 214
Accounts receivable, net 10,680 3,155
Inventory, net 8,510 3,039
Prepaid expenses and other current assets 1,602 1,238
Total current assets 43,903 15,887
Property, plant and equipment, net 6,454 3,578
Secured promissory note receivable 3,774 2,750
Prepaid expenses, net of current portion 460 2,084
Right-of-use asset, net 4,484 4,731
Intangible assets, net 11,562 1,234
Goodwill 1,385 901
Other assets 608 240
TOTAL ASSETS 72,630 31,405
Current liabilities    
Accounts payable 2,394 3,771
Accrued diagnostic services 3,260
Accrued advertising and other allowances 344 463
Lease liabilities 676 329
Deferred revenue 1,517
Other current liabilities 1,741 1,731
Total current liabilities 9,932 6,294
Non-current liabilities:    
Deferred revenue, net of current portion 106 162
Note payable 81
Unsecured convertible promissory notes, net 9,995 9,991
Lease liabilities, net of current portion 4,252 4,402
Total non-current liabilities 14,434 14,555
Total liabilities 24,366 20,849
Stockholders’ equity    
Preferred stock authorized 1,000,000, $.0005 par value, no shares issued and outstanding
Common stock authorized 50,000,000, $.0005 par value, 15,652,724 and 11,604,253 shares outstanding, respectively 16 14
Additional paid-in capital 103,807 61,674
Accumulated deficit (7,947) (3,631)
Treasury stock, at cost, 16,652,022 and 16,652,022 shares, respectively (47,490) (47,490)
Accumulated other comprehensive loss (122) (11)
Total stockholders’ equity 48,264 10,556
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 72,630 $ 31,405
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred Stock, Shares Authorized 1,000,000 1,000,000
Preferred Stock, Par or Stated Value Per Share $ 0.0005 $ 0.0005
Preferred Stock, Shares Outstanding 0 0
Preferred Stock, Shares Issued 0 0
Common Stock, Shares Authorized 50,000,000 50,000,000
Common Stock, Par or Stated Value Per Share $ 0.0005 $ 0.0005
Common Stock, Shares, Outstanding 15,652,724 11,604,253
Treasury Stock, Shares 16,652,022 16,652,022
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenues, net $ 9,472 $ 3,840 $ 33,885 $ 9,351
Cost of revenues 5,495 2,798 16,515 6,615
Gross profit 3,977 1,042 17,370 2,736
Operating expenses:        
Diagnostic expenses 1,478 6,117
General and administration 5,938 1,552 14,713 3,875
Research and development 208 57 416 181
Total operating expenses 7,624 1,609 21,246 4,056
Loss from operations (3,647) (567) (3,876) (1,320)
Interest income, net 230 39 531 53
Interest expense (296) (41) (870) (41)
Change in fair value of investment securities (265) (101)
Loss from continuing operations (3,978) (569) (4,316) (1,308)
Discontinued Operations:        
Income from discontinued operations 161 161
Net loss (3,978) (408) (4,316) (1,147)
Other comprehensive loss:        
Unrealized loss on marketable debt securities (33) (8) (111) (2)
Total comprehensive loss $ (4,011) $ (416) $ (4,427) $ (1,149)
Basic and diluted earnings (loss) per share:        
Loss from continuing operations $ (0.26) $ (0.05) $ (0.29) $ (0.11)
Income from discontinued operations 0.01 0.01
Net loss per share $ (0.26) $ (0.04) $ (0.29) $ (0.10)
Weighted average common shares outstanding:        
Basic and diluted 15,439 11,604 15,055 11,593
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 14 $ 60,215 $ (1,506) $ (2) $ (47,490) $ 11,231
Balance, shares at Dec. 31, 2019 11,573,593          
Issuance of common shares related to business acqusition          
Unrealized loss on marketable debt securities, net of realized losses of net of taxes (2) (2)
Stock-based compensation 679 679
Stock-based compensation,shares 30,660          
Net loss (1,147) (1,147)
Ending balance, value at Sep. 30, 2020 $ 14 60,894 (2,653) (4) (47,490) 10,761
Balance, shares at Sep. 30, 2020 11,604,253          
Beginning balance, value at Jun. 30, 2020 $ 14 60,611 (2,245) 4 (47,490) 10,894
Balance, shares at Jun. 30, 2020 11,591,648          
Unrealized loss on marketable debt securities, net of realized losses of net of taxes (8) (8)
Cashless warrants exercise 5,986          
Stock-based compensation 283 283
Stock-based compensation,shares 12,605          
Net loss (408) (408)
Ending balance, value at Sep. 30, 2020 $ 14 60,894 (2,653) (4) (47,490) 10,761
Balance, shares at Sep. 30, 2020 11,604,253          
Beginning balance, value at Dec. 31, 2020 $ 14 61,674 (3,631) (11) (47,490) 10,556
Balance, shares at Dec. 31, 2020 11,604,253          
Issuance of common stock and warrants for cash from public offering, net of offering cost $ 2 35,133 35,135
Issuance of common stock and warrants for cash from public offering, net of $2,365 offering cost, shares 3,000,000          
Issuance of common stock and warrants for cash from private offering 5,500 5,500
Issuance of common stock and warrants for cash from private offering, shares 550,000          
Issuance of common shares related to business acqusition 3,608 3,608
Issuance of common shares related to business acqusition, shares 483,685          
Cash dividends (4,546) (4,546)
Unrealized loss on marketable debt securities, net of realized losses of net of taxes (111) (111)
Cashless warrants exercise
Cashless warrants exercise 5,986,000          
Stock-based compensation 2,438 2,438
Stock-based compensation,shares 8,800          
Net loss (4,316) (4,316)
Ending balance, value at Sep. 30, 2021 $ 16 103,807 (7,947) (122) (47,490) 48,264
Balance, shares at Sep. 30, 2021 15,652,724          
Beginning balance, value at Jun. 30, 2021 $ 16 99,265 (3,969) (89) (47,490) 47,733
Balance, shares at Jun. 30, 2021 15,154,253          
Issuance of common shares related to business acqusition 3,608 3,608
Issuance of common shares related to business acqusition, shares 483,685          
Unrealized loss on marketable debt securities, net of realized losses of net of taxes (33) (33)
Cashless warrants exercise
Stock-based compensation 934 934
Stock-based compensation,shares 8,800          
Net loss (3,978) (3,978)
Ending balance, value at Sep. 30, 2021 $ 16 $ 103,807 $ (7,947) $ (122) $ (47,490) $ 48,264
Balance, shares at Sep. 30, 2021 15,652,724          
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]      
Marketable Securities, Gain (Loss) $ 4   $ 4
Offering cost   $ 2,365  
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities    
Net loss $ (4,316) $ (1,147)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Realized (gain) loss on marketable debt securities 40 (2)
Depreciation and amortization 2,044 253
Amortization of debt discount 4
Amortization on right-of-use assets 247
Lower of cost or net realizable value inventory adjustment 17
Stock-based compensation expense 2,438 679
Change in fair value of investment securities 101
Non-cash interest income on secured promissory note receivable (315)
Changes in operating assets and liabilities:    
Accounts receivable (7,327) (1,015)
Escrow receivable 4,812
Inventory (5,036) (696)
Prepaid and other assets 1,639 (30)
Other assets (368)
Accounts payable and accrued expenses (1,749) 470
Accrued diagnostic services 3,260
Deferred revenue 1,461  
Lease liabilities 197
Other liabilities (1,292) 835
Net cash (used in) provided by operating activities (8,972) 4,176
Cash flows from investing activities    
Business acquisitions, net of cash acquired (9,066)
Issuance of secured promissory note receivable (1,000) (2,974)
Purchase of marketable securities (21,527) (4,317)
Proceeds from sale of marketable debt securities 10,701 3,839
Capital expenditures (4,258) (222)
Net cash used in investing activities (25,150) (3,674)
Cash flows from financing activities    
Proceeds from issuance of common stock from public offering, net 35,135
Proceeds from issuance of common stock and warrants from private offering 5,500
Proceeds from unsecured convertible promissory notes 10,000
Issuance costs on unsecured convertible promissory notes (10)
Payment of issuance costs in connection with ATM (66)
Payment of dividends (4,546)
Net cash provided by financing activities 36,089 9,924
Increase in cash, cash equivalents and restricted cash 1,967 10,426
Cash, cash equivalents and restricted cash, at the beginning of the period 6,816 434
Cash, cash equivalents and restricted cash, at the end of the period 8,783 10,860
Supplemental disclosures:    
Cash paid for income taxes
Interest payment on the promissory notes 750
Supplemental disclosure of non-cash investing and financing activities:    
Issuance of common shares related to business acqusition 3,608
Net unrealized loss, investments in marketable debt securities $ (111) $ (2)
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Business
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Business

Note 1 - Organization and Business

 

ProPhase Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a diversified biotech and genomics company with deep experience with over-the- counter (“OTC”) consumer healthcare products and dietary supplements. We currently conduct our operations through two operating segments: diagnostic services and consumer products. Until late Fiscal 2020, we were engaged primarily in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. However, commencing in December 2020, we also began offering COVID-19 and other Respiratory Pathogen Panel (RPP) molecular tests through our new diagnostic services business and in August 2021 we began offering personal genomics products and services.

 

Our wholly-owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers a variety of medical tests, including COVID-19 and Respiratory Pathogen Panel (RPP) molecular tests. On October 23, 2020, we acquired Confucius Plaza Medical Laboratory Corp. (“CPM”), including a 4,000 square foot Clinical Laboratory Improvement Amendments (“CLIA”) accredited laboratory located in Old Bridge, New Jersey (see Note 3, Business Acquisitions). As part of the acquisition of CPM in October 2020, we entered into a new business line, diagnostic services. In December 2020, we expanded our diagnostic service business with the build out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in February 2021.

 

Our wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.

 

On August 10, 2021, we acquired Nebula Genomics, Inc., a privately owned personal genomics company, through our new wholly-owned subsidiary, ProPhase Precision Medicine, Inc. (see Note 3, Business Acquisitions).

 

In addition, we continue to actively pursue acquisition opportunities for other companies, technologies and products within and outside the consumer products industry.

  

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Business and Liquidity Uncertainties
9 Months Ended
Sep. 30, 2021
Business And Liquidity Uncertainties  
Business and Liquidity Uncertainties

Note 2 - Business and Liquidity Uncertainties

 

Basis of Presentation

 

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of operating results that may be achieved over the course of the full year.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Segments

 

Operating segments are defined as components of an enterprise that engage in business activities for which separate financial information is available and is evaluated by the Chief Operating Decision Maker (“CODM”), which for the Company is its Chief Executive Officer, in deciding how to allocate resources and assess performance. For the three and nine months ended September 30, 2021, we maintained two operating segments: diagnostic services (which includes our COVID-19 and other diagnostic testing services) and consumer products (which includes our contract manufacturing, retail customers and personal genomics products and services). For the three and nine months ended September 30, 2020, we only had the consumer products operating segment. (see Note 15, Segment Information).

 

Business and Liquidity Uncertainties

 

We launched our diagnostic service business in December 2020 and expanded in February 2021 with the opening of our new Garden City, New York CLIA accredited laboratory. Our diagnostic service business is and will continue to be influenced by the level of demand for COVID-19 and other diagnostic testing, the prices we are able to receive for performing our testing services, and the length of time for which that demand persists, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.

 

While our revenues increased for the three and nine months ended September 30, 2021 as a result of revenues from our new diagnostic services business line, we have made and will continue to make substantial investments to secure the necessary equipment, supplies and personnel to provide these testing services. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will be successful in the future or that the revenue and operating profits from such business will increase or maintain their current level.

 

We acquired and commenced our personal genomics business in August 2021. This business will be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.

 

There are still numerous uncertainties associated with the COVID-19 pandemic, including the efficacy of the vaccines that have been developed to treat the virus and their ability to protect against new strains of the virus, people’s willingness to receive a vaccine, possible resurgences of the coronavirus and/or new strains of the virus, the extent and duration of protective and preventative measures that may be adopted by local, state and/or the federal government in the future as a result of future outbreaks, the duration of any future business closures, the ongoing impact of COVID-19 on the U.S. and world economy and consumer confidence, and various other uncertainties.

 

The Company used cash in operating activities of $9.0 million for the nine months ended September 30, 2021. The Company had cash, cash equivalents and marketable securities of $22.9 million as of September 30, 2021. Based on management’s current business plan, the Company estimates it will have enough cash and liquidity to finance its operating requirements for at least one year from the date of filing these financial statements.

 

The Company’s future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily limited to, the actual cost and time necessary to achieve sustained profitability within its newly launched diagnostic services and personal genomics businesses. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Use of Estimates

 

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, diagnostic services reimbursements, inventory obsolescence, useful lives of property and equipment, impairment of goodwill, intangibles and property and equipment, income tax valuations and assumptions related to accrued advertising. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these securities.

 

Marketable Debt Securities

 

We have classified our investments in marketable debt securities as available-for-sale and as a current asset. Our investments in marketable debt securities are carried at fair value, with unrealized gains and as a separate component of stockholders’ equity. Realized gains and losses from our marketable debt securities are recorded as interest income (expense). These investments in marketable debt securities, carry maturity dates between one and three years from date of purchase and interest rates of 1.90% to 3.62% during the first three quarters of Fiscal 2021. For the three and nine months ended September 30, 2021, we reported unrealized losses of $32,000 and $111,000, respectively. Unrealized gains and losses are classified as other comprehensive loss and the cost is determined on a specific identification basis. The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (see fair value of financial instruments) (in thousands):

 

   As of September 30, 2021 
   Amortized   Unrealized   Fair 
   Cost   Losses   Value 
U.S. government obligations  $324   $(1)  $323 
Corporate obligations   13,912    (121)   13,791 
   $14,236   $(122)  $14,114 

 

   As of December 31, 2020 
   Amortized   Unrealized   Fair 
   Cost   Losses   Value 
U.S. government obligations  $1,021   $(7)  $1,014 
Corporate obligations   629    (4)   625 
   $1,650   $(11)  $1,639 

 

We believe that the unrealized gains or losses generally are the result of a change in the risk premiums required by market participants rather than an adverse change in cash flows or a fundamental weakness in the credit quality of the issuer or underlying assets.

 

Marketable Equity Securities

 

Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net in the consolidated statements of income.

 

On June 25, 2021, we were issued 1,260,619 common shares (the “Investment Shares”) as an interest payment under our note receivable (see Note 14, Secured Promissory Note Receivable and Consulting Agreement) with a fair value of $315,000. The fair value of the Investment Shares as of September 30, 2021 was based upon the closing stock price of $0.17 per share. The investment was classified as a Level 1 financial instrument. We recorded a $265,000 and $101,000 decrease in fair value of investment securities within the statement of operations for the three and nine months ended September 30, 2021, respectively.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Inventories, net

 

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or net realizable value. Inventory items are analyzed to determine cost and the net realizable value and appropriate valuation adjustments are then established. At September 30, 2021 and December 31, 2020, the financial statements include non-cash adjustments to adjust inventory for excess, obsolete or short-dated shelf-life inventory by $87,000 and $167,000, respectively. The components of inventory are as follows (in thousands):

 

   September 30,   December 31, 
   2021   2020 
Diagnostic services testing material  $6,203   $1,028 
Raw materials   1,464    1,404 
Work in process   407    437 
Finished goods   436    170 
Inventory, net  $8,510   $3,039 

 

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years.

 

We did not identify any indicators of impairment of our property, plant and equipment for the nine months ended September 30, 2021 and 2020 and concluded there were no impairments or changes in useful lives.

 

Concentration of Risks

 

Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity and marketing and distribution capabilities, as well as our ability to comply with the regulatory requirements associated with the development of OTC consumer healthcare products, dietary supplements and other remedies in order to compete on a national level and/or international level. Our diagnostic services business will be influenced by demand for our diagnostic testing services, particularly COVID-19 testing services, our marketing and service capabilities, and our ability to comply with regulatory requirements associated with operating under and maintaining our CLIA license. Our personal genomics business is and will continue to be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.

 

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products and services. The manufacturing and distribution of OTC healthcare and dietary supplement products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States. The FDA is also responsible for the regulation of diagnostic testing instruments, test kits, reagents and other devices used by clinical laboratories.

 

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and trade accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.

 

We maintain cash and cash equivalents with certain major financial institutions. As of September 30, 2021, our cash and cash equivalents balance were $8.5 million and our bank balance was $8.7 million. Of the total bank balance, $1.0 million was covered by federal depository insurance and $7.7 million was uninsured at September 30, 2021.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depend on information provided and billing services of third parties. These credit concentrations impact our overall exposure to credit risk, which could be further affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of trade receivables and diagnostic test receivables. Additionally, the reimbursement receivables from the diagnostic service business are subject to billing errors and related disputes.

 

We also assess the financial condition of the debtor under our note receivable (see Note 14, Secured Promissory Note Receivable and Consulting Agreement), balances due to us. As of September 30, 2021, December 31, 2020 and the financial statements reporting date, the Company expects full realization upon maturity.

 

Leases

 

At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. We have elected not to recognize on the balance sheet leases with terms of 12 months or less. We typically only include an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in our assessment unless there is reasonable certainty that we will renew.

 

Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in our leases is typically not readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 11, Leases).

 

The components of a lease should be allocated between lease components (e.g., land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

 

Goodwill and Intangible Assets

 

Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill and other intangibles at that time.

 

In testing for goodwill impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, we conclude that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If we conclude otherwise, we are required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than the carrying value, an impairment charge will be recorded to reduce the reporting unit to fair value.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Intangible assets deemed to have finite lives are amortized on a straight-line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to our future cash flows.

 

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, including property and equipment and finite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when the asset’s carrying value exceeds the total undiscounted cash flows expected from its use and eventual disposition. The amount of the impairment loss is determined as the excess of the carrying value of the asset over its fair value. For the three and nine months ended September 30, 2021 and 2020, the Company did not have an impairment of the intangible assets.

 

Fair Value of Financial Instruments

 

We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

  Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

  Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, secured note receivable and unsecured note payable, approximate their fair values because of the current nature of these instruments.

 

We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity change in fair value reported on the condensed consolidated statement of operations (see Note 14, Secured Promissory Note Receivable and Consulting Agreement). The components of marketable securities and are as follows (in thousands): 

 

   As of September 30, 2021 
   Level 1   Level 2   Level 3   Total 
Marketable debt securities                    
U.S. government obligations  $-   $323   $-   $323 
Corporate obligations   -    13,791    -    13,791 
Marketable equity securities   214    -    -    214 
   $214   $14,114   $-   $14,328 

 

   As of December 31, 2020 
   Level 1   Level 2   Level 3   Total 
Marketable debt securities                    
U.S. government obligations  $-   $1,014   $-   $1,014 
Corporate obligations   -    625    -    625 
   $-   $1,639   $-   $1,639 

 

There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the nine months ended September 30, 2021.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Revenue Recognition

 

We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

Contract with Customers and Performance Obligations

 

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. We had historically generated sales principally through two types of customers, contract manufacturing and retail customers for our consumer products. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. As of December 2020, we also began generating revenues through diagnostic services and in August 2021 we acquired a personal genomics business, which we now include in our consumer products revenue. See Note 3, Business Acquisitions, for additional information on our October 2020 and August 2021 acquisitions. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue over time as the services are provided to the customer.

 

The Company’s performance obligation for contract manufacturing and retail customers is to provide the goods ordered by the customer. The Company’s has one performance obligation for its diagnostic services, which is to provide the results of the laboratory test to the customer. Our personal genomics business has separate performance obligations to provide initial testing and genome results and subscriptions services to our customers.

 

Transaction Price

 

For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.

 

Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

 

We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers, including health plans, government agencies and consumers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on, the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.

 

For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. If the customer does not return the test kit, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. The Company recognizes the breakage amounts as revenue, proportionate to the pattern of revenue recognition of the returning test kits. The Company estimates breakage for the portion of test kits not expected to be returned using an analysis of historical data and considers other factors that could influence customer test kit return behavior. The Company recognized breakage revenue from unreturned test kits of $0.1 million for the three and nine months ended September 30, 2021. 

 

Recognize Revenue When the Company Satisfies a Performance Obligation

 

Performance obligations related to contract manufacturing and retail customers are satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped. For diagnostic services, the Company satisfies its performance obligation at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control. For genomic services, the Company satisfies its product performance obligation at a point in time when the genetics testing results are provided to the customer. For subscriptions services associated with its genomic testing, the Company satisfies its performance obligation over time as the applicable services are provided to the customer

 

Contract Balances

 

As of September 30, 2021 and December 31, 2020, we have deferred revenue of $1,623,000 and $331,000, respectively. Our newly launched personal genomics business contributed $1,403,000 to our deferred revenue as of September 30, 2021. The remainder of deferred revenue relates to research and development (“R&D”) stability and release testing programs recognized as contract manufacturing revenue. Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&D work. We recognize deferred revenues as revenues when the services are performed and the corresponding revenue recognition criteria are met. Customer prepayments are generally applied against invoices issued to customers when services are performed and billed.

 

The following table disaggregates our deferred revenue by recognition period (in thousands):

 

   As of September 30, 2021   As of December 31, 2020 
Recognition Period          
0-12 Months  $1,517   $169 
13-24 Months   71    84 
Over 24 Months   35    78 
Total  $1,623   $331 

 

Disaggregation of Revenue

 

We disaggregate revenue from contracts with customers into four categories: contract manufacturing, retail and others, diagnostic services and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table disaggregates our revenue by revenue source for the three and nine months ended September 30, 2021 and 2020 (in thousands):

 

                             
   For the three months ended   For the nine months ended 
Revenue by Customer Type  September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Contract manufacturing  $1,120   $3,630   $4,069   $8,825 
Retail and others   1,210    210    2,400    526 
Diagnostic services   7,142    -    27,416    - 
Total revenue, net  $9,472   $3,840   $33,885   $9,351 

 

Customer Consideration

 

The Company makes payments to certain diagnostic services customers for distinct services that approximate fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, logistics services, as well as other information requirements. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations. Diagnostic services cost of revenue includes specimen collection payments to customers and other costs incurred in connection with the Company operated laboratories, including reagent and other raw material costs, direct and indirect labor and other laboratory facility overhead (see Note 15, Segment Information).

 

Shipping and Handling Activities

 

We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the goods.

 

Advertising and Incentive Promotions

 

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended September 30, 2021 and 2020 were $136,000 and $451,000, respectively. Advertising and incentive promotion expenses incurred for the nine months ended September 30, 2021 and 2020 were $415,000 and $547,000, respectively.

 

Share-Based Compensation

 

We recognize all share-based payments to employees, directors and consultants, including grants of stock options and common shares, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.

 

Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans. Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.

 

For the three months ended September 30, 2021 and 2020, we charged to operations $934,000 and $283,000, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services. For the nine months ended September 30, 2021 and 2020, we charged to operations $2,438,000 and $679,000, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Research and Development

 

R&D costs are charged to operations in the period incurred. R&D costs incurred for the three months ended September 30, 2021 and 2020 were $208,000 and $57,000, respectively. R&D costs incurred for the nine months ended September 30, 2021 and 2020 were $416,000 and $181,000, respectively. R&D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation fees in association with the diagnostic services business including the validation work of the diagnostic services business.

 

Income Taxes

 

We utilize the asset and liability approach, which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided.

 

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to income taxes will be recorded as interest or administrative expense, respectively.

 

As a result of our historical losses from continuing operations, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefit.

 

Recently Issued Accounting Standards, Not Yet Adopted

 

In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.

 

The FASB recently issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We are currently assessing the impact of the adoption of this ASU on our financial statements.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on the Company’s financial statements or disclosures.

 

In October 2021, the FASB issued ASU 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). The standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. ASU 2021-08 will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are in the process of evaluating the impact that ASU 2021-08 will have on our condensed consolidated financial statements and associated disclosures.

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Business Acquisitions
9 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Business Acquisitions

Note 3 - Business Acquisitions

 

Nebula Acquisition

 

On August 10, 2021 (the “Effective Date”), the Company and its wholly-owned subsidiary, ProPhase Precision Medicine, Inc. (“ProPhase Precision”), entered into and closed a Stock Purchase Agreement (the “Nebula Stock Purchase Agreement”) with Nebula Genomics, Inc., a privately owned personal genomics company (“Nebula”), each of the stockholders of Nebula (the “Seller Parties”), and Kamal Obbad, as Seller Party Representative. Pursuant to the terms of the Nebula Stock Purchase Agreement, ProPhase Precision acquired all of the issued and outstanding shares of common stock of Nebula from the Seller Parties, for an aggregate purchase price of approximately $14.6 million, subject to post-closing adjustments (the “Nebula Acquisition”). A portion of the purchase price equal to $3.6 million was paid in shares of the Company to certain Seller Parties and noteholders of Nebula, based on their election to receive shares of Company common stock in lieu of cash, which shares were valued at a price per share of $7.46, which is equal to the average closing price of the Company’s common stock on Nasdaq for the five trading days preceding the signing of the Nebula Stock Purchase Agreement. A portion of the purchase price equal to $1,080,000 (the “Escrow Amount”) will be held in escrow by Citibank, N.A. (the “Escrow Agent”) until February 23, 2023 (“Escrow Termination Date”), pursuant to the terms and conditions of an escrow agreement entered into with the Escrow Agent, as security for the indemnification obligations of the Seller Parties. At the Escrow Termination Date, the remaining amount, if any, of the Escrow Amount, less any amount reasonably necessary to pay any claim with respect to which a notice of claim has been timely and properly given, will be delivered to the Seller Parties, as applicable.

 

In connection with the Nebula Acquisition, ProPhase Precision entered into an employment agreement with Kamal Obbad, the Chief Executive Officer of Nebula, on the Effective Date, pursuant to which Mr. Obbad will serve as Senior Vice President, Director of Sales and Marketing of ProPhase Precision. As a condition to the employment agreement, Mr. Obbad was awarded a stock option to purchase 250,000 shares of Company common stock at an exercise price equal to $7.67 per share, the closing price of the Company common stock on the Effective Date. The award was issued as a material inducement to Mr. Obbad’s acceptance of employment with ProPhase Precision in accordance with Nasdaq Listing Rule 5635(c)(4) and was approved by the Company’s Compensation Committee (see Note 7, Stockholders’ Equity).

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Based on the preliminary valuation, the total consideration of $12.7 million, which is net of $1.6 million in cash acquired and $0.3 million anticipated to be paid back to the Company from the Escrow Amount, has been allocated to assets acquired and liabilities assumed based on their respective fair values as follows (amounts in thousands):

 

      
Short term investments  $1,800 
Accounts receivable   222 
Inventory   435 
Prepaid and other current assets   379 
Definite-lived intangible assets   10,990 
Total assets acquired   13,826 
Accounts payable   (372)
Accrued expenses and other current liabilities   (43)
Deferred revenue   (1,140)
Note payable   (81)
Total liabilities assumed   (1,636)
Net identifiable assets acquired   12,190 
Goodwill   484 
Total consideration, net of cash acquired (1)  $12,674 

 

(1) Net of $1,639 cash acquired and $257 anticipated amounts due back to the Company from the escrow account.

 

Goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired. The Company believes the goodwill related to the acquisition was a result of the expected synergies to be realized from combining operations and is not deductible for income tax purposes. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.

 

The intangible assets preliminarily identified in conjunction with the Nebula Acquisition are as follows (amount in thousands): 

   Gross Carrying Value  

Estimated Useful

Life (in years)

 
Trade names  $5,550    15 
Proprietary intellectual property   4,260    5 
Customer relationships   1,180    1 
Total  $10,990      

 

The Company recognized $336,000 amortization expense on the above identified intangible assets during the three and nine months September 30, 2021.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Pro Forma Results

 

The following table summarizes, on a pro forma basis, the combined results of the Company as though the Nebula Acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are (in thousands):

 

   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Revenue, net  $9,843   $4,131   $36,007   $9,890 
Net loss  $(4,020)  $(764)  $(4,454)  $(2,425)

 

CPM Acquisition

 

On October 23, 2020, the Company acquired all of the issued and outstanding shares of capital stock of CPM for approximately $2.5 million in cash, subject to certain adjustments, pursuant to the terms of a Stock Purchase Agreement, by and among the Company, CPM, Pride Diagnostics LLC (“Pride Diagnostics”) and the members of Pride Diagnostics (together with Pride Diagnostics, the “Seller Parties”), and Arvind Gurnani, as representative of the Seller Parties. As part of the acquisition, we acquired a 4,000 square foot (CLIA) accredited laboratory located in Old Bridge, New Jersey owned by CPM (now known as ProPhase Diagnostics NJ, Inc.).

 

Based on valuation, the total consideration of $2.5 million has been allocated to assets acquired and liabilities assumed based on their respective fair values as follows (amount in thousands):

 

      
Clinical lab material  $180 
Lab equipment   112 
Definite-lived intangible asset   1,307 
Total assets acquired   1,599 
Liabilities assumed   - 
Net identifiable assets acquired   1,599 
Goodwill   901 
Total consideration  $2,500 

 

Goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed in the amount of $901,000, which was primarily related to the acquisition of the assembled workforce. Other definite-lived intangible asset of approximate $1.3 million were related to the CLIA license, which was determined to have an estimated useful life of three years. The Company recognized $924,000 and $1,131,000 aggregate amortization expense during the three and nine months September 30, 2021, respectively.

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Acquired Intangible Assets
9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Acquired Intangible Assets

Note 4 – Goodwill and Acquired Intangible Assets

 

Goodwill

 

Changes in goodwill for the nine months ended September 30, 2021 are as follows (in thousands):

 

   September 30, 2021 
Goodwill, beginning of period  $901 
Acquisition of Nebula   484 
Goodwill, end of period  $1,385 

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Intangible Assets, Net

 

Intangible assets as of September 30, 2021 and December 31, 2020 consisted of the following (in thousands):

 

   September 30,   December 31,   Estimated Useful 
   2021   2020   Life (in years) 
Trade names  $5,550   $-    15 
Proprietary intellectual property   4,260    -    5 
Customer relationships   1,180    -    1 
CLIA license   1,307    1,307    3 
Total intangible assets, gross   12,297    1,307      
Less: accumulated amortization   (735)   (73)     
Total intangible assets, net  $11,562   $1,234      

 

Amortization expense for acquired intangible assets was $445,000 and $662,000 during the three and nine months ended September 30, 2021, respectively. The estimated future amortization expense of acquired intangible assets as of September 30, 2021 is as follows (in thousands):

 

      
Three months ended December 31, 2021  $709 
Year ended December 31, 2022   2,378 
Year ended December 31, 2023   1,585 
Year ended December 31, 2024   1,222 
Year ended December 31, 2025   1,222 
Thereafter   4,446 
Total  $11,562 

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment

Note 5 - Property, Plant and Equipment

 

The components of property and equipment are as follows (in thousands):

 

   September 30,   December 31,    
   2021   2020   Estimated Useful Life
Land  $352   $352    
Building improvements   1,859    1,729   10-39 years
Machinery   4,672    4,441   3-7 years
Lab equipment   4,316    1,002   3-7 years
Computer equipment   1,189    881   3-5 years
Furniture and fixtures   468    194   5 years
Property, Plant and Equipment, Gross   12,856    8,599    
Less: accumulated depreciation   (6,402)   (5,021)   
Total property, plant and equipment, net  $6,454   $3,578    

 

Depreciation expense for the three months ended September 30, 2021 and 2020 was $481,000 and $86,000, respectively. Depreciation expense incurred for the nine months ended September 30, 2021 and 2020 was $1,381,000 and $253,000, respectively.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Unsecured Convertible Promissory Notes Payable
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Unsecured Convertible Promissory Notes Payable

Note 6 -Unsecured Convertible Promissory Notes Payable

 

On September 15, 2020, we issued two unsecured, partially convertible, promissory notes (the “September 2020 Notes”) for an aggregate principal amount of $10 million to two investors (collectively, the “Lenders”).

 

The September 2020 Notes are due and payable on September 15, 2023, and accrue interest at a rate of 10% per year from the closing date, payable on a quarterly basis, until the September 2020 Notes are repaid in full. We have the right to prepay the September 2020 Notes at any time after the 13 month anniversary of the closing date after providing written notice to the Lenders, and may prepay the September 2020 Notes prior to such time with the consent of the Lenders. The Lenders have the right, at any time, and from time to time, on and after the 13-month anniversary of the closing date to convert up to an aggregate of $3.0 million of the September 2020 Notes into common stock of the Company at a conversion price of $3.00 per share. Repayment of the September 2020 Notes has been guaranteed by our wholly-owned subsidiary, PMI.

 

The September 2020 Notes contain customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the September 2020 Notes may be accelerated. The September 2020 Notes also contain certain restrictive covenants which, among other things, restrict our ability to create, incur, assume or permit to exist, directly or indirectly, any lien (other than certain permitted liens described in the September 2020 Notes) securing any indebtedness of the Company, and prohibits us from distributing or reinvesting the proceeds from any divestment of assets (other than in the ordinary course) without the prior approval of the Lenders.

 

For the three months ended September 30, 2021 and 2020, we incurred $251,000 and $0, respectively, in interest expense under the September 2020 Notes. For the nine months ended September 30, 2021 and 2020, we incurred $753,000 and $0, respectively, in interest expense under the September 2020 Notes

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders’ Equity
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Stockholders’ Equity

Note 7 - Stockholders’ Equity

 

Our authorized capital stock consists of 50 million shares of common stock, $0.0005 par value, and one million shares of preferred stock, $0.0005 par value.

 

Preferred Stock

 

The preferred stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of September 30, 2021 and December 31, 2020, no shares of preferred stock have been issued.

 

Common Stock Dividends

 

On May 13, 2021, the Board declared a special cash dividend of $0.30 per share on the Company’s common stock to holders of record on May 25, 2021, resulting in the payment of $4.5 million to stockholders on June 3, 2021.

 

In Fiscal 2020, no cash dividends were declared.

 

Common Stock

 

Registered Direct Offering

 

On January 5, 2021, we entered into a securities purchase agreement with certain accredited investors and qualified institutional buyers, pursuant to which we issued and sold to the purchasers an aggregate of (i) 550,000 shares of our common stock, and (ii) warrants to purchase up to 275,000 shares of common stock in a registered direct offering.

 

The shares and warrants were sold at a purchase price of $10.00 per share for net proceeds to us of $5.5 million. Each Warrant has an exercise price equal to $11.00 per share of common stock, will be exercisable at any time and from time to time, subject to certain conditions described in the Warrant, after the date of issuance, and will expire on the date that is three years from the date of issuance. The Shares and the Warrants are immediately separable and were issued separately.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Public Offering

 

On January 18, 2021, we entered into an underwriting agreement for the public offering of three million shares of common stock, at a price to the public of $12.50 per share. On January 21, 2021, we completed the offering for net proceeds of $35.1 million, after deducting the underwriting discounts and commissions and estimated offering expenses. As part of the offering, we also issued to the Underwriters warrants to purchase up to an aggregate of 180,000 shares of common stock (6% of the shares of common stock sold in the offering) at an exercise price of $15.625 per share (equal to 125% of the public offering price per share).

 

Nebula Acquisition

 

As part of Nebula Acquisition (see Note 3, Business Acquisitions), a portion of the purchase price was paid in shares to certain Seller Parties and noteholders of Nebula, based on their election to receive shares of Company common stock in lieu of cash, which shares have been valued at a price per share of $7.46, which is equal to the average closing price of the Company’s common stock on Nasdaq for the five trading days preceding the signing of the Nebula Stock Purchase Agreement.

 

The Company issued 483,685 shares of common stock in in lieu of $3.6 million cash payment to Seller Parties and noteholders of Nebula.

 

Stock Repurchase Program

 

On September 8, 2021, the Company announced that its board of directors (the “Board”) had approved a new stock repurchase program. Under the stock repurchase program, the Company is authorized to repurchase up to $6.0 million of its outstanding shares of common stock from time to time, over a six month period. The number of shares to be repurchased and the timing of the repurchases, if any, will depend on a number of factors, including, but not limited to, price, trading volume and general market conditions, along with the Company’s working capital requirements and general business conditions. The Board will re-evaluate the program from time to time, and may authorize adjustments to its terms.

 

The Company did not repurchase any shares of common stock during the three and nine months ended September 30, 2021.

 

The 2010 Directors’ Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Directors’ Equity Compensation Plan (the “Amended 2010 Directors’ Plan”) at the 2021 Annual Meeting of Stockholders of the Company (the “2021 Annual Meeting”). The Amended 2010 Directors’ Plan authorizes the issuance of up to 775,000 shares of common stock.

 

During the three and nine months ended September 30, 2021, stock options to purchase an aggregate of 224,874 shares of our common stock were granted to our directors in lieu of director fees under the 2010 Directors’ Plan with a strike price of $5.28 per share under the Amended 2010 Directors’ Plan. During the three and nine months ended September 30, 2020, common stock and stock options to purchase an aggregate of 212,605 and 230,660 shares of common stock, respectively, were granted to our directors under the 2010 Directors’ Plan in lieu of director fees.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

At September 30, 2021, there were 424,874 stock options outstanding and there were 3,252 shares of common stock available to be issued pursuant to the terms of the Amended 2010 Directors’ Plan. No stock options were exercised during the three and nine months ended September 30, 2021.

 

The 2010 Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Equity Compensation Plan (the “Amended 2010 Plan”) at the 2021 Annual Meetings. The Amended 2010 Plan authorizes the issuance of up to 4,900,000 shares of common stock.

 

There were 975,000 stock options granted under the 2010 Plan during the nine months ended September 30, 2021 for a total fair value of $2,891,000.

 

There were 250,000 stock options granted under the 2010 Plan during the three and nine months ended September 30, 2020 for a total fair value of $269,000.

 

As of September 30, 2021, there were 1,884,449 stock options outstanding and there were 184,657 shares of common stock available to be issued pursuant to the terms of the Amended 2010 Plan. We will recognize an aggregate of approximately $1,373,000 of remaining share-based compensation expense related to outstanding stock options over a weighted average period of 2.8 years.

 

The 2018 Stock Incentive Plan

 

On April 12, 2018, our stockholders approved the 2018 Stock Incentive Plan (the “2018 Stock Plan”). At April 12, 2018, all 2.3 million shares available for issuance under the 2018 Stock Plan have been granted in the form of a stock option with an initial exercise price of $3.00 per share, which is exercisable in 36 monthly installments, to Ted Karkus (the “CEO Option”), our Chief Executive Officer. No portion of the CEO Option was exercised during the nine months ended September 30, 2021 and 2020.

 

The 2018 Stock Plan requires certain proportionate adjustments to be made to stock options granted upon the occurrence of certain events, including a special distribution (whether in the form of cash, shares, other securities, or other property) in order to maintain parity. Accordingly, the Compensation Committee of the board of directors, as required by the terms of the 2018 Stock Plan, adjusted the terms of the CEO Option, such that the exercise price of the CEO Option was reduced from $3.00 per share to $2.00 per share, effective as of September 5, 2018, the date a special $1.00 special cash dividend was paid to the Company’s stockholders. The exercise price of the CEO Option was further reduced from $2.00 to $1.75 per share, effective as of January 24, 2019, the date a $0.25 special cash dividend was paid to the Company’s stockholders. The exercise price of the CEO Option was further reduced from $1.75 to $1.50 per share, effective as of December 12, 2019, the date another $0.25 special cash dividend was paid to Company’s stockholders. The exercise price of the CEO Option was further reduced from $1.50 to $1.20 per share, effective as of June 3, 2021, the date another $0.30 special cash dividend was paid to Company’s stockholders.

 

Inducement Option Award

 

As part of Nebula Acquisition, the Company issued a non-qualified stock option to Kamal Obbad, the Chief Executive Officer of Nebula, as an inducement to his employment with the Company (the “Inducement Award”). The Inducement Award entitles Mr. Obbad to purchase up to 250,000 shares of the Company’s common stock at an exercise price of $7.67 per share, the closing price of the Company’s common stock on the closing date of the Nebula Acquisition. The Inducement Award was granted to Mr. Obbad on the closing date of the Nebula Acquisition. The Inducement Award vested 25% on the grant date and will vest 25% per year for the next three years subject to Mr. Obbad’s continued employment with the Company. The Inducement Award expires on the seventh anniversary of the grant date. Any portion of the Inducement Award that does not vest and become exercisable will be forfeited for no consideration. The grant date fair value of the Inducement Award was approximately $1,128,000.

 

For the three months ended September 30, 2021 and 2020, we charged to operations an aggregate of $863,000 and $267,000, respectively, for share-based compensation expense associated with the vesting of outstanding equity awards under the Amended 2010 Directors’ Plan, the Amended 2010 Plan, the 2018 Stock Plan and the Inducement Award. For the nine months ended September 30, 2021 and 2020, we charged to operations an aggregate of $2,175,000 and $663,000, respectively, for share-based compensation expense associated with the vesting of outstanding equity awards under the 2010 Directors’ Plan, the 2010 Plan, the 2018 Stock Plan and the Inducement Award..

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table summarizes stock options activity during the nine months ended September 30, 2021 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Award (in thousands, except per share data): 

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
   Total Intrinsic Value 
Outstanding as of January 1, 2021   3,795   $2.21    3.4   $26,441 
Granted   1,450    7.48    5.0    - 
Forfeited   (398)   8.32    -    - 
Outstanding as of September 30, 2021   4,847   $3.15    3.5   $12,559 
Options vested and exercisable   3,829   $2.46    2.7   $12,012 

 

The aggregate weighted average grant date fair value for the options granted during the three and nine months ended September 30, 2021 was approximately $2.7 and $4.7 million, respectively. The following table summarizes weighted average assumptions used in determining the fair value of the options at the date of grant for the nine months ended September 30, 2021:

 

   For the nine months ended 
   September 30, 2021 
Exercise price  $7.48 
Expected term (years)   3.9 
Expected stock price volatility   80%
Risk-free rate of interest   0.7%
Expected dividend yield (per share)   0%

 

Stock Warrants Issued

 

During the nine months ended September 30, 2021, we issued warrants to purchase 275,000 shares of common stock in a registered direct offering and warrants to purchase 180,000 shares of common stock to the underwriters in a public offering.

 

During the nine months ended September 30, 2021, we issued 5,986 shares of common stock through a cashless exercise of 50,000 common stock warrants.

 

The following table summarizes warrant activities during the nine months ended September 30, 2021 (in thousands, except per share data).

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of January 1, 2021   450   $3.22    2.7 
Warrants granted   455    12.83    3.0 
Cashless exercise   (50)   5.00    - 
Outstanding as of September 30, 2021   855   $8.23    2.1 
Warrants vested and exercisable   805   $8.56    2.1 

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table summarizes weighted average assumptions used in determining the fair value of the warrants at the date of grant for the nine months ended September 30, 2021:

 

   For the nine months ended 
   September 30, 2021 
Exercise price  $12.83 
Expected term (years)   3.0 
Expected stock price volatility   81%
Risk-free rate of interest   0.2%
Expected dividend yield (per share)   0%

 

As of September 30, 2021, there were warrants to purchase 855,000 shares of our common stock outstanding and we recognized $59,000 and $252,000 of share-based compensation expense during the three and nine months ended September 30, 2021, respectively. We recognized $16,000 in share-based compensation expense during the three and nine months ended September 30, 2020.

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Defined Contribution Plans
9 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
Defined Contribution Plans

Note 8 - Defined Contribution Plans

 

We maintain the ProPhase Labs, Inc. 401(k) Savings and Retirement Plan, a defined contribution plan for our employees. Our contributions to the plan are based on the amount of the employee plan contributions and compensation. Our contributions to the plan in the three and nine months ended September 30, 2021 were $34,000 and $69,000, respectively. Our contributions to the plan in the three and nine months ended September 30, 2020 were $19,000 and $52,000, respectively.

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Other Current Liabilities
9 Months Ended
Sep. 30, 2021
Other Liabilities Disclosure [Abstract]  
Other Current Liabilities

Note 9 - Other Current Liabilities

 

The following table sets forth the components of other current liabilities at September 30, 2021 and December 31, 2020, respectively (in thousands):

 

   September 30,   December 31, 
   2021   2020 
Accrued commissions  $1,054   $461 
Accrued payroll   56    464 
Accrued expenses   251    304 
Accrued returns   331    291 
Accrued income tax payable   -    8 
Accrued benefits and vacation   49    34 
Deferred revenue   -    169 
Total other current liabilities  $1,741   $1,731 

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 10- Commitments and Contingencies

 

Manufacturing Agreement

 

The Company and its wholly-owned subsidiary, PMI, entered into a manufacturing agreement (the “Manufacturing Agreement”) with Mylan Consumer Healthcare Inc. (formerly known as Meda Consumer Healthcare Inc.) (“MCH”) and Mylan Inc. (together with MCH, “Mylan”) in connection with the asset purchase agreement we entered into with Mylan in 2017. Pursuant to the terms of the Manufacturing Agreement, Mylan (or an affiliate or designee) purchased the inventory of the Company’s Cold-EEZE® brand and product line, and PMI agreed to manufacture certain products for Mylan, as described in the Manufacturing Agreement, at prices that reflect current market conditions for such products and include an agreed upon mark-up on our costs. On May 1, 2021, the Manufacturing Agreement was assigned by Mylan to Nurya Brands, Inc. (“Nurya”) in connection with Nurya’s acquisitions of certain assets from Mylan, including the Cold-EEZE® brand and product line. Unless terminated sooner by the parties, the Manufacturing Agreement will remain in effect until March 29, 2022. Thereafter, the Manufacturing Agreement may be renewed by Nurya for up to five successive one-year periods by providing notice of its intent to renew not less than 90 days prior to the expiration of the then-current term.

 

Litigation

 

In the normal course of our business, we may be named as a defendant in legal proceedings. It is our policy to vigorously defend litigation or to enter into a reasonable settlements where management deems it appropriate.

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Leases
9 Months Ended
Sep. 30, 2021
Leases  
Leases

Note 11 – Leases

 

On October 23, 2020, we completed the acquisition of CPM, which included the acquisition of a 4,000 square foot CLIA accredited laboratory located in Old Bridge, New Jersey, which was owned by CPM (which is now known as ProPhase Diagnostics NJ, Inc.). The lease is for a term of 24 months with a monthly base lease payment of $5,950.

 

On December 8, 2020, we entered into a Lease Agreement (the “New York Lease”) pursuant to which the Company has agreed to lease certain premises located on the second floor (the “Leased Premises”) of 711 Stewart Avenue, Garden City, New York (the “Building”). The Leased Premises serve as the Company’s second laboratory location, offering a wide range of laboratory testing services for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel Molecular tests.

 

The New York Lease was effective as of December 8, 2020 and commenced in December 2020 when the facility was made available to us by the landlord. The initial term of the New York Lease is 10 years and seven months (the “Initial Term”), unless sooner terminated as provided in the New York Lease. We may extend the term of the New York Lease for one additional option period of five years. We have the option to terminate the New York Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee.

 

For the first year of the New York Lease, the base rent is $56,963 per month (subject to a seven month abatement period), with a gradual rental rate increase of 2.75% for each 12 month period, culminating in a monthly base rent of $74,716 during the final months of the Initial Term. In addition to the monthly base rent, we are responsible for our proportionate share of real estate tax escalations in accordance with the terms of the New York Lease.

 

We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the New York Lease. We also have a right of first offer to purchase the Building during the term of the New York Lease.

 

At September 30, 2021, we had operating lease liabilities for the New York and New Jersey leases of approximately $4.9 million and right of use assets of approximately $4.5 million, which were included in the condensed consolidated balance sheet.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following summarizes quantitative information about our operating leases (amounts in thousands): 

 

  

For the Nine Months Ended

September 30, 2021

 
Operating leases     
Operating lease cost  $611 
Variable lease cost   - 
Operating lease expense   611 
Short-term lease rent expense   - 
Total rent expense  $611 

 

   For the Nine Months Ended September 30, 2021 
Operating cash flows used in operating leases  $(168)
Right-of-use assets obtained in exchange for operating lease liabilities  $- 
Weighted-average remaining lease term – operating leases (in years)   9.7 
Weighted-average discount rate – operating leases   10.00%

 

Maturities of the Company’s operating leases, excluding short-term leases, are as follows (amounts in thousands):

 

      
Remaing Months Ended December 31, 2021  $190 
Year Ended December 31, 2022   774 
Year Ended December 31, 2023   738 
Year Ended December 31, 2024   747 
Year Ended December 31, 2025   768 
Thereafter   4,659 
Total   7,876 
Less present value discount   (2,948)
Operating lease liabilities  $4,928 

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Customers
9 Months Ended
Sep. 30, 2021
Risks and Uncertainties [Abstract]  
Significant Customers

Note 12- Significant Customers

 

Revenue for the three months ended September 30, 2021 and 2020 was $9.5 million and $3.8 million, respectively. Three diagnostic services clients accounted for 19.6%, 12.0% and 10.4% of our revenue for the three months ended September 30, 2021. No contract manufacturing customer accounted for a significant portion of our revenue for the three months ended September 30, 2021. Two third-party contract manufacturing customers accounted for 57.6% and 15.9%, respectively, of our revenue from continuing operations for the three months ended September 30, 2020. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.

 

Revenue for the nine months ended September 30, 2021 and 2020 was $33.9 million and $9.4 million, respectively. Two diagnostic services clients accounted for 28.4% and 20.7%, respectively, of our revenue for the nine months ended September 30, 2021. Two third-party contract manufacturing customers accounted for 56.2% and 16.6%, respectively, of our revenue for the nine months ended September 30, 2020. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.

 

Five diagnostic services clients generated 19.5%, 19.3%, 12.0%, 11.7% and 11.6% of our total reimbursement receivable balances from government agencies and healthcare issuers at September 30, 2021. Three of our customers represented 36%, 20% and 13% of our total trade receivable balances at December 31, 2020.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings (Loss) Per Share
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Earnings (Loss) Per Share

Note 13 - Earnings (Loss) Per Share

 

Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.

 

For the three and nine months ended September 30, 2021, dilutive loss per share were the same as basic loss per share due to the exclusion of Common Stock in the form of stock options (“Common Stock Equivalents”), which in a net loss position would have an anti-dilutive effect on loss per share. The potentially anti-dilutive effect of stock options, warrants, and convertible debt for the three and nine months ended September 30, 2021 was 2,929,000 and 3,029,000 shares, respectively.

 

For the three and nine months ended September 30, 2020, dilutive loss per share were the same as basic earnings per share due to the exclusion of Common Stock Equivalents. For the three and nine months ended September 30, 2020, there were 4,932,000 potentially dilutive Common Stock Equivalents that were excluded from the loss per share computation as a consequence of their anti-dilutive effect which in a net loss position would have an anti-dilutive effect on loss per share.

 

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Secured Promissory Note Receivable and Consulting Agreement
9 Months Ended
Sep. 30, 2021
Secured Promissory Note Receivable And Consulting Agreement  
Secured Promissory Note Receivable and Consulting Agreement

Note 14 - Secured Promissory Note Receivable and Consulting Agreement

 

Consulting Agreement

 

On September 25, 2020, we entered into a consulting agreement (the “Consulting Agreement”) with a company acting as a consultant (the “Consultant”). The Consulting Agreement was to be effective through September 1, 2022; provided, however, that we could terminate this agreement at any time on five days’ prior written notice.

 

The Consultant’s duties were to include, among other things, (i) identifying and introducing us to new opportunities in the medical technology and testing fields, (ii) assisting and advising us in acquiring one or more CLIA certified labs suitable for COVID-19 and other testing (“Test Labs”); (iii) assisting us in equipping and staffing any Test Labs acquired by us; (iv) advising and assisting in the operation of such Test Labs; (v) validating and obtaining certification of such Test Labs; and (vi) assisting us in obtaining a flow of business, orders and revenues from multiple sources in the industry, including but not limited to at least one significant, nation-wide manufacturer and distributor of COVID-19 saliva sample collection test kits (“COVID-19 Test Kits”).

 

All compensation earned by the Consultant would first be applied to the acceleration and prepayment of all sums due to us, including but not limited to sums due pursuant to the Amended and Restated Promissory Note (“Secured Note”) described below.

 

Promissory Note and Security Agreement

 

On September 25, 2020 (the “Restatement Effective Date”), we entered into the Secured Note with the Consultant, pursuant to which we loaned $3.0 million to the Consultant (inclusive of $1.0 million in the aggregate previously loaned to the Consultant, as described below).

 

The Secured Note amended and restated in its entirety (i) that certain Promissory Note and Security Agreement, dated July 21, 2020 (the “Original July 21 Note”), pursuant to which we loaned $750,000 to the Consultant and (ii) that certain Promissory Note and Security Agreement, dated July 29, 2020 (the “Original July 29 Note”, and, together with the Original July 21 Note, the “Original Notes”), pursuant to which we loaned $250,000 to the Consultant.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The Secured Note bears interest at a rate of 15% per annum from and including the Restatement Effective Date until the principal amount is repaid in full plus any Principal Increases (as defined below) together with any accrued interest that has not been capitalized; provided, however, that upon the occurrence and during an Event of Default (as defined in the Secured Note), the interest rate payable under the Secured Note will automatically increase to 9% above the rate of interest then applicable to the Secured Note.

 

Interest under the Secured Note will be payable monthly in arrears on the first day of each month for the prior monthly period, as well as at maturity (whether upon demand, by acceleration or otherwise) (each such date, a “Payment Date”); provided, however, that prior to September 1, 2021, interest will be paid and capitalized in kind by increasing the principal amount of the Secured Note (any such increase, a “Principal Increase”) by an amount equal to the interest accrued on the principal amount (as increased by the Principal Increases) during the prior month. On each Payment Date commencing after September 1, 2021, in addition to payments of interest described in the preceding sentence, the Consultant will also make payments on the principal amount of the loan equal to 1/36 of the then outstanding principal amount. The amount of the monthly payments will be equal to the amount required to amortize fully the outstanding principal amount of the loan, together with interest, over a period of 36 months.

 

The entire remaining unpaid principal amount of the Secured Note, together with all accrued and unpaid interest thereon and all other amounts payable under the Secured Note, will be due and payable, if not sooner paid, on September 30, 2022 or an earlier date as a result of a maturity, whether by acceleration or otherwise. The Secured Note may be prepaid in full or in part at any time without penalty or premium.

 

The Secured Note contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the Secured Note may be accelerated.

 

The Secured Note contains customary representation and warranties and certain restrictive covenants which, among other things, restrict the Consultant’s ability to (i) sell, transfer, finance, lease, license, or dispose of all or substantially all of its property or assets, liquidate, windup, or dissolve, (ii) acquire all or substantially all of the property or assets of, or the equity interests in, any other person, (iii) participate in any merger, consolidation, share exchange, division, conversion, reclassification, or other absorption or reorganization, (iv) except for those existing as of the Restatement Effective Date, create, incur, assume, permit, or suffer to exist any pledges, liens, security interests, and other encumbrances of its property or assets, whether now owned or hereafter owned or acquired, and (v) create, incur or permit to exist any debt that is senior to, or pari passu with the Secured Note.

 

In order to secure the Consultant’s obligations under the Secured Note, the Consultant granted to the Company a continuing security interest in certain property and assets.

 

Total interest income recorded in the three and nine months ended September 30, 2021 was $230,000 and $531,000, respectively.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Amendment and Termination Agreement

 

On January 14, 2021, we entered into an Amendment and Termination Agreement (the “Termination Agreement”) with the Consultant pursuant to which the parties amended the Secured Note and terminated the Consulting Agreement. Pursuant to the terms of the Termination Agreement, the Company loaned an additional $1 million to the Consultant in consideration for the termination of the Consulting Agreement and termination of the Company’s obligation to pay the Consultant additional consulting fees beyond the $250,000 already earned by the Consultant under the Consulting Agreement. As a result, the initial principal amount due under the Secured Note was increased from $2.75 million to $3.75 million plus all accrued and unpaid interest arising under the Secured Note through and including January 14, 2021.

 

Under the terms of the Termination Agreement, the Consultant will sell and process its viral test by RT-PCR (together with other viral and other types of tests). Until the Secured Note is paid in full, each COVID-19 Test Kit sold or processed from and after January 14, 2021, and for which payment of at least the specified amount as defined for the test, is received by the Consultant, the Consultant will pay us a specified amount (the “Test Fee”). The total payments will not exceed the aggregate amounts due under the Secured Note and shall be applied first to interest and other amounts due under the Secured Note and then to the then-current outstanding principal. Test Fees will be due and payable on the 10th business day after the end of each month commencing in February 2021, and until the Secured Note is paid in full. We received the first payment in the amount of $95,000 with respect to the Test Fees from January 15 through February 2021. On June 25, 2021, we were issued 1,260,619 common shares of the Consultant with a fair value of $315,000 as an interest payment under the Secured Note in lieu of Test Fees from March through June 2021.

 

Effective September 1, 2021, in addition to the payment of the Test Fees described above, the Consultant also is also required to make payments to us in an amount equal to the greater of (x) the Test Fee, or (y) 1/36th of the then outstanding principal amount together with interest thereon and interest accruing on the Secured Note, in accordance with the Secured Note. Accordingly, effective September 1, 2021, the minimum number of monthly payments due and payable to us is equal to the amount required to amortize fully the outstanding principal amount of the Secured Note, together with interest over a period of 36 months with level monthly payments.

 

The Secured Note is currently in default for nonpayment with accrued interest of $132,000 outstanding as of September 30, 2021.

 

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Segment Information

Note 15 - Segment Information

 

The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO as CODM assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table is a summary of segment information for three and nine months ended September 30, 2021 and 2020 (amounts in thousands): 

 

   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Net revenues                    
Diagnostic services  $7,142   $-   $27,416   $- 
Consumer products   2,330    3,840    6,469    9,351 
Consolidated net revenue   9,472    3,840    33,885    9,351 
Cost of revenue                    
Diagnostic services   4,009    -    11,833    - 
Consumer products   1,486    2,798    4,682    6,615 
Consolidated cost of revenue   5,495    2,798    16,515    6,615 
Depreciation and amortization expense                    
Diagnostic services   401    -    1,138    - 
Consumer products   -    3    6    13 
Total Depreciation and amortization expense   401    3    1,144    13 
Operating and other expenses   13,020    1,608    20,542    4,031 
Income (loss) from continuing operations, before income taxes                    
Diagnostic services   (1,145)   -    2,859    - 
Consumer products   (958)   1,039    (453)   2,723 
Unallocated corporate   (1,875)   (1,608)   (6,722)   (4,031)
Total loss from continuing operations, before income taxes   (3,978)   (569)   (4,316)   (1,308)
Income from discontinued operations, before income taxes   -    161    -    161 
                     
Net loss  $(3,978)  $(408)  $(4,316)  $(1,147)

 

The following table is a summary of segment balance sheets information as of September 30, 2021 and December 31, 2020 (in thousands):

 

   September 30,   December 31, 
   2021   2020 
         
ASSETS          
Diagnostic services  $28,738   $13,410 
Consumer products   20,986    6,261 
Unallocated corporate   22,906    11,734 
Total assets  $72,630   $31,405 

 

 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Event
9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
Subsequent Event

Note 16 – Subsequent Event

 

Pursuant to the stock repurchase program on September 8, 2021 (see Note 7), as of November 10, 2021, we have repurchased 140,769 shares for an aggregate amount of $791,000, including commissions.

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Business and Liquidity Uncertainties (Policies)
9 Months Ended
Sep. 30, 2021
Business And Liquidity Uncertainties  
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, including property and equipment and finite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when the asset’s carrying value exceeds the total undiscounted cash flows expected from its use and eventual disposition. The amount of the impairment loss is determined as the excess of the carrying value of the asset over its fair value. For the three and nine months ended September 30, 2021 and 2020, the Company did not have an impairment of the intangible assets.

 

Fair Value of Financial Instruments

 

We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

  Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

  Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, secured note receivable and unsecured note payable, approximate their fair values because of the current nature of these instruments.

 

We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity change in fair value reported on the condensed consolidated statement of operations (see Note 14, Secured Promissory Note Receivable and Consulting Agreement). The components of marketable securities and are as follows (in thousands): 

 

   As of September 30, 2021 
   Level 1   Level 2   Level 3   Total 
Marketable debt securities                    
U.S. government obligations  $-   $323   $-   $323 
Corporate obligations   -    13,791    -    13,791 
Marketable equity securities   214    -    -    214 
   $214   $14,114   $-   $14,328 

 

   As of December 31, 2020 
   Level 1   Level 2   Level 3   Total 
Marketable debt securities                    
U.S. government obligations  $-   $1,014   $-   $1,014 
Corporate obligations   -    625    -    625 
   $-   $1,639   $-   $1,639 

 

There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the nine months ended September 30, 2021.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Revenue Recognition

 

We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

Contract with Customers and Performance Obligations

 

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. We had historically generated sales principally through two types of customers, contract manufacturing and retail customers for our consumer products. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. As of December 2020, we also began generating revenues through diagnostic services and in August 2021 we acquired a personal genomics business, which we now include in our consumer products revenue. See Note 3, Business Acquisitions, for additional information on our October 2020 and August 2021 acquisitions. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue over time as the services are provided to the customer.

 

The Company’s performance obligation for contract manufacturing and retail customers is to provide the goods ordered by the customer. The Company’s has one performance obligation for its diagnostic services, which is to provide the results of the laboratory test to the customer. Our personal genomics business has separate performance obligations to provide initial testing and genome results and subscriptions services to our customers.

 

Transaction Price

 

For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.

 

Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

 

We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers, including health plans, government agencies and consumers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on, the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.

 

For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. If the customer does not return the test kit, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. The Company recognizes the breakage amounts as revenue, proportionate to the pattern of revenue recognition of the returning test kits. The Company estimates breakage for the portion of test kits not expected to be returned using an analysis of historical data and considers other factors that could influence customer test kit return behavior. The Company recognized breakage revenue from unreturned test kits of $0.1 million for the three and nine months ended September 30, 2021. 

 

Recognize Revenue When the Company Satisfies a Performance Obligation

 

Performance obligations related to contract manufacturing and retail customers are satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped. For diagnostic services, the Company satisfies its performance obligation at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control. For genomic services, the Company satisfies its product performance obligation at a point in time when the genetics testing results are provided to the customer. For subscriptions services associated with its genomic testing, the Company satisfies its performance obligation over time as the applicable services are provided to the customer

 

Contract Balances

 

As of September 30, 2021 and December 31, 2020, we have deferred revenue of $1,623,000 and $331,000, respectively. Our newly launched personal genomics business contributed $1,403,000 to our deferred revenue as of September 30, 2021. The remainder of deferred revenue relates to research and development (“R&D”) stability and release testing programs recognized as contract manufacturing revenue. Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&D work. We recognize deferred revenues as revenues when the services are performed and the corresponding revenue recognition criteria are met. Customer prepayments are generally applied against invoices issued to customers when services are performed and billed.

 

The following table disaggregates our deferred revenue by recognition period (in thousands):

 

   As of September 30, 2021   As of December 31, 2020 
Recognition Period          
0-12 Months  $1,517   $169 
13-24 Months   71    84 
Over 24 Months   35    78 
Total  $1,623   $331 

 

Disaggregation of Revenue

 

We disaggregate revenue from contracts with customers into four categories: contract manufacturing, retail and others, diagnostic services and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table disaggregates our revenue by revenue source for the three and nine months ended September 30, 2021 and 2020 (in thousands):

 

                             
   For the three months ended   For the nine months ended 
Revenue by Customer Type  September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Contract manufacturing  $1,120   $3,630   $4,069   $8,825 
Retail and others   1,210    210    2,400    526 
Diagnostic services   7,142    -    27,416    - 
Total revenue, net  $9,472   $3,840   $33,885   $9,351 

 

Customer Consideration

 

The Company makes payments to certain diagnostic services customers for distinct services that approximate fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, logistics services, as well as other information requirements. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations. Diagnostic services cost of revenue includes specimen collection payments to customers and other costs incurred in connection with the Company operated laboratories, including reagent and other raw material costs, direct and indirect labor and other laboratory facility overhead (see Note 15, Segment Information).

 

Shipping and Handling Activities

 

We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the goods.

 

Advertising and Incentive Promotions

 

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended September 30, 2021 and 2020 were $136,000 and $451,000, respectively. Advertising and incentive promotion expenses incurred for the nine months ended September 30, 2021 and 2020 were $415,000 and $547,000, respectively.

 

Share-Based Compensation

 

We recognize all share-based payments to employees, directors and consultants, including grants of stock options and common shares, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.

 

Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans. Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.

 

For the three months ended September 30, 2021 and 2020, we charged to operations $934,000 and $283,000, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services. For the nine months ended September 30, 2021 and 2020, we charged to operations $2,438,000 and $679,000, respectively, for share-based compensation expense associated with vesting of outstanding equity awards and common shares issued for services.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Research and Development

 

R&D costs are charged to operations in the period incurred. R&D costs incurred for the three months ended September 30, 2021 and 2020 were $208,000 and $57,000, respectively. R&D costs incurred for the nine months ended September 30, 2021 and 2020 were $416,000 and $181,000, respectively. R&D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation fees in association with the diagnostic services business including the validation work of the diagnostic services business.

 

Income Taxes

 

We utilize the asset and liability approach, which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided.

 

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to income taxes will be recorded as interest or administrative expense, respectively.

 

As a result of our historical losses from continuing operations, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefit.

 

Recently Issued Accounting Standards, Not Yet Adopted

 

In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.

 

The FASB recently issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We are currently assessing the impact of the adoption of this ASU on our financial statements.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on the Company’s financial statements or disclosures.

 

In October 2021, the FASB issued ASU 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). The standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. ASU 2021-08 will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are in the process of evaluating the impact that ASU 2021-08 will have on our condensed consolidated financial statements and associated disclosures.

 

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Business and Liquidity Uncertainties (Tables)
9 Months Ended
Sep. 30, 2021
Business And Liquidity Uncertainties  
Summary of Components of Marketable Securities

 

   As of September 30, 2021 
   Amortized   Unrealized   Fair 
   Cost   Losses   Value 
U.S. government obligations  $324   $(1)  $323 
Corporate obligations   13,912    (121)   13,791 
   $14,236   $(122)  $14,114 

 

   As of December 31, 2020 
   Amortized   Unrealized   Fair 
   Cost   Losses   Value 
U.S. government obligations  $1,021   $(7)  $1,014 
Corporate obligations   629    (4)   625 
   $1,650   $(11)  $1,639 
Schedule of Components of Inventory

 

   September 30,   December 31, 
   2021   2020 
Diagnostic services testing material  $6,203   $1,028 
Raw materials   1,464    1,404 
Work in process   407    437 
Finished goods   436    170 
Inventory, net  $8,510   $3,039 
Schedule of Fair Value of Financial Instruments

 

   As of September 30, 2021 
   Level 1   Level 2   Level 3   Total 
Marketable debt securities                    
U.S. government obligations  $-   $323   $-   $323 
Corporate obligations   -    13,791    -    13,791 
Marketable equity securities   214    -    -    214 
   $214   $14,114   $-   $14,328 

 

   As of December 31, 2020 
   Level 1   Level 2   Level 3   Total 
Marketable debt securities                    
U.S. government obligations  $-   $1,014   $-   $1,014 
Corporate obligations   -    625    -    625 
   $-   $1,639   $-   $1,639 
Schedule of Deferred Revenue

The following table disaggregates our deferred revenue by recognition period (in thousands):

 

   As of September 30, 2021   As of December 31, 2020 
Recognition Period          
0-12 Months  $1,517   $169 
13-24 Months   71    84 
Over 24 Months   35    78 
Total  $1,623   $331 
Schedule of Disaggregation by Revenue

The following table disaggregates our revenue by revenue source for the three and nine months ended September 30, 2021 and 2020 (in thousands):

 

                             
   For the three months ended   For the nine months ended 
Revenue by Customer Type  September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Contract manufacturing  $1,120   $3,630   $4,069   $8,825 
Retail and others   1,210    210    2,400    526 
Diagnostic services   7,142    -    27,416    - 
Total revenue, net  $9,472   $3,840   $33,885   $9,351 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Business Acquisitions (Tables)
9 Months Ended
Sep. 30, 2021
Business Acquisition [Line Items]  
Schedule of Intangible Assets Acquisition

The intangible assets preliminarily identified in conjunction with the Nebula Acquisition are as follows (amount in thousands): 

   Gross Carrying Value  

Estimated Useful

Life (in years)

 
Trade names  $5,550    15 
Proprietary intellectual property   4,260    5 
Customer relationships   1,180    1 
Total  $10,990      

Schedule of Pro-forma Results

The following table summarizes, on a pro forma basis, the combined results of the Company as though the Nebula Acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are (in thousands):

 

   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Revenue, net  $9,843   $4,131   $36,007   $9,890 
Net loss  $(4,020)  $(764)  $(4,454)  $(2,425)
Nebula Acquisition [Member]  
Business Acquisition [Line Items]  
Schedule of Assets Acquired and Liabilities Assumed

 

      
Short term investments  $1,800 
Accounts receivable   222 
Inventory   435 
Prepaid and other current assets   379 
Definite-lived intangible assets   10,990 
Total assets acquired   13,826 
Accounts payable   (372)
Accrued expenses and other current liabilities   (43)
Deferred revenue   (1,140)
Note payable   (81)
Total liabilities assumed   (1,636)
Net identifiable assets acquired   12,190 
Goodwill   484 
Total consideration, net of cash acquired (1)  $12,674 

 

(1) Net of $1,639 cash acquired and $257 anticipated amounts due back to the Company from the escrow account.
C P M Acquisition [Member]  
Business Acquisition [Line Items]  
Schedule of Assets Acquired and Liabilities Assumed

 

      
Clinical lab material  $180 
Lab equipment   112 
Definite-lived intangible asset   1,307 
Total assets acquired   1,599 
Liabilities assumed   - 
Net identifiable assets acquired   1,599 
Goodwill   901 
Total consideration  $2,500 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Acquired Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes In Goodwill

Changes in goodwill for the nine months ended September 30, 2021 are as follows (in thousands):

 

   September 30, 2021 
Goodwill, beginning of period  $901 
Acquisition of Nebula   484 
Goodwill, end of period  $1,385 
Schedule of Intangible Assets

Intangible assets as of September 30, 2021 and December 31, 2020 consisted of the following (in thousands):

 

   September 30,   December 31,   Estimated Useful 
   2021   2020   Life (in years) 
Trade names  $5,550   $-    15 
Proprietary intellectual property   4,260    -    5 
Customer relationships   1,180    -    1 
CLIA license   1,307    1,307    3 
Total intangible assets, gross   12,297    1,307      
Less: accumulated amortization   (735)   (73)     
Total intangible assets, net  $11,562   $1,234      
Schedule of Amortization Expense for Acquired Intangible Assets

 

      
Three months ended December 31, 2021  $709 
Year ended December 31, 2022   2,378 
Year ended December 31, 2023   1,585 
Year ended December 31, 2024   1,222 
Year ended December 31, 2025   1,222 
Thereafter   4,446 
Total  $11,562 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment (Tables)
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment

The components of property and equipment are as follows (in thousands):

 

   September 30,   December 31,    
   2021   2020   Estimated Useful Life
Land  $352   $352    
Building improvements   1,859    1,729   10-39 years
Machinery   4,672    4,441   3-7 years
Lab equipment   4,316    1,002   3-7 years
Computer equipment   1,189    881   3-5 years
Furniture and fixtures   468    194   5 years
Property, Plant and Equipment, Gross   12,856    8,599    
Less: accumulated depreciation   (6,402)   (5,021)   
Total property, plant and equipment, net  $6,454   $3,578    
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders’ Equity (Tables)
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Schedule of Stock Options Activity

The following table summarizes stock options activity during the nine months ended September 30, 2021 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Award (in thousands, except per share data): 

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
   Total Intrinsic Value 
Outstanding as of January 1, 2021   3,795   $2.21    3.4   $26,441 
Granted   1,450    7.48    5.0    - 
Forfeited   (398)   8.32    -    - 
Outstanding as of September 30, 2021   4,847   $3.15    3.5   $12,559 
Options vested and exercisable   3,829   $2.46    2.7   $12,012 
Summary of Weighted Average Assumptions Used In Determining Fair Value of Options

The aggregate weighted average grant date fair value for the options granted during the three and nine months ended September 30, 2021 was approximately $2.7 and $4.7 million, respectively. The following table summarizes weighted average assumptions used in determining the fair value of the options at the date of grant for the nine months ended September 30, 2021:

 

   For the nine months ended 
   September 30, 2021 
Exercise price  $7.48 
Expected term (years)   3.9 
Expected stock price volatility   80%
Risk-free rate of interest   0.7%
Expected dividend yield (per share)   0%
Schedule of Warrant Activity

The following table summarizes warrant activities during the nine months ended September 30, 2021 (in thousands, except per share data).

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of January 1, 2021   450   $3.22    2.7 
Warrants granted   455    12.83    3.0 
Cashless exercise   (50)   5.00    - 
Outstanding as of September 30, 2021   855   $8.23    2.1 
Warrants vested and exercisable   805   $8.56    2.1 
Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants

The following table summarizes weighted average assumptions used in determining the fair value of the warrants at the date of grant for the nine months ended September 30, 2021:

 

   For the nine months ended 
   September 30, 2021 
Exercise price  $12.83 
Expected term (years)   3.0 
Expected stock price volatility   81%
Risk-free rate of interest   0.2%
Expected dividend yield (per share)   0%
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Other Current Liabilities (Tables)
9 Months Ended
Sep. 30, 2021
Other Liabilities Disclosure [Abstract]  
Schedule of Other Current Liabilities

The following table sets forth the components of other current liabilities at September 30, 2021 and December 31, 2020, respectively (in thousands):

 

   September 30,   December 31, 
   2021   2020 
Accrued commissions  $1,054   $461 
Accrued payroll   56    464 
Accrued expenses   251    304 
Accrued returns   331    291 
Accrued income tax payable   -    8 
Accrued benefits and vacation   49    34 
Deferred revenue   -    169 
Total other current liabilities  $1,741   $1,731 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Tables)
9 Months Ended
Sep. 30, 2021
Leases  
Summary of Quantitative Information About Operating Leases

The following summarizes quantitative information about our operating leases (amounts in thousands): 

 

  

For the Nine Months Ended

September 30, 2021

 
Operating leases     
Operating lease cost  $611 
Variable lease cost   - 
Operating lease expense   611 
Short-term lease rent expense   - 
Total rent expense  $611 

 

   For the Nine Months Ended September 30, 2021 
Operating cash flows used in operating leases  $(168)
Right-of-use assets obtained in exchange for operating lease liabilities  $- 
Weighted-average remaining lease term – operating leases (in years)   9.7 
Weighted-average discount rate – operating leases   10.00%
Schedule of Maturity of Operating Leases

Maturities of the Company’s operating leases, excluding short-term leases, are as follows (amounts in thousands):

 

      
Remaing Months Ended December 31, 2021  $190 
Year Ended December 31, 2022   774 
Year Ended December 31, 2023   738 
Year Ended December 31, 2024   747 
Year Ended December 31, 2025   768 
Thereafter   4,659 
Total   7,876 
Less present value discount   (2,948)
Operating lease liabilities  $4,928 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information (Tables)
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Schedule of Segment Information

The following table is a summary of segment information for three and nine months ended September 30, 2021 and 2020 (amounts in thousands): 

 

   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Net revenues                    
Diagnostic services  $7,142   $-   $27,416   $- 
Consumer products   2,330    3,840    6,469    9,351 
Consolidated net revenue   9,472    3,840    33,885    9,351 
Cost of revenue                    
Diagnostic services   4,009    -    11,833    - 
Consumer products   1,486    2,798    4,682    6,615 
Consolidated cost of revenue   5,495    2,798    16,515    6,615 
Depreciation and amortization expense                    
Diagnostic services   401    -    1,138    - 
Consumer products   -    3    6    13 
Total Depreciation and amortization expense   401    3    1,144    13 
Operating and other expenses   13,020    1,608    20,542    4,031 
Income (loss) from continuing operations, before income taxes                    
Diagnostic services   (1,145)   -    2,859    - 
Consumer products   (958)   1,039    (453)   2,723 
Unallocated corporate   (1,875)   (1,608)   (6,722)   (4,031)
Total loss from continuing operations, before income taxes   (3,978)   (569)   (4,316)   (1,308)
Income from discontinued operations, before income taxes   -    161    -    161 
                     
Net loss  $(3,978)  $(408)  $(4,316)  $(1,147)

 

The following table is a summary of segment balance sheets information as of September 30, 2021 and December 31, 2020 (in thousands):

 

   September 30,   December 31, 
   2021   2020 
         
ASSETS          
Diagnostic services  $28,738   $13,410 
Consumer products   20,986    6,261 
Unallocated corporate   22,906    11,734 
Total assets  $72,630   $31,405 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Components of Marketable Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost $ 14,236 $ 1,650
Unrealized Losses (122) (11)
Fair Value 14,114 1,639
U.S. Government Obligations [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost 324 1,021
Unrealized Losses (1) (7)
Fair Value 323 1,014
Corporate Obligations [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost 13,912 629
Unrealized Losses (121) (4)
Fair Value $ 13,791 $ 625
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Components of Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Business And Liquidity Uncertainties    
Diagnostic services testing material $ 6,203 $ 1,028
Raw materials 1,464 1,404
Work in process 407 437
Finished goods 436 170
Inventory, net $ 8,510 $ 3,039
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Fair Value of Financial Instruments (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities $ 14,328,000 $ 1,639,000
Marketable equity securities 214,000
Fair Value, Inputs, Level 1 [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities 214,000
Marketable equity securities 214,000  
Fair Value, Inputs, Level 2 [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities 14,114,000 1,639,000
Marketable equity securities  
Fair Value, Inputs, Level 3 [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities
Marketable equity securities  
U.S. Government Obligations [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities 323,000 1,014,000
U.S. Government Obligations [Member] | Fair Value, Inputs, Level 1 [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities
U.S. Government Obligations [Member] | Fair Value, Inputs, Level 2 [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities 323,000 1,014,000
U.S. Government Obligations [Member] | Fair Value, Inputs, Level 3 [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities
Corporate Obligations [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities 13,791,000 625,000
Corporate Obligations [Member] | Fair Value, Inputs, Level 1 [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities
Corporate Obligations [Member] | Fair Value, Inputs, Level 2 [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities 13,791,000 625,000
Corporate Obligations [Member] | Fair Value, Inputs, Level 3 [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Fair value of marketable debt securities
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Deferred Revenue (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Total $ 1,623,000 $ 331,000
0-12 Months [Member]    
Total 1,517,000 169,000
13-24 Months [Member]    
Total 71,000 84,000
Over 24 Months [Member]    
Total $ 35,000 $ 78,000
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Disaggregation by Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Product Information [Line Items]        
Total revenue, net $ 9,472 $ 3,840 $ 33,885 $ 9,351
Contract Manufacturing [Member]        
Product Information [Line Items]        
Total revenue, net 1,120 3,630 4,069 8,825
Retail And Other [Member]        
Product Information [Line Items]        
Total revenue, net 1,210 210 2,400 526
Diagnostic Services [Member]        
Product Information [Line Items]        
Total revenue, net $ 7,142 $ 27,416
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Business and Liquidity Uncertainties (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Jun. 25, 2021
Dec. 31, 2020
Other than Temporary Impairment, Credit Losses Recognized in Earnings [Line Items]            
Net Cash Provided by (Used in) Operating Activities     $ 8,972,000 $ (4,176,000)    
Cash Equivalents, at Carrying Value $ 22,900,000   22,900,000      
Marketable securities, unrealized loss 32,000   111,000      
[custom:DecreaseInFairValueOfInvestmentSecurities] 265,000   101,000      
Inventory Adjustments 87,000   $ 87,000     $ 167,000
Estimated useful lives description     ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years.      
Cash and Cash Equivalents, at Carrying Value 8,533,000   $ 8,533,000     6,816,000
Cash 8,700,000   8,700,000      
Cash, FDIC Insured Amount 1,000,000.0   1,000,000.0      
Cash, Uninsured Amount 7,700,000   7,700,000      
Breakage revenue 100,000   100,000      
Contract with Customer, Liability 1,623,000   1,623,000     $ 331,000
Deferred revenue 1,403,000   1,403,000      
Share-based Payment Arrangement, Noncash Expense 934,000 $ 283,000 2,438,000 679,000    
Share-based Payment Arrangement, Expense     2,438,000 679,000    
Research and Development Expense 208,000 57,000 416,000 181,000    
Cooperative Incentive Promotion Costs [Member]            
Other than Temporary Impairment, Credit Losses Recognized in Earnings [Line Items]            
Advertising and incentive promotion expenses, continuing operation $ 136,000 $ 451,000 $ 415,000 $ 547,000    
Investment Shares [Member]            
Other than Temporary Impairment, Credit Losses Recognized in Earnings [Line Items]            
Investment Owned, Balance, Shares         1,260,619  
Investment Owned, at Fair Value         $ 315,000  
Share Price         $ 0.17  
Marketable Securities [Member] | Minimum [Member]            
Other than Temporary Impairment, Credit Losses Recognized in Earnings [Line Items]            
Debt Instrument, Interest Rate During Period     1.90%      
Marketable Securities [Member] | Maximum [Member]            
Other than Temporary Impairment, Credit Losses Recognized in Earnings [Line Items]            
Debt Instrument, Interest Rate During Period     3.62%      
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Oct. 23, 2021
Sep. 30, 2021
Aug. 10, 2021
Dec. 31, 2020
Oct. 23, 2020
Business Acquisition [Line Items]          
Goodwill $ 901 $ 1,385   $ 901  
Nebula Acquisition [Member]          
Business Acquisition [Line Items]          
Short term investments     $ 1,800    
Accounts receivable     222    
Inventory     435    
Prepaid and other current assets     379    
Definite-lived intangible asset     10,990    
Total assets acquired     13,826    
Accounts payable     (372)    
Accrued expenses and other current liabilities     (43)    
Deferred revenue     (1,140)    
Note payable     (81)    
Liabilities assumed     (1,636)    
Net identifiable assets acquired     12,190    
Goodwill     484    
Total consideration [1]     $ 12,674    
C P M Acquisition [Member]          
Business Acquisition [Line Items]          
Clinical lab material         $ 180
Lab equipment         112
Definite-lived intangible asset         1,307
Total assets acquired         1,599
Liabilities assumed        
Net identifiable assets acquired         1,599
Goodwill         901
Total consideration         $ 2,500
[1] Net of $1,639 cash acquired and $257 anticipated amounts due back to the Company from the escrow account.
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) - Nebula Acquisition [Member]
$ in Thousands
Aug. 10, 2021
USD ($)
Business Acquisition [Line Items]  
Cash acquired $ 1,639
Escrow amount $ 257
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Intangible Assets Acquisition (Details) - USD ($)
$ in Thousands
Aug. 10, 2021
Sep. 30, 2021
Dec. 31, 2020
Business Acquisition [Line Items]      
Gross carying value   $ 12,297 $ 1,307
Trade Names [Member]      
Business Acquisition [Line Items]      
Gross carying value   5,550
Intellectual Property [Member]      
Business Acquisition [Line Items]      
Gross carying value   4,260
Customer Relationships [Member]      
Business Acquisition [Line Items]      
Gross carying value   $ 1,180
Nebula Acquisition [Member]      
Business Acquisition [Line Items]      
Gross carying value $ 10,990    
Estimated useful life 0 years    
Nebula Acquisition [Member] | Trade Names [Member]      
Business Acquisition [Line Items]      
Gross carying value $ 5,550    
Estimated useful life 15 years    
Nebula Acquisition [Member] | Intellectual Property [Member]      
Business Acquisition [Line Items]      
Gross carying value $ 4,260    
Estimated useful life 5 years    
Nebula Acquisition [Member] | Customer Relationships [Member]      
Business Acquisition [Line Items]      
Gross carying value $ 1,180    
Estimated useful life 1 year    
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Pro-forma Results (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Business Combination and Asset Acquisition [Abstract]        
Revenue, net $ 9,843 $ 4,131 $ 36,007 $ 9,890
Net loss $ (4,020) $ (764) $ (4,454) $ (2,425)
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Business Acquisitions (Details Narrative)
3 Months Ended 9 Months Ended
Aug. 10, 2021
USD ($)
$ / shares
shares
Aug. 10, 2021
USD ($)
$ / shares
Oct. 23, 2020
USD ($)
ft²
Oct. 23, 2020
USD ($)
ft²
Sep. 30, 2021
USD ($)
ft²
Sep. 30, 2021
USD ($)
ft²
$ / shares
Oct. 23, 2021
USD ($)
Dec. 31, 2020
USD ($)
Business Acquisition [Line Items]                
Option, exercise price | $ / shares           $ 7.48    
Amortization expenses         $ 445,000 $ 662,000    
Goodwill         1,385,000 1,385,000 $ 901,000 $ 901,000
Amortization         924,000 1,131,000    
CLIA License [Member]                
Business Acquisition [Line Items]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets     $ 1,300,000 $ 1,300,000        
Nebula Acquisition [Member]                
Business Acquisition [Line Items]                
Business combination amount paid in cash $ 3,600,000              
Total consideration 12,700,000              
Cash Acquired from Acquisition 1,639,000              
Escrow amount 257,000              
Amortization expenses         $ 336,000 $ 336,000    
Goodwill 484,000 $ 484,000            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets $ 13,826,000 13,826,000            
Nebula Acquisition [Member] | Mr. Kamal Obbad [Member]                
Business Acquisition [Line Items]                
Stock option awarded | shares 250,000              
Option, exercise price | $ / shares $ 7.67              
Nebula Acquisition [Member] | Nebula Stock Purchase Agreement [Member]                
Business Acquisition [Line Items]                
[custom:PurchasePriceOfCommonStock]   $ 14,600,000            
Shares Issued, Price Per Share | $ / shares $ 7.46 $ 7.46            
Nebula Acquisition [Member] | Nebula Stock Purchase Agreement [Member] | CitiBankm, N.A. [Member]                
Business Acquisition [Line Items]                
[custom:PurchasePriceOfEscrowAmount]   $ 1,080,000            
[custom:EscrowMaturityDate]   Feb. 23, 2023            
Plaza Medical Laboratory Corp [Member]                
Business Acquisition [Line Items]                
Total consideration       $ 2,500,000        
Area of Land | ft²     4,000 4,000 4,000 4,000    
C P M Acquisition [Member]                
Business Acquisition [Line Items]                
Total consideration     $ 2,500,000          
Goodwill     901,000 $ 901,000        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets     $ 1,599,000 $ 1,599,000        
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Changes In Goodwill (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2021
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill, beginning of period $ 901
Acquisition of Nebula 484
Goodwill, end of period $ 1,385
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross $ 12,297 $ 1,307
Less: accumulated amortization (735) (73)
Total intangible assets, net 11,562 1,234
Trade Names [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross $ 5,550
Estimated useful life 15 years  
Intellectual Property [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross $ 4,260
Estimated useful life 5 years  
Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross $ 1,180
Estimated useful life 1 year  
License [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross $ 1,307 $ 1,307
Estimated useful life 3 years  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Amortization Expense for Acquired Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Three months ended December 31, 2021 $ 709  
Year ended December 31, 2022 2,378  
Year ended December 31, 2023 1,585  
Year ended December 31, 2024 1,222  
Year ended December 31, 2025 1,222  
Thereafter 4,446  
Total $ 11,562 $ 1,234
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Acquired Intangible Assets (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of Intangible Assets $ 445,000 $ 662,000
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 12,856 $ 8,599
Less: accumulated depreciation (6,402) (5,021)
Total property, plant and equipment, net 6,454 3,578
Land [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 352 352
Building Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 1,859 1,729
Building Improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 10 years  
Building Improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 39 years  
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 4,672 4,441
Machinery and Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Machinery and Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 7 years  
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 4,316 1,002
Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 7 years  
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 1,189 881
Computer Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Computer Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 5 years  
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 468 $ 194
Property, Plant and Equipment, Useful Life 5 years  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Property, Plant and Equipment [Abstract]        
Depreciation $ 481,000 $ 86,000 $ 1,381,000 $ 253,000
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Unsecured Convertible Promissory Notes Payable (Details Narrative) - September 2020 Notes [Member] - Unsecured Debt [Member] - USD ($)
3 Months Ended 9 Months Ended
Sep. 15, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Short-term Debt [Line Items]          
Debt Instrument, Maturity Date Sep. 15, 2020        
Debt Instrument, Face Amount $ 10,000,000        
Debt Instrument, Interest Rate, Stated Percentage 10.00%        
Debt Conversion, Description We have the right to prepay the September 2020 Notes at any time after the 13 month anniversary of the closing date after providing written notice to the Lenders, and may prepay the September 2020 Notes prior to such time with the consent of the Lenders. The Lenders have the right, at any time, and from time to time, on and after the 13-month anniversary of the closing date to convert up to an aggregate of $        
Convertible Debt $ 3,000,000.0        
Debt Instrument, Convertible, Conversion Price $ 3.00        
Interest expense   $ 251,000 $ 0 $ 753,000 $ 0
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Stock Options Activity (Details)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2021
USD ($)
$ / shares
shares
Offsetting Assets [Line Items]  
Weighted Average Exercise Price, Granted $ 7.48
Equity Option [Member]  
Offsetting Assets [Line Items]  
Number of Shares Options Outstanding - Beginning | shares 3,795,000
Weighted Average Exercise Price Options Outstanding - Beginning $ 2.21
Weighted Average Remaining Contractual Life (in Years) - Beginning 3 years 4 months 24 days
Total Intrinsic Value - Beginning | $ $ 26,441
Number of Shares, Granted | shares 1,450,000
Weighted Average Exercise Price, Granted $ 7.48
Weighted Average Remaining Contractual Life (in Years) - Granted 5 years
Total Intrinsic Value - Granted | $
Number of Shares, Forfeited | shares (398,000)
Weighted Average Exercise Price, Forfeited $ 8.32
Total Intrinsic Value - Forfeited | $
Number of Shares Options Outstanding - Ending | shares 4,847,000
Weighted Average Exercise Price Options Outstanding - Ending $ 3.15
Weighted Average Remaining Contractual Life (in Years) - Ending 3 years 6 months
Total Intrinsic Value - Ending | $ $ 12,559
Number of Shares Options Vested and Exercisable | shares 3,829,000
Weighted Average Exercise Price, Options Vested and Exercisable $ 2.46
Weighted Average Remaining Contractual Life (in Years) - Options Vested and Exercisable 2 years 8 months 12 days
Total Intrinsic Value, Options Vested and Exercisable | $ $ 12,012
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Weighted Average Assumptions Used In Determining Fair Value of Options (Details)
9 Months Ended
Sep. 30, 2021
$ / shares
Equity [Abstract]  
Exercise price $ 7.48
Expected term (years) 3 years 10 months 24 days
Expected stock price volatility 80.00%
Risk-free rate of interest 0.70%
Expected dividend yield (per share) 0.00%
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Warrant Activity (Details) - Warrant [Member]
9 Months Ended
Sep. 30, 2021
$ / shares
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Shares Warrants Outstanding - Beginning | shares 450,000
Weighted Average Exercise Price Warrants Outstanding - Beginning | $ / shares $ 3.22
Weighted Average Remaining Contractual Life (in Years) - Beginning 2 years 8 months 12 days
Warrants granted | shares 455,000
Weighted Average Exercise Price, Granted | $ / shares $ 12.83
Weighted Average Remaining Contractual Life (in Years) - Granted 3 years
Weighted Average Exercise Price, Exercise | shares (50,000)
Weighted Average Exercise Price Warrants Outstanding - Exerisce | $ / shares $ 5.00
Weighted Average Remaining Contractual Life (in Years) - Exercised
Number of Shares Warrants Outstanding - Ending | shares 855,000
Weighted Average Exercise Price Warrants Outstanding - Ending | $ / shares $ 8.23
Weighted Average Remaining Contractual Life (in Years) - Ending 2 years 1 month 6 days
Number of Shares Warrants Vested and Exercisable | shares 805,000
Weighted Average Exercise Price, Warrants Vested and Exercisable | $ / shares $ 8.56
Weighted Average Remaining Contractual Life (in Years) - Vested and Exercisable 2 years 1 month 6 days
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants (Details) - Warrant [Member]
Sep. 30, 2021
Measurement Input, Exercise Price [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Warrants outstanding, measurement input, percentage 12.83
Measurement Input, Expected Term [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Warrants measurement, expected term 3 years
Measurement Input, Price Volatility [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Warrants outstanding, measurement input, percentage 0.81
Measurement Input, Risk Free Interest Rate [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Warrants outstanding, measurement input, percentage 0.2
Measurement Input, Expected Dividend Rate [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Warrants outstanding, measurement input, percentage 0
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders’ Equity (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended 21 Months Ended
Dec. 12, 2021
Sep. 05, 2021
Aug. 10, 2021
Jun. 03, 2021
May 20, 2021
May 13, 2021
Apr. 12, 2021
Jan. 18, 2021
Jan. 05, 2021
Dec. 12, 2019
Jan. 24, 2019
Sep. 05, 2018
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Jan. 21, 2021
Sep. 30, 2021
Sep. 08, 2021
Dec. 31, 2020
Apr. 12, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Common Stock, Shares Authorized                         50,000,000   50,000,000     50,000,000   50,000,000  
Common Stock, Par or Stated Value Per Share                         $ 0.0005   $ 0.0005     $ 0.0005   $ 0.0005  
Preferred Stock, Shares Authorized                         1,000,000   1,000,000     1,000,000   1,000,000  
Preferred Stock, Par or Stated Value Per Share                         $ 0.0005   $ 0.0005     $ 0.0005   $ 0.0005  
Preferred Stock, Shares Issued                         0   0     0   0  
Common Stock, Dividends, Per Share, Cash Paid           $ 0.30                              
Proceeds from issuance of common stock and warrants from private offering                             $ 5,500,000          
Proceeds from offering                             35,135,000 $ 35,100,000        
Share-based Payment Arrangement, Expense                             2,438,000 679,000          
Share based compensation expense                         $ 934,000 $ 283,000 2,438,000 679,000          
Two Thousand And Twenty Directors Equity Compensation Plan [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Number of shares authorized in share based compensation         775,000                                
Share based compensation expense                         $ 863,000 $ 267,000 $ 2,175,000 $ 663,000          
Two Thousand Ten Directors Equity Compensation Plan [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                           212,605   230,660          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number                         424,874   424,874     424,874      
Common Stock, Capital Shares Reserved for Future Issuance                         3,252   3,252     3,252      
Amended 2010 Plan [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Number of shares issued         4,900,000                                
Two Thousand Ten Equity Compensation Plan [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                             975,000 250,000          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number                         1,884,449   1,884,449     1,884,449      
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture                             $ 2,891,000     $ 269,000      
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant                         184,657   184,657     184,657      
Share-based Payment Arrangement, Expense                             $ 1,373,000            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term                             2 years 9 months 18 days            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period                             0 0          
Two Thousand Eighteen Stock Incentive Plan [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Common Stock, Capital Shares Reserved for Future Issuance                                         2,300,000
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit             $ 3.00                            
Share Repurchase Program [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Stock Repurchase Program, Remaining Authorized Repurchase Amount                                     $ 6,000,000.0    
Nebula Acquisition [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Number of shares issued                             483,685            
Business Acquisition, Share Price                         $ 7.46   $ 7.46     $ 7.46      
Stock Issued During Period, Value, New Issues               $ 3,600,000                          
Nebula Acquisition [Member] | Mr. Kamal Obbad [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     250,000                                    
Inducement Option Award [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Business Acquisition, Share Price                         7.67   $ 7.67     7.67      
Share-based Payment Arrangement, Plan Modification, Incremental Cost                             $ 1,128,000            
Registered Direct Offering [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Number of shares issued                 550,000                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                 275,000                        
Class of Warrant or Right, Exercise Price of Warrants or Rights                 $ 10.00                        
Proceeds from issuance of common stock and warrants from private offering                 $ 5,500,000                        
Shares Issued, Price Per Share                 $ 11.00                        
IPO [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Number of shares issued               3,000,000                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights               180,000                          
Class of Warrant or Right, Exercise Price of Warrants or Rights               $ 15.625                          
Shares Issued, Price Per Share               $ 12.50                          
CEO Options [Member] | Two Thousand Eighteen Stock [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit   $ 2.00   $ 1.20           $ 1.50 $ 1.75                    
Stock Option Plan Reduced Exercise Price Per Share Description The exercise price of the CEO Option was further reduced from $     The exercise price of the CEO Option was further reduced from $             The exercise price of the CEO Option was further reduced from $ per share to $                  
CEO Options [Member] | Two Thousand Eighteen Stock [Member] | Stock Holders [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Common Stock, Dividends, Per Share, Cash Paid       $ 0.30           $ 0.25 $ 0.25 $ 1.00                  
Inducement Option Award [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent                             25.00%            
Inducement Option Award [Member] | Mr. Kamal Obbad [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number                             250,000            
Common Stock [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Payments of Ordinary Dividends, Common Stock       $ 4,500,000                                  
Common Stock [Member] | Two Thousand Ten Directors Plan [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares Issued, Price Per Share                         $ 5.28   $ 5.28     $ 5.28      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                         224,874                
Warrant [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                         5,986   5,986     5,986      
Share-based Payment Arrangement, Expense                         $ 252,000   $ 59,000,000,000 $ 16,000          
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised                             50,000            
Class of Warrant or Right, Outstanding                         855,000   855,000     855,000      
Warrant [Member] | Registered Direct Offering [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                         275,000   275,000     275,000      
Warrant [Member] | IPO [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                         180,000   180,000     180,000      
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Defined Contribution Plans (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Retirement Benefits [Abstract]        
Defined contribution amount $ 34,000 $ 19,000 $ 69,000 $ 52,000
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Other Current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Other Liabilities Disclosure [Abstract]    
Accrued commissions $ 1,054 $ 461
Accrued payroll 56 464
Accrued expenses 251 304
Accrued returns 331 291
Accrued income tax payable 8
Accrued benefits and vacation 49 34
Deferred revenue 169
Total other current liabilities $ 1,741 $ 1,731
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Details Narrative)
9 Months Ended
Sep. 30, 2021
Mylan and Escrow Agent [Member] | Escrow Agreement [Member]  
Agreement termination date Mar. 29, 2022
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Quantitative Information About Operating Leases (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2021
USD ($)
Leases  
Operating lease cost $ 611
Variable lease cost
Operating lease expense 611
Short-term lease rent expense
Total rent expense 611
Operating cash flows used in operating leases (168)
Right-of-use assets obtained in exchange for operating lease liabilities
Operating Lease, Weighted Average Remaining Lease Term 9 years 8 months 12 days
Operating Lease, Weighted Average Discount Rate, Percent 10.00%
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Maturity of Operating Leases (Details)
$ in Thousands
Sep. 30, 2021
USD ($)
Leases  
Remaing Months Ended December 31, 2021 $ 190
Year Ended December 31, 2022 774
Year Ended December 31, 2023 738
Year Ended December 31, 2024 747
Year Ended December 31, 2025 768
Thereafter 4,659
Total 7,876
Less present value discount (2,948)
Operating lease liabilities $ 4,928
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Details Narrative)
9 Months Ended
Dec. 08, 2020
USD ($)
Oct. 23, 2020
USD ($)
ft²
Sep. 30, 2021
USD ($)
ft²
Dec. 31, 2020
USD ($)
Operating Lease, Payments     $ 168,000  
Operating Lease, Liability     4,928,000  
Operating Lease, Right-of-Use Asset     4,484,000 $ 4,731,000
Operating Lease Liabilities [Member]        
Operating Lease, Liability     4,900,000  
Operating Lease Right Of Use Asset [Member]        
Operating Lease, Right-of-Use Asset     $ 4,500,000  
Plaza Medical Laboratory Corp [Member]        
Area of Land | ft²   4,000 4,000  
Confucius Labs [Member] | Old Bridge New Jersey [Member]        
Operating Lease, Payments $ 56,963 $ 5,950    
Lessor, Operating Lease, Term of Contract   10 years    
Lessee, Operating Lease, Description For the first year of the New York Lease, the base rent is $ We have the option to terminate the New York Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee. We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the New York Lease. We also have a right of first offer to purchase the Building during the term of the New York Lease  
Gradual rental rate increase percentage 2.75%      
Confucius Labs [Member] | Old Bridge New Jersey [Member] | Final Months [Member]        
Operating Lease, Payments $ 74,716      
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Customers (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Concentration Risk [Line Items]          
Revenues net $ 9,472 $ 3,840 $ 33,885 $ 9,351  
Revenue Benchmark [Member] | Diagnostic Services Clients One [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage 19.60%   28.40%    
Revenue Benchmark [Member] | Diagnostic Services Clients Two [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage 12.00%   20.70%    
Revenue Benchmark [Member] | Diagnostic Services Clients Three [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage 10.40%        
Revenue Benchmark [Member] | Third Party Contract Manufacturing Customer One [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage   57.60%   56.20%  
Revenue Benchmark [Member] | Third Party Contract Manufacturing Customer Two [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage   15.90%   16.60%  
Trade Receivable [Member] | Diagnostic Services Clients One [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage     19.50%    
Trade Receivable [Member] | Diagnostic Services Clients Two [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage     19.30%    
Trade Receivable [Member] | Diagnostic Services Clients Three [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage     12.00%    
Trade Receivable [Member] | Diagnostic Services Clients Four [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage     11.70%    
Trade Receivable [Member] | Diagnostic Services Clients Five [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage     11.60%    
Trade Receivable [Member] | Customer One [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage         36.00%
Trade Receivable [Member] | Customer Two [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage         20.00%
Trade Receivable [Member] | Customer Three [Member] | Customer Concentration Risk [Member]          
Concentration Risk [Line Items]          
Concentration Risk, Percentage         13.00%
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings (Loss) Per Share (Details Narrative) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Stock Options Warrants And Convertible Debt [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,929,000 3,029,000  
Common Stock Equivalents Two [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount     4,932,000
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.21.2
Secured Promissory Note Receivable and Consulting Agreement (Details Narrative) - USD ($)
2 Months Ended 3 Months Ended 9 Months Ended
Sep. 25, 2020
Feb. 28, 2021
Sep. 30, 2021
Sep. 30, 2021
Jun. 25, 2021
Jul. 29, 2020
Jul. 21, 2020
Interest and Fee Income, Loans and Leases     $ 230,000 $ 531,000      
Investment Shares [Member]              
Investment Owned, Balance, Shares         1,260,619    
Investment Owned, at Fair Value         $ 315,000    
Consulting Agreement [Member]              
Business Combination, Acquisition Related Costs $ 250,000            
Termination Agreement [Member]              
Test fees received   $ 95,000          
Secured Debt [Member]              
Accrued interest, debt     $ 132,000 $ 132,000      
Unrelated Third party [Member] | Minimum [Member]              
Debt Instrument, Face Amount 2,750,000            
Unrelated Third party [Member] | Maximum [Member]              
Debt Instrument, Face Amount 3,750,000            
Unrelated Third party [Member] | Secured Debt [Member]              
Debt Instrument, Face Amount 1,000,000.0            
Unrelated Third party [Member] | Revision of Prior Period, Adjustment [Member] | Secured Debt [Member]              
Debt Instrument, Face Amount $ 3,000,000.0         $ 250,000 $ 750,000
Debt Instrument, Interest Rate, Stated Percentage 15.00%            
Increase in interest rate payable percentage 9.00%            
Debt Instrument, Term 36 months            
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Segment Reporting Information [Line Items]          
Revenues, net $ 9,472 $ 3,840 $ 33,885 $ 9,351  
Consolidated cost of revenue 5,495 2,798 16,515 6,615  
Total Depreciation and amortization expense 401 3 1,144 13  
Diagnostic services 13,020 1,608 20,542 4,031  
Total loss from continuing operations, before income taxes (3,978) (569) (4,316) (1,308)  
Income from discontinued operations, before income taxes 161 161  
Net loss (3,978) (408) (4,316) (1,147)  
Total assets 72,630   72,630   $ 31,405
Diagnostic Services [Member]          
Segment Reporting Information [Line Items]          
Revenues, net 7,142 27,416  
Consolidated cost of revenue 4,009 11,833  
Total Depreciation and amortization expense 401 1,138  
Diagnostic services (1,145) 2,859  
Total assets 28,738   28,738   13,410
Consumer Products [Member]          
Segment Reporting Information [Line Items]          
Revenues, net 2,330 3,840 6,469 9,351  
Consolidated cost of revenue 1,486 2,798 4,682 6,615  
Total Depreciation and amortization expense 3 6 13  
Total loss from continuing operations, before income taxes (958) 1,039 (453) 2,723  
Total assets 20,986   20,986   6,261
Unallocated Corporate [Member]          
Segment Reporting Information [Line Items]          
Total loss from continuing operations, before income taxes (1,875) $ (1,608) (6,722) $ (4,031)  
Total assets $ 22,906   $ 22,906   $ 11,734
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information (Details Narrative)
9 Months Ended
Sep. 30, 2021
Segment
Segment Reporting [Abstract]  
Number of Operating Segments 2
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Event (Details Narrative) - Subsequent Event [Member]
Nov. 10, 2021
USD ($)
shares
Subsequent Event [Line Items]  
Number of shares repurchased | shares 140,769
Aggregate amount of shares repurchased | $ $ 791,000
EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 80 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 81 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 282 421 1 true 92 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://prophaselabs.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://prophaselabs.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://prophaselabs.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) Sheet http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://prophaselabs.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://prophaselabs.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Business Sheet http://prophaselabs.com/role/OrganizationAndBusiness Organization and Business Notes 8 false false R9.htm 00000009 - Disclosure - Business and Liquidity Uncertainties Sheet http://prophaselabs.com/role/BusinessAndLiquidityUncertainties Business and Liquidity Uncertainties Notes 9 false false R10.htm 00000010 - Disclosure - Business Acquisitions Sheet http://prophaselabs.com/role/BusinessAcquisitions Business Acquisitions Notes 10 false false R11.htm 00000011 - Disclosure - Goodwill and Acquired Intangible Assets Sheet http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssets Goodwill and Acquired Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Property, Plant and Equipment Sheet http://prophaselabs.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 12 false false R13.htm 00000013 - Disclosure - Unsecured Convertible Promissory Notes Payable Notes http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayable Unsecured Convertible Promissory Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders??? Equity Sheet http://prophaselabs.com/role/StockholdersEquity Stockholders??? Equity Notes 14 false false R15.htm 00000015 - Disclosure - Defined Contribution Plans Sheet http://prophaselabs.com/role/DefinedContributionPlans Defined Contribution Plans Notes 15 false false R16.htm 00000016 - Disclosure - Other Current Liabilities Sheet http://prophaselabs.com/role/OtherCurrentLiabilities Other Current Liabilities Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://prophaselabs.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Leases Sheet http://prophaselabs.com/role/Leases Leases Notes 18 false false R19.htm 00000019 - Disclosure - Significant Customers Sheet http://prophaselabs.com/role/SignificantCustomers Significant Customers Notes 19 false false R20.htm 00000020 - Disclosure - Earnings (Loss) Per Share Sheet http://prophaselabs.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 20 false false R21.htm 00000021 - Disclosure - Secured Promissory Note Receivable and Consulting Agreement Sheet http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreement Secured Promissory Note Receivable and Consulting Agreement Notes 21 false false R22.htm 00000022 - Disclosure - Segment Information Sheet http://prophaselabs.com/role/SegmentInformation Segment Information Notes 22 false false R23.htm 00000023 - Disclosure - Subsequent Event Sheet http://prophaselabs.com/role/SubsequentEvent Subsequent Event Notes 23 false false R24.htm 00000024 - Disclosure - Business and Liquidity Uncertainties (Policies) Sheet http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesPolicies Business and Liquidity Uncertainties (Policies) Policies 24 false false R25.htm 00000025 - Disclosure - Business and Liquidity Uncertainties (Tables) Sheet http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesTables Business and Liquidity Uncertainties (Tables) Tables http://prophaselabs.com/role/BusinessAndLiquidityUncertainties 25 false false R26.htm 00000026 - Disclosure - Business Acquisitions (Tables) Sheet http://prophaselabs.com/role/BusinessAcquisitionsTables Business Acquisitions (Tables) Tables http://prophaselabs.com/role/BusinessAcquisitions 26 false false R27.htm 00000027 - Disclosure - Goodwill and Acquired Intangible Assets (Tables) Sheet http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables Goodwill and Acquired Intangible Assets (Tables) Tables http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssets 27 false false R28.htm 00000028 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://prophaselabs.com/role/PropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://prophaselabs.com/role/PropertyPlantAndEquipment 28 false false R29.htm 00000029 - Disclosure - Stockholders??? Equity (Tables) Sheet http://prophaselabs.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://prophaselabs.com/role/StockholdersEquity 29 false false R30.htm 00000030 - Disclosure - Other Current Liabilities (Tables) Sheet http://prophaselabs.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) Tables http://prophaselabs.com/role/OtherCurrentLiabilities 30 false false R31.htm 00000031 - Disclosure - Leases (Tables) Sheet http://prophaselabs.com/role/LeasesTables Leases (Tables) Tables http://prophaselabs.com/role/Leases 31 false false R32.htm 00000032 - Disclosure - Segment Information (Tables) Sheet http://prophaselabs.com/role/SegmentInformationTables Segment Information (Tables) Tables http://prophaselabs.com/role/SegmentInformation 32 false false R33.htm 00000033 - Disclosure - Summary of Components of Marketable Securities (Details) Sheet http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails Summary of Components of Marketable Securities (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Components of Inventory (Details) Sheet http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails Schedule of Components of Inventory (Details) Details 34 false false R35.htm 00000035 - Disclosure - Schedule of Fair Value of Financial Instruments (Details) Sheet http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails Schedule of Fair Value of Financial Instruments (Details) Details 35 false false R36.htm 00000036 - Disclosure - Schedule of Deferred Revenue (Details) Sheet http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails Schedule of Deferred Revenue (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Disaggregation by Revenue (Details) Sheet http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails Schedule of Disaggregation by Revenue (Details) Details 37 false false R38.htm 00000038 - Disclosure - Business and Liquidity Uncertainties (Details Narrative) Sheet http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative Business and Liquidity Uncertainties (Details Narrative) Details http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesTables 38 false false R39.htm 00000039 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) Sheet http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails Schedule of Assets Acquired and Liabilities Assumed (Details) Details 39 false false R40.htm 00000040 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) Sheet http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Intangible Assets Acquisition (Details) Sheet http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails Schedule of Intangible Assets Acquisition (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Pro-forma Results (Details) Sheet http://prophaselabs.com/role/ScheduleOfPro-formaResultsDetails Schedule of Pro-forma Results (Details) Details 42 false false R43.htm 00000043 - Disclosure - Business Acquisitions (Details Narrative) Sheet http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative Business Acquisitions (Details Narrative) Details http://prophaselabs.com/role/BusinessAcquisitionsTables 43 false false R44.htm 00000044 - Disclosure - Schedule of Changes In Goodwill (Details) Sheet http://prophaselabs.com/role/ScheduleOfChangesInGoodwillDetails Schedule of Changes In Goodwill (Details) Details 44 false false R45.htm 00000045 - Disclosure - Schedule of Intangible Assets (Details) Sheet http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails Schedule of Intangible Assets (Details) Details 45 false false R46.htm 00000046 - Disclosure - Schedule of Amortization Expense for Acquired Intangible Assets (Details) Sheet http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails Schedule of Amortization Expense for Acquired Intangible Assets (Details) Details 46 false false R47.htm 00000047 - Disclosure - Goodwill and Acquired Intangible Assets (Details Narrative) Sheet http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsDetailsNarrative Goodwill and Acquired Intangible Assets (Details Narrative) Details http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables 47 false false R48.htm 00000048 - Disclosure - Schedule of Property, Plant and Equipment (Details) Sheet http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails Schedule of Property, Plant and Equipment (Details) Details 48 false false R49.htm 00000049 - Disclosure - Property, Plant and Equipment (Details Narrative) Sheet http://prophaselabs.com/role/PropertyPlantAndEquipmentDetailsNarrative Property, Plant and Equipment (Details Narrative) Details http://prophaselabs.com/role/PropertyPlantAndEquipmentTables 49 false false R50.htm 00000050 - Disclosure - Unsecured Convertible Promissory Notes Payable (Details Narrative) Notes http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative Unsecured Convertible Promissory Notes Payable (Details Narrative) Details http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayable 50 false false R51.htm 00000051 - Disclosure - Schedule of Stock Options Activity (Details) Sheet http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails Schedule of Stock Options Activity (Details) Details 51 false false R52.htm 00000052 - Disclosure - Summary of Weighted Average Assumptions Used In Determining Fair Value of Options (Details) Sheet http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfOptionsDetails Summary of Weighted Average Assumptions Used In Determining Fair Value of Options (Details) Details 52 false false R53.htm 00000053 - Disclosure - Schedule of Warrant Activity (Details) Sheet http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails Schedule of Warrant Activity (Details) Details 53 false false R54.htm 00000054 - Disclosure - Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants (Details) Sheet http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants (Details) Details 54 false false R55.htm 00000055 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://prophaselabs.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://prophaselabs.com/role/StockholdersEquityTables 55 false false R56.htm 00000056 - Disclosure - Defined Contribution Plans (Details Narrative) Sheet http://prophaselabs.com/role/DefinedContributionPlansDetailsNarrative Defined Contribution Plans (Details Narrative) Details http://prophaselabs.com/role/DefinedContributionPlans 56 false false R57.htm 00000057 - Disclosure - Schedule of Other Current Liabilities (Details) Sheet http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails Schedule of Other Current Liabilities (Details) Details 57 false false R58.htm 00000058 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://prophaselabs.com/role/CommitmentsAndContingencies 58 false false R59.htm 00000059 - Disclosure - Summary of Quantitative Information About Operating Leases (Details) Sheet http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails Summary of Quantitative Information About Operating Leases (Details) Details 59 false false R60.htm 00000060 - Disclosure - Schedule of Maturity of Operating Leases (Details) Sheet http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails Schedule of Maturity of Operating Leases (Details) Details 60 false false R61.htm 00000061 - Disclosure - Leases (Details Narrative) Sheet http://prophaselabs.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://prophaselabs.com/role/LeasesTables 61 false false R62.htm 00000062 - Disclosure - Significant Customers (Details Narrative) Sheet http://prophaselabs.com/role/SignificantCustomersDetailsNarrative Significant Customers (Details Narrative) Details http://prophaselabs.com/role/SignificantCustomers 62 false false R63.htm 00000063 - Disclosure - Earnings (Loss) Per Share (Details Narrative) Sheet http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative Earnings (Loss) Per Share (Details Narrative) Details http://prophaselabs.com/role/EarningsLossPerShare 63 false false R64.htm 00000064 - Disclosure - Secured Promissory Note Receivable and Consulting Agreement (Details Narrative) Sheet http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative Secured Promissory Note Receivable and Consulting Agreement (Details Narrative) Details http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreement 64 false false R65.htm 00000065 - Disclosure - Schedule of Segment Information (Details) Sheet http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails Schedule of Segment Information (Details) Details 65 false false R66.htm 00000066 - Disclosure - Segment Information (Details Narrative) Sheet http://prophaselabs.com/role/SegmentInformationDetailsNarrative Segment Information (Details Narrative) Details http://prophaselabs.com/role/SegmentInformationTables 66 false false R67.htm 00000067 - Disclosure - Subsequent Event (Details Narrative) Sheet http://prophaselabs.com/role/SubsequentEventDetailsNarrative Subsequent Event (Details Narrative) Details http://prophaselabs.com/role/SubsequentEvent 67 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm prph-20210930.xsd prph-20210930_cal.xml prph-20210930_def.xml prph-20210930_lab.xml prph-20210930_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true JSON 85 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 32, "contextCount": 282, "dts": { "calculationLink": { "local": [ "prph-20210930_cal.xml" ] }, "definitionLink": { "local": [ "prph-20210930_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "prph-20210930_lab.xml" ] }, "presentationLink": { "local": [ "prph-20210930_pre.xml" ] }, "schema": { "local": [ "prph-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 605, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 114, "http://prophaselabs.com/20210930": 48, "http://xbrl.sec.gov/dei/2021": 5, "total": 167 }, "keyCustom": 58, "keyStandard": 363, "memberCustom": 56, "memberStandard": 34, "nsprefix": "PRPH", "nsuri": "http://prophaselabs.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://prophaselabs.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Business Acquisitions", "role": "http://prophaselabs.com/role/BusinessAcquisitions", "shortName": "Business Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Goodwill and Acquired Intangible Assets", "role": "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssets", "shortName": "Goodwill and Acquired Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Property, Plant and Equipment", "role": "http://prophaselabs.com/role/PropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Unsecured Convertible Promissory Notes Payable", "role": "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayable", "shortName": "Unsecured Convertible Promissory Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Stockholders\u2019 Equity", "role": "http://prophaselabs.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Defined Contribution Plans", "role": "http://prophaselabs.com/role/DefinedContributionPlans", "shortName": "Defined Contribution Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Other Current Liabilities", "role": "http://prophaselabs.com/role/OtherCurrentLiabilities", "shortName": "Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Commitments and Contingencies", "role": "http://prophaselabs.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Leases", "role": "http://prophaselabs.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Significant Customers", "role": "http://prophaselabs.com/role/SignificantCustomers", "shortName": "Significant Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://prophaselabs.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Earnings (Loss) Per Share", "role": "http://prophaselabs.com/role/EarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "PRPH:SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Secured Promissory Note Receivable and Consulting Agreement", "role": "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreement", "shortName": "Secured Promissory Note Receivable and Consulting Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "PRPH:SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Segment Information", "role": "http://prophaselabs.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Subsequent Event", "role": "http://prophaselabs.com/role/SubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Business and Liquidity Uncertainties (Policies)", "role": "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesPolicies", "shortName": "Business and Liquidity Uncertainties (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Business and Liquidity Uncertainties (Tables)", "role": "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesTables", "shortName": "Business and Liquidity Uncertainties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Business Acquisitions (Tables)", "role": "http://prophaselabs.com/role/BusinessAcquisitionsTables", "shortName": "Business Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Goodwill and Acquired Intangible Assets (Tables)", "role": "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables", "shortName": "Goodwill and Acquired Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://prophaselabs.com/role/PropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Stockholders\u2019 Equity (Tables)", "role": "http://prophaselabs.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://prophaselabs.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Other Current Liabilities (Tables)", "role": "http://prophaselabs.com/role/OtherCurrentLiabilitiesTables", "shortName": "Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Leases (Tables)", "role": "http://prophaselabs.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Segment Information (Tables)", "role": "http://prophaselabs.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Summary of Components of Marketable Securities (Details)", "role": "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails", "shortName": "Summary of Components of Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:InventoryLabMaterial", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Components of Inventory (Details)", "role": "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails", "shortName": "Schedule of Components of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:InventoryLabMaterial", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Schedule of Fair Value of Financial Instruments (Details)", "role": "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "shortName": "Schedule of Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Schedule of Deferred Revenue (Details)", "role": "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails", "shortName": "Schedule of Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "PRPH:ScheduleOfDeferredRevenueTableTextBlock", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_custom_ZeroToTwelveMonthsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Disaggregation by Revenue (Details)", "role": "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "shortName": "Schedule of Disaggregation by Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30_custom_ContractManufacturingMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Business and Liquidity Uncertainties (Details Narrative)", "role": "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "shortName": "Business and Liquidity Uncertainties (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "lang": null, "name": "PRPH:MarketableSecuritiesUnrealizedLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-23", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details)", "role": "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "Schedule of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-08-10_custom_NebulaAcquisitionMember", "decimals": "-3", "lang": null, "name": "PRPH:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)", "role": "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-092021-08-10_custom_NebulaAcquisitionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical)", "role": "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "shortName": "Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Intangible Assets Acquisition (Details)", "role": "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "shortName": "Schedule of Intangible Assets Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-08-10_custom_NebulaAcquisitionMember", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Pro-forma Results (Details)", "role": "http://prophaselabs.com/role/ScheduleOfPro-formaResultsDetails", "shortName": "Schedule of Pro-forma Results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Business Acquisitions (Details Narrative)", "role": "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "shortName": "Business Acquisitions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Schedule of Changes In Goodwill (Details)", "role": "http://prophaselabs.com/role/ScheduleOfChangesInGoodwillDetails", "shortName": "Schedule of Changes In Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Schedule of Intangible Assets (Details)", "role": "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails", "shortName": "Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Schedule of Amortization Expense for Acquired Intangible Assets (Details)", "role": "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails", "shortName": "Schedule of Amortization Expense for Acquired Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Goodwill and Acquired Intangible Assets (Details Narrative)", "role": "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsDetailsNarrative", "shortName": "Goodwill and Acquired Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Schedule of Property, Plant and Equipment (Details)", "role": "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "shortName": "Schedule of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Property, Plant and Equipment (Details Narrative)", "role": "http://prophaselabs.com/role/PropertyPlantAndEquipmentDetailsNarrative", "shortName": "Property, Plant and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://prophaselabs.com/role/StatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-09-132020-09-15_custom_SeptemberTwoThousandAndTwentyNoteMember_us-gaap_UnsecuredDebtMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Unsecured Convertible Promissory Notes Payable (Details Narrative)", "role": "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative", "shortName": "Unsecured Convertible Promissory Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-09-132020-09-15_custom_SeptemberTwoThousandAndTwentyNoteMember_us-gaap_UnsecuredDebtMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Schedule of Stock Options Activity (Details)", "role": "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails", "shortName": "Schedule of Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_StockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Summary of Weighted Average Assumptions Used In Determining Fair Value of Options (Details)", "role": "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfOptionsDetails", "shortName": "Summary of Weighted Average Assumptions Used In Determining Fair Value of Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "PRPH:ScheduleOfWarrantActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Schedule of Warrant Activity (Details)", "role": "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails", "shortName": "Schedule of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "PRPH:ScheduleOfWarrantActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants (Details)", "role": "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails", "shortName": "Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "role": "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-05-122021-05-13", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Defined Contribution Plans (Details Narrative)", "role": "http://prophaselabs.com/role/DefinedContributionPlansDetailsNarrative", "shortName": "Defined Contribution Plans (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - Schedule of Other Current Liabilities (Details)", "role": "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails", "shortName": "Schedule of Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-09-30_custom_MylanandEscrowAgentMember_custom_EscrowAgreementMember", "decimals": null, "first": true, "lang": "en-US", "name": "PRPH:AgreementTerminationDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-09-30_custom_MylanandEscrowAgentMember_custom_EscrowAgreementMember", "decimals": null, "first": true, "lang": "en-US", "name": "PRPH:AgreementTerminationDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - Summary of Quantitative Information About Operating Leases (Details)", "role": "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails", "shortName": "Summary of Quantitative Information About Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-07-012020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecuritiesGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "role": "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-07-012020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecuritiesGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - Schedule of Maturity of Operating Leases (Details)", "role": "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails", "shortName": "Schedule of Maturity of Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - Leases (Details Narrative)", "role": "http://prophaselabs.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_custom_OperatingLeaseLiabilitiesMember", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - Significant Customers (Details Narrative)", "role": "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative", "shortName": "Significant Customers (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30_us-gaap_SalesRevenueNetMember_custom_DiagnosticServicesClientsOneMember_us-gaap_CustomerConcentrationRiskMember", "decimals": "INF", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30_custom_StockOptionsWarrantsAndConvertibleDebtMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - Earnings (Loss) Per Share (Details Narrative)", "role": "http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative", "shortName": "Earnings (Loss) Per Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30_custom_StockOptionsWarrantsAndConvertibleDebtMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "p", "PRPH:SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestAndFeeIncomeLoansAndLeases", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - Secured Promissory Note Receivable and Consulting Agreement (Details Narrative)", "role": "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative", "shortName": "Secured Promissory Note Receivable and Consulting Agreement (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "PRPH:SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestAndFeeIncomeLoansAndLeases", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000065 - Disclosure - Schedule of Segment Information (Details)", "role": "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "shortName": "Schedule of Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "00000066 - Disclosure - Segment Information (Details Narrative)", "role": "http://prophaselabs.com/role/SegmentInformationDetailsNarrative", "shortName": "Segment Information (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-082021-11-10_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000067 - Disclosure - Subsequent Event (Details Narrative)", "role": "http://prophaselabs.com/role/SubsequentEventDetailsNarrative", "shortName": "Subsequent Event (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-082021-11-10_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://prophaselabs.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Organization and Business", "role": "http://prophaselabs.com/role/OrganizationAndBusiness", "shortName": "Organization and Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Business and Liquidity Uncertainties", "role": "http://prophaselabs.com/role/BusinessAndLiquidityUncertainties", "shortName": "Business and Liquidity Uncertainties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "PRPH:BusinessAndLiquidityUncertaintiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 92, "tag": { "PRPH_AccruedReturn": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued return.", "label": "Accrued returns" } } }, "localname": "AccruedReturn", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_AdvertisingAndIncentivePromotionExpensesContinuingOperation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advertising and incentive promotion expenses, continuing operation.", "label": "Advertising and incentive promotion expenses, continuing operation" } } }, "localname": "AdvertisingAndIncentivePromotionExpensesContinuingOperation", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_AgreementTerminationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement termination date.", "label": "Agreement termination date" } } }, "localname": "AgreementTerminationDate", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "dateItemType" }, "PRPH_AmendedTwoThousandTenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended 2010 Plan [Member]", "label": "Amended 2010 Plan [Member]" } } }, "localname": "AmendedTwoThousandTenPlanMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_BreakageRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Breakage revenue.", "label": "Breakage revenue" } } }, "localname": "BreakageRevenue", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_BusinessAcquisitionsNetOfCashAcquired": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "BusinessAcquisitionsNetOfCashAcquired", "negatedLabel": "Business acquisitions, net of cash acquired" } } }, "localname": "BusinessAcquisitionsNetOfCashAcquired", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_BusinessAndLiquidityUncertaintiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business and Liquidity Uncertainties [Text Block]", "label": "Business and Liquidity Uncertainties" } } }, "localname": "BusinessAndLiquidityUncertaintiesTextBlock", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertainties" ], "xbrltype": "textBlockItemType" }, "PRPH_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable", "verboseLabel": "Note payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInShortTermInvestments": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Short term investments" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInShortTermInvestments", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_CEOOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO Options [Member]", "label": "CEO Options [Member]" } } }, "localname": "CEOOptionsMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_CPMAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "C P M Acquisition [Member]" } } }, "localname": "CPMAcquisitionMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/BusinessAcquisitionsTables", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "PRPH_ChangeInFairValueOfInvestmentSecurities": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value of investment securities", "negatedLabel": "Change in fair value of investment securities" } } }, "localname": "ChangeInFairValueOfInvestmentSecurities", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "PRPH_CitiBankNAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CitiBankm, N.A. [Member]", "label": "CitiBankm, N.A. [Member]" } } }, "localname": "CitiBankNAMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ClinicalLaboratoryImprovementAmendmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "foot Clinical Laboratory Improvement Amendments [Memebr]", "label": "CLIA License [Member]" } } }, "localname": "ClinicalLaboratoryImprovementAmendmentsMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_CommonStockEquivalentsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Equivalents Two [Member]" } } }, "localname": "CommonStockEquivalentsTwoMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ConfuciusLabsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Confucius Labs [Member]", "label": "Confucius Labs [Member]" } } }, "localname": "ConfuciusLabsMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Agreement [Member]", "label": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ConsumerProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consumer Products [Member]", "label": "Consumer Products [Member]" } } }, "localname": "ConsumerProductsMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "PRPH_ContractManufacturingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract Manufacturing [Member]" } } }, "localname": "ContractManufacturingMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails" ], "xbrltype": "domainItemType" }, "PRPH_CooperativeIncentivePromotionCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cooperative Incentive Promotion Costs [Member]", "label": "Cooperative Incentive Promotion Costs [Member]" } } }, "localname": "CooperativeIncentivePromotionCostsMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_CorporateObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate Obligations [Member]", "label": "Corporate Obligations [Member]" } } }, "localname": "CorporateObligationsMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "PRPH_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One [Member]", "label": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Two [Member]", "label": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DecreaseInFairValueOfInvestmentSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[custom:DecreaseInFairValueOfInvestmentSecurities]" } } }, "localname": "DecreaseInFairValueOfInvestmentSecurities", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_DiagnosticExpenses": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Diagnostic expenses" } } }, "localname": "DiagnosticExpenses", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "PRPH_DiagnosticServicesClientsFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diagnostic Services Clients Five [Member]" } } }, "localname": "DiagnosticServicesClientsFiveMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticServicesClientsFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diagnostic Services Clients Four [Member]" } } }, "localname": "DiagnosticServicesClientsFourMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticServicesClientsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostic Services Clients One [Member]", "label": "Diagnostic Services Clients One [Member]" } } }, "localname": "DiagnosticServicesClientsOneMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticServicesClientsThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diagnostic Services Clients Three [Member]" } } }, "localname": "DiagnosticServicesClientsThreeMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticServicesClientsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostic Services Clients Two [Member]", "label": "Diagnostic Services Clients Two [Member]" } } }, "localname": "DiagnosticServicesClientsTwoMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diagnostic Services [Member]" } } }, "localname": "DiagnosticServicesMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "PRPH_DisclosureBusinessAndLiquidityUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business And Liquidity Uncertainties", "verboseLabel": "Schedule Of Components Of Inventory" } } }, "localname": "DisclosureBusinessAndLiquidityUncertaintiesAbstract", "nsuri": "http://prophaselabs.com/20210930", "xbrltype": "stringItemType" }, "PRPH_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Schedule Of Maturity Of Operating Leases", "verboseLabel": "Summary Of Quantitative Information About Operating Leases" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://prophaselabs.com/20210930", "xbrltype": "stringItemType" }, "PRPH_DisclosureSecuredPromissoryNoteReceivableAndConsultingAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Promissory Note Receivable And Consulting Agreement" } } }, "localname": "DisclosureSecuredPromissoryNoteReceivableAndConsultingAgreementAbstract", "nsuri": "http://prophaselabs.com/20210930", "xbrltype": "stringItemType" }, "PRPH_EscrowAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Escrow Agreement [Member]", "label": "Escrow Agreement [Member]" } } }, "localname": "EscrowAgreementMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_EscrowMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Escrow Maturity Date.", "label": "[custom:EscrowMaturityDate]" } } }, "localname": "EscrowMaturityDate", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "PRPH_FinalMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Final Months [Member]", "label": "Final Months [Member]" } } }, "localname": "FinalMonthsMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_GradualRentalIncreaseRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gradual rental rate increase percentage.", "label": "Gradual rental rate increase percentage" } } }, "localname": "GradualRentalIncreaseRate", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "PRPH_IncreaseDecreaseInAccruedDiagnosticServices": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInAccruedDiagnosticServices", "verboseLabel": "Accrued diagnostic services" } } }, "localname": "IncreaseDecreaseInAccruedDiagnosticServices", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_IncreaseDecreaseInEscrowReceivable": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInEscrowReceivable", "negatedLabel": "Escrow receivable" } } }, "localname": "IncreaseDecreaseInEscrowReceivable", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInLeaseLiabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_IncreaseInInterestRatePayablePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in interest rate payable percentage.", "label": "Increase in interest rate payable percentage" } } }, "localname": "IncreaseInInterestRatePayablePercentage", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "percentItemType" }, "PRPH_InducementOptionAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inducement Option Award [Member]" } } }, "localname": "InducementOptionAwardMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_InventoryLabMaterial": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory lab material.", "label": "Diagnostic services testing material" } } }, "localname": "InventoryLabMaterial", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_InvestmentSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment Shares [Member]", "label": "Investment Shares [Member]" } } }, "localname": "InvestmentSharesMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_IssuanceOfCommonSharesRelatedToBusinessAcqusition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common shares related to business acqusition.", "label": "Issuance of common shares related to business acqusition" } } }, "localname": "IssuanceOfCommonSharesRelatedToBusinessAcqusition", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRPH_IssuanceOfCommonSharesRelatedToBusinessAcqusitionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ssuance of common shares related to business acqusition.", "label": "Issuance of common shares related to business acqusition, shares" } } }, "localname": "IssuanceOfCommonSharesRelatedToBusinessAcqusitionShares", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRPH_IssuanceOfCommonStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and warrants for cash from public offering, net of $855 warrant liability and $2,365 offering cost.", "label": "Issuance of common stock and warrants for cash from public offering, net of offering cost" } } }, "localname": "IssuanceOfCommonStockAndWarrants", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRPH_IssuanceOfCommonStockAndWarrantsForCashFromPrivateOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and warrants for cash from private offering.", "label": "Issuance of common stock and warrants for cash from private offering" } } }, "localname": "IssuanceOfCommonStockAndWarrantsForCashFromPrivateOffering", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRPH_IssuanceOfCommonStockAndWarrantsForCashFromPrivateOfferingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants for cash from private offering, shares" } } }, "localname": "IssuanceOfCommonStockAndWarrantsForCashFromPrivateOfferingShares", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRPH_IssuanceOfCommonStockAndWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants for cash from public offering, net of $2,365 offering cost, shares" } } }, "localname": "IssuanceOfCommonStockAndWarrantsShares", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRPH_IssuanceOfSecuredPromissoryNoteReceivable": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "IssuanceOfSecuredPromissoryNoteReceivable", "negatedLabel": "Issuance of secured promissory note receivable" } } }, "localname": "IssuanceOfSecuredPromissoryNoteReceivable", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_LowerOfCostOrNetRealizableValueInventoryAdjustment": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "LowerOfCostOrNetRealizableValueInventoryAdjustment", "negatedLabel": "Lower of cost or net realizable value inventory adjustment" } } }, "localname": "LowerOfCostOrNetRealizableValueInventoryAdjustment", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities [Member]", "label": "Marketable Securities [Member]" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_MarketableSecuritiesUnrealizedLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in marketable security.", "label": "Marketable securities, unrealized loss" } } }, "localname": "MarketableSecuritiesUnrealizedLoss", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_MrKamalObbadMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr. Kamal Obbad [Member]", "label": "Mr. Kamal Obbad [Member]" } } }, "localname": "MrKamalObbadMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_MylanandEscrowAgentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mylan and Escrow Agent [Member]", "label": "Mylan and Escrow Agent [Member]" } } }, "localname": "MylanandEscrowAgentMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_NebulaAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nebula Acquisition [Member]" } } }, "localname": "NebulaAcquisitionMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/BusinessAcquisitionsTables", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_NebulaStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nebula Stock Purchase Agreement [Member]", "label": "Nebula Stock Purchase Agreement [Member]" } } }, "localname": "NebulaStockPurchaseAgreementMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_NoncashInterestIncomeOnSecuredPromissoryNoteReceivable": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "NoncashInterestIncomeOnSecuredPromissoryNoteReceivable", "negatedLabel": "Non-cash interest income on secured promissory note receivable" } } }, "localname": "NoncashInterestIncomeOnSecuredPromissoryNoteReceivable", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_OfferingCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering cost.", "label": "Offering cost" } } }, "localname": "OfferingCost", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "PRPH_OldBridgeNewJerseyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Old Bridge New Jersey [Member]", "label": "Old Bridge New Jersey [Member]" } } }, "localname": "OldBridgeNewJerseyMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_OperatingAndOtherExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating and other expenses.", "label": "Diagnostic services" } } }, "localname": "OperatingAndOtherExpenses", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_OperatingLeaseLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease Liabilities [Member]", "label": "Operating Lease Liabilities [Member]" } } }, "localname": "OperatingLeaseLiabilitiesMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_OperatingLeaseRightOfUseAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease Right Of Use Asset [Member]", "label": "Operating Lease Right Of Use Asset [Member]" } } }, "localname": "OperatingLeaseRightOfUseAssetMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_OverTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Over 24 Months [Member]", "label": "Over 24 Months [Member]" } } }, "localname": "OverTwentyFourMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "PRPH_PlazaMedicalLaboratoryCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plaza Medical Laboratory Corp [Member]", "label": "Plaza Medical Laboratory Corp [Member]" } } }, "localname": "PlazaMedicalLaboratoryCorpMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Of Common Stock And Warrants From Private Offering.", "label": "Proceeds from issuance of common stock and warrants from private offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_ProceedsFromMaturitiesOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from sale of marketable debt securities" } } }, "localname": "ProceedsFromMaturitiesOfMarketableSecurities", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_PurchasePriceOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate Purchase Price Of Common Stock.", "label": "[custom:PurchasePriceOfCommonStock]" } } }, "localname": "PurchasePriceOfCommonStock", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_PurchasePriceOfEscrowAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Price Of Escrow Amount.", "label": "[custom:PurchasePriceOfEscrowAmount]" } } }, "localname": "PurchasePriceOfEscrowAmount", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_RegisteredDirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registered Direct Offering [Member]", "label": "Registered Direct Offering [Member]" } } }, "localname": "RegisteredDirectOfferingMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_RetailAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retail And Other [Member]" } } }, "localname": "RetailAndOtherMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails" ], "xbrltype": "domainItemType" }, "PRPH_ScheduleOfDeferredRevenueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Revenue" } } }, "localname": "ScheduleOfDeferredRevenueTableTextBlock", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesTables" ], "xbrltype": "textBlockItemType" }, "PRPH_ScheduleOfWarrantActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Warrant Activity" } } }, "localname": "ScheduleOfWarrantActivityTableTextBlock", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "PRPH_SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Promissory Note Receivable and Consulting Agreement" } } }, "localname": "SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreement" ], "xbrltype": "textBlockItemType" }, "PRPH_SecuredPromissoryNoteReceivableNonCurrent": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Secured promissory note receivable" } } }, "localname": "SecuredPromissoryNoteReceivableNonCurrent", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "PRPH_SeptemberTwoThousandAndTwentyNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 2020 Notes [Member]", "label": "September 2020 Notes [Member]" } } }, "localname": "SeptemberTwoThousandAndTwentyNoteMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Warrants Outstanding - Exerisce" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options outstanding granted weighted average exercise price 1.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price 1.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1", "periodEndLabel": "Weighted Average Exercise Price Warrants Outstanding - Ending", "periodStartLabel": "Weighted Average Exercise Price Warrants Outstanding - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options vested and exercisable weighted average exercise price 1.", "label": "Weighted Average Exercise Price, Warrants Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options vested and expected to vest exercisable number.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber", "periodStartLabel": "Number of Shares Warrants Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation Arrangement by share Based payment award options forfeited in Period intrinsic value.", "label": "Total Intrinsic Value - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options grants in period intrinsic value.", "label": "Total Intrinsic Value - Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Member]" } } }, "localname": "ShareRepurchaseProgramMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (in Years) - Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisedWeightedAverageRemainingContractualTerm", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options granted weighted average remaining contractual term.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm", "verboseLabel": "Weighted Average Remaining Contractual Life (in Years) - Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term 1.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "verboseLabel": "Weighted Average Remaining Contractual Life (in Years) - Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2", "verboseLabel": "Weighted Average Remaining Contractual Life (in Years) - Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options vested and exercisable weighted average remaining contractual term 2.", "label": "Weighted Average Remaining Contractual Life (in Years) - Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm2", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award options granted weighted average remaining contractual term.", "label": "Weighted Average Remaining Contractual Life (in Years) - Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1.", "label": "Weighted Average Remaining Contractual Life (in Years) - Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_StockHoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Holders [Member]", "label": "Stock Holders [Member]" } } }, "localname": "StockHoldersMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_StockIssuedDuringPeriodSharesCashlessWarrantsExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StockIssuedDuringPeriodSharesCashlessWarrantsExercise", "verboseLabel": "Cashless warrants exercise" } } }, "localname": "StockIssuedDuringPeriodSharesCashlessWarrantsExercise", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRPH_StockIssuedDuringPeriodValueCashlessWarrantsExercise": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cashless warrants exercise" } } }, "localname": "StockIssuedDuringPeriodValueCashlessWarrantsExercise", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRPH_StockOptionPlanReducedExercisePricePerShareDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option plan reduced exercise price per share description.", "label": "Stock Option Plan Reduced Exercise Price Per Share Description" } } }, "localname": "StockOptionPlanReducedExercisePricePerShareDescription", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "PRPH_StockOptionsWarrantsAndConvertibleDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options Warrants And Convertible Debt [Member]", "label": "Stock Options Warrants And Convertible Debt [Member]" } } }, "localname": "StockOptionsWarrantsAndConvertibleDebtMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TerminationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination Agreement [Member]", "label": "Termination Agreement [Member]" } } }, "localname": "TerminationAgreementMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TestFeesReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Test fees received.", "label": "Test fees received" } } }, "localname": "TestFeesReceived", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_ThirdPartyContractManufacturingCustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Contract Manufacturing Customer One [Member]", "label": "Third Party Contract Manufacturing Customer One [Member]" } } }, "localname": "ThirdPartyContractManufacturingCustomerOneMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ThirdPartyContractManufacturingCustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Contract Manufacturing Customer Two [Member]", "label": "Third Party Contract Manufacturing Customer Two [Member]" } } }, "localname": "ThirdPartyContractManufacturingCustomerTwoMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ThirteenToTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "13-24 Months [Member]", "label": "13-24 Months [Member]" } } }, "localname": "ThirteenToTwentyFourMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "PRPH_TradeReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade Receivable [Member]", "label": "Trade Receivable [Member]" } } }, "localname": "TradeReceivableMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandAndTwentyDirectorsEquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty Directors Equity Compensation Plan [Member]" } } }, "localname": "TwoThousandAndTwentyDirectorsEquityCompensationPlanMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandEighteenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousand Eighteen Stock Incentive Plan [Member]" } } }, "localname": "TwoThousandEighteenStockIncentivePlanMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandEighteenStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Eighteen Stock [Member]", "label": "Two Thousand Eighteen Stock [Member]" } } }, "localname": "TwoThousandEighteenStockMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandTenDirectorsEquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Ten Directors Equity Compensation Plan [Member]", "label": "Two Thousand Ten Directors Equity Compensation Plan [Member]" } } }, "localname": "TwoThousandTenDirectorsEquityCompensationPlanMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandTenDirectorsPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Ten Directors Plan [Member]", "label": "Two Thousand Ten Directors Plan [Member]" } } }, "localname": "TwoThousandTenDirectorsPlanMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandTenEquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Ten Equity Compensation Plan [Member]", "label": "Two Thousand Ten Equity Compensation Plan [Member]" } } }, "localname": "TwoThousandTenEquityCompensationPlanMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_USGovernmentObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Government Obligations [Member]", "label": "U.S. Government Obligations [Member]" } } }, "localname": "USGovernmentObligationsMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "PRPH_UnallocatedCorporateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unallocated Corporate [Member]" } } }, "localname": "UnallocatedCorporateMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "PRPH_UnrelatedThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrelated Third party [Member]", "label": "Unrelated Third party [Member]" } } }, "localname": "UnrelatedThirdPartyMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ZeroToTwelveMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0-12 Months [Member]", "label": "0-12 Months [Member]" } } }, "localname": "ZeroToTwelveMonthsMember", "nsuri": "http://prophaselabs.com/20210930", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r613", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r639" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Series [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r192", "r327", "r330", "r561" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r272", "r305", "r352", "r355", "r488", "r489", "r490", "r491", "r492", "r493", "r512", "r560", "r562", "r601", "r602" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r272", "r305", "r352", "r355", "r488", "r489", "r490", "r491", "r492", "r493", "r512", "r560", "r562", "r601", "r602" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r192", "r327", "r330", "r561" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r272", "r305", "r331", "r352", "r355", "r488", "r489", "r490", "r491", "r492", "r493", "r512", "r560", "r562", "r601", "r602" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r272", "r305", "r331", "r352", "r355", "r488", "r489", "r490", "r491", "r492", "r493", "r512", "r560", "r562", "r601", "r602" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r138", "r139", "r141", "r142", "r149", "r429", "r430" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r149", "r209", "r210", "r387", "r393", "r428", "r429", "r430", "r431", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r641", "r642" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r149", "r209", "r210", "r387", "r393", "r428", "r429", "r430", "r431", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r641", "r642" ], "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r137", "r143", "r353" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r137", "r143", "r255", "r353", "r480" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r194", "r473" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r52", "r477" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r14", "r35", "r195", "r196" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r19", "r20", "r56" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued benefits and vacation" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxes": { "auth_ref": [ "r29", "r32", "r391", "r533", "r547" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.", "label": "Accrued income tax payable" } } }, "localname": "AccruedIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r56" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes": { "auth_ref": [ "r555" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.", "label": "Accrued commissions" } } }, "localname": "AccruedLiabilitiesForCommissionsExpenseAndTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued advertising and other allowances" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r20", "r56" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued payroll" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r19", "r20", "r56" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued diagnostic services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r50", "r244" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r38", "r77", "r78", "r79", "r550", "r568", "r572" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r85", "r86", "r441", "r442", "r443", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r76", "r79", "r85", "r86", "r87", "r128", "r129", "r130", "r416", "r563", "r564", "r642" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Estimated useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r36", "r387", "r477" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r128", "r129", "r130", "r384", "r385", "r386", "r429" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r110", "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r358", "r381", "r389" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r97", "r110", "r292", "r449" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r110", "r229", "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expenses", "verboseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of Land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r121", "r171", "r178", "r185", "r207", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r414", "r417", "r439", "r475", "r477", "r531", "r546" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r16", "r17", "r71", "r121", "r207", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r414", "r417", "r439", "r475", "r477" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r199", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r360", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r420", "r423" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingImprovementsMember": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building Improvements [Member]" } } }, "localname": "BuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r351", "r354" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/BusinessAcquisitionsTables", "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r351", "r354", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/BusinessAcquisitionsTables", "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/BusinessAcquisitionsTables", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Schedule of Pro-forma Results" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r395", "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "verboseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPro-formaResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r395", "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Revenue, net" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPro-formaResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r405", "r406", "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Total consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r405", "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business combination amount paid in cash" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Clinical lab material" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Prepaid and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Definite-lived intangible asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net identifiable assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Lab equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r400" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r48", "r477", "r574", "r575" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash acquired", "verboseLabel": "Cash Acquired from Acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r12", "r48", "r112" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents, at Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r106", "r112", "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, at the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash, at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r106", "r440" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r62", "r254", "r536", "r554" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r251", "r252", "r253", "r256", "r597" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r128", "r129", "r429" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r34", "r318" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r34", "r477" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock authorized 50,000,000, $.0005 par value, 15,652,724 and 11,604,253 shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r81", "r83", "r84", "r91", "r539", "r558" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r154", "r155", "r192", "r436", "r437", "r596" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r154", "r155", "r192", "r436", "r437", "r573", "r596" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r154", "r155", "r192", "r436", "r437", "r573", "r596" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Significant Customers" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r154", "r155", "r192", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r152", "r154", "r155", "r156", "r436", "r438", "r596" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r154", "r155", "r192", "r436", "r437", "r596" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r324", "r325", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Total", "verboseLabel": "Contract with Customer, Liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r324", "r325", "r328" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r324", "r325", "r328" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r30", "r534", "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r94", "r514" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of revenues", "verboseLabel": "Consolidated cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r153", "r192" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Description" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r118", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r286", "r293", "r294", "r296", "r302" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Unsecured Convertible Promissory Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r28", "r29", "r30", "r120", "r122", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r298", "r299", "r300", "r301", "r452", "r532", "r534", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r271", "r297" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r269", "r298", "r299", "r450", "r452", "r453" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative", "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r59", "r289", "r450" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r59", "r270" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative", "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r60", "r272", "r434" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r61", "r120", "r122", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r298", "r299", "r300", "r301", "r452" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined contribution amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/DefinedContributionPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r110", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r110", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Total Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r110", "r166" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r74", "r421", "r422", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Schedule of Disaggregation by Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "auth_ref": [ "r2", "r4", "r6", "r9" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Income from discontinued operations" } } }, "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r8", "r89", "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income from discontinued operations, before income taxes" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted earnings (loss) per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r146", "r147", "r148", "r150" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r85", "r86", "r87", "r128", "r129", "r130", "r132", "r139", "r142", "r151", "r208", "r318", "r320", "r384", "r385", "r386", "r392", "r393", "r429", "r441", "r442", "r443", "r444", "r445", "r446", "r563", "r564", "r565", "r642" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails", "http://prophaselabs.com/role/StatementsOfStockholdersEquity", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r435" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Marketable equity securities, at fair value", "verboseLabel": "Marketable equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1": { "auth_ref": [ "r114", "r115", "r116" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of escrow deposit disbursements related to property acquisition in noncash investing or financing transactions.", "label": "Escrow amount" } } }, "localname": "EscrowDepositDisbursementsRelatedToPropertyAcquisition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r284", "r298", "r299", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r347", "r432", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r284", "r332", "r334", "r339", "r347", "r432", "r485" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r284", "r298", "r299", "r332", "r334", "r339", "r347", "r432", "r486" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r284", "r298", "r299", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r347", "r432", "r487" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r284", "r298", "r299", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r347", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r201", "r202", "r204", "r205", "r206", "r211", "r212", "r213", "r214", "r215", "r218", "r219", "r220", "r221", "r295", "r316", "r427", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r619", "r620", "r621", "r622", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Estimated useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r235" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Less: accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r237" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Three months ended December 31, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r237" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r237" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r237" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r230", "r232", "r235", "r238", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r235", "r516" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Gross carying value", "verboseLabel": "Total intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r230", "r234" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r235", "r515" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Total intangible assets, net", "verboseLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAmortizationExpenseForAcquiredIntangibleAssetsDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administration" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r216", "r542", "r543", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r542", "r543", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r223", "r224", "r477", "r530" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, end of period", "periodStartLabel": "Goodwill, beginning of period" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://prophaselabs.com/role/ScheduleOfChangesInGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Acquisition of Nebula" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfChangesInGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Acquired Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r93", "r121", "r171", "r177", "r181", "r184", "r187", "r207", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r439" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r240", "r247" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r121", "r131", "r171", "r177", "r181", "r184", "r187", "r207", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r413", "r431", "r439" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Total loss from continuing operations, before income taxes", "totalLabel": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations:" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share", "verboseLabel": "Income from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r109" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r109" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r109" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r109" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r109" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r109" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r109" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InformationByCategoryOfDebtSecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.", "label": "Debt Security Category [Axis]" } } }, "localname": "InformationByCategoryOfDebtSecurityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r228", "r233" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestAndFeeIncomeLoansAndLeases": { "auth_ref": [ "r540" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases.", "label": "Interest and Fee Income, Loans and Leases" } } }, "localname": "InterestAndFeeIncomeLoansAndLeases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r88", "r165", "r448", "r451", "r541" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r105", "r107", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest payment on the promissory notes" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r20", "r21", "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest, debt" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryAdjustments": { "auth_ref": [ "r70", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.", "label": "Inventory Adjustments" } } }, "localname": "InventoryAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r66" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r13", "r69", "r477" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, net", "totalLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r68" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r67" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r96", "r164" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income, net" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r576", "r585", "r591" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Investment Owned, at Fair Value" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r577", "r581" ], "lang": { "en-us": { "role": { "documentation": "Balance held at close of period in number of shares.", "label": "Investment Owned, Balance, Shares" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r578", "r579", "r580", "r582", "r583", "r584", "r586", "r587", "r588", "r589", "r590", "r592", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r578", "r579", "r580", "r582", "r583", "r584", "r586", "r587", "r588", "r589", "r590", "r592", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r466", "r468" ], "calculation": { "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total rent expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Summary of Quantitative Information About Operating Leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee, Operating Lease, Description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Maturity of Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r467" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r467" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r467" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year Ended December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r467" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year Ended December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r467" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year Ended December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r467" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year Ended December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r467" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Remaing Months Ended December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r467" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r54", "r121", "r179", "r207", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r415", "r417", "r418", "r439", "r475", "r476" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r41", "r121", "r207", "r439", "r477", "r535", "r552" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r58", "r121", "r207", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r415", "r417", "r418", "r439", "r475", "r476", "r477" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r23", "r24", "r25", "r30", "r31", "r121", "r207", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r415", "r417", "r418", "r439", "r475", "r476" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r61" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Note payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative", "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r61", "r257" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative", "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Fair value of marketable debt securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r15", "r55" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable debt securities, available for sale", "verboseLabel": "Fair Value" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Gain (Loss)" } } }, "localname": "MarketableSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLoss": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Realized Gain (Loss)", "negatedLabel": "Realized (gain) loss on marketable debt securities" } } }, "localname": "MarketableSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Summary of Components of Marketable Securities" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Unrealized loss on marketable debt securities, net of realized losses of net of taxes" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r106", "r108", "r111" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r10", "r80", "r82", "r87", "r90", "r111", "r121", "r131", "r133", "r134", "r136", "r137", "r141", "r142", "r144", "r171", "r177", "r181", "r184", "r187", "r207", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r431", "r439", "r538", "r557" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SegmentInformationDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r171", "r177", "r181", "r184", "r187" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r459", "r468" ], "calculation": { "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r456" ], "calculation": { "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "totalLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease liabilities", "verboseLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r455" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r455" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r457", "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "negatedLabel": "Operating cash flows used in operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r454" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use asset, net", "verboseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r110" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization on right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r465", "r468" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r464", "r468" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r11", "r419" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization and Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/OrganizationAndBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r75", "r77" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized loss on marketable debt securities", "verboseLabel": "Net unrealized loss, investments in marketable debt securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Schedule of Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/OtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r18", "r19", "r56", "r477" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities", "totalLabel": "Total other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Current Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/OtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income." } } }, "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings [Line Items]" } } }, "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r103" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Issuance costs on unsecured convertible promissory notes" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r102" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Payment of dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r104" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of issuance costs in connection with ATM" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r198" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r99", "r408", "r409", "r410" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r331", "r333", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r356" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Defined Contribution Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/DefinedContributionPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r360", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r33", "r303" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r33", "r303" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r33", "r477" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock authorized 1,000,000, $.0005 par value, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r16", "r46", "r47" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid expenses, net of current portion" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r100" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from issuance of common stock from public offering, net", "verboseLabel": "Proceeds from offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r101" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from unsecured convertible promissory notes" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r50", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r248", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Estimated useful lives description" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r49", "r243" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r26", "r27", "r245", "r477", "r544", "r553" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, net", "verboseLabel": "Total property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r26", "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r26", "r243" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r341", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r341", "r471", "r474", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r390", "r513", "r603" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r117", "r529", "r549" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r320", "r387", "r477", "r551", "r567", "r572" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r128", "r129", "r130", "r132", "r139", "r142", "r208", "r384", "r385", "r386", "r392", "r393", "r429", "r563", "r565" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r162", "r163", "r176", "r182", "r183", "r189", "r190", "r192", "r326", "r327", "r514" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenues, net", "terseLabel": "Revenues net", "verboseLabel": "Total revenue, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r463", "r468" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r154", "r192" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SignificantCustomersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/BusinessAcquisitionsTables", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Fair Value of Financial Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r230", "r234", "r515" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r230", "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Intangible Assets Acquisition" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Changes In Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r22", "r43", "r44", "r45" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Components of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsTable": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed as a tabular roll forward of the amount of other than temporary impairment (OTTI) related to credit losses recognized in earnings including: (a) the beginning balance of the amount related to credit losses on debt securities held by the investor at the beginning of the period for which a portion of an OTTI was recognized in other comprehensive income; (b) additions for the amount related to the credit loss for which an OTTI was not previously recognized; (c) reductions for securities sold during the period (realized); (d) reductions for securities for which the amount previously recognized in other comprehensive income was recognized in earnings because the investor intends to sell the security or more likely than not will be required to sell the security before recovery of its amortized cost basis; (e) additional increases to the amount related to the credit loss for which an OTTI was previously recognized when the investor does not intend to sell the security and it is not more likely than not that the investor will be required to sell the security before recovery of its amortized cost basis; (f) reductions for increases in cash flows expected to be collected that are recognized over the remaining life of the security; and (g) the ending balance of the amount related to credit losses on debt securities held by the entity at the end of the period for which a portion of an OTTI was recognized in other comprehensive income.", "label": "Schedule of Other than Temporary Impairment, Credit Losses Recognized in Earnings [Table]" } } }, "localname": "ScheduleOfOtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r50", "r245" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r171", "r174", "r180", "r226" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r171", "r174", "r180", "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r363", "r370", "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Summary of Weighted Average Assumptions Used In Determining Fair Value of Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Amortization Expense for Acquired Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r158", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r176", "r177", "r178", "r179", "r181", "r182", "r183", "r184", "r185", "r187", "r192", "r249", "r250", "r559" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r158", "r160", "r161", "r171", "r175", "r181", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r109" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense", "terseLabel": "Share based compensation expense", "verboseLabel": "Share-based Payment Arrangement, Noncash Expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative", "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield (per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free rate of interest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Weighted Average Exercise Price, Exercise" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Warrants granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r364", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Shares Warrants Outstanding - Ending", "periodStartLabel": "Number of Shares Warrants Outstanding - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Number of shares authorized in share based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Stock option awarded", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Total Intrinsic Value - Ending", "periodStartLabel": "Total Intrinsic Value - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r365", "r383" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares Options Outstanding - Ending", "periodStartLabel": "Number of Shares Options Outstanding - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Options Outstanding - Ending", "periodStartLabel": "Weighted Average Exercise Price Options Outstanding - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "periodEndLabel": "Total Intrinsic Value, Options Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "periodEndLabel": "Number of Shares Options Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Options Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r357", "r362" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Option, exercise price", "terseLabel": "Exercise price", "verboseLabel": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails", "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program." } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r376", "r388" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life (in Years) - Ending", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted Average Remaining Contractual Life (in Years) - Options Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r460", "r468" ], "calculation": { "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease rent expense" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r7", "r158", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r176", "r177", "r178", "r179", "r181", "r182", "r183", "r184", "r185", "r187", "r192", "r226", "r246", "r249", "r250", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r65", "r85", "r86", "r87", "r128", "r129", "r130", "r132", "r139", "r142", "r151", "r208", "r318", "r320", "r384", "r385", "r386", "r392", "r393", "r429", "r441", "r442", "r443", "r444", "r445", "r446", "r563", "r564", "r565", "r642" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails", "http://prophaselabs.com/role/StatementsOfStockholdersEquity", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r128", "r129", "r130", "r151", "r514" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r33", "r34", "r318", "r320" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r33", "r34", "r318", "r320" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock-based compensation,shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r33", "r34", "r318", "r320", "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r33", "r34", "r318", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r33", "r34", "r320", "r359", "r371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r33", "r34", "r318", "r320" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Number of shares repurchased" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r33", "r34", "r318", "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Aggregate amount of shares repurchased" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r34", "r39", "r40", "r121", "r197", "r207", "r439", "r477" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r119", "r304", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r320", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r447", "r479" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r447", "r479" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r447", "r479" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r447", "r479" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r478", "r481" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r201", "r202", "r204", "r205", "r206", "r295", "r316", "r427", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r619", "r620", "r621", "r622", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r64", "r321" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r64", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r64", "r321", "r322" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 16,652,022 and 16,652,022 shares, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionsDetailsNarrative", "http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://prophaselabs.com/role/SecuredPromissoryNoteReceivableAndConsultingAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UnsecuredLongTermDebt": { "auth_ref": [ "r61" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Unsecured convertible promissory notes, net" } } }, "localname": "UnsecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r123", "r124", "r125", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves." } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r123", "r124", "r125", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/BusinessAndLiquidityUncertaintiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r461", "r468" ], "calculation": { "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/ScheduleOfWarrantActivityDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants outstanding, measurement input, percentage" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants measurement, expected term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/SummaryOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r411": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r469": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r481": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.1)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r604": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r605": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r606": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r607": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r608": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r609": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r611": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r612": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r613": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r614": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r615": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r616": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r617": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r618": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r619": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r621": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r622": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r623": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)" }, "r624": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)" }, "r625": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(i)" }, "r626": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(ii)" }, "r627": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r628": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r629": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1402", "Subsection": "Instruction 5" }, "r631": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)" }, "r632": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)" }, "r633": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(3)" }, "r634": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(4)" }, "r635": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(5)" }, "r636": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1406" }, "r637": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r638": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r639": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" } }, "version": "2.1" } ZIP 86 0001493152-21-028235-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-028235-xbrl.zip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�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� BZ&!KR)PH#K^AQMT1[A[#>)H+CYT//1OB;FTV:P MADFZC\>L=AW^1CH*!P;.OF:@3LE(A 0S.4?BK\LK!FVAS71':E(@H4"Q((' M;YL';^#/7<"8]>,9STVAVZ1 M3AU42]*"('%@1X_31Q1_CN4+]V<@8Q;=**6#7HE"+L)_@GY3[E.ET&;T172> M@H:##A0UL!,%%5P9?8D7I$5@ Z'/=9EDCD-']X(>5\9)@00]MP[_*\US2 ,/]9BNAV TF[K:.$J MW;& LP/9BO";M&9] ,F9@^9.3S. ?0F/6J3UT?$(L#YIEFKP"E5U4' [F(6# MHI*T9+V'FQ 0\)F257/,0*^D+0I0([3(L>?1B6*'F^)/L/6N<)WI/51=N0G" M?Q%8U/0+0]A!R_),?B,%X:# Z+<"BX)V#JJI@=X,>(/_VR+CJ^GI;<4TCR&& M,0KE6B8.SDQCRB&5,?U@@;P;+? J4;2E@@" M',#;#Y=.[ZH\?#7/1A\Z.<"- ;,BL-A M,A3/?6 /ED[?[C)0AP(B0IDB "8V\E29P@#T==9(OF!GR\ M$#,E0W?PJ3JW8FT6#+BS"[&S$>QZ'CU#'@1&?>BP1^89E)=(MKJOO18^ S(8 M@'\*K\&;V,&HQ""51$CN2)5O139PG+E20+:!)(J9!D&<^*8'(&$<;IGS6_#B M%%;I5.1 (#>(@+_?MQ%)KGZ\!RF3Q$=I+?DV@78@:Y)[>412(486T)'J6V3I M*\Y44 KU2*1P1L@9*;K/7$R$)$Y@4+XB2%Z;&VRQA)$X).ZVSEKZ@^4FX[MJ MXD)T)$]-?@B=:,?QN6"G_^&T$I7*%2MW3'81.!0K"L71W M%S5F?WH*']U/E798\8RH=NZP;R.2+N-OU2;[5BGYK??_'I[]\@P@T?JPRKFK MZZL/;_N63%;,G0)0>%?VO:UB:?K^[+M1[5RUOW;N^5O"_P_<3#=5W$Z;5SCP M"\&RZ7^T-BH@&,"-%+:6Q[C4GJC0:UWEP.J%TZ\E>6/./J?J[S(_2;* &R65 M-SVC- _!9X <5\,24M1PV^01>HH?1KF7%*0&&03Z,/G1,=80)Z)1N@\]W[(Z M'?H42@\U ]6G^$F7<:>XFKE(>W)M*21U']W\_;DY/@^,T_J4AB;"*V^2^H9; MQT"#SQF]L$E\U&9$A-3R[WUQVBYH^R1HXI1*O1$P+_U$/&\NQ;(K)% ]SEH' M*38TJ54D=":A2<)VNC1")?$INHL(%'7FL ;M(E+C5?,9H:Y3[H35E[V(!I4 MH[B:;4U20S]F)CRB""&9+I@ S^9&*GRBP$DZF#@=CL0[G@#I\R?'I$$F$7(P M#U))O.K/@\2]#N1!#KWV82EL:)[")I0D2<5SD!7X'\I0E M*Y\MO6[95M"[L\ZPETFGJ QH>JH=GKIG-\Z9_O/7N*X6(Q?/8(12/+:XF-+= MHEPI%(O% 0T86U&H.O",5X07,0#9_=D@R]N2/'W[WJU\_[#WJW.QFSUDIVL< M,@*R%<"Z-+AF M4"NA!\-,.M!V;W>+*)P[IV3[/UT*%4CQ%YQ21FK7J( F?@ M"3J0M"M>AH/B7ULZ&^KZ0#;;WX_A.,1W' MI7DGDB$&N().^EJ*/<>C QYKZ\C(J%)UX&6N!9-BB;8=IG%"40[F7%CT0Y>4.4[<@%U7\W5+L$+-L" MM"&?C,\KM803*LX>HMI4$;) 6/7EGJJE1%@^9CYP523=-X4GZGBLH_>X^S>9 MQCILI4A?B4,DTA87P-O?5]-;O^MJ*XU18E-:D/]01@ CL?#%Z8"S\2A M0*D#5=[2<8'-C38+MJ/*QL1A<7U>!85>19G]HC=1^PUDAB[&3/Q0YBO&"3[, M&;51?C\OQDF>:(,TL7>( 3ON8+Z#A[Q$\3?=($\,;7;9Z.,XMZ@.W\+:A[9K MW+]*-%PZV(W=1V>!!_<#V&UD6V'ICF5Z:!32]2 :Z+9D>7KS:;' MFL2_4CECO9= ?Y$4^)I,.S?T 1_]-V]73;]-"+K]P\K=TW>W^JE>M?YU/N]& M=P6G[]AZ[ZT&Z ?B2]X[+VX48!!7WR?+\[&,BQC&EI;*E+*+80>J#9'IZSZC M;ECSW#4:8CGE^(E_E*8MZ.<%#K2*(]!6:S=S:;LLAZ_M__7J'S2@M'.*ARQJ M;,WA5.8D=K54YV?[7@#272:HW0!!@$;L)KN(_\L\]]:][3+[@?&SB1:F3T?P MYD7QNUF[V(EL()H#V3^AIER>94+-S*X!V1I\V,XSZ8RY6]I;I[%6Q[/AB>B! M^SP\J39_!K6]^HWUWEH-/.EK(3]//*F.[Y^Z]%E&_Y0J6^6=/L;U/,8=(UYI M[@SJMF5Y 5CI=(5.T#L%K5VB7LDZ/GOL[?Y[?M,:@GJ+9TO#]YL!PNVE!?@7 M*;*?+9JF8#FC;O[RT+Z]L'\W2S_JR[OY/D8SUYO?'S\U;06F4I#FC[5GV@#' M&?G*PD:Q%.?.K_#T@_AZQNQNX_*[H9=^#<'7.0Q=>38O2SM+!KA<^6,&1OS;#U_EOU_OI@E5&LCVG."<7V]E=NLL\4XR;[QB?0+:[2J(7IM#Z< MA:$&URXKMM^X<8S?;"I$?>: A<6%HM,&+90K+WG@RM%L^""BWM6K[_KU5S_< M_5A::7R8-8 ^*/\JX]7XQ8S= &H,]>^7[-C\H)]55VKL1E]CZ!6)M\"NCN,8 M$B5.NXTX:+)".UW7S"?J4**$Z9(E#C(10+2;5F/J@0N$B?U+X*6FBZ7&;X?D M#11DAFY4\0:?3VN'%W>9LXRX^07UF5,;94HZ8; M+0L>X&F,6 5GNW[H4=[Q+YX%P\LN.Q8@8 MO$=(T%/S%*@Z1?=;6L-VNSS(KC<:O-JEWM,80(I.*2I67DJP?8HV%;MYFXIL MVU3LYFTJ\C85*]@$(6]3L>H'>Z%M*K)+_(IR3!.ZZ&5CDLPOU04ZT?MW3T^7 M3>/'^P]![^3%Y'TETKW$/!'XO1%7"4]7"$D/4DOT.:>*I4(PX_RQZMW3[_+# M^Z/]CZW+RL%$^6,)1$*H+B61;#+9/I BECC8\ 2KN6:,3:QD3ICVE/H1><4[ M![6[M!+OA]938#WM/=[4ZE-XC9^SH_PC,U[@,5Y;,;K (K_ ,ZM8-B^_/5WM M_)KK!:Y&.N&"0;Y[E]:JX-O7+^['H/)P^*65T\PJ?B2^P"-.*:4DS>Q6=\__ M?;1__CR9[P4N*MET4:G-U>RA=9K0O525:X6XSB( ,*!R+@N#)CUAU+H==;^H M0 @]1,M/()\0]B\O2'+^.!\]O/"O^$@G=HAH<%CP"W1UI\=>31]'! ML>;[#/[?O-4?[UIJ:!D/P)L'7EO^_6'OD#E&"Z?9)S-DY.+G:MA')LI87UOL M?7#,;FH[KT;SP1G3.(2I6:FFYOS*O25C4O/-%.][>J9$[!GN;K)V7#(5:,2E M99+37RJGU4FO6$[_*MU4,;JIXB)OJE*H5O*;FI:F2DN@J9U",\Q#P.*>(_O>_VONW7]FH^FT'$ M#\MV'X3)=7\>R;P+(Y8YQ(<*S7E!O+"3 MVJGG3X+Y4/$W)YCOEJL9UDW%HNY@":+N.,I0O!'9AU+(]:S+5I,HMGQF;%F/ M6RW+-!D\ X1?MA[KGET\*.^\^FKYX#(;#@N47<\VVRG*%9 9D?E#8V9M> M"*Y\:=X:W.: O9N)YWA_9[R%E=_FW$3T+ --1MTG7.C^],T"\@N=@Z&>";.M M[*Y*Y6OE[JE]VOSMGY^<^8U6MFGMSRR 6,$F_P)[;TGS-.&!#E(W6XX<> M']*(3;%U/J=2G9KB,/B&3[,182O1'$S'W-Q0OV.[33R7X2MS4'1?ZS(<5R_' MK*GKTO!2C]-QQ6W31YNW2 MW0]N#EZ"]BCHQN&!POX(^;&[XLX:)) M.QUQ)APJFH8:R:W*N_13CYS MWAH430.E!\*E@BQ13 AF;>..)M@J0ZPH7O M#^TSIF&1G%;:17IK$O3.8F1YDWF9\TMK=U#'C=V( M45$<\!_@OXA6:UB=;@66'/F2?:'>'R<,L/D!4GT(>(IL40[I(BIH2<#K$>#% MZ&46CWOV$W]UM49H-Y0QO6W+Y[.OQ-2P>$37ZI#"JND_1 ,UDQQ$?D0&9Q2V MP?8,5P!6EWCQRM$!W[O*6-:QFG8 ]E8$^XZ$O2)YA1@UI8 EU.=M_.$G/N<- M?M>CA\, A,833J53OJ(-^XA8FNL&(.X\FI0+T$6DDD$+@?HX!01C=:*OWG;B M,MLN@_.-FFRK[*;FF!&Y1M1Z(G:"9K+EA/#8I52J$C.ODB62=Y'3&9N%T-,U MK#6FT6?PG6N&.ACSL?*A/ROJ]UUQ9\1J<>+PI^=W9%CS@8&E3V/^TW78R"=^96S9WZEA3._TR.K]/WA MX=?'1VM=D7=$-O;"D!*Z!C5+HXP2+#5]$X"ESC'OB( M:KBUVS2 ';[%O=F&O[V]HI_+"YP7]* MV8#7UZ_2<\,F]]^&/I.3XRD4B8,!7315^;LX4A,[\X"68C)[6[NE"("R<3(' M+3\&*2 Q^J/B(Z%G5CC,?X? +H,H^B -=#FY'D?*2Q,T]$.:*6FX %_+%)YS M>NY!S@VEMZD9I^H^@_\TF(6M,GW:"EG]K@&J5\ZQ%K;O&\0_KG D41'HJA-Z M!K;BHY9)G>])@@EOXO;VYT M;!T#)S<#E,$>F6=8/N\9QF?,ZA(U%:JI]P I"UH]Q)"6YL#&'C"R@%-Q$;\1 M2O@;K<=T#,Z!@.;=73$&)XZ3(^#"]GV*(:/I/4PT4QVPTVN*VN]]>/*#:[O__W9;>Z-2_)(7WQQ27.5M&$T7"\$ MG5'+:KSZYL800)>F ?1 CZQ&L[?7/0F.?CY4,@3T//+9ROMI8P,B0,]CX'I! MQ)UB/2A5.>F/I$M!C*'I, !-A0^41C&/H[Y1G*# .JR;[V +S[,J%G4K: MP)0%DG3Y.9I>6D']"R?Y]=,IGMMLOIHW MF\^VV7PU;S:?-YM?P5;F>;/Y53_8"VTVOV37,$9R=,]H<L[F1GJ(NIJHVN0H M4G-,!3_23*T^3TGOZ7VKT3 .+R['5\.,^,3"_"7EXFCC*C466YX!4@.NCLO] MO?K>!\=_^#'6*)T>5//P>.SNC8)47]1Q',IFD5,Q&\+V^09^A5[E5^/VZF/5 MC$+2?@.TBODD\@MS3Z%;">S(3=?59^L7M[\^UI;S<\O5\B M6.?A!2CMI]7)34@'R/H['L;*.A0W\YBMBP *,'T?*S?L.!.)!IR 4!%YG[#! M&&86;,JB; -IR@(P>'-Y>Z2UF&[C4#Z^ 3XM#P.F+, R'S_L=&PE M)/.@D^:(5]!@O.A%+IPH*TFK?*J'/M"V[ZLA5XH'QFMV7>]>AA-'+?%2G _+ MUI_ L'';8.;L\3.[[C%=(V7)R+:_WTXV6C)Z+>CA? MQ-TI-$\$ K1AL@8CB1GHCWPQ/[$:UI!(8=H(,8Y.3V+2@W"P^#3_E,*?HA@E M#MS&>0!(V\@D4G,9<'U8U&.P/D9ESQP-/8M8H054/>2SY.UO,@>T6IX:P,O\ M@#?9G+?18$OQLM@>KQBC\"QS@*F*SS=03W::<=D=?LO6N[@QK&.#+7UU .C MP!H-RZ!"1GB$O$ 6(3TIV(T&W@6/1;<[K@!9]5# M[D5*:N:RG! W -I*:(A?#[S!2R.[NH>Q9"6^K93^4/:_CY-$S0) A;)#.&/4 M9<(=NFIU6[+.@)J2#&($9G34&259>.X# #D/72^'X'4MZ+I;?L Z$8TC-D@J MDZF-;:;[/',AF@1+E]EQ?4L4C-Y26I'G!QJM9O$4)XXA+,) ^0)R P8Q)RC MWHN2(? [%A>RO"\\TI/^H%LV82M#A$%4PPI.@X:O$9.P"*W:+B"I;=V##L/) MTG$#_G!M.*$(W19Y.L*O5=.Y2L32H] "K02HC+($,3 M\\D ?%A]3&6IL%^GQX'BXQA<4X4*AV8,E#JPG ;LGB<3;6[8:&$#(/D@7G$X M<3(Z4L-J %,&&C+;0#7J<-9!=P56E;JSD]G!P, M[ .+;3Q8R@$M"TD\UNM(#2)&A,(W AC>F6?RXB-U"=W$F_,#46$4U1[E*9W+ M*6]#E1J!#_?/HVF>UH+K<3WT^FNVBX@:C[_NSTSFLI#$;GSA6/=IIS)]O0DT MA!A+-6 JOR?%GB'*F291'HK6>'$D3N4#L<:!&D+H*-)>(902!,/G,*?WWK=L!"K92K M;[@XPC5()P<* V-8U_[O_]LOEXOOR,T%TD3JN9L;!E\(604]4WJGO3XZ.?K\ MAB?KIID"LEN#(N02NK.RI+ "8NW=4D[Q_[/WI[OQ!"$B!;2%A"MN'7OY55*FUH R26/I[E7K<-4E565N[Y MY$!2D#@8$W6H2\CRQ4R):QWM,F67.(,7Z#(8!3F&;@2TKFS),K!AD%HTD/@! M"P*B!NB1^&?(RPJ\,<8F#"XT'BF\8.U'^I1)/8*#4P%KMPB FSX,L 84M K+ MD(:O67NGN!K>78/Q8V_:\H^L+^ ](ZV/=CN52&0$OP2_@;3>&Z"1D5^PU^45 M$+V[.\9 0I?3>@H#48HCQ>"0!2%,ALPN'F->48='1N\5X-#).GC1*G/'E$"\ M EO2POW6+\VV6H@D?!MT2PW.7@LD@I%F.92Z8W01\'_A &)#4]\EW: 011A< MG&E9%=_?;\WN&%^28B6_AQ[TPXH:Z_*[*^IY(HE]8)H]AB*JX;@C>+?[>ZX#H,QT.U2 /W(L)&,7+L77+L7X:QD'PG<'QCI MU$8E00X\L7NHO=-[; M^NABXS_S8T7;0)D?A4-S=(<1$%0CDD,TF/8G'#2-D M';PQ"/PCHB*A0PYIZ!$/<2+$E7:E_P"I \C$^K8)[IMW-S-D1"S=P.S(Y=VZ MQ/TH-[%@'S:B!0,24!0ET;7DW1UG0SHUXC%A<$( R>2NW#-U7 'I73]V-O"@ M,BR._2 0HG-+L +C+:>!Z"Z7[->E=]F0B) U!.2VH!,3)")K\0N=)[GYQ"(% MN4#$_M ER2XS#.9AS)^4"/;&"0X:VGU7&P_@ZHK2)]D^U@,@2G3[>FD?M 4% M,X ' S_?J I:,6&]06;#=QL22^:H,L8T\HA.>R#? .QA_5L ;MHF!,,#^4H MF(E@96\L%Q$]&,<7$M #!_AZ$WKOK-I,[XMW=[ZC9^!CTW'I6PYS2=2!__!@ ML/6D#R149\E.-@WOIE?$(P<">6U_=^?.RSZ8#QS!@GB5((9AKB+P1;[;PY7S M6!D<\3H8" ;31I_'U;U88!)*XO/PB 9D6P@F1%08459,;%9+] G("B'UJ\SW MH_;MCQDAYJ8Y;@ZRC8S>GO4Y"4)SXP%TJ7ENB[V$(=*<&# &/<=ZF1,'0M<8 MA(>I(YN1M/71Y9+X,EXP@]:&I(&$M8:S)*2N)SA^AI]&D.Q KM&B7RLB&$YS MS(?4(MJ3;"UJ]T&=DFD<@+]C=2?:&?'*;E-E9+'D<$V="((+N7 M+^:865.7AO^0,8RL=0B([%UJHFWT$U?IZ!/L,U,V!L2"\@9$2O!-=R_WP4[8S%S:#_)M0L+DLZCB7_I/YSOY [MP'7A8^8.1@:*:"/*DQ M,A/&,QOHN;$;=%<:('9OR0Z*<1V',>-WQQ[(+^8[%[PA3UT \3G(&K,[(.\N MDG/5+P+P60C9B)VV=6<%%MC+X@Q->LSW NCJ+Z M8UKH?CJE$CB%%B%B &\&AT$L,O;&%@I.< K&>8W?(<6PLRZ/U*E]<5Q6R_10*BW/G?'><":?[>0>0G7JEJCMQ2(7M[DY859^(:*]8*:XO"R$K M"Z$EC#62AHZV$JJY@!P$B>_6GZ. M]2XK"6WEL0VK0 $8"2FVX)P +U@A4CJR0/"^T!E, #QNEV]#<*F+&) 6IEG: M"$M7VTR KXQP';TUD +*I51#-I!X$CP%\J#!?$6RZ&#LM=DA<5>]+4A7I"8L MN#!+FUFEG(#$144J.E_DOF G>VQOTE4UT[6D#'F7ON\^NQ!QESQ_B@VE!1.H MM&&,U,PQN-Z7%!9YHU98ML\L&@L3*V@E4"\(YT8<-RA0@N!-.)T&*YFX=R:0YNP=^CI!PHR\;]Y9B4! MJ+;=K)/L 9UIX?1/Z>5!*K^^]I8=KK2L![Z[4V#V&&\'4I6K=*;*.D"0XI MF[[U42M!-;$W19[EV@?4VEOFN3L'#+^S%NE>]ZT$"3!$$5X'^\EY#I#@G!^B M5[>Z75[$653R808^.V%N)&MB!(Z?[,.F@V$.X1\QY'%.T74VCBF#G;*>DP$7 MR3@F%Y*/!=B#!SVXD!F=/=LI7-<>["P?F$U]M)8^N#84YQ&F58 -!F:5,Y<, MGN/UM(TLXC((_2ZM4ARM/'M UZ %X17:M]"A25NF8TN5'MJ50-4,OQY&VTB>.71WUO E= U)T//4:LXP2'$W8(BC'R"[Y./P6KH^69; MKW\>WU7L#NJ#(,_*ZF\9\;)=/Q#729TB%2)8OY:8]5-@Z$( /]-Q(A9#,A]X M0 XADR-!Q^XICZY2/*_D),W8R&2=T2\Y/^2S1(?WD18P"12^\SKZ)H_@1J]3 M9,G$'9MP@+0JV/H:QC_ L-&DMMEB>:?T!7TM$AX!YQVLP\/BJRWI^'<=^91R ML(=OEQ>K:=P!_>&^-SI6V/>\D@@.-&B'7@:M&ZU>&%M&;B<5!CZ]:GKYMDV6 M_>UW9;\8RK]+(PK:XZ)L&8FC&>_HMO9_ ]G<..Z3S#Y:1MJ70ZV3(T/0M8\Z%I>>22H;;9XX MSR(]!$UKEJ9O!@=Z_0&OOE[5Z=UY^'-Y?#OZ\Z+?S&/4N&FT8JO&'J3AVTH* MXZ9RZ(@#1V:D9/%XG#Q,08:0T.4'D2 AM.3@@)]$/M:=,+#?+MIOCKG:K^\S M0<_JNUTJ$W>\^]F^ZK ]^=8EE'HB/@%7LR.*,:R^-CY-0TU(1X7[]_/ZA3+@ MOB6+S*V5A2&PBJ&/D*"$@*^D?G/?R-GC^_:;MB#M[G %4A$Y&Z!T\S&S*"-[ M&>\.-Y(3,],3LD#.8J#[:S4(V*EB'**W6-V&_??&'FPP&3>S8_?;0!RMTRY6 M[ RKHC147>G'KF)UC1NV9O%:;4B1C-T/]V\HYYL136QIVGF>H\K'XLP9OX'OEW##\4$\X"QMU UGJ M,4>?Z%Z1ZGODV<37L3#P4C03)71?7T MED:K!J<2[LRA-9L'WG5+IZQ"$14=LXI^/[M;='_1!QV10KD\:-,Y]Y* ZP'F M&DN:8605 M*^@8^ABI<(@1M'JGB%3OLHC,8^^7+W7,#Y@^5'$^OIV9M\+UF_BIV#$&]^05 M2L/%9C$L1:M4X@KTS[-[7\AAH\X:5\K0FHR0'#-!!! DCE^6T5MQQ$&E\W?\ M#E@ @&#\"! 79QASL<8C!K*1Q#KQ78^L-6'GI3.2Q8[I.-4;=]MDX?K];#P> MG-6<\9DM"S#*2]VE[UMZ5-W$>^@-G)1G<4FSOHAVX(WH52N"XLJ@N#-Z_M#) MK'JUJL#@?+#FHDD?PU/II4*!+:ECT1Q5YRZLE49CTF0+=2".AL3&0( E <4Z M H#&X"I6DJDC89T+JVWWQE0DIE0NE+X+/[X720OV!S$HH5C(+HSQ1XO<7(EC MJ[@L3F*^&^@_(._/5'(D^./KV"31YA]_BYDZ1P=5]:N#*MT.JNI7!]57!]4& M]N=\=5!M^L:^IDZL:=W6=&6-%K5*"F"T0BS-1LO+N0!1!7?*.C %VE@L\\]F MG-K_/)BV"OI]^=Z(A?Z?9]6;DHIGN?V,3')7;8F=TP2HQ*"SK[G.OL$;@[I5 M705T<>TZXZ,6[]71G[[!/TV[<4<=L[MH$$YP\E M#$I[*!M=4S>(LKDAS0-W6AM'S\<3%TVRON.WG^>5/VJS/GH5;&??2B.0K$$< M.RRXK4UAE?S^['S4E%F%5Y$5+(]H?TA7(L4]X+5;<6*GKL>NA_2EG K#"31A'C6C=WT<@H:';?^D1XD*IKJJNAJ0*H3 M0MR!LQ#2HU!S2^*4W]09I'!51V>%BQ/VO-INEI;MAUB9;>?MF#BH(H'S4!:O M[OBKY^*+O0M1-D8*/_G)(&:2OOVFQ,=]AH3%ZVX6=S>66>3V75C*GW.YO//2 M<@_-/I_US_G_K)]L,5:-5VMQ//RY*9?NYY<2-^"5H/I M-[.<1,N&J &EN+U^R*C11068LK,R /@J@10X56\'FCZ&=/ZI"M-NL6*$8L8A M?]"X.:U/CR;/G6G^Z4;6N=?BZW7_6R9L8+%@%5APECQXC;@R HE[>Y5^LEK/ MX+Q1F+!7L8%O^I^0A[)EW\>M XXH",O^F))79"YLF$3-;\I5 U)W8?0+I'8\ MVQ]%.YX+$[1!P,G()V]P;3%\OE8]YEOE13C_D:0Y$@@NJV_9L J= M83'IB,!PX32WPYPZM=?+P!S'Q;+O(CS+K8)G,?AV<85R_.-P44) M:!%DP?QB,M;A#456R6 'OFMGWA;DYQF1',3*"QR;]] J&1T:=2W;"O*RT"<@ M,8<'SX6)8^K:S4 BA7=:SIDQD] MH+X=WU:'S_6K&RY="^BW_'85 KZM2Q"%L:9RHL]C MB4_^-L.=I>NSU^M"O5IN5#.U4JQ%D39:#)A%QUN02,_?P\*)SV*]+%ZHU+:* MQ4_5,:_VY4!3^_Y-*=>TVZ)17H2)%[!3?C%6T,4N]6"A0.!0ZL%06&D/*L)Q M?;"U9!^3T\<&/B3J L17H"2](O,]:0UZP#[M-?NJ^5RM%N^L!ISD8FYK/J/K M0\7_';HZ8^?JT&MT\SY!%N3P]%#6])?Q'S9%74!)0T**$(.T2FO(2$1XI!+ MN"%7[ [GG7W9 ?]I!#P^@ZN68!.+W[Z8AZ_\0FZ"RF(+N2H7U*.;X"[.?5C! MUS,&R&!9H\']!RNLT^8G&.I OCKMB+)]896WE\ZT^_S1'^DOI9M'835ZSQ5M M&I%U96VW?5^YX19^!NLVV!8).OV(XN9:-JF!0$+JID3-8(/:P;,?=)MVF,4/ MWC^%P[QTS*F]K*.HL$(Z[M4(<%1U2I*C538L55B7BZ+ K#^5>+>-\9K#LQQA;C?8U- M%?)0C6Q;*SXQWN*NFN+%G_-J]R5#,1YBYN-V%Y^]LJTN^/HT@^MX-T3V5]FT M_'+/!?)>GY@"YH4)[#%ZKNZ(Y!\[5V9HN#SSV_N;\\98.WYB%[D^";1 %DZZ M9S0FK67ZESKJ*]1Q:[31_-JL7,C26X_4>C&HS M3]TH:>X)H<#VIIGO@GCO3 M<^YB*E[U"[UFF@Y+(H*@M3&R:SMSA\FB+]H2UVC3HEF(4FN^&UR.31!63BEJ MY:XK.=8T$>!"W"8:9MP_9E[[U-K:ZV4Y6QWCD>QT.=MNET7S+MWEFK/:U>+J M$ADI1$HIU1()8LS#\O#E_/VD: R.5RM[9\T6#OAEB19(FY+-8KXS9=67ME)M M'K3E"K6N/*UW.=J#Y6W<^8]ACEP/:J)+_L&]&;)\IY=+R"AAD0I%'_$BT,]M MH5E;G?MRXN\QHF:B@T^H\F7* M_!("4WN9!(O5Y[XE';+!G;W)NC$(MR[6F.&!)G C(&!?S0<\@>$*B"<;#EA MVS,BG4 /Y?;([ZRE%/Y97+YY!!/2%5/SO?^L71>*SV\]CV!RA-)RBZU5[-7: M[V79SK1VK!V9#Z/3_%-E[D,A4J.G:6- I287TOI'/H\."AWSYU#YJ?!P_)*Z M=W]+;/2@7ME\XEY9*/S,JF62?7J;?(X.S/-&V6Z9;+A5RCC10QYV; M8V7ZS'V^"X6'R9_;^OBT>?7"'S^\BH^?RNEQ;7AZU)P*W$->F!P:+/]T MIOQI' RZP^O^W;$R>!XJ!O]T,_KS=-F_?KJ:BH\L^GM=NSE^R#\_*H8P>>V? M-P\&PO#!%(\'BGBLO#P_?HSJ]4YG6_IY8YSDH$(L@B&:H ^WF4H?;I9,U3I[ M>3BJ/\F-5S:D#W>KF&H;NH*C>A=*L\@ E-W<[;RT2U8TI=T=5T,O,]//2\%E M2;)\'S^="D6O66G%5UT*/V#,EZMOM7[0F;Y\"!=O3?ZI]M1?0&MN#ZQ-%K8* MM3]W=W0Z.H=,%Y0^Z;"Z &!W[=V:P*GZXTE..:,:4-UH"RH"ID;YI"LILF2- M-=S=Z5M+P*G,5$E1$1X'FXXUR5$0)@0B/F1 M3.7 8*8CRS M0$&N4U1*W+3(EOFCP);YQ$_K3&^.'R<7]=?N^7-A\WO:[^!NSMYHYQ;(RL26 M!1*9W[JH?^M.G$8IUO_J#,]*GV\G;?RQO59+4FWOG/ MD'JF0N[$/-]+\C]+[NA"[DGS+>H[T@AX^/(/V%!*K.+.362(/E$.1I^XTWE1 MPI9)QI 3=CB@ZFZ_BC!6"!A^R.2Q%(8N1;SZ8'+)OVAZ UQ^\EAG! [0"V!D M#1H[& ZGFJ >'Y>J)3MV0"2+P!/!@@&>OOGI-1?H!C4:X^BU1+B>[K'CWV(* M'GTI5RJE"*>1+H]&/CGTF"*"HW8\+_RP?&#J1$J"0.J(X^?,,.E3Y_WQ]6M7 M?6J\%82:*VYF*0K&Q+M"WE[/P:J/G;@T!UY\(H;=,R3AIVCJ(+?]+M@R!_7M M-UL*':^4 DQ,IHW.VDB7I3$$#I!#!;. A#$,:AA90<%T\:EJU5H*$G\QECUU M;8^&/%.<*=8]>=9ZI^_]RKD2X\B(UX6F"H440?W8& MWJHD]4;RK%HH5)^[;Z;.O2XFE=-EN>SDK4KH0&3H3T:-:4[D]F;@7(:66N (T45W>TF69R:).A^N,.DWK M/:%5/#ZY5C^*B8)$C%U4L29Z7MJ8I MI:9I/B\RJ](J'KT^L).3IF8XHQ%__GPZ?/KYLYU_]E$#1/6>_+DWD$510A1# M^^3DSZZNL'FV,I/EGT?6+G;>L[7$6YC2_!>M.+)R.=UA4AL]ZY>\E5[^HC#DHH%-C:? #72)5(.JB(68(:+% .;/C\9X8[L[A7R. 3IL> 7B M'%-B:U]38MTU&,M/B:U]38G]FA*[<9;9UY38S=]8QE-B-XR_%Z>4#+R\N],$ M(X.YP6T5Z'SE32=8^ET! 98NH@RFRZG38!'6$5 /0#1(^*3.M-_HJNW)Q[UV M)ZS"=^.6PQ_ +A2IV,>F'E:ZI#Q!J[[[X?V"PQXD=$$#+HIHD_O[J 'G/&J"04U++8F\[A%!_?C MT 70ET&S ?3YT$8[V_3HJ_GE4:KG'&8S+2;*=]/-$S'/9\E,192@^- M;;MXS'4Q5L,V&L.Q*AEJ70 M,G; M5,H3*GWHQY.KT^;;K2RO@$KYC:<2UPD(=4W/:P^3[GU3,5^^> FH5"(#A;0*794@ M=X@NM?TG+GM8H6+\U\JG[1 YV[CQKQ-/2TA$CV)T.8(&=:@I/#Y!J9F>54?B MY;5V75&RG2C-!??T6:O!B'O9-O6ET=*6@*[)4E@I%"'5V&63/ MVV3/IT;V8HXMQ .E_ZO)'AA(7'Y@#V1G@\"6OBCO9G@V;89'.2X^6; M"977E30^Q1A#%U#Z:JFP:W9\*]Q]GG.CP@(J+'DO(H -*NB]"W:!)9F?G1#8 M/I8T&6JAL,E!.6S=+#IL9?NHF8YR":%FI1R/'/L7T3(MC1'*F\72OXJ>Z>B! M$&IRN2*WR#QO_X )-U!Q5*DFVYD^F>9Q_4R2K\K+9OO^FBQT%Q+1C?;E[HX' M.$O^O5&Y>[1,2KBL"R"RJ'UMJ;L[+6&L@0?/%8@'G_/F7VTT646AN4O9,$P+ M7U8SQ\88_0!)2V/ ZY)!8.5',H#.&V-->(5?H',DN_!?UL_%6@A:-SZDDJ_DBW]RC-";W]6Y#&^ M/.MB/#:4%04]#? ",4!QCC',[HLDC 'P4D!F+(_^0& Q<2E1#@ T#9-7QQ3L M_?4#/Q0>-\24-D@^VO=AYOM8 MZTMX^B>&-ISY0(Z@F5HONX56?9UI\SJ@;M(WY?"KZOH[NMK,L:FKO"ICE% ; MC-53E.!]R#Y3AQF[^MBI6;!Y/<=\H'<[%YGQ7SLW)$A=E_A6[P(M!1KOS-NW MWMB^7>G>J:EV*%SHT,9]'5\.;J\JL#$NF^MR>M5TW1*@!/8" BJHT[DHQIN) M!"@4TFACYGOCXK3^ U"2T9E!S1JCV#MA,* L@=5L*2)S@-BM+^7PD\\0CTH3 M1ON FAIT)T#R?E>U#^85_8<*[$0+%3T,?'66V]V!DL4?J9=>KVO&PN:O^P"= M@KB[@[C=QN0ERG<\.[(E< I S+#!<'V)]9E]K[G%M"9BK8 FC^GT[%HYN3W[ M<_=JMZ@$C*!9D3+E9J5#T+(S4J"T@\)2@0RZ=DQ7DE2*"4WPK'UPV&&HS% U M!T5BN/%"!N@1 S"ND4I (H-'O\!=RT9B\-RY"R=G&U2"29D,:'EV((XD)AC% M%@G"G \$84[E39W!LA?C;)I_'YKU^E&]NOD S\&E>\7.](37*@/N1GOJE9*4 M[KFQCREONTC-U.F@SU46]"V$VEMU#=*9'[4WM6G;:>)T.?5)Q1050&DX?KF[ M[CX76@Z?!\2'XC'#DL;6B]E.8">?Q&/MP22V8O(?S_6W-_&/,+A=)":?/*U< M#4XK-Q19A5>!59XDO@&RVC_*,2,!"A+&:20TJ CA8M# M7A.BIBH>H<^.P*>VN3W3I!-RT!B)OC)S_,&5<6Q+'DX-)QL/-8V::'DH]#,JRIP JRTSC4)O1,:_SZTD;KP#IJAN/@\=A(4B)DY_G5KH@]ZK1>F5 L: M19C1A:ED=&%8COU#=37J:YF(V&+3U]R0A/%BQ M^NWW7E+1>ND\H)(:X]'.S%.=QO+#&:\7E2H'X M;9F*]:1EC%QGJG/F6V4L7#78RM:DN+:N:L"9TFRGDX<2;Y@$_R1@7G-@-0$= MVDSG=B,[$*W8&; <923Z,]2 FA@R0(;:1=@Y$FJ3+0P)&$S'VFA9ZH;,9HD,2 MF0]-?T6;%*1]!J=#T+8B(Y2XHLXIR)P]JT*V,:J@LC( _VOUZKJ.5HH+^WP9 M1ROMY51UG0[1!M[)1]%_B+B$<,FJS57$9.;92 K5*>S^;"LER//TZCN9#TF7 M_/P*16Q(4@B (I=C,(,C/D<<+DI0U"E; F? OP,L*",%C:LCC Y@#'CKP?QUJXO;6JZ&Z.U,QKE1_E R-MIZ>#CI:L_Z:6[6"X*?7ZJC4IY^X!G MP%UK7'!I8DJ'#!)_AL#EN0GL@XF1M6FU]_XR*MZD3^ %^VTB2,Q"9VRF1.[W M=:D/HC@0-J93%LJ45%)#09 MYX;_Y86Q\3A?RV+O-0(1"M7*>T.Z/C+9OI. F"\6OQ3X4Y*X=B$P5')+4RC] MH]Y(DV^J#Y](-O,Q;??=6]PBF U_SM2 M;4$GL$+HH&(U'OTAM71;,5 L'=F%\4="Y>SB("^V7E>3V;6@RQT))4%?>IAL M6OW8R\6>LKQ82X^]V%RA&@^(L= TR+FS3,BL*K7X^D0V"Z\Y(C)I8< M%<3EOT8%I3HJB,M_C0KZ&A6T@8-HOD8%;?K&,AX5E+W:67>4S8G[[NZ0P"_ M4XSMX)L,F!D;-%+(%[5<76@PP8#G@\DE_Z+I#84WC+ (8B,P@KCHPSO3H^G) M;>.*\\0.C]S5 M %>/-V:#-2HW3K(N-AX8]-(YUU FO?E<@>U,V<)GN]E6'@4A>@UNOE]X"1'/ M/[(+-*D\#O;]"*+Z"\!\0NKNSY,??B$W/8 M23$^T7QXEZ_%!6D(D7Y^?X2OBX1*=/E#Q(ZXXX?@ZLY4N?#:1WI55K M_KF76=F6+$=!!:+?DM>$S2L#@)5^BJ8.^LGOPR4AU[??;&DFG.VSL%-(#Z:6 MUYM])>"8Z+(TAG&J2*(#Z"B9ACJR $[2A:*J5:MK5G&GKDU2$!?*DB)_=7YU MJCW?3]E \WAUFBM\E:F,@.'*BXPZR *;K%9MKEE!13'$(%^1[T]O)\,+.9(A MDJJG2KAZRI;<<6MW-$9]4S1&U+D\WY6T?*LPX@U^.>V0\)XMKR?"U<2B^$Q9 M.$0!0'2XGT722><'3'$8R*-%)\B$R@!VS4J![O+&O4D;\?:Z<)"*+V]UH\+EUHJ>J&:WWR]L#&>1.3!/!SP MP\/&2>7NXG4YQ9#TJJ7@0:Q?,R1U%T+&DKJ[ #>A'M 1(LF8-CN]*ZY98?EX[:1=,<3)RW2L+1K%SX[7 MK(KL?Q6OI?VVB+BAH[2/-D5I^YA3;S^T!J^G??%)64Y-AW/.\HJYD% QIU9Y MGRBD6YWMM64]%0=6)6/""'5T\LA' MXO7@1"^C/].07ER.J\6+K[4Y!IGI@Y5)_G61+KV9")5DHJ(N".;0Q) ='LP& M1W@8+N'!S=)5N7\L9@@)'^)$7$B&\1/F8=$%>T 2-L'46\:(BIF6.O\1 MIBZ#P@;Y%N;O# E1@'/7?_P[#W$981AZB)MSABNQ@Q?\]B(M>H"!O'8N^P3>[,2VF8[39F=Y7 MQY_]Q^9S?R@N4*2^K2!#V4.1NFV5W1V*4X8'?5, J!G-@0$N9Z#DW/Z*^ZFM MGO\R!T/U35ZJ[6*CF3_\C$4+C7Y\VGA]OLJ:8FGE*'V%>4GK0TII73]>7'#= M)^Y5SH:TBR/U>8E;+G-9$MO+DP)RX!*-774STY%++B< YOM;D:;F#6AG M,VGUT"59'U1)KYUPIV53B:H222\JF##='7!9;J0A#S:#WD)W#:S@9V2(S>88 MKOAR9]KDS+.C2^5=>"IFX[PZ[(#\4RR*/1+8W_0YT\:U>7-14SB,C#W22CY^ MGDR* T[G(\@5>MO=AZ2\2Y>8$4(8\ZY4>KI[X#[*HIQ"_/HW4#V$Y;B-3;(D MH%[&G,3E"I5J)G-($[8R!9 CO+N0POAF_*T\-AM59_D]Y2C<5$L5-@F%K+H MESD.52D!#M4BG%->CG- !X7P3E6ZJS3>D.V]J9JCY-!*YA_O)R?U069VT*6T;\P !MY9WJAV)3C29;^?UWEC2 M8_CGX:0W.?LP6M/;6M:(GW<#29=X6-.VIVZ#V;-]TSZ9DS<])Y0Q@Q9SQ6)Y M=<"?A26RFI@S#\J?^NWG6[TP7M'D=BM#DFII6L(BOW];+FT[9BZ\-Q1]D-3:#=D6^'5<5T5C]Y,>00 ?_$C4]Q5Q_,\ M!ME&QP>#_"U__?Q>WKA$'AF84F+V&/^LE&IGVNZ.*OWW/^:T3UKJ84TG^<[^T1!(5&5&[ M.X(V'"%]!),8 ;K:V@1F#8GN8,4S,E).8I0ZTUZY5M,K!E__+"9)8B2[)RM) M5R1 ILNO%IFNZLHC'"F3X?VD7#X:1Z.VI8U,5W8XZ#L.*X_"+9M>@] M)NMVM7>1@H=3*,6[-QN$$%>>CUW\W:K_!G:9:5C]>]AEAGRVR<,%30U8 239 M@2DKH!D8V1F9G#KBS,$J923=D6L&M+'\)5B'G S?22H!^6HIO@IA50 TI56* MQ>WE$+]HS)A#*MP*.22DJSZ1PDS25&_HX[V]&Q@*2=@!__M25N6A.;1./P.& MFN;9%O/S0^[CHK_9\/3M;]?D6:B'G2]#'LW7Y?E_RPD!6)3UUO-3& M*@T5>Q?N3VZ''O);*A%;224U6ZXL6SN0'H_45VFJ;#&/^&V5K'FD6(R?%YNU ML9*Q,DO%6(EBJ>EUMZ9WCV^-^G03K)6D++.\.DMJK7!;8*U$'O#M0*R=24_] MRG5U \R5E1UP)6MS)7G$Y8+O.FG(M)53(@&4E@&S90K);[1DH80*;'P-V:H, ME3FC;LL9*EO&"W[C)'U>8'/Y_ J-UA"#))%#LV:#9$9'U2XN[CFY^UB]DC; M"-D,PV,;PB0S!SF\Z;7[D]I-_K"\ <;&=AL8BPT4T(8C1TE2!S4GJS&F,+F> ;"EO^ V1['BC6EU_?*2X!>9(&"--JW]8 MX>3@M?MQRV^ 69*$459GGF1L9Z9BGH0>[)^Z7BZ=LLW)G]H&F"DK.=BP"4DK MCX>$ -0V31T)+PSE@PC?0UM&/\],AEWO#((Y:Q:6,WUL@J!/-BUR+*_A,IA1 MD()]%+[7-&(TY7B\A"T>C%%=IYT),]1^^#JE6^WZT=7TUKQ M3V=Z,&Y\OI9>'F\NG'["S1J'D40,;<10C,65:#HC,:JE=:>*"7)C7Y,NLC_3]&1? M*8=[*C?E3)/:K_-A4X42UX?3XA*&?'DL5_2+D3I->4A8RE7FD3YQK\18>5GC@KY$H)@#57?U@)Y-KL4_XS-U1/LS,] M/C[DR@.E53QUYN>N"?UB?;,L= 'F0L,";P<,:#EWJ MQ?VVX-$,UY_-[K#\4JP,8N<'N!^6\2"&*AL]*X /&J50C]IXWMYXWII)H;TJ M;*W'GDS*2V\\;V\\O]S&J^7 ?5N[]DTJ0-18[!($\J"L"J8.V/, 1 ^\F&AX M0@POEL..9#3*C_+!$RUNSXI')^?"8:G<3X,C%Y]?84GRF4-B'ZO*DS-N1R+EY/(R07*D0Q>[+43&WN^.Y M+=LWOR=05Q%,+^E34$Q1^OV?_]K;8YJRI(@_F3;?1R;1+3*])560D-9F?S$/ MO&+"C\S>'M7\KGE-\<"!P%%70YY*A#;PFM D M\5@;!9E$(48-@9+QO.Z;AW"49+\8"/__9.HZWY6%7\P5NB"$K%<:$!!YHZYO M_1_]&OS),8JH043'7\W07)?XU[VNA.X.>O@(GYE%9;2MOXG$?G,QD#)N@@*E M"3%='+X18&F9BH[E@2:15],>\(:TNW/!=]%?3E5A'ROF6[-KR*+,ZS*4.F0] MPVSYC0!(HX$L88UI:"!"#61TH)^P,,*1UZ:L\BK24@IS.T:_L+!%-G]CWTV5 M-T49;>''=LZ2"[X(V>.8'DK=!)"E7I?QQUN/;4X-O;WX^[HY.7;[WO$_L@D)U< RV?0">BN#V7#T/0)@V\+TD\3 M$*M;ATRZ^3S?4JF'%5QO"IQVJAJ(;7%1'3\V=7D\.41RJ2.*ED%>8PO4(&=+ MKJH"[W=)R0$%G;?=K+L/[ M$+!FK\,!"@%[IR(_@5($20V2'<'GXP;;9$O8DPV#%\DQ'\@W-@P3W['3C*\P_A/[ MZP<9S8F8CN_W=:F/UHF>A=QR>83T'3_43'4,P*LSGF$IE">;O "S]4S5RB64 MU;+-EYO%C8?"H3(2WZ7C^V(X-\)V&+*?>'/R3)0A MU"]FAK*BP):1G00L*2/F0PO7$:>!Y4\]WASCXKL+B.#H-JO]+=[P%JP; T@' M77L,&"V:I"!Y1+0X@TYU1C05*A$"XL MZ#X9V&B.^ LBX^QU/@D21;7-DBFG5TU;J.QQ+JD"!QHE5OYA1HCG0)4R/:3" ML/0 *QJP'$'9YG9W7%S*,V\FTG^2CM1?ES=DQ/!(O,H*_EHHN^O2B)=A6"[3 M,Q5E?X9MCWQL2RQ? UP@Q[CVL'Y;:I;; XG][?>C MQ SX=PD?+$X0@MX9P4E.0@\;V3!0"( ^@&0A@V<0X<^R!9)10']397@9CZPD M)+[\O&9]!2#'9 PF^H%,M[&D@D4E(R, -!_ZBJ75B'P3@9"6__P42+'N+9)5D&N#CP7UHA_#;<% M0OIN,NPE(P-ZAF5;,N8(_H5NBV,=8F,PV&R-RHVYW$DX=F(:EC;6-#RY.+V^ MO[L_-\3PV3AA[MOR9DGLO5*X%5C8CS<#+<8)%+K(6@ 6&B)VV]U! M^Q)>Z<>A*PQ8%YL1@GWUX88(4J"?40VU*5SD=81(&Q[$4I-B,WGKXJS)'HKL M>;'_&FY)--S>G;,_!F]P/C,B@E";Q9/8BG"S8OMV@!2X@3DRG"7!@C#@@_O, M#4CBH4N>!O+G@#>8KH0$>Q]9$SS:/[+1ND@6FCKS,4#.S&1/^U E)#P-&LJ& M6OO+TR\'9@,<&&!8'MERA#M!ATGODC4D1Y1ZO*F,]YG3'I(OUK\834#L:&!% M*1N@S!D2X00=C.?E(,T_&BFR0/)?T*Z)6$K61 9I;1F9%?"5#QY&G^6PXM7, ML3%&CP.-J741$7 "VT"L*UJZ-G#E8"MT)7"I)$4"'THD:C[8<%4,S=DKNK[H MOW%R>8PN+OC:Z(]HWSSL_&,@"X,<1&M@0>C]L BT. /7;N O8.;FN[("<360 MSKJ$/11<@(&^:AA(5,!^TV?!"K@G_!]]!4!77?KT_ 648:_4YG! MXXEVGBU9"]9T=-[ ;@(BI2']P.R#.,%ZK S55(B-D/'(*WYK;OONW[;*C>9B M16TDX$J+D6:,D+S+"*%.N37O:GJ[\T)EW;Y+!C%58Q M5IQ1$;3Q9!5YJ[NS^&K]-.G;VY$2\Z=7>RFPO^V.? MJ4?<@&-/6-4(>M")<=+BQ !U[G;K]Y/@_K)YL_XZI$K 0.1:9SIJ3F[>;N\5O3WX]MN] M-4@@LY5?#-GB5]%1ZG>@98+S:B)_5I>GR*Q 7"M#ER6)W4** KG51E#*M^H) M\4/$%Q\P-91/?Y)X-6R"JX?M>BK62+6TCN&M-D;WT[9UU:L[_R+_M(]_= MP8>.*+]Q"AXMD](NF\6M**OB$Q2,2^\3VQY2!1#'EWNR8&7\9570])&FD^Y- M*Y%A%:C.%!^ VX D%@B H:9+C"%!*\@^4\=R*JR?TST%WHK)1L7C@J3V*5X0 MR"Q14;<"(*H=^-:-LV%2SA5CH>#\O#S\OF=3_[^ M.42D>P6)Q2+&:$.B\4/3D1Y3P^4BE8FIKB@(XF#N%:E:@(2.=HPM ;[@_2': M=G=G5MV2&AV<5";7XBOGDX[(;5AE))BMF$/Y749;%8TO!9&-(X@H?8FD.UL@ MDIF4D+U/NY\N-6Q,3PN)F@GZV("IR5+B&=C@PN]&LW\JN.'1O>M/H6RON!_NL;BZ-PQ79 W8YLQ$MIIUW[_\F96M^Q2) MVJ8,9QEB[1[.*SI]>1IL>XY$<5$)"=8581Z/F#>8#PEZ2"QM\,4Q&=@Y_TKK M9O'%R;]OI+YL0*(*Z;-#7*+&M'K(/D=*C"QW0Y:ZK6558!>>\:H)ZM.V$SXD M!F,4X*(^:!.PRO?&,O0\F+H \! ,W]@P)R:XY@:Z+W1WT9,,$S$?T2ESYZ&J6A0<82+717@VZ"OQL M;Q/#=_G'C,B=R:T1#_80UR2V<4TH,>N\OIQ].?)DX0611#%D50Y9%XP.SD+'-;/0 M3F0QQ^X.:7.)FI+<4'@#67Z/Y.LM_08Z<:Y,V%2K=VNS?8-7%$D\F%B?,ZP/ M&MXX>BK\T1N>7'?%_E X<_@#KQ(H8+T?0G WI&>(K)4$X.Q+2I8+M>]TP?8W M8KEG28J$Q:E6Q$Q% @NY!_195G%T>AC9&%?09_5AK*M4X+;;5]L M;)UB'8";C&P]%-YBU(B[YT>?DB[(AH1[9NP_VJS,9G"[#P.6O*;KYPYLL/F@IIZ4ZMV

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end